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Abstract  
Introduction: Malignant Rhabdoid Tumours (MRT) are especially lethal cancers that 
predominantly occur in infants and young children. MRT are caused by biallelic 
inactivation of a single gene; SMARCB1 which is a component of SWI/SNF chromatin 
remodelling complex. The tumours can be found almost everywhere in the body and the 
cell of origin for MRT is still unknown. Expression profiling of primary MRT 
demonstrates strong overexpression of a large number of stemness/self-renewal genes 
(PBTG, unpublished). Previous studies have shown that expression of these genes are 
deregulated by SMARCB1 and/or larger SWI/SNF complex. Therefore, this project was 
aimed to uncover the potential cell of origin and to examine if expression of self-renewal 
genes could potentially contribute towards disease aggressiveness. The understanding of 
other mechanisms involved in MRT tumourigenesis is essential to identify therapeutic 
targets that can improve the outcomes of MRT patients. 
Methods: I performed a meta-analysis cross-referencing expression profiles from 
primary MRT (n= 119), and functional models in which SMARCB1 was re-expressed (n=5 
lines) with expression profiles from multiple candidate stem cell types including 
epithelial, embryonal, neural, mesenchymal and neural crest (n= 446). I developed a 
lentiviral CRISPR/Cas9 system to efficiently model Smarcb1 mutation in primary 
candidate cells of origin ex vivo. To understand how SMARCB1 loss is capable of 
hijacking active stemness/self-renewal machinery to initiate MRT tumourigenesis, an 
integrated data analysis was performed to identify stemness/self-renewal genes whose 
expression are SMARCB1-dependent, by cross-referencing a manually curated 
stemness/self-renewal gene list with existing RNA-seq data from primary MRT and MRT 
cell lines with and without re-expression of SMARCB1 and with CRISPR/Cas9 genome-
wide screening data from MRT cells with and without re-expression of SMARCB1. 
Finally, the expression of stemness/self-renewal genes and their relevance as a therapeutic 
target in MRT, specifically the protein BMI1, was studied using shRNA and a small 
molecular inhibitor.  
  
ii 
Results:  Bioinformatic analysis of potential cells of origin suggests three putative 
candidate cell populations within the family of neural crest (NC), neural progenitor and 
mesenchymal stem cells. The extent of transcriptional overlap clearly reflects differences 
in tumour location and molecular subgroup. Unlike most cells tested, early neural crest 
(NC) cells tolerated Smarcb1 mutation and conferred proliferative advantage resembling 
human MRT molecularly and immunophenotypically. From my integrated bioinformatic 
analysis of self-renewal/stemness, BMI1 was identified as a functional SMARCB1-
dependent gene. Here, I show that targeted disruption of BMI1 by shRNA or 
pharmacologic inhibition using PTC209 strongly impairs MRT cell growth, suppresses 
tumour cell self-renewal, induces apoptosis and senescence. Using functional gene 
expression analysis, I found that BMI1 knockdown in MRT cells transcriptionally 
activates critical genes in MRT such as p21, p16 and CD44.  
Conclusion: Our findings suggest NC cells as a potential cell of origin for MRT. I 
describe a system for ranking putative cells of origin and a practical means for inducing 
Smarcb1 mutations ex vivo. Furthermore, I show evidence that subtypes within MRT have 
different cells of origin. Here, I also establish the role of BMI1 in self-renewal and 
survival of MRT cells. In addition, I show that the effects of BMI1 knockdown 
recapitulates the effect of SMARCB1 re-expression in MRT cells, demonstrating an 
attractive therapeutic target for MRT.  
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Chapter 1 Introduction 
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1.1 Malignant Rhabdoid Tumours (MRT) 
Malignant Rhabdoid Tumours (MRT) are one of the most aggressive paediatric cancers 
with a poor survival rate (Kato et al., 2003, Reinhard et al., 2008). The tumour was 
originally described in the kidney by The National Wilms Tumour study in 1978 as a rare 
rhabdomyosarcomatoid variant of Wilms’ tumour (Grupenmacher et al., 2013, Tomlinson 
et al., 2005, Biegel et al., 2002b, Biegel, 2006). However, tumours with similar rhabdoid 
morphology were later found in other parts of body such as soft tissues and brain. MRT 
most commonly occur in the kidney designated as rhabdoid tumours of kidney (RTK) and 
central nervous system (CNS) termed as Atypical Teratoid/Rhabdoid Tumours (ATRT).  
1.1.1 Atypical Teratoid/ Rhabdoid Tumour (ATRT) 
Although ATRT was first described as MRT of the central nervous system in 1987, it was 
recognised as a distinct entity of primary brain and spinal tumours in 1996 (Rorke et al., 
1996). This tumour possesses unique characteristic due to its complex 
immunophenotypes and multi-lineage differentiation potential (e.g neuronal, 
mesenchymal and glial). In most cases of ATRT, 50% of the tumours arise in the 
cerebellum or brain stem. Another 40% of ATRT can be found as a mass in the cerebral 
or suprasellar supratentorial regions.  
1.1.1.1 Extracranial Rhabdoid Tumour (ECRT) 
MRT that arise outside the brain such as liver, soft tissues, peripheral nerves and others 
are known as extracranial rhabdoid tumour (ECRT). Despite different anatomical sites 
and clinical behaviours to ATRT, ECRT is also characterised by biallelic mutation in 
SMARCB1 (also known as SNF5/INI1/BAF47, hereafter referred to as SMARCB1 in this 
thesis) and therefore are related entities. RTK was the first tumour classified as MRT. 
However, features of typical renal rhabdoid tumour were also found in liver and soft tissue 
of the chest wall in 1982  (Oda and Tsuneyoshi, 2006) paravertebral region in 1983 and 
in other soft tissues three years later.  Since then, various tumours observed outside the 
renal which demonstrated similar morphology to RTK has been reported. ECRT can be 
further divided into renal and extra-renal rhabdoid tumour. This sub-classification is made 
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as renal tumour tends to develop at early onset and has the capacity to disseminate into 
the brain. Moreover, patients with ECRT are commonly linked to germline mutations and 
therefore at high risk of developing multiple primary MRT at different locations in the 
body.  
1.1.1.2 Clinical histology 
The histopathological hallmarks of MRT cells are large and round undifferentiated 
epithelial and mesenchymal cells with prominent nucleoli and eosinophilic cytoplasmic 
inclusions (Figure 1.1). MRT cells are highly proliferative and mitotic figures are often 
seen in the nucleus (Sredni and Tomita, 2015). The diagnosis of MRT can be quite 
difficult due to tumour heterogeneity and several anatomical locations. In contrast to RTK 
which can easily be identified, ATRT often demonstrates pleomorphic features and 
sometimes typical rhabdoid cells are either undetected or absent (Bourdeaut et al., 2008). 
MRT exhibit multiphenotype immune profiles with common expression of vimentin, 
cytokeratin and smooth muscle antigen (Sigauke et al., 2006). 
 
 
Figure 1.1 Immunohistochemistry of Atypical Teratoid/Rhabdoid Tumour A) negative 
SMARCB1 staining B) SMARCB1 positive staining in endothelial and inflammatory cell. 
Pictures were taken from Sigauke et al. (2006). 
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1.1.1.3 Embryonal central nervous system (CNS) tumours 
Despite its unique and well-defined tumour biology, ATRT has been often misdiagnosed 
as other types of embryonal tumours such as Medulloblastoma (MB), primitive 
neuroectodermal tumour or choroid plexus carcinoma since the tumour can be found in 
similar regions of the CNS (Louis et al., 2007). 
Embryonal tumours of CNS are the most common paediatric brain tumour characterised 
by various group of neoplasms in infants and young children less than 36 months of age 
(MacDonald, 2008). Each type of embryonal tumours is highly homogenous consisting 
of undifferentiated small round cells with multiple lineages arrangements and often with 
high mitotic turnover rate. The tumours are quite rare accounting for 3.3% of all brain 
tumours (McGovern et al., 2014). However, they represent around 15.7% and 4.3% of 
malignant brain tumours in children (ages 0-14) and adolescents (ages 15-19) 
respectively. In 2007, The World Health Organization (WHO) includes MB, 
supratentorial primitive neuroectodermal tumours (sPNETs) and ATRT into CNS 
classification based on lineage arrangements and location of the primary tumour (Louis 
et al., 2007). Advances in molecular profiling of these CNS neoplasms have enabled 
better understanding of the tumour entities especially ATRT which previously had been 
misdiagnosed as MB but it is now recognised as a distinct entity.   
1.1.1.4 Incidence and epidemiology 
MRT in infants and children were initially described as a distinct tumour in 1978, arising 
almost everywhere in the body with high prevalence in the kidney and brain (Venneti et 
al., 2011a). Regardless of the primary tumour location, the tumours are highly malignant 
with a tendency to metastasize early and have poor survival rates in comparison to other 
childhood tumours (Reinhard et al., 2008). The actual incidence in children and infants is 
yet to be determined due to lack of systematic diagnosis protocol which often associates 
with inaccurate diagnosis evaluation. However, discovery of genetic alterations that affect 
the SMARCB1 locus on chromosome 22 as a leading cause of MRT has advanced the 
diagnosis accuracy and introduction of specific antibodies against SMARCB1 (Ab 
No.612110, BD Transduction Laboratories, San Jose, Calif) offers a better clinical 
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management since then (Woehrer et al., 2010). It is evident in the population-based study 
conducted by Austrian Brain Tumour Registry where half of the ATRT was correctly 
diagnosed after the introduction of WHO classification of CNS neoplasms and prior to 
the use of antibody against SMARCB1 in immunohistochemistry (IHC) diagnosis (Figure 
1.2). Furthermore, recognised patients (with ATRT) showed better overall 5 years survival 
compared to unrecognised patients (p-value: 0.00469).  
 
 
 
Figure 1.2 Kaplan-Meier survival curves of ATRT showing differences in survival of 
patients of initially recognised ATRT compared to misdiagnosed ATRT tumours before 
disease stratification using anti-SMARCB1 antibody. The tumours wrongly classified as 
other types of CNS tumours i.e Medulloblastoma have led to inappropriate treatments to 
the patients. Consequently, the overall survival of misdiagnosed patients was significantly 
poor relative to initially recognised ATRT patients (p = 0.0469) (Picture was taken from 
(Woehrer et al., 2010). 
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MRT occur most commonly in infants and young children. Report from Austrian Brain 
Tumour Registry (1996-2006) study illustrated ATRT as the sixth most common 
malignant brain tumours with an incidence rate of 1.38 per 1,000,000 person/years and 
peak incidence from birth to three years of age (median age between 12 and 24 months) 
with male predominance over female (Woehrer et al., 2010). Of 113 CNS tumours 
included in the Austrian Brain Tumour Registry, the incidence of ATRT of the brain 
reported in children aged below 3 years (17.3%) is almost comparable to MB (16%) and 
PNET (13.3%). Of note, this population-based study also reported low incidence of ATRT 
in other age groups. Another report from The Central Brain Tumour Registry of the 
United States also demonstrated the effect of age at time of diagnosis on incidence rate 
(Ostrom et al., 2014). According to this study, the highest cases were reported among 
children <1-year old and the rate of incidence decreased with increasing age. Similar to 
the report by Woehrer et al. (2010), the prevalence of ATRT was higher in children 
younger than 3 years accounting for 68.4% of all cases. Other studies of ATRT reported 
the median age at time of diagnosis between 1-3 years old (Lafay-Cousin et al., 2012, 
Panandiker et al., 2012). Categorization of children according to age of group at time of 
diagnosis suggests that ATRT occurs more predominantly in patients less than 3 years old 
(Figure 1.3). To date, only 31 cases of ATRT observed in adults have been reported in the 
literature (Buscariollo et al., 2012). Altogether, these studies demonstrated that ATRT is 
more prevalent in children aged 0-2 years old than in other age groups. 
Similarly, the incidence of ECRT in children reported in the UK between 1993 and 2010 
was five per 1,000,000 in the first year of life and the prevalence decreased in older age 
groups (Brennan et al., 2013a). Notably, the incidence rate varied depending on age and 
primary site of which the tumour was diagnosed (Table 1.1). The table shows that the 
most common tumour location for all age groups was kidney accounting for 51% of 
reported cases followed by 26% in other parts of bodies such as trunk and arms, 15% of 
the cases found in the head and neck and 14% of the cases found in liver. However, the 
incidence of tumours in infants (0-12 months) was higher compared to other age groups 
(2-4 years and 5-14 years). No cases were recorded in the liver for patients aged 2-14 
years old. A comparable early-onset disease was also observed in an institution study in 
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South Korea which recorded a median age of 9 months of age for 11 patients with ECRT 
(Hong et al., 2015).   
 
 
Figure 1.3 Population based study demonstrates relative incidence of the 6 most 
common malignant central nervous system (CNS) tumours in 5 different age groups. 
ATRT represents Atypical Teratoid Rhabdoid Tumour where as PNET indicates primitive 
neuroectodermal tumour. ATRT presents a peak incidence between 0 and 3 years age 
group in comparison to other CNS tumour entities demonstrating early onset phenotype 
of disease. The graph was taken from Woehrer et al. (2010). 
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Table 1.1 Population based study showing distribution of extracranial rhabdoid 
tumours in 4 different age groups between 1993 and 2010 in United Kingdom. The 
tumour locations reported in this study were kidney, liver, head and neck, and others 
which consist of arm/shoulder (five cases), thorax (nine cases), abdomen/pelvis (five 
cases), trunk not otherwise specified (four cases), omentum (one case), ovary (one case) 
and bladder (one case). Data was taken from the National Registry of Childhood 
Tumours. The table was adapted from (Brennan et al., 2013a). 
 
MRT are often described as extremely aggressive childhood cancers and show only a little 
evidence of improving survival rate at presentation (Figure 1.4). The survival analysis of 
MRT patients indicates that age at time of diagnosis is the prognostic factor. A study by 
Tomlinson et al. (2005) demonstrated strong correlation of improved OS with increase in 
age of diagnosis partly due to limitations in treatment received by younger and infant 
patients. In line with this, analysis of the data collected from SEER program showed the 
younger patients (0-24 months) have poor prognosis compared to older patients (>18 
years old) (Sultan et al., 2010). Similarly, a UK based population study reported worse 
prognosis in younger patients (0-12 months) than did the patients aged 1 year or older.  
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Table 1.2 Clinical presentation of MRT found in various part of the body reported from 
published studies. Clinical presentation of MRT found in various parts of the body 
reported from published studies. The overall survival is less than 25% in infants (10 
months) and young patients (24 months). This table was adapted from Bourdeaut et al. 
(2008). 
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Figure 1.4 Kaplan-Meier curves illustrate the overall survival (OS) of patients with 
MRT, stratified by tumour locations. In general, there is no significant difference in OS 
between RTK, ATRT and soft tissues (p= 0.64) (Reinhard et al., 2008).  
 
1.1.1.5 Survival 
The factors associated with a poor prognosis in MRT are metastatic disease at time of 
diagnosis and younger age. Analysis of data from National Cancer Institute (NCI) 
Surveillance, Epidemiology, and End Results (SEER) showed disease prognosis is poor. 
The database was utilised to identify 144 patients with ATRT from 1973 to 2008. Overall 
median survival (OS) for an ATRT cohort was 10 months from time of diagnosis and the 
year of diagnosis had no effect on survival (Buscariollo et al., 2012). In addition, patients 
diagnosed as metastatic suffered with remarkably shorter median OS (3 months) relative 
to patients with focal disease at the time of diagnosis (13 months). Another population-
based study from the German HIT database from 1998-2004 demonstrated patients with 
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77% of patients with ATRT died of disease with 13±5% of 3 years event-free survival 
(EFS) and 22±6% of the overall survival (OS) (von Hoff et al., 2011). In addition to this, 
retrospective review from The Hospital for Sick Children showed the median survival of 
143 cases reported from 1995 to 2007 was 17.3 months (Athale et al., 2009).  
1.1.1.6 Clinical management of MRT and treatment response 
Disease management for patients with MRT includes initial therapy for patients with MRT 
which consists of surgical resection to remove the primary tumour followed by therapy 
(Bansal and Goel, 2007). The current treatments for MRT include multimodal 
chemotherapy, radiotherapy (RT) and surgical interventions. Radiotherapy treatment is 
often delayed and avoided for patients younger than 3 years old due to radio-toxicity 
which has severe side effects on brain development and endocrine dysfunction (Bansal 
and Goel, 2007).  
The younger patients ( age < 3 years old) are often prescribed with a combination of high 
dose chemotherapy using methotrexate and autologous stem cell transplantation (Gardner 
et al., 2008). The treatment historical series from St Jude Children’s Research Hospital 
(Memphis, TN, USA) reported an impressive impact of high dose chemotherapy (HDCT) 
in patients with ATRT (> 3 years old). However, it is worth noting that from this series 
only one of three patients were alive after receiving RT as their upfront treatment. 
Interestingly, a new treatment approach using cycles of ifosfamide, carboplatin, etoposide 
(ICE) was administered in the patients 3 years of age of older. Of 4 patients, 3 of them 
were successfully recovered from the disease after 5 years of treatment (Tekautz et al., 
2005). Prolonged survival (median of 42 months from diagnosis) was also achieved in 5 
out 10 patients who received cycles of carboplatin, escalating doses of thiotepa and 
chemotherapy. Nevertheless, it is still unclear whether the better survival seen in older 
patients reflects the more aggressive treatment or age-related factors.  
The higher incidence of MRT in patients less than 3 years old confers a challenge in 
clinical management of disease due to prevention of RT in this age group. However, a 
recent study showed a strong correlation between RT and OS  in younger patients (< 3 
years)(Buscariollo et al., 2012)(Figure 1.5). Median OS for patients who did not receive 
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RT as upfront treatment was 6 months. However, the study was not able to measure the 
actual OS for patients who received RT. Despite controversial issues regarding the 
adverse effect of RT on neurological sequelae of the youngest patient, this aggressive 
treatment is still considered the best therapy to cure MRT (Chen et al., 2006, Chi et al., 
2009, Tekautz et al., 2005). Particularly, patients with localised tumour can receive more 
benefit from RT since they can be treated with focal irradiation thus minimizing toxicities.  
 
 
 
Figure 1.5 Kaplan-Meier curves showing overall survival (OS) for patients with ATRT 
who either received or did not receive radiotherapy (RT) as their upfront treatment. A 
retrospective review by Buscariollo et al. (2012) showed the positive correlation between 
RT and overall survival (OS). They reported that the median OS for patients receiving 
initial radiotherapy was improved as median survival has not yet reached at the time the 
patients were recorded (from 34 months to not yet reached). In contrast, the median OS 
for patients who did not receive the RT as initial treatment was 6 months (p < 0.001). The 
plot was reproduced from (Buscariollo et al., 2012). 
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High dose chemotherapy is also used in conjunction with analogous stem cell rescue 
therapy (ASCT) as part of MRT treatment. This intensive chemotherapy was used as an 
alternative to RT in young children (<3 years old) (Sung et al., 2016). Gidwani et al. 
(2008) published a single case report of a 4-month old boy who had received high dose 
myeloablative therapy followed by autologous peripheral blood stem cell transplantation 
as a treatment for ATRT. Surprisingly, he achieved long-term disease-free survival after 
treatment although he underwent incomplete tumour resection. Of note, RT was not 
included in the treatment course at all and no late side effects were recorded. A separate 
clinical study using the same treatment regimen was conducted in a 21-month-old patient 
diagnosed with metastatic rhabdoid tumour of kidney (RTK). However, the patient died 
9 months after diagnosis due to chemo-resistance as the same agents used in the two 
courses (cyclophosphamide, etoposide, carboplatin and melphalan). Additionally, a small 
cohort of ATRT patients in the USA also received myeloablative regimen and stem cell 
rescue according to CCG-99703 clinical protocol. All the patients were treated with 
intensive myeloablative chemotherapy followed by ASCT if they were in complete 
remission. Of 6 patients who received this treatment regimen, 3 of them were reported 
alive with two of these demonstrating long-term survival (>5 years survival). These 
studies showed that overall survival of small number of patients with MRT can be 
improved when treated using HD-ASCT. Nevertheless, the efficacy of this treatment 
modality needs to be explored further in MRT.  
Overall, several reports which have described multiple combinations of treatments for 
ATRT including intravenous chemotherapy, intrathecal chemotherapy, high-dose 
chemotherapy followed by autologous stem cell rescue (HD-SCR) and radiotherapy, 
showed variable results. Since the outcomes from the current treatments are far from 
satisfactory, novel approaches with fewer or zero side effects are very much needed to 
improve the survival rates of patients with MRT.  
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1.1.1.7 Biology and Genetics 
1.1.1.7.1 SMARCB1 loss: a classic feature of MRT 
Regardless of the anatomical site of the primary tumour, MRT at all sites are classified as 
the same entity given that they exhibit a common genetic origin, tumour morphology and 
characteristics (Versteege et al., 1998, Grupenmacher et al., 2013). The first genetic 
characteristic identified in MRT was monosomy 22 and subsequently translocation and 
deletions of the 22q11.2 cytoband (Versteege et al., 1998, Biegel et al., 2002b, Biegel et 
al., 1999). Positional cloning studies revealed the bi-allelic inactivation of SMARCB1 at 
this cytoband location was responsible for initiation of MRT (Versteege et al., 1998). 
SMARCB1 is universally expressed in all tissues and is a highly conserved subunit of the 
SWI/SNF chromatin remodelling complex (Versteege et al., 1998, Grupenmacher et al., 
2013).  
MRT possess unique genetic homogeneity compared to other embryonal tumours as the 
malignancy is caused by mutation of a single gene and no other mutation (Roberts and 
Biegel, 2009). High-resolution genomic analysis of ATRT identified no recurrent 
genomic alterations other than SMARCB1 (Hasselblatt et al., 2013). Additionally, Lee et 
al. (2012) described MRT as a “remarkably simple” disease genetically due to extreme 
low mutation rate identified in 35 MRT with SMARCB1 as sole event driver. SMARCB1 
mutation was recurrently mutated at very high frequency in this cohort (25 out of 32 cases 
that were whole exome sequenced). Also, they reported the mean mutation rate of 0.19 
mutations per Mb with a minimum of 0 and a maximum of 0.45 mutations per Mb. This 
rate marked the lowest mutation rate that has ever been reported in comparison with other 
types of cancers sequenced to date such as prostate and melanoma. Apart from SMARCB1 
mutation, the authors also identified GABRB2, TP53 and NF2 as recurrently mutated 
genes. However, these mutations were found in small subclonal populations. Collectively, 
it highlights the stability of SMARCB1 in MRT and therefore leads to a question of how 
such a single underlying cause can result in such a profoundly aggressive childhood 
cancer. Recent whole-genome sequencing of ATRT showed the locus that was most 
commonly affected was SMARCB1 thus corroborating the previous finding that 
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SMARCB1 is the only recurrent mutation commonly mutated in MRT (Johann et al., 
2016). 
Mutation analysis of the coding sequencing has identified a few “hot spots” of mutation 
in SMARCB1 gene. Deletion or mutation of the SMARCB1 locus on chromosome 22 have 
been found in MRT implying the role of SMARCB1 as tumour suppressor gene (Versteege 
et al., 1998, Biegel et al., 1999). However, type of mutations and position of mutations 
vary depending on the location of tumour in the body. ATRT (~50 of cases) has a high 
frequency of monosomy 22 or a deletion/translocation in the band 22q11.2 (Versteege et 
al., 1998, Biegel et al., 2002b). On the other hand, most of the ECRT samples present 
high frequency of homozygous mutation in SMARCB1 (Biegel et al., 2002b). 
Furthermore, ECRT tends to harbour unbalanced translocations or deletions of 
chromosome 22 which are not usually detected in CNS (ATRT)(Biegel et al., 2002b, 
Biegel et al., 1999).  
Coding sequence analysis shows some discrepancy in the distribution of mutation in 
exons between ATRT and ECRT. Higher frequency of SMARCB1 mutation for kidney 
(ECRT) was observed in exon 2, 6 and 7 whereas exons 5 and 9 are frequently mutated 
in CNS tumour of ATRT (Biegel et al., 2002b) (Figure 1.6). Notably, two hotspot 
mutations were reported in CNS ATRT cases only including cysteine deletion in exon 9 
and a C to T transition in codon 201 in exon 5.  
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Figure 1.6  Coding sequence analysis of 58 primary MRT revealed distribution of 
mutation in SMARCB1. Biegel et al. (2002b) identified variation of frequently mutated 
exon in SMARCB1 between ATRT and ECRT. Notably, no coding sequence mutations 
were reported for exons 1 and 8 in this study. Despite a small number of kidney tumours 
analysed in this study, these tumours showed a higher frequency of mutation in exon 7 
compared to ATRT (brain). Strikingly, recurrent mutation of cysteine in exon 9 was 
reported in ATRT (brain) only. The figure was taken from (Biegel et al., 2002b). 
 
Single nucleotide polymorphism (SNP) array analysis demonstrated the majority of the 
MRT tumours (50 of 51 samples) have either deletions, mutations or loss of 
heterozygosity (LOH) on chromosome 22 that leads to the inactivation of SMARCB1 
(Figure 1.7)   (Jackson et al., 2009, Lee et al., 2012, Hasselblatt et al., 2013).  
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Figure 1.7 Jackson et al. (2009) reported copy number alterations (CNA) on 
chromosome 22 by single nucleotide polymorphism (SNP) array analysis. There are 
three major groups; top group represents the large deletions; the middle cluster 
represents small deletions whereas the bottom cluster represents the large region of copy 
number LOH. In general, neoplasm with large deletions or large regions of copy number 
LOH were almost exclusively brain malignancies. Soft tissue tumours were found 
primarily to contain small deletions. The figure was taken from  Jackson et al. (2009).  
 
1.1.1.7.2 Genetic alteration of SMARCA4 as a second mutational driver in MRT 
Patients with MRT are commonly described with bi-allelic inactivation of SMARCB1. 
However, it was discovered, initially in a familial case, that patients could predispose to 
MRT tumourigenesis while retaining SMARCB1 expression (Frühwald et al., 2006). In 
this familial case, two sisters were affected by MRT (a sister with RTK and another sister 
with ATRT) and demonstrated the typical morphological and clinical features associated 
with MRT. Nevertheless, molecular studies including CGH and array CGH, FISH, gene 
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dosage analysis by denaturing high-performance liquid chromatography (dHPLC), and 
DNA-sequencing showed no evidence for mutation in SMARCB1. In addition to this, 
immunohistochemistry of the tumours also demonstrated positive staining of SMARCB1 
within the nuclei of tumour cells. The findings from this familial case ruled out SMARCB1 
as a mutation driver and strongly pointed to the existence of a second locus that 
contributes to MRT tumourigenesis. SNP array of the tumour samples identified 
SMARCA4 nonsense mutation and the tumour cells demonstrated negative 
immunoreactivity for SMARCA4 by immunohistochemistry. Copy neutral LOH covering 
the SMARCA4 locus in 19p13 further supported SMARCA4 as the second hit in tumour 
cells (Schneppenheim et al., 2010). After that, a sporadic case of ATRT in 9-month-old 
boy presented with no genetic alteration in SMARCB1 and expression of SMARCB1 as 
evaluated by immunohistochemistry. However, the tumour demonstrated a lack of 
immunoreactivity for the SMARCA4 antibody. The finding was corroborated by a 
homozygous mutation in the SMARCA4 gene (Hasselblatt et al., 2011). These studies 
provide the evidence that another component of SWI/SNF complex also contributes 
towards MRT tumourigenesis.  
SMARCA4 plays a critical role in the SWI/SNF chromatin remodelling complex as the 
ATPase subunit (Biegel et al., 2014). This gene is located on the chromosomal region 
19p13.2, spanning a total genomic size of about 100Kb. Mutation in SMARCA4 was 
found in several human cancers including prostate, breast, lung, pancreas and colon 
(Medina and Sanchez-Cespedes, 2008). In mouse models, homozygous deletion of 
SMARCB1 and SMARCA4 leads to embryonic lethality, thus establishing its role as 
tumour suppressor gene (Tolstorukov et al., 2013, Bultman et al., 2000). Gene expression 
analysis of SMARCA4 deleted tumour from SMARCA4 conditional mouse model showed 
enrichment of cell cycle progression related gene, thus consistent with the association 
between SWI/SNF complex and tumourigenesis. 
Patients with SMARCA4 mutation have a high tendency to carry germline mutation and 
present poorer disease prognosis compared to SMARCB1 deficient patients with known 
germline status (Figure 1.8) (Hasselblatt et al., 2014). 
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Figure 1.8 Overall survival of patients with SMARCA4 mutation (n=9) compared to 
patients with SMARCB1 deficient (n=33) with known germline status. Log-Rank test 
p<0.001. Graph was taken from (Hasselblatt et al., 2014). 
 
The role of SMARCA4 in MRT oncogenesis was studied in mouse embryonic fibroblast 
(MEF) by (Wang et al., 2009). The authors reported the expression of SMARCA4 is 
required for tumour formation to compensate SMARCB1 loss. In this study, SMARCA4 
was found in proliferating cells and was critical for mouse development and mutation in 
this gene impeded cell proliferation 5 days after deletion. Furthermore, co-inactivation of 
SMARCB1 and SMARCA4 resulted in rapid cell apoptosis.  
1.1.1.8 Genetic abnormality 
1.1.1.8.1  Rhabdoid tumour predisposition syndrome (RTPS)  
Rhabdoid tumour predisposition syndrome (RTPS)  was first described in 1999 based on 
rare familial syndrome cases where two or more family members inferred heterozygous 
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germline mutations in SMARCB1 on chromosome 22q11.2 leading to aggressive MRT 
disease. Sévenet et al. (1999) defined a new hereditary syndrome based on constitutional 
mutation of SMARCB1 capable of predisposing to MRT. Additionally, Proust et al. (1999) 
reported a case of two sisters presenting with ATRT almost simultaneously and died 
shortly after treatment (14 months and 26 months).  
Patients who present multiple primary tumours are inevitably associated with germline 
mutation (Eaton et al., 2011) and exhibit aggressive clinical behaviour. Older children 
with RTPS tend to develop multiple schwannomas. (Bourdeaut et al., 2011, Kordes et al., 
2010, Bruggers et al., 2011). The possibility of incomplete penetrance and gonadal 
mosaicism in familial cases may confer challenges for screening of an individual’s cancer 
risk (Eaton et al., 2011). Genetic screening and counselling should be provided to the 
families with RTPS. Notably, as cases are more readily recognised and diagnosed, 
favourable outcomes for the familial cases have been reported (Ammerlaan et al., 2008, 
Kordes et al., 2014, Modena et al., 2013) 
1.1.1.8.2 Genetic epidemiology in MRT 
RTPS cases exhibited high penetrance due to aggressive nature of MRT and high 
mortality rate, the tumour predisposition can be observed more than one generation in the 
family (Janson et al., 2006, Sévenet et al., 1999, Kordes et al., 2010, Taylor et al., 2000). 
In-depth knowledge of RTPS including its frequency, penetrance and expression as well 
as family member recurrence risk is critically needed. A retrospective study was 
performed in 115 tumours by Bourdeaut et al. (2011) has provided genetic epidemiologic 
information and guidelines for genetic counselling of this disease. High frequency of 
germline mutation can be found in MRT patients at any group and the patients tend to 
develop tumours at a very young age; median age at time of diagnosis was 6 months 
compared to median 8 months at time of diagnosis for patients with wild-type alleles 
(Figure 1.9). Also, 2-year OS was 7.6% in patients with germline mutation relative to 
29.45% for patients with wild-type germline alleles (Figure 1.10a). As previously 
reported, OS of patients is highly correlated to the age of patients (Tomlinson et al., 2005, 
Tekautz et al., 2005); in which patients older than 2 years showed better survival than 
younger patients (Figure 1.10b) (Bourdeaut et al., 2011).  
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The majority of germline cases occur through de novo mutations and the pedigree of 
inheritance pattern of the SMARCB1 mutation across the generations is rare (Ammerlaan 
et al., 2008, Frühwald et al., 2006). It has been reported that SMARCB1 germline mutation 
are not always inherited and unaffected adult carriers are known. This situation is known 
as gonadal mosaicism. In a series of familial cases (100 cases), the parents of children 
with SMARCB1 germline mutation are completely unaffected (4 out of 7 inherited cases). 
Eaton et al. (2011) in her study suggested that familial cases may present incomplete 
penetrance and gonadal mosaicism i.e the SMARCB1 mutation must appear within the 
parental gametes and not somatic cells (Eaton et al., 2011). A familial case study with 
posterior fossa brain tumours revealed splice mutations of SMARCB1 in some affected 
and unaffected family members (Taylor et al., 2000). The proband's parents were healthy. 
However, the proband's maternal uncle was diagnosed with a posterior fossa choroid 
plexus carcinoma and died of disease. Additionally, the maternal grandfather's sibling 
also died from paediatric brain tumour at infancy. Gonadal mosaicism is therefore the 
most likely explanation for this germline inheritance as the proband’s unaffected mother 
showed absence of disease symptoms.  
 
Figure 1.9 A retrospective study of germline mutation by Bourdeaut et al. (2011) 
indicates the incidence of germline mutation at any age. There are 4 different age 
clusters and the majority of MRT cases (60%) occur before 6 months of age. The data 
was presented as a ratio of the number of patients with germline SMARCB1 mutation vs 
the number of patients with mutated or wild type alleles for SMARCB1 for whom the 
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constitutional studies could be performed. The graph was taken from Bourdeaut et al. 
(2011). 
 
 
Figure 1.10 Bourdeaut et al. (2011) in their retrospective study of 115 tumours revealed 
a strong correlation of age with disease prognosis for patients with germline mutation. 
(a) The overall survival (OS) of patients with germline SMARCB1 mutations was poor 
relative to patients with wild type SMARCB1. (b) age at time of diagnosis also plays a 
critical role in conferring disease prognosis according to mutation status. Poor survival 
was observed in germline patients aged below 2 years old relative to older patients (>2 
years old). The graphs were taken from Bourdeaut et al. (2011). 
 
1.1.1.8.3 Non-rhabdoid SMARCB1-deficient tumours 
MRT are commonly defined by alterations of SMARCB1. The introduction of a diagnostic 
antibody has improved the ability to recognise previously misdiagnosed MRT and 
immunostaining using a monoclonal anti-SMARCB1 antibody presents a gold standard 
for detection of MRT. However, SMARCB1 mutations were also found in non-rhabdoid 
cancers that have composite rhabdoid cells as well as cancers that are lacking typical 
rhabdoid cell characteristics.  
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Immunohistochemical analysis of 55 tumours identified four CNS and three peripheral 
tumours with negative staining for SMARCB1 which only weakly resemble MRT 
histologically (Bourdeaut et al., 2007). CNS tumours which were found in choroid plexus 
were diagnosed as choroid plexus carcinomas due to different cell morphology despite a 
loss of SMARCB1 expression. The three peripheral tumours with negative IHC staining 
exhibited rare cell features in MRT such as “rosette-like” pattern, spindle or clear cells. 
Furthermore, the cells demonstrated positive immunoreactivity staining for vimentin and 
cytokeratin. However, the characteristic of rhabdoid cells such as abundant cytoplasm 
with inclusion bodies and a big nucleus with prominent nuclei were not detected within 
the cells. These findings illustrated that peripheral tumours can also exhibit similar 
patterns as are associated with ATRT.  
Close to 80-90% cases with epithelioid sarcomas demonstrated loss of SMARCB1 
regardless of distal or proximal location (Margol and Judkins, 2014). Extra-skeletal 
myxoid chondrosarcomas also have been reported to exhibit typical rhabdoid cells and 
negative immunoreactivity for SMARCB1 (Oda and Tsuneyoshi, 2006). These tumours 
also present aggressive clinical behaviour similar to MRT.  
Mutation of SMARCB1 has also been implicated in familial schwannomas. Patients 
present both constitutional and somatic mutation of SMARCB1 and the tumours 
demonstrated a mosaic pattern of  SMARCB1 loss by immunohistochemistry (Patil et al., 
2008). Analysis of the coding region of SMARCB1 by direct sequencing and multiplex 
ligation-dependent probe amplification (MLPA) of patients with schwannomatosis 
revealed partial LOH of the SMARCB1 region. These alterations were found both in 
tumour samples with and without NF2 gene expression (Boyd et al., 2008).  
Altogether, the cell morphology needs to be interpreted carefully along with 
immunohistochemistry profiles for characterisation of MRT especially ATRT as 
SMARCB1-deficient tumours can also be found in the same location as other SMARCB1 
negative non-rhabdoid tumours and may share clinical features with MRT including early 
onset and unfavourable outcomes.  
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1.1.1.9 MRT: a single entity containing molecularly defined subgroups  
MRT arising at different anatomic locations are characterised as the same entity as they 
share similar cell morphology, biology and clinical behaviours. Previous studies reported 
MRT harboured very few mutations and a remarkably simple genome (Lee et al., 2012). 
However, it is not fully understood if ECRT and ATRT are molecularly distinct due to 
conflicting results from the previous studies (Pomeroy et al., 2002, Grupenmacher et al., 
2013). Based on microarray analysis of primary MRT (5 RTK and 5 ATRT),  Pomeroy et 
al. (2002) concluded that MRT  which arise from different locations in the body are 
molecularly distinct. However, studies by Grupenmacher et al. (2013) and Paediatric 
Brain Tumour Group (PBTG) at Northern Institute for Cancer Research (NICR) 
illustrated otherwise. Gene expression analysis of primary MRT (10 RTK and 13 ATRT) 
and cell lines (G401-RTK and MON-AT/RT) demonstrated a separation between two 
subgroups related to anatomical location (Grupenmacher et al., 2013). However, miRNA 
expression analysis demonstrated MRT as a single entity regardless of tumour origin. 
Their findings illustrate that MRT are indeed a single entity that consist of two molecular 
subgroups. PBTG’s work to elucidate the degree of overlapping between expression 
profiles between ATRT and ECRT further validated the existence of two molecular 
subgroups related to tumour location in the body. Consensus clustering of non-negative 
matrix factorisation (NMF) of primary MRT (10 ATRT, 13 ECRT) two subgroups within 
MRT, one group that is not exclusively ECRT while the other group is made up 
exclusively of ATRT. To identify if MRT is a single entity regardless of anatomical 
origins, the expression profiles of MRT were compared with medulloblastoma. 
Medulloblastoma consists of four molecular subgroups namely Wnt, Shh, Grp3 and Grp 
4 (Taylor et al., 2012). NMF clustering of these tumours showed MRT as a single entity 
regardless of anatomical origin while medulloblastoma retained the four subgroups.  
Recent omics studies using whole-genome DNA, RNA, microRNA, ChIP sequencing and 
genome-wide DNA methylation assays illustrates multiple subgroups within ECRT and 
ATRT. In 2015, Torchia et al. (2015) reported two molecular subgroups of ATRT with 
differential gene enrichment profiles, survival and distinct clinicopathlogical 
characteristics. Following this report, analysis of 450K DNA methylation of 192 primary 
ATRT demonstrated three distinct subgroups within ATRT that are associated with 
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SMARCB1 mutations, tumour locations and demographics (Johann et al., 2016). The 
subgroups are called ATRT-TYR, ATRT-SHH and ATRT-MYC. Whole DNA genome and 
RNA sequencing analyses in these subgroups revealed no recurrent gene alteration in 
addition to SMARCB1. However, these subgroups are epigenetically very different based 
on whole-genome bisulfite sequencing and H3K27Ac chromatin-immunoprecipitation 
sequencing studies. Almost concurrently, Torchia et al. (2016) reported three epigenetic 
subgroups within ATRT with distinct genomic profiles, chromatin and functional 
landscape that links to various signalling and epigenetic pathways.   
Transcriptional and methylation analysis of ECRT also segregated this tumour into two 
subgroups. RNA-sequencing analysis of ECRT demonstrated two molecular subgroups 
associated with organ site called sub-group 1 and sub-group 2 (Chun et al., 2016). Cross-
referencing of the differentially expressed genes between MRT subgroups of their cohort 
with 29 genes reported by Grupenmacher et al. (2013) as overexpressed in ATRT relative 
to RTK. The cross-referencing analysis showed that sub-group 1 may share a closer 
expression profile to ATRT while sub-group 2 may be similar to ECRT (Chun et al., 
2016).  
Molecular subgroups were also observed in mouse models for MRT and reflect the 
heterogeneity observed in human MRT (Han et al., 2016). Analysis of tumours from 
Smarcb1-deficient mouse models from Smarcb1wt/del_ex1-2 and 
Smarcb1flox/flox;Rosa26-CreERT2 (lymphomas, intracranial and extra-cranial MRT). 
Transcription profiles of these mouse models were compared with non-Smarcb1 deficient 
mouse models (medulloblastoma and neuroblastoma). Unsupervised hierarchical 
clustering revealed two major branches; the first branch consists of medulloblastoma, 
neuroblastoma and intracranial MRT, while the second branch consists of lymphomas and 
extracranial MRT. NMF consensus clustering on the same dataset (medulloblastoma and 
neuroblastoma served as the control) showed three subgroups within Smarcb1-deficient 
tumours; one group exclusively CD8(+)T-cell lymphomas, one group exclusively 
intracranial tumours and the third group contained mixtures of intracranial and 
extracranial tumours. The intracranial tumours were segregated into two subgroups 
showed different enrichment of gene expression that possibly related to cell of origin. 
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Collectively, multi-platform analyses of human and mouse MRT tumours demonstrated 
molecular subgroups within primary MRT and further segregated into subgroups within 
ECRT and ATRT.  
1.1.1.10 MRT mouse models: history and challenges 
Attempts to generate Smarcb1-deficient mouse models for MRT have met variable 
success. Homozygous deletion of Smarcb1 is associated with early embryonic lethality 
(E7) (Roberts et al., 2000). However, heterozygous Smarcb1+/- engineered mice are 
capable of developing tumours that resemble human MRT. (Roberts et al., 2000, Guidi et 
al., 2001, Klochendler-Yeivin et al., 2000). However, these tumours were found almost 
exclusively in the soft tissue of the neck. Notably, almost no tumours were developed in 
the brain from this model. More importantly, this model was not practical to study the 
role of Smarcb1 in tumourigenesis due to low tumour penetrance and higher latency for 
tumour development. To circumvent the problems, a conditional inversion of Smarcb1 in 
mice was engineered using loxP-Cre system (SMARCB1inv; Mx-Cre model) (Roberts et 
al., 2002). Nevertheless, most mice died 1 to 3 weeks after induction due to disease 
aggressiveness and a fully penetrant tumour. The mice were discovered to develop mature 
CD8+ T cell lymphoma or rarely rhabdoid tumours with a median onset of only 11 weeks. 
More recently, Han et al. (2016) generated a Smarcb1 flox/flox; Rosa26-CreERT2 mouse 
model and injected tamoxifen into the mice at various time points to control inactivation 
of Smarcb1. Mutation at an early embryonic stage results in an aggressive neoplasm 
recapitulating human MRT with full penetrance and with early onset (median 2.5 mo). 
Importantly, the mouse model used in this study demonstrated phenotypes and expression 
profiles that resemble human MRT. Findings from this study provide an important insight 
for discovery of cell of origin as the effect of SMARCB1 inactivation at different 
developmental stages towards MRT tumourigenesis could be controlled using tamoxifen 
injection.  
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1.2 SWI/SNF chromatin remodelling complex 
1.2.1 Introduction of SWI/SNF complex 
The SWI/SNF (switch/sucrose nonfermenting) complex was first described in yeast but 
later was also found in all eukaryotes (Cristofaro et al., 2001, Kaeser et al., 2008, Moshkin 
et al., 2007). The mammalian SWI/SNF complex consists of at least nine subunits either 
of two highly homologous ATPase catalytic subunits; SMARCA4 (BRG1) or SMARCA2 
(BRM), invariant core subunits including SMARCB1, SMARCC1 (BAF155) and 
SMARCC2 (BAF170) (Prasad et al., 2015, Wilson and Roberts, 2011, Cristofaro et al., 
2001, Willis et al., 2012, Weissman and Knudsen, 2009) and 4-8 cellular lineage-
restricted subunits. ARID1A and ARID1B are found in the BAF-A and BAF-B (Brahma 
Associated Factor) complex respectively, while ARID2 is found in the PBAF (Polybromo 
BAF) complex (Figure 1.11). 
 
 
Figure 1.11 Two types of SWI/SNF chromatin remodelling complexes in humans. The 
SWI/SNF complex consists of evolutionary conserved core subunits (green) and variant 
subunit (purple). BAF represents BRG1 SWI/SNF complex while pBAF represents 
polybromo BRG1 associated SWI/SNF complex. ARID1 (A or B, in orange) is a unique 
component for the BAF complex while BAF200, BAF180 and BRD7 are specific for pBAF 
complex. The figures are reproduced from (Wilson and Roberts, 2011). 
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The complex is evolutionarily conserved and present at all developmental stages. The 
chromatin remodelling complex alters the structure of chromatin during gene regulation 
in an ATP-dependent manner (Tang et al., 2010, Flaus and Owen-Hughes, 2004). The 
SWI/SNF complex regulates DNA accessibility through two mechanisms; firstly, 
translocation of the nucleosome along the DNA during transcriptional regulation and 
secondly dimer replacement during DNA repair. At present, the mechanism of action of 
the SWI/SNF complex in chromatin remodelling process is not fully explained. However, 
two chromatin remodelling models have been proposed so far; one model involves 
twisting of the DNA helix along the histone octamer using torsion force like a screw in a 
slot. Repeated twisting and pulling movement allows sliding of the nucleosome (Saha et 
al., 2006)(Figure 1.12).  
 
 
Figure 1.12 The wave-ratchet-wave model using torsion force. A half-nucleosome shown 
in a top view (blue) and STH1 represent the tracking domain and tension force that twist 
the DNA helix along the nucleosome. The figures were taken from Saha et al. (2005).  
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The second model involves unwrapping DNA from the nucleosome dyad at a histone 
octamer to form a DNA loop and translocating DNA around the nucleosome in a wave-
like formation (Saha et al. (2005)) (Figure 1.13). The second model is by far the most 
practical rather than just the simple twisting-diffusion mechanism (first theory) because 
the presence of massive hairpins on DNA will obstruct the twisting and diffusion motion 
of DNA helix on the histone surface and therefore inhibit the sliding. A study performed 
by Aoyagi and Hayes (2002) supported the second model that DNA maintains its 
rotational position during the sliding process and that DNA translocation occurs at 
minimal contact on histone octamer and partially dissociates from the nucleosome.   
 
 
Figure 1.13 Bulge theory of nucleosome mobilisation by SWI/SNF complex involving 
DNA translocation steps along the nucleosome. The nucleosome is viewed 
perpendicular to the DNA superhelix, with the location of the DNA represented by black 
bars. The figures were taken from (Zofall et al., 2006). 
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1.2.1 Role of SWI/SNF complex in gene transcription and cellular development 
SWI/SNF chromatin remodelling complex executes lots of biological function such as 
cell differentiation (Gresh, Bourachot et al. 2005), proliferation (Hah, Kolkman et al. 
2010), neural development (Yoo and Crabtree 2009, Weinberg, Flames et al. 2013) and 
tumourigenesis. Studies have illustrated significant roles for SWI/SNF in cell 
differentiation. The conformation of subunits diverges between type of cells or tissues 
and it can change during differentiation and developmental stages (Sokpor et al., 2017). 
SMARCE1 and SMARCA4 are both required for activation of CD8 and silencing of CD4 
during T-lymphocyte development (Chi et al., 2002). Additionally, the BAF complex also 
plays a role in maintenance and pluripotency of mouse embryonic stem cells (Ho et al., 
2009, Kidder et al., 2009). Mutation of SMARCA4 in vivo is associated with early 
embryonic lethality (Bultman et al., 2000). Chromatin immunoprecipitation (ChIP) 
analysis revealed that SMARCA4 binds to promoter regions of self-renewal and 
pluripotency-related genes such as OCT4, SOX2, NANOG and SALL4 (Kidder et al., 
2009). Additionally, SMARCA4 also binds to the promoter region of genes that are 
involved in maintaining an undifferentiated state of cells such as DNM3L, DPPA2, FBX15 
and TDGF1.  
In vitro and in vivo studies demonstrate that SWI/SNF enzymes have been implicated in 
gene transcription by facilitating the binding of the transcriptional activators at TATA-
binding protein (TBP), formation of RNA polymerase II related pre-initiation complex 
and elongation (Kim et al., 2005, Kuras and Struhl, 1999, Reppas et al., 2006, Ryan et al., 
1998). The study in yeast illustrates that the transcriptional activation of several 
promoters was required at the SUC2 promoter and mutation in SWI/SNF subunits greatly 
impaired transcription induction process (Hirschhorn et al., 1992, Neigeborn and Carlson, 
1984). Biochemical and genetic analysis provide the evidence that the complex involved 
in transcription initiation that neutralises the repressive effects of contracting DNA into a 
chromatin structure (Ryan et al., 1998).  
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1.2.2 SWI/SNF mutations and silencing in cancer 
Chromatin remodelling and tumour suppressor function are reported to play a role in 
cancer development. A study by Kadoch et al. (2013) has demonstrated that subunits of 
SWI/SNF chromatin remodelling complex are most commonly mutated in human cancer, 
accounting for 19.6% of all human cancers that have been reported in 44 exome 
sequencing studies. The discovery of SMARCB1 mutation in MRT has elucidated the role 
of the complex as a tumour suppressor (Roberts et al., 2000, Roberts et al., 2002). 
Moreover, mutations in at least 8 genes encoding SWI/SNF complex subunits have been 
implicated in various malignancies (Figure 1.14). Genome-wide analysis of 18 different 
tumours samples showed a very high mutation frequency in SWI/SNF subunits (20%) 
and this figure was nearly comparable to that of TP53 mutation (Agaimy, 2014). In 
addition to mutation of SMARCB1, mutation in other subunits has been discovered 
including ARID1A, SMARCA4, PBRM1 and BRD7 subunits. ARID1A and SMARCA4 
have been associated with formation of various aggressive cancers such as MB, ovarian 
clear cell carcinomas (OCCCs), endometrioid carcinomas, lung adenocarcinoma and 
breast cancer thus suggesting the role of this subunit in different cell or tissue lineages. 
Heterozygous mutation in ARID1B results in Coffin-Siris syndrome which is associated 
with difficulty in language acquisition and mental retardation (Kadoch et al., 2013, 
Hodges et al., 2016, Shain and Pollack, 2013).  
Although complete loss of function of the genes is commonly associated with tumour 
formation, several human cancers were identified to harbour heterozygous mutations in 
SWI/SNF subunits. Reduced expression of the subunits such as ARID1A and SMARCB1 
is still capable of driving tumourigenesis and similar events have been found in steroid-
refractory acute lymphoblastic leukaemia (Wilson and Roberts, 2011, Kadoch et al., 
2013). While exome sequencing studies demonstrated that mutations in specific subunits 
of SWI/SNF complex have been implicated in tumourigenesis, many subunits which are 
ubiquitously expressed in cells do not contribute towards either tumour suppression or 
development (Kadoch et al., 2013). For instance, neuron-specific subunits such as 
BAF45c, BAF45b and BAF53b did not appear in dividing cells, therefore have no 
remarkable role in suppressing tumour progression. In addition, BAF53a is a universally 
expressed subunit that binds directly to SMARCA4. Mutation in SMARCA4 has been 
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implicated in many tumour formations but mutation in BAF53a is not. Other BAF 
subunits that are mutated in human cancers are summarised in Figure 1.14.  
 
 
Figure 1.14 Mutations in the specific genes encoding SWI/SNF chromatin remodelling 
complex present in specific malignancies. Mammalian SWI/SNF complexes are divided 
into two groups: SMARCA4/2 associated factor (BAF or SWI/SNF-A) and polybromo-
associated BAF (PBAF or SWI/SNF-B). Figures were taken from (Kadoch et al., 2013). 
 
1.2.3 Deregulation in SWI/SNF chromatin remodelers: a central key to MRT 
tumourigenesis 
The first event that linked SWI/SNF complex to tumourigenesis was mutation in 
SMARCB1, discovered in the late 1990s (Versteege et al., 1998). SMARCB1 is a highly 
conserved subunit and ubiquitously present in almost every combination of SWI/SNF 
chromatin remodelling complexes. This subunit was inactivated in most case of MRT by 
biallelic mutation (Roberts et al., 2002, Versteege et al., 1998, Biegel et al., 2002a).  
SMARCB1 may also have a role in DNA damage response, and when mutated lead to an 
increase in the expression of phosphorylated p53 and aberrant mitotic features hence 
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activation of a specific subset of p53 target genes (Klochendler-Yeivin et al., 2006). 
Inactivation of the p53 checkpoint did not rescue cell proliferation but instead decreased 
apoptosis in SMARCB1 deficient cells (Isakoff et al., 2005, Klochendler-Yeivin et al., 
2006). Heterozygous mutation in these two suppressor genes in mice (SMARCB1+/- p53-
/-) increased the frequency of tumour formation and reduced the tumour latency in 
comparison to SMARCB1 +/- mice.  
Inactivation of SMARCB1 in MRT has been shown to cause downregulation of many 
genes including cell cycle-related genes. The expression of p16Ink4a is downregulated 
after inactivation of SMARCB1 and it has been postulated the aberrant function of p16 
leads to MRT tumourigenesis (Venneti et al., 2011a, Versteege et al., 2002). The situation 
was reversed following SMARCB1-reexpression in MRT cell lines consequently leading 
to cell cycle arrest in the G1-phase. The p16 is a tumour suppressor protein that functions 
as a cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) inhibitor which in turn inhibits 
phosphorylation of retinoblastoma tumour suppressor protein, RB (Imbalzano and Jones, 
2005, Versteege et al., 2002). Re-expression of SMARCB1 also causes activation of 
senescence-associated proteins such as Rb, downregulation of E2F (acts as cyclin 
transcription activator) and Cyclin D1, accompanied by upregulation of both p16 and p21 
(Versteege et al., 2002, Versteege et al., 1998, Chai et al., 2005, Oruetxebarria et al., 2004, 
Kia et al., 2008). Inactivation of pRb did not induce cell senescence in SMARCB1-
deficient cells. However, re-expression of Rb or p21 in these cells restored the normal 
biological activity of cell senescence. Additionally, the double mutation in SMARCB1 
with Rb or p16 does not increase the cellular proliferation rate. However, the tumour 
formed following inactivation in SMARCB1 alone is much faster and occurs at various 
sites in mice than tumours that arise following mutation in Rb and p16. Overall, these 
results indicate the role of SMARCB1 in cell cycle regulation.  
A recent study by Tolstorukov et al. (2013) has identified interaction between SWI/SNF 
remodelers and chromatin at transcription start site (TSS) in controlling nucleosome 
occupancy. Deregulation of the subunit of SWI/SNF complex such as SMARCB1 and 
SMARCA4 reduced the occupancy of the complex to nucleosome at TSS and leads to 
downstream changes in gene expression. SMARCA4 ChIP-seq analysis demonstrated 
high enrichment of this protein at promoter gene following SMARCA4 deletion and this 
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finding is positively correlated with expression level of target genes. Affymetrix 
microarray analysis of similar samples showed a modest association between nucleosome 
occupancy and down- or up-regulation of genes in general. However, subsets of genes 
were remarkably upregulated in SMARCA4- and SMARCB1-deficient cells. Interestingly, 
a higher degree of overlap between genes that were downregulated following SMARCB1 
loss and genes that were downregulated following SMARCA4 loss suggests comparable 
but not identical effects on gene expression of these two genes. Together, conditional 
deletion of Smarcb1 in vivo demonstrated dependency on Smarca4 expression to initiate 
tumourigenesis and co-inactivation of Smarca4 and Smarcb1 failed to initiate tumour in 
vivo. These findings suggest two possibilities; 1) dependency on SMARCA4 to initiate 
tumourigenesis to compensate for the loss of function of SMARCB1 and 2) loss of 
SMARCB1 activates the hyperactivity of residual SMARCA4-containing SWI/SNF 
complex.  
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1.3 Mechanisms of tumourigenesis caused by SMARCB1 loss in 
Malignant Rhabdoid Tumour (MRT) 
MRT is considered a remarkably simple genetic disease as there is no second driver to 
trigger tumour development (Lee et al., 2012). Mutation in tumour suppressor SMARCB1 
is minimally sufficient to initiate tumour formation as shown by MRT mouse model 
studies (Han et al., 2016, Vitte et al., 2017). However, it is not enough to conclude that 
the mutation alone can cause such an aggressive and lethal disease. Although the detailed 
role of SMARCB1 in malignant transformation is not fully elucidated, it seems that 
SMARCB1 loss contributed towards tumourigenesis through p16/Rb/E2F and p53 
pathways (Isakoff et al., 2005, Klochendler-Yeivin et al., 2006, Chai et al., 2005). MRT 
are lethal cancers that strike predominantly in very young patients. Early embryonic 
lethality was observed when SMARCB1 was inactivated at E1-E6 with no apparent 
SMARCB1 deleted pup (Klochendler-Yeivin et al., 2000, Guidi et al., 2001). However, 
temporal control of SMARCB1 inactivation between E6-E10  in Smarcb1flox/flox; 
Rosa26-CreERT2 mice increased the tumour latency, high penetrance and developed 
tumours that resemble human MRT (Han et al., 2016). Importantly, low and null 
penetrance of tumours were observed when tamoxifen injections were given at E8-10 and 
E11-18 respectively. Notably, SMARCB1 loss at P2-P3 resulted in growth failure and 
rapid death. Altogether, these studies demonstrate mutation of SMARCB1 must occur in 
a specific window during development to provoke genome-wide chromatin remodelling 
which interrupts normal cell differentiation thus contributing to disease aggressiveness. 
Furthermore, mutation of SMARCB1 in these cells is taught to have the capacity to hijack 
and aberrantly maintain the inherent “stemness/self-renewal” programme active in these 
cells and that contributes critically to MRT tumourigenesis. Moreover, SMARCB1 
inactivation in specific cell population resulted in MRT tumourigenesis at various 
locations in the body. Recent omics and mouse model studies of primary MRT highlight 
the possibility of MRT derived from either mesenchymal, neural or neural crest cells 
(Chun et al., 2016, Han et al., 2016). Therefore, this field should be explored further as it 
may allow better prediction of disease prognosis and development of therapeutic target 
for MRT. 
  
36 
1.3.1 SMARCB1 tumour suppressor inactivation in the cell of origin potentially 
contributes to MRT aggressiveness 
1.3.1.1 MRT: genetically homogeneous but phenotypically highly heterogeneous 
MRT are teratoid in nature containing cells demonstrating morphology and differentiation 
markers from multiple lineages even within the same tumour (Ho et al., 2000). Re-
expression of SMARCB1 in MRT prompts the individual cells within a population to 
differentiate towards a variety of lineages such as epithelial, neural and mesenchymal. 
Different gene enrichment expression profiles of primary MRT were identified in the 
same tumour highlighting their phenotypic heterogeneity and molecular complexity 
(Chun et al., 2016, Johann et al., 2016). It is still not fully understood how SMARCB1 loss 
activates the MRT cells to become undifferentiated. However, re-expression of 
SMARCB1 in MRT cell lines triggered adipocyte  (Caramel et al., 2008) and hepatocyte 
(Gresh et al., 2005) differentiation. 
1.3.1.2 Evidence of potential cell of origins in MRT 
Numerous opinions of the cell of origin for MRT have been proposed due to the multi-
phenotypic nature of the tumours. However, their true cell of origin is still a subject of 
debate and it is hard to establish due to the various bodily locations of the primary 
tumours. 
Attempting to identify a cell of origin for ATRT, SMARCB1 and SMARCA4 were 
conditionally inactivated in cerebellar granule neurons of Math1-cre:: Smarcb1fl/f and 
Math1-cre:: Smarca4fl/f mice respectively (Moreno et al., 2014). Although the mice 
demonstrated severe neurologic defects and hypomorphic cerebellum, no tumour 
formation within the cerebellum was observed. This result eliminates cerebellar granule 
precursors as potential cells of origin for MRT. However, cumulative genome-wide 
profiling of MRT showed dysregulation of neural progenitor stem cell markers and 
expression of genes that regulate neural progenitor and neural crest cell differentiation 
thus possibly neural progenitor cells or neural crest origin for MRT (Okuno et al., 2010, 
Chun et al., 2016). Gene set enrichment analysis (GSEA) of primary MRT showed that 
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genes that were downregulated in embryonic stem cells (ESC) were significantly 
downregulated in MRT. In addition to this, the expression of gene sets known to be 
polycomb targets in ESC were also downregulated in MRT. These analyses suggested the 
possibility that tumours originate from early types of stem cells where chromatin around 
specific genes remains dominated by PRC2 histone marking (Gadd et al., 2010). 
Recent mouse model studies by Han et al. (2016) and Vitte et al. (2017) have suggested 
neural crest  (NC) cells as potential cell of origin for MRT.  Inactivation of Smarcb1 in 
protein zero (P0) in neural crest cells developed tumours that phenotypically resembled 
human MRT (Vitte et al., 2017). In addition, cross-referencing of transcriptome profiles 
of MRT mouse and human tumours with stem cell expression profiles including  
embryonic stem  cell (GSE44175), neural progenitor (GSE44175 and GSE44175), neuron 
(GSE46150), oligodendrocytes derived from neural stem cells (GSE9566), astrocytes 
derived from neural stem cells (GSE9566), ectomesodermal tissue from the palate 
(GSE9566) and neural crest (GSE11149) suggests neural progenitor and NC as potential 
cell of origin for MRT (Han et al., 2016). Gene expression analysis of tumours from (Han 
et al., 2016)'s mouse model reflected the diversity within human MRT. Nevertheless, Han 
et al. (2016) failed to observe the tumour formation in the CNS although the mouse was 
modelled for ATRT. 
 Genome analysis of primary ATRT by Torchia et al. (2016) and Lafay-Cousin et al. 
(2012) revealed significant enrichment of mesenchymal gene signatures in subgroups 
within ATRT. Torchia et al. (2016) presented two subgroups within ATRT in which 
subgroup 1 showed enrichment of neural-related gene expression. Whilst, subgroup 2 
demonstrated upregulation of genes that involve in mesenchymal cell lineage and 
signalling such as BMP and cell differentiation (i.e ERPINF1, CLDN10, FBN2). This 
study provides an indication of two potential cells of origin for ATRT. Likewise, gene 
expression analysis of primary ECRT also suggested two possible cell of origins which 
are neural crest cells and mesenchymal stem cells. An experimental study by Caramel et 
al. (2008) showed re-introduction of SMARCB1 into MRT cells (ECRT cell lines) 
provoked differentiation towards the adipocyte lineage thus illustrating the possibility that 
MRT originate from mesenchymal stem cells.  
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All these studies outline potential cells of origin for MRT. It remains to be determined 
through systematic analysis and experimental work if MRT arise at different locations in 
the body derive from different progenitor cells or share a common cell of origin. 
1.3.1.3 Deregulation of self-renewal pathways: A classic tale in cancer 
Embryonic stem cells are defined by their properties of self-renewal and multi-lineage 
differentiation with the capability to develop into every cell, tissue and organs in humans 
(Hadjimichael et al., 2015). Self-renewal is a process by which stem cells divide 
asymmetrically to generate two or more daughter cells, perpetuating the stem cell pool 
throughout life (Shenghui et al., 2009). The process involves the maintenance of the 
undifferentiated state of stem cells and multipotency or pluripotency, depending on the 
type of stem cells. Stem cell self-renewal machinery involves a balance of function 
between tumour suppressor genes (limiting self-renewal activity) and proto-oncogenes 
(promoting self-renewal activity). Self-renewal machinery is not restricted to only stem 
cell population as other types of restricted progenitors or differentiated cells including 
lymphocytes and restricted glial progenitors also possess the capacity to self-renew. The 
lymphocytes were shown to share at least some self-renewal mechanism similarly to stem 
cells such as dependence on the BMI1 proto-oncogene (Van der Lugt et al., 1994). 
However, stem cells possess extensive self-renewal potential and can be distinguished 
from the more lineage-restricted progenitor cells which have limited self-renewal 
capacity (Shenghui et al., 2009). It is important to note, although stem cells have extensive 
self-renewal potential, this does not essentially mean that the cells continue to self-renew 
under physiological conditions. For instance, neural crest cells possess substantial 
potential to self-renew in culture (Kruger et al., 2002), however, the cells can undergo 
few cycles of cell division before differentiating in vivo (Fraser and Bronner-Fraser, 1991, 
Morrison et al., 1999).  
1.3.1.4 Deregulation of classic self-renewal properties of normal stem cells 
implicated in the development of human cancers 
Self-renewal is described as a classic feature of stem cells. The self-renewal genes play a 
critical role in various cellular activities including embryogenesis, normal tissue repair 
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and homeostasis (Horne and Copland, 2017).  In cancer, normal signalling pathways that 
are associated with self-renewal such as Wnt, Notch and Hedgehog are often deregulated. 
The mutation of these signalling pathways may occur in stem cells or progenitor cells that 
possess self-renewal properties which result in tumourigenesis.  
 A pathway that is commonly associated with embryogenesis and adult tissue homeostasis 
is the Wnt pathway (Logan and Nusse, 2004). The pathway is a key regulator of stem cell 
maintenance and regulation (Reya and Clevers, 2005). Activating the Wnt signalling 
cascade in many tissue types leads to tumour development by activating self-renewal 
pathways while inhibiting cell differentiation. For instance, the expression of Wnt3a 
protein in ESC inhibited cell differentiation in epiblast stem cells and increased self-
renewal capacity of cells as illustrated by the increase in the number of colonies (Ten 
Berge et al., 2011). In the context of neural stem cell, Wnt signalling through b-catenin 
regulates the cycling and expansion of neural progenitor cells. However, aberration 
function of this pathway in the spinal cord and brain of mice led to upregulation of neural 
precursor population and increased the tumour mass of the spinal cord and brain (Zechner 
et al., 2003, Chenn and Walsh, 2002). Evidently, the mutation in b-catenin has been 
implicated in medulloblastoma (Zurawel et al., 1998). Mutation in Wnt signalling has 
been associated with the development of many human cancers including colon cancers, 
skin cancers and also leukaemia. 
Other pathways which also affect normal self-renewal machinery and have also been 
implicated in cancer when mutated include the Hedgehog (Hh) pathway. This pathway is 
involved in many fundamental processes associated with embryonic development such 
as stem cell maintenance, cell differentiation, tissue polarity and cell proliferation 
(Taipale and Beachy, 2001). Aberrations in the Hh pathway can cause tumourigenesis as 
seen in medulloblastoma (MB), basal cell carcinoma, lung, breast and prostate cancers. 
The role of the Hh pathway in mediating stem cell maintenance and cell differentiation 
was studied in mammary stem/progenitor cells in vitro. The experimental study revealed 
that the components of the Hh pathway such as PTCH and SMO were highly expressed 
in mammary stem/progenitor cells compared to differentiated cells (Liu et al., 2006b). 
For instance, mRNA expression of PTCH was ~4 fold higher in mammary 
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stem/progenitor cells relative to the differentiated cells. In another experiment, the 
mammary epithelial cells were grown as mammospheres in order to measure self-
renewal. Overexpression of GLI1 and GLI2 (downstream effector of Hh pathways) in 
mammary epithelial cells increased the number of mammospheres by 49% and 66% 
respectively compared to uninfected cells. These results indicate the Hh pathways 
mediates the self-renewal machinery through the downstream effectors such as GLI, 
PTCH, SMO. In other types of human cancer such as breast cancer and medulloblastoma, 
the downstream effector of Hh signalling pathway which is BMI1 was found to be 
upregulated. BMI1 is a subunit of the Polycomb repressive complex 1 and is also known 
to be the key regulator in the self-renewal pathway (Wang et al., 2012, Srinivasan et al., 
2017). Overexpression of BMI1 has been implicated in medulloblastoma tumourigenesis 
through the Hh pathway (Wang et al., 2012). Chromatin immunoprecipitation (ChiP) 
study of primary medulloblastoma and cell line (DAOY) showed significant enrichment 
of GLI1 and GLI2 at the BMI1 promoter, suggesting the expression of BMI1 is regulated 
by the Hh pathway. In line with this, small interference RNA (siRNA) targeting GLI1 
showed positive correlation between BMI1 expression and Hh pathway inhibition by 
which downregulation of GLI1 reduced the transcript of BMI1. Altogether, findings from 
this study suggest the role of Hh in mediating self-renewal through the BMI1 pathway. 
1.3.1.5 Mechanisms of self-renewal in Malignant Rhabdoid Tumour (MRT) 
SMARCB1, a hallmark in MRT is a member of the SWI/SNF chromatin remodelling 
complex (Roberts et al., 2002, Versteege et al., 1998, Biegel et al., 2002a). Mammalian 
BAF is reported to play a role in regulating pluripotency during embryogenesis (Ho et al., 
2009). The study in mouse embryonic stem cells revealed the involvement of the BAF 
complex in self-renewal and pluripotency pathways. Knockdown of Brahma related 
genes (Brg) using shRNA in mice reduced proliferation capacity indicated by a small size 
of colonies assessed by colony formation assay. Also, Brg-deficient cells showed a 
decrease in expression of self-renewal genes such as Oct4, Sox2 and Nanog (Ho et al., 
2009).  Findings from these studies describe the role of SWI/SNF complex in self-renewal 
and pluripotency.  
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In the context of MRT, SMARCB1 loss reduced the capacity of SWI/SNF complex to 
impede the repressive function of EZH2, which is an enzymatic subunit of the histone 
H3K27 methyltransferase Polycomb complex, PRC2 (Wilson et al., 2010a). 
Consequently, SMARCB1-deficient MRT caused upregulation of PRC2 mediated 
repression and activation of stem cell-associated programs to facilitate tumour 
development. In addition, primary MRT also showed expression of embryonic gene 
signatures (Richer et al., 2017). Transcriptomic analysis of primary MRT showed 
enrichment of stem cell-related genes such as SALL4 and LIN28B. In addition to this, 
immunohistochemistry of primary ATRT also provides evidence of MRT expressing stem 
cell markers involved in self-renewal such as SOX2, NANOG, KLF4, MUSHASHI and 
OCT4 (Deisch et al., 2011, Venneti et al., 2011b). Given that SMARCB1 is a member of 
the SWI/SNF complex and MRT express stem cells markers, it is noteworthy to 
investigate if mutation in SMARCB1 causes deregulation in self-renewal and pluripotency 
mechanisms to initiate tumourigenesis and disease aggressiveness.  
RNA-seq analysis of primary MRT and cell lines available in Paediatric Brain Tumour 
Group (PBTG) demonstrated overexpression of many self-renewal genes such as GLI2, 
JAK2, FGF1 and BMI1. As previously discussed in section 1.3.1.4, downstream effectors 
of Hh such as BMI1 have been implicated in the embryonal tumour, medulloblastoma. 
From cross-referencing analysis of stemness/self-renewal gene list with genomic data that 
are available in the group including RNA seq of primary and SMARCB1 re-expression 
model cell and CRISPR/Cas9 GeCKO screening with and without SMARCB1 in MRT 
cells (detailed in Chapter 2 and 6), BMI1 was identified as SMARCB1 dependent gene. 
Hence, the role of BMI1 was studied in MRT tumourigenesis.  
1.3.1.6 BMI1 
Oncogenic transformations are usually associated with the acquisition of developmental 
programs that resulted in extensive self-renewal and pluripotency, the classic features of 
stem cells (Suvà et al., 2013). Studies have reported the epigenetic programmes including 
DNA methylation, histone modification and nucleosome remodelling in regulating many 
cellular activities that are also fundamental to cancer development such as DNA repair, 
transcription and replication (Dawson and Kouzarides, 2012). The earliest evidence that 
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links epigenetic abnormalities to cancer were from gene expression and DNA methylation 
studies (Feinberg and Vogelstein, 1983). The researchers found a high frequency of 
methylation at CpG in the normal tissues as opposed to unmethylated CpG regions in 
cancer tissue. Subsequent experiments using high-performance liquid chromatography 
revealed global reduction of 5-methylcytosine content in the tumour sample (Gama-Sosa 
et al., 1983). Following this discovery, many types of epigenetic abnormalities were found 
in human cancers (Dawson and Kouzarides, 2012). Recently, SWI/SNF chromatin-related 
components such as polycomb repressive complex (PRC) have been linked to 
tumourigenesis of SMARCB1- and SMARCA4-deficient tumours (Januario et al., 2017, 
Knutson et al., 2013, Alimova et al., 2012).  
BMI1 is the most extensively studied Polycomb Repressive Complex 1 (PRC1) subunit 
because of its significant role as a transcriptional regulator for self-renewal mechanisms 
in stem cells. The BMI1 (B cell-specific Moloney murine leukaemia virus insertion site -
1) gene is located on the plus strand of chromosome 10 (10p13) (Alkema et al., 1993, 
Jiang et al., 2009). The gene extends over a 4.9 kb range and consists of 10 exons and 9 
introns (Jiang et al., 2009). The functional promoter region of BMI1 has not been fully 
elucidated and most of the studies use a sequence of 20-30 base pairs (bp) upstream of 
the translational start site as the promoter of this gene (Alkema et al., 1993, Jiang et al., 
2009, Abdouh et al., 2009). The BMI1 protein is 37 kDa consisting of 326 amino acids 
(Alkema et al., 1993).  
Inactivation of this gene has been implicated in many types of cancers. It has been shown 
that BMI1 expression is required for maintenance of self-renewal machinery and 
proliferative potential of both normal and leukemic mouse hematopoietic stem cells (Park 
et al., 2003, Iwama et al., 2004) as well as mouse neural stem cells (Molofsky et al., 2005). 
Bmi1 null mice are embryonic lethal and display striking abnormalities including 
neurological, morphological and haematopoiesis (Park et al., 2004).  
Most mouse hematopoietic stem cells (HSC) models express high levels of Bmi1 and 
inactivation of this gene in vivo results in a 10-fold reduction of the phenotypic 
hematopoietic stem cells as assessed by flow cytometry (Iwama et al., 2004). To 
determine the role of BMI1 in haematopoiesis, the expression of HSC was examined in 
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Bmi1-/- mice. This study revealed that Bmi1-/- mice have a normal number of HSC. 
However, the number of HSC was significantly reduced in postnatal Bmi1-/- mice (Van 
der Lugt et al., 1994). Transplanted bone marrow and fetal liver cells from this Bmi1 null 
mice gave only transient haematopoiesis. These findings suggest that Bmi1 loss impairs 
the maintenance of self-renewing hematopoietic stem cells.  
The requirement of BMI1 for regulating self-renewal also has been studied in mouse 
neural stem cells (Molofsky et al., 2003). Knockout of Bmi1 in central nervous system 
(CNS) stem cells from the telencephalon at embryonic day 14.5 (E14.5) resulted in less 
primary tumourspheres relative to wild-type accounting for 14-fold smaller volume (P < 
0.01). Strikingly, less secondary tumourspheres were observed (33-fold fewer (P < 0.01)) 
signifying deficiencies in self-renewal. Notably, there was no significant difference in the 
number of primary tumourspheres of BMI1-deficient neural crest stem cells (NCSCs) 
derived from the gut at E14.5 (enteric nervous system) compared to wild type. However, 
secondary tumoursphere formation was abrogated in BMI1-deficient neural crest cells 
(60-fold fewer secondary multipotent neurospheres (P < 0.01)). Altogether, this 
experimental study illustrates the defect of self-renewal machinery following BMI1 loss 
in both neural crest cells and CNS.  
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Figure 1.15 PRC complexes involved in stem cell maintenance by either activating or 
repressing specific genes that promote self-renewal or specific cell lineage 
differentiation. Deregulation of the PRC has been implicated in the formation of cancer 
stem cells (CSCs). Figure was taken from (Richly et al., 2011). 
 
BMI1 also has a central role as an epigenetic chromatin modifier capable of regulating a 
large number of target genes (Richly et al., 2011).  Gene expression profiling studies 
illustrate that BMI1 modulates self-renewal mechanisms in HSC though regulation of the 
genes involved in stem cell fate decisions, stem cell-associated genes and survival genes 
(Park et al., 2004). BMI1 encodes two tumour suppressor genes known as p16Ink4A  
(referred to as p16 in this thesis) and p14Arf  (referred to as p14 in the thesis) that regulates 
cell cycle through TP53 and RB pathways (Jacobs et al., 1999a, Sharpless and DePinho, 
1999). In cancer development, BMI1 negatively regulates p16 suppressing transcription 
at the promoter region which then initiates the formation of Cyclin dependent kinase 4 
and the Cyclin D complex and promotes phosphorylation of Rb and cell progression. 
Simultaneously, the inhibition of Mdm2 by p14 is blocked by BMI1 thus preventing the 
activation of the p53 pathway and subsequently cell apoptosis and senescence (Honda 
and Yasuda, 1999, Weber et al., 1999). In summary, transcriptional regulation by BMI1 
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through suppression of Ink4a/Arf locus promotes extensive self-renewal and cell 
proliferation while obstructing senescence and the apoptosis pathways. BMI1 regulates 
transcriptional silencing of target genes by acting as a cofactor for Ring1/2 through 
monoubiquitination of lysine 119 of histone H2A, a mark associated with repressive 
chromatin structure  (Richly et al., 2011).  
Although numerous studies have illustrated a significant role of BMI1 in various type of 
human cancers, very little is known about explicit functions of BMI1 in cancer 
development and progression, and the precise involvement of PRC1 in cancer through 
epigenetic antagonism with SWI/SNF chromatin remodelling complex. 
1.3.2 Epigenetic antagonism between SWI/SNF complex and Polycomb Repressive 
Complex (PRC): Additional mechanism drives the formation of Malignant 
Rhabdoid Tumour 
Approximately 20% of SWI/SNF chromatin components have been found mutated in 
several human cancers (Alver et al., 2017). Wilson et al. (2010a) proposed that 
development of cancer can occur through an antagonistic mechanism between the 
SWI/SNF complex and Polycomb Repressive Complex (PRC). The idea of an 
antagonistic relationship evolved from genetic experiments in D. melanogaster, in which 
the mutation in subunits of the SWI/SNF chromatin remodelling complex was identified 
to suppress the defects that were caused by aberrant function of PRC. The SWI/SNF 
complex was needed for activation of HOX expression while PRC was required for gene 
silencing through repression of HOX expression.  
The mammalian polycomb repressive complex (PRC) consists of two complexes namely 
PRC1 and PRC2 that together represent the polycomb group complex (PcG). The PRC1 
complex consists of two common components which are RING1A/B with BMI1, MEL18 
(PCGF2) or NSPC1 (PCGF1) (Margueron and Reinberg, 2011). PRC2 is an 
evolutionarily conserved complex comprising four components; EZH1/2, SUZ12, EED 
and RbAp46/48 (also known as RBBP7/4). 
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The PCG proteins have been shown to be implicated in epigenetic gene silencing during 
developmental and potentially a role in tumourigenesis. In many cancers such as prostate 
cancer, PCG protein repressed the expression of tumour suppressors (Dietrich et al., 2007, 
Gil and Peters, 2006) through methylation on Lys27 of histone H3 thus resulting in DNA 
hypermethylation (Schlesinger et al., 2007). Additionally, overexpression of PRC along 
with their histone marks i.e methylation on chromatin can lead to tumourigenesis. For 
instance, studies have demonstrated bi-allelic inactivation of SMARCB1, a core subunit 
of the SWI/SNF chromatin remodelling complex and tumour suppressors initiate MRT 
tumourigenesis dependency on a component of the PRC2 complex which is EZH2 
(Knutson et al., 2013, Alimova et al., 2012). Gene expression analysis of primary CNS 
MRT demonstrated high expression of EZH2 in these tumours (Wilson et al., 2010a). 
Mechanistically, mutation of SMARCB1 mediates the recruitment of EZH2 of PRC2 to 
Polycomb target genes that become broadly H3K27-trimethylated and repressed in 
Smarcb1-deficient mouse embryonic fibroblasts. The antagonistic effect between the 
SWI/SNF complex and PRC was evident as inactivation of Ezh2 stopped tumour growth 
following a conditional Smarcb1 loss (Figure 1.16) however in inactivation of Ezhw had 
no effect on osteosarcomas driven by p53/Rb mutation in vivo. The effectiveness of 
targeting EZH2 as a mean to counteract MRT tumourigenesis was studied using orally 
bioavailable small molecule inhibibitors of EZH2 enzymatic ((N-((4,6-dimethyl-2-oxo-
1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-
4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide) (Knutson et al., 2013) and 
chemical inhibitors of EZH2 (3-deazaneplanocin A (DZNep) (Alimova et al., 2012) in 
MRT cell lines. Both of the studies demonstrated EZH2 inhibition by the inhibitors 
suppresses the MRT cells growth, leads to cycle arrest and increases the cell apoptosis, 
thus establishing attractive therapeutic option for MRT.   
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Figure 1.16 Ezh2 is essential for rhabdoid tumour development following SMARCB1 
inactivation in vivo (Figure was taken from (Wilson et al., 2010a). 
 
Notably, restoration of SMARCB1 functionality in MRT cells leads to activation of tumour 
suppressor p16. Wilson et al. (2010a), also reported epigenetic silencing of p16 by EZH2 
following SMARCB1 loss in MRT. ChIP analysis showed strong binding of PRC 
complexes; BMI1, SUZ12 and EZH2 at INK4b-ARF-INK4a locus in the absence of 
SMARCB1. However, the binding of the PRC complexes was greatly reduced following 
SMARCB1 re-expression in the cells. This study established the activation of p16 occurs 
through displacement of PRC at promoter region in the presence of SMARCB1.  
Unlike other human cancers which present more frequent genetic alterations, MRT are a 
good candidate to study the mechanism of epigenetic alterations in driving oncogenesis 
as its genome is remarkably stable with only one recurrent mutation reported so far 
(Torchia et al., 2016, Haberler et al., 2006, Lee et al., 2012). A better understanding of an 
association between SWI/SNF chromatin remodelling and epigenetic in cancer will 
provide an insight for new therapeutic approaches targeting chromatin remodelling in 
MRT. 
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1.4 Research background  
MRT are one of the most lethal paediatric cancers known (Brennan et al., 2013b). It is 
unique not only in terms of its extremely poor prognosis and its occurrence almost entirely 
in infants but also in its biology. Mutation of a single gene (SMARCB1 which encodes for 
a core subunit of the SWI/SNF complex) is minimally sufficient to cause tumourigenesis 
(Lee et al., 2012) and re-expression of SMARCB1 in MRT cells is capable of reversing 
tumourigenesis, provoking growth arrest and differentiation (Caramel et al., 2008, Betz 
et al., 2002). Although genetically extremely homogeneous, MRT are phenotypically 
highly heterogeneous. They may occur at almost any part of the body (although with a 
tendency to occur in the brain and kidney). MRT are teratoid in nature containing cells 
demonstrating morphology and differentiation markers from multiple lineages even 
within the same tumour (Ho et al., 2000). Re-expression of SMARCB1 in MRT cells 
causes individual cells within a population to become differentiated towards a variety of 
lineages (epithelial, neural, mesenchymal)(Albanese et al., 2006b, Caramel et al., 2008). 
Preliminary analysis done by Dr Dan Williamson indicates their expression profiles in 
this differentiated state most closely resembles that of cells derived from adult multipotent 
stem cells. Expression profiling of primary MRT tumours shows strong overexpression 
of a large number of “stemness/self-renewal” genes (e.g BCL6, BM11, FGF2, GLI2, 
JAK1). The Paediatric Brain Tumour Group at NICR and others have shown that a 
number of these genes are demonstrably deregulated by loss of SMARCB1 and/or the 
larger SWI/SNF complex. For instance, RNA-seq profiling showed that BCL6 is 
expressed at 6 times greater than related SMARCB1 positive paediatric tumour types and 
that upon re-expression of SMARCB1 in MRT tumour cells BCL6 is transcriptionally 
repressed by 9-fold. PcG proteins and SWI/SNF complexes serve antagonistic 
developmental roles (Wilson et al., 2010b). Upon re-expression of SMARCB1, the 
chromatin environment of the p16 loci is wholesale remodelled, Polycomb silencing 
complexes removed and histone–marks altered (Kia et al., 2008). Loss of SMARCB1 in a 
mouse model leads to elevated expression of the Polycomb gene EZH2 and H3K27-ME3 
remodelling of a large number of repressed genes (Wilson et al., 2010b). 
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Taken as a whole these facts lead us to hypothesize that not only is mutation of SMARCB1 
itself critical but that the type of cell in which this mutation occurs is also critically 
important to conferring the aggressive MRT state. Other tumour types such as Choroid 
Plexus Carcinomas, Schwannomatosis, Epitheliod Sarcoma, etc (Hornick et al., 2009, 
Hulsebos et al., 2007, Zakrzewska et al., 2005) may possess SMARCB1 mutations without 
necessarily demonstrating the aggressive clinical behavior and early onset of disease that 
makes MRT so difficult to treat. Therefore, I hypothesised in this study that the cell of 
origin is highly particular and that SMARCB1 mutation in an early multipotent stem cell 
provokes genome-wide chromatin remodelling which interrupts normal differentiation. It 
was further hypothesised that SMARCB1 mutation in MRT cells is capable of hijacking 
and aberrantly maintaining the inherent “stemness/self-renewal” programme active in 
these cells and that this contributes critically to MRT tumourigenesis. 
Current therapies for children with MRT are ineffective (Brennan et al., 2013b) and there 
is a desperate need for novel biological therapies. This study aimed to discover 
therapeutically targetable “stemness/self-renewal” pathways/genes downstream of 
SMARCB1 mutation as the most efficient means to counteract MRT tumourigenesis and 
induce differentiation/growth arrest in MRT cells. 
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1.5 Overall objectives and specific aims of the study 
This project aims to explore other possible mechanisms that may contribute towards MRT 
aggressiveness and to use this understanding to identify potential therapeutic targets and 
cell of origin for this lethal childhood cancer, with the following specific aims: 
Aim 1: To identify a likely cell of origin for MRT through bioinformatics analysis and 
CRISPR/Cas9 SMARCB1 knockout in an appropriate cell of origin. Bioinformatics 
analysis will provide important data to prioritise the candidate cell of origin for 
CRISPR/Cas9 experiment. Bioinformatics analysis is presented in chapter 3 while the 
functional CRISPR/Cas9 experiment is described in chapter 4.  
Aim 2: To characterize how SMARCB1 mutations alter “stemness/self-renewal” 
programmes in order to affect tumourigenesis. The candidate stemness/self-renewal 
genes that are SMARCB1-dependent and highly expressed in MRT are identified through 
cross-referencing of curated stemness/self-renewal genes with RNA-seq and 
CRISPR/Cas9 GeCKO screening data of MRT. The expression of target genes will be 
studied in MRT cell lines. This part of the study is presented in chapter 2 and 6.  This 
analysis will generate lead “stemness/self-renewal” genes/pathways active in MRT 
tumourigenesis that will require further validation (aim 3). 
Aim 3: To test and validate at least one targetable “stemness/self-renewal” gene/pathway 
as a potential novel anti-MRT therapy using shRNA and the available small molecular 
inhibitors. This study is described in chapter 6.  
Overview of the project to achieve the specified aims is presented in Figure 1.17
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Chapter 2 Materials and Methods 
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2.1 Introduction 
This chapter presents all the material and methods used in this thesis. This chapter is 
divided into two major sections; “dry lab” and “wet lab”. The “dry lab” section contains 
the bioinformatics analysis performed to identify a putative cell of origin for MRT 
(Chapter 3) and stemness/self-renewal candidates in MRT (Chapter 6). Whilst, the “wet 
lab” section includes all the techniques and materials used to achieve the aims discussed 
in chapter 4, 5 and 6. 
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2.2 “Dry lab” methods and materials 
2.2.1 Bioinformatics analysis of potential cell of origin for MRT 
For identification of cell of origin for MRT, various stem cells profiles were searched and 
catalogued in this study for identification of the cell of origin for MRT. Details are 
discussed below: 
2.2.1.1 Quantification and Statistical Analysis 
The bioinformatics analysis was accomplished using R (version 3.3.1) and Bioconductor 
(version 3.4). 
2.2.1.2 Expression profile analysis of primary tumours 
The published Affymetrix HGU133Plus2 expression array datasets for various stem cell 
types were obtained from NCBI GEO ((https://www.ncbi.nlm.nih.gov/geo/). These 
datasets were used in cross-referencing analysis with MRT primary and cells RNA-seq 
data for identification of cellular origin for MRT. Details of GEO accession number for 
each dataset were tabulated in Appendix  2.1. To generate various stem cell profiles for 
the analysis, the expression profile was searched for “RNA signature” from various stem 
cell types. The stem cell types are listed in Appendix  2.1. To identify a stem cell 
population with potential to become a candidate cell of origin for MRT, the expression 
profiles were filtered with the following requirement: HGU133plus2 platform, non-
cancerous cell line, human expression profiles and no specific treatment that could change 
the expression of many genes. For instance, GSE32727 contains a dataset for human 
mammary epithelial cells and breast cancer cells. Therefore, only the expression profiles 
for epithelial cells were selected for cell of origin analysis. Likewise, there were 16 
embryonic stem cell expression profiles in GSE24844, however, the platform that was 
used to analyse these profiles was Affymetrix human promoter 1.0 Array. Hence, this data 
was not included in the analysis.  
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Affymetrix HGU133Plus2 expression array datasets for primary MRT used in this study 
for the purpose of comparison and/or validation of potential cells of origin for MRT were 
also obtained from GEO NCBI database. These included 106 ATRT and 20 ECRT 
Affymetrix HGU133plus2 expression profiles (GEO: GSE35493, GSE64019, 
GSE70678, GSE73038), 10 ECRT Affymetrix HGU133a expression profiles (GEO: 
GSE11482). An ECRT RNA-seq dataset comprising gene counts of 65 ECRT was 
obtained from the open-access component of dbGaP phs000470. 
Affymetrix dataset arrays (. cel file) were processed and normalized using the rma 
package (R/Bioconductor). Differential expression analysis was performed using limma 
(R/Bioconductor) for array data. 
For differential expression tests genes were pre-filtered to remove those for which fold 
change < 3-fold and/or the range < 300 between maximum and minimum values (with 
the top/bottom 5% most extreme values removed). Genes were also removed if <40% of 
samples showed normalized counts of less than 20. Consensus bootstrapped Non-
negative Matrix Factorization (NMF) was performed as described by Schwalbe et al. 
(2013) to determine the optimal number of clusters and to assign individuals to clusters 
with a given probability/confidence. Optimal metagene solutions were selected based on 
cluster stability measures of individual NMF runs as well as the average silhouette score 
obtained from bootstrapped NMF. t-Distributed Stochastic Neighbour Embedding (t-
SNE) dimensionality reduction package Rtsne (R/Cran) was used to visualize and 
confirm NMF consensus clustering assignments. Probes significantly associated with 
each metagene were identified by carrying out a bootstrapped Pearson correlation with a 
significance cut-off of p < 0.001. 
Top discriminatory genes were selected based on the p-value < 0.05 and selecting genes 
specific for neural using a limma (R/Bioconductor) discriminatory statistical 
coefficient >2 between embryonic and neural, or mesenchymal and neural stem cells. 
Mesenchymal specific genes were selected as coefficient greater than 3 compared to 
neural and embryonal, while embryonal related genes were chosen as those with >3 
compared to neural and mesenchymal. Neural crest genes were selected as those with a 
coefficient greater than 2 compared to mesenchymal cells. In some analyses (to produce 
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a heatmap), neural crest cell-specific genes were manually curated as previously 
described (Ishii et al., 2012, Chun et al., 2016). The MRT-specific genes were selected by 
significant ANOVA F-statistic (p<0.01) and selecting only genes whose positive and 
negative log-fold change exceeded 1.5 for each comparison between MRT and each an 
embryonal tumour (ET) type.  
NMF projection was performed using column-rank normalization, pseudo-inverse 
method and post-projection normalization as previously described by Tamayo et al. 
(2007). Pre-filtering of genes was applied to each dataset; either unlogged vst for RNA-
seq or unlogged probe intensity for expression array. Genes were pre-filtered by applying 
a lower threshold of 20 and a ceiling of 10000, a fold change and delta from maximum-
minimum of 3 and 300 respectively. Genes/probes were mapped by Ensembl Gene id. 
Where multiple probes exist for one gene the probe with greatest mean intensity across 
all samples was used. 
2.2.1.3 Gene Set Enrichment Analysis (GSEA) 
Gene Set Enrichment Analysis (GSEA) is described as a complete mathematical method 
to classify correlation between genes and clusters them into uniform classes 
(Subramanian et al., 2005).  GSEA is a method that distinguishes if a pre-ranked gene set 
shows any statistically significant difference between two experimental conditions, for 
example, ECRT vs ATRT. The analysis requires a dataset pre-processing step, which 
ranks genes according to a phenotype or profile defining the distribution of the set of 
genes across a priori predefined gene-sets. The pre-ranked data sets are further processed 
and for each gene set an enrichment score (ES) is given; ES corresponds to the degree of 
correlation between the ranked gene list and predefined gene-sets. An empirical 
phenotype-based permutation test is utilised to measure significance levels of the 
observed ES, estimating p-values relative to ES null distribution. Finally, ES are 
normalised to the size of the original set, resulting normalised enrichment scores (NES) 
and false discovery rate (FDR) for each NES. FDR represents to the projected possibility 
that identified genes as differentially expressed are false positive. Gene Set Enrichment 
  
57 
Analysis (GSEA) using MSigDB libraries v6.0 C1-7 & Hallmark. was used to examine 
for differentially regulated pathways.  
2.2.1.4 Principle component analysis  
The principle component analysis (PCA) is a statistical technique that transforms a 
number of possibly correlated variables into a limited number of uncorrelated variables 
known as principle components. This technique can decrease dimensionality of complex 
data sets and computational costs and error of parameter estimation. PCA is an orthogonal 
transformation method that is aimed to maximise the component vector variance of the 
data set. The analysis establishes the direction that corresponds to maximal variance 
between the data points and projects the obtained data on the hyperplane orthogonal to 
that direction. Using this mathematical projection, it is possible to achieve a simpler data 
set, in which the dimensions are reduced. PCA is often used as a tool in explanatory data 
analysis or making the predictive models. In addition, PCA is utilised for visualisation of 
genetic distance or relatedness between populations.  
2.2.1.5 Non-negative matrix factorisation 
Non-negative matrix factorization (NMF) is a mathematical analysis based on an 
algorithm that decreases the dimension of NGS or microarray data (Brunet et al., 2004, 
Devarajan, 2008). It has previously been shown to be a useful decomposition of 
multivariate data. In particular, it allows the characterisation of aggregate patterns of gene 
expression (metagene) from thousands of genes. In contrast to other clustering methods, 
NMF groups the genes and samples by factorisation into matrices with non-negative 
entries; this results in an analysis with higher biological significance than PCA and t-
SNE. NMF is more efficient technique for discovery of distinct molecular configurations 
and offers a robust technique for class identification. Furthermore, NMF is more strategic 
than t-SNE and PCA in terms of hierarchical clustering or self-organising maps.  
NMF is more complex algorithmically, however it allows decomposition of data and also 
cross-referencing of different dataset (Figure 2.1). Data sets consist of expression levels 
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of N genes in M samples. The data are compressed into an expression matrix V composed 
of values N × value M; rows represent expression levels of the N genes in the M samples.   
The metagenes (positive linear combination of the N genes) are obtained by factorisation 
of the matrix A into two matrices characterised by positive entries. Particularly, the two-
matrix derived are W (composed by N genes x k metagene) and H (composed by k 
metagene x M samples), which are approximately equivalent to the matrix A. Each k 
column of the first matrix illustrates a metagene, while each M column of H matrix 
corresponds to metagene expression pattern of the corresponding sample. 
 
 
 
Figure 2.1 An example of NMF analysis of expression datasets consists of N genes, M 
samples and imposed k=2. Matrix V represents a mock microarray expression 
data: low expressed genes are coloured in green, with the highly expressed in 
red while Matrix W is composed of k metagenes and the number of genes and 
each column corresponds to the expression level of each sample for a given 
metagene. The matrix H = N sample with k metagenes; in this case, each 
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column represents a metagene profile for each sample. Heat colour maps are 
used to represent the level of metagene expression (dark blue= minimum; dark 
red= maximum). 
 
2.2.1.6 t-Distributed Stochastic Neighbour Embedding (t-SNE) 
t-Distributed Stochastic Neighbour Embedding (t-SNE) is another technique for 
dimensionality reduction and is particularly suitable for visualisation of high-dimensional 
datasets, while preserving some features of the original data. This method is efficient for 
capturing much of the local structure as well as global structure of the high-dimensional 
data. t-SNE reduces the deviation between two distributions: a distribution that calculates 
the pairwise similarities of the input objects and a distribution that calculates the pairwise 
similarities of the corresponding low-dimensional points in the embedding (Maaten and 
Hinton, 2008). The dimensionality reduction techniques convert the high-dimensional 
data set X = (x1, x2,...,xn) into two or three-dimensional data Y = (y1,y2,...,yn) which can 
be presented in a scatterplot. t-SNE plots define a soft border between the local and global 
structure of the data and for pairs of data that are close together. Furthermore, t-SNE 
defines the local neighbourhood size for each data distinctly based on the local density of 
the data (by forcing each conditional probability distribution Pi to have the same 
perplexity).  
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Table 2.1 Expression profiles of primary MRT. 
GEO accession 
number/Deposited 
provisional number
Tumour type Source Number of dataset
GSE64019 ATRT & ECRT 
Gene Expression Omnibus 
(GEO) NCBI
50
GSE65132 ATRT
Gene Expression Omnibus 
(GEO) NCBI
9
GSE35493 ATRT
Gene Expression Omnibus 
(GEO) NCBI
2
GSE70678 ATRT
Gene Expression Omnibus 
(GEO) NCBI
49
phs000470 ECRT
Database of Genotypes and 
Phenotypes (dbGaP)
65
GSE11482 ATRT
Gene Expression Omnibus 
(GEO) NCBI
10
GSE73038 ATRT
Gene Expression Omnibus 
(GEO) NCBI
5
GSE70421 ECRT
Gene Expression Omnibus 
(GEO) NCBI
3
GSE28026 ATRT
Gene Expression Omnibus 
(GEO) NCBI
18
Deposited data primary tumours expression profiles
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Table 2.2 Software and algorithms used for analysis of cell of origin for MRT. 
 
2.2.2 Identification of self-renewal/stemness pathways/genes in MRT 
MRT is a highly aggressive disease that occurs predominantly in very young children. 
There are a few tumour types such as choroid plexus carcinomas, schwannomatosis, 
epitheliod sarcoma, etc  (Hornick et al., 2009, Hulsebos et al., 2007, Zakrzewska et al., 
2005) may possess SMARCB1 mutations without necessarily demonstrating the 
aggressive clinical behaviour. Therefore, it has been hypothesized in this study that 
SMARCB1 mutation in the cell of origin is capable of hijacking and aberrantly 
maintaining the inherent "stemness/self-renewal" programme active in these cells and that 
this contributes critically to MRT tumourigenesis. Stemness can be defined as potential 
of stem cell niches to undergo self-renewal, differentiation and pluripotent (Anton et al., 
2007, Leychkis et al., 2009). Cross-platform analysis of CRISPR data and RNA-seq of 
MRT primary and model lines illustrates pathways that are deregulated by SMARCB1 
such as polycomb, JAK-STAT, stemness and many more (PBTG). JAK-STAT pathway 
was previously studied in MRT (PBTG). 
affy (R/Bioconductor) (Gautier et al., 2004) http://bioconductor.org/packages/release/bioc/html/affy.html
Limma (R/Bioconductor) (Ritchie et al., 2015) http://bioconductor.org/packages/release/bioc/html/limma.html
Rtsne (R/Cran) (Maaten and Hinton, 2008)
https://cran.r-
project.org/web/packages/Rtsne/index.h
tml
Ingenuity Pathway 
Analysis (IPA) Qiagen https://www.qiagenbioinformatics.com
Gene Set Enrichment 
Analysis (GSEA)
(Subramanian et al., 
2005)
http://software.broadinstitute.org/gsea/in
dex.jsp
Software and Algorithms
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2.2.2.1 Quantification and Statistical Analysis 
The bioinformatics analysis was performed using R (version 3.3.1) and Bioconductor 
(version 3.4) (Table 2.2).  
2.2.2.2 Reconstruction of stemness/self-renewal pathways/genes that are directly 
affected by SMARCB1 loss in MRT 
The genes that involved in stemness/self-renewal was identified through prior knowledge, 
canonical pathways and ontology (Kegg, GO, etc), ingenuity knowledgebase and direct 
reference to published literature. As the self-renewal pathways are not readily built on 
Ingenuity Pathway Analysis (IPA) software, the list of self-renewal genes was manually 
curated for the purpose of cross-referencing analysis with MRT primary and cell data. 
The genes were searched for their role in pluripotency and self-renewal.  
To identify stemness/self-renewal genes which are active in primary MRT and whose 
activity is SMARCB1 dependent, the list of stemness/self-renewal genes was cross-
referenced with RNA-seq data of primary MRT and SMARCB1 re-expression in MRT 
cells. Analysis of pathways/genes was performed using pathway analysis tools such as 
ingenuity analysis (Qiagen). Appropriate R/Bioconductor packages such as limma were 
used to identify statistically significant differentially expression/methylation between 
Medulloblastoma, and between MRT cells with and without re-expression of SMARCB1.  
For validation of SMARCB1 dependency, the list of stemness/self-renewal genes (56 
genes) was integrated with whole genome CRISPR/Cas9 GeCKO screening data from 4 
MRT cell lines with and without SMARCB1 expression (Dr Selby, PhD thesis). Potential 
self-renewal genes that showed SMARCB1 dependency was selected if the gene present 
in both cross-referencing analyses (RNA seq and CRISPR). 
The workflow for identification of stemness/self-renewal candidate in this study was 
illustrated in Figure 2.2. 
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Figure 2.2 Workflow to identify stemness/self-renewal genes that are SMARCB1 
dependent in MRT. 
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2.3 “Wet lab” methods and material 
2.3.1 Cell lines 
2.3.1.1 Cell line culture 
List of cell lines used in this thesis is tabulated in Table 2.3. The role of Smarcb1 in 
mediating tumourigenesis in a putative cell of origin for MRT was studied in a neural 
crest (NC) stem cell and a non-stem cell line NIH3T3. NIH3T3 were used as a control 
cell line in this study.  
Neural crest cells were seeded on Matrigel (Fisher Cat No. CB-40234) coated plate or 
T75 flask (Corning®) at 200,000 and 1 x 10^6 cells respectively and split every 2-3 days 
as appropriate. 
The effect of downregulation of BMI1 was evaluated in four different human cell lines; 
two were Atypical Teratoid Rhabdoid Tumour (BT16 and CHLA-266) and remaining two 
were Extra Cranial Rhabdoid Tumour (A204 and G401). Cells were seeded at appropriate 
cell densities in T75 and T175 flasks (Corning®) and were split every 2-3 days as 
appropriate (Table 2.5). 293T cell line was used as host cells for lentiviral packaging 
system. SMARCB1 re-expression in MRT cells were obtained from Dr Finetti (PBTG). 
In general, for sub-culturing, cells were washed twice with PBS and treated with either 
Accumax solution (1x; Millipore Cat No. SCR006) or 0.05% trypsin in 0.5mM EDTA at 
37ᵒC for 2-3 minutes. Cell cultures were neutralised inappropriate cell medium (as 
described in Table 2.4) and centrifuged at 1200rpm for 3-5 minutes to pellet the cells. The 
cells were gently pipetted and diluted to 5-10 times at the seeding density mentioned in 
Table 2.5. The cell viability was measured by staining an aliquot of culture with Trypan 
Blue (Thermo Fisher Scientific) and counted using Countess II FL automated cell counter 
(Thermo Fisher Scientific). The cells were maintained at 37ᵒC in a 5% CO2 humidified 
incubator.  
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Cells were cryopreserved in cell media with 10% DMSO (Table 2.4) using a Nalgene 
slow freeze Mr Frosty container at -80ᵒC for the first 24 hours and subsequently 
transferred to liquid nitrogen.  
 
Table 2.3 Information of cell lines used in this thesis 
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Table 2.4 Media used for culturing cell lines 
 
Media Cell line Composition of media Cryopreservation of cells
15% FBS and mLIF complex ES
cell medium (Cat. No. ES-101-B)
25 ng/ml FGF-2 (Cat. No.
Milipore GF003)
1% L-glutamine
1% sodium pyruvate
1% penicilin/streptomycin
10% foetal bovine
DMEM 5876 (Sigma Aldrich)
1% L-glutamine 
1% penicillin/streptomycin 
10% foetal bovine 
RPMI 1640 (Sigma-Aldrich)
1% L-glutamine 
1% penicillin/streptomycin 
20% foetal bovine 
IMDM (Thermo Fisher Scientific)
1% L-glutamine
1% penicilin/streptomycin
10% foetal bovine
DMEM 5876 (Sigma Aldrich)
10% DMSO,  40% cell 
media, 50% Foetal calf 
serum 
IMDM 20% CHLA-266
DMEM 10% BT16
10% DMSO, 90% ES cell 
medium 
10% DMSO,  40% cell 
media, 50% Foetal calf 
serum 
10% DMSO,  40% cell 
media, 50% Foetal calf 
serum 
10% DMSO,  40% cell 
media, 50% Foetal calf 
serum 
ES cell medium O9-1
DMEM 10% NIH3T3, 293T
RPMI 10% A204, G401
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Table 2.5 Cell density used for culturing cell lines in various plating formats. 
 
2.3.1.2 Formation of tumourspheres from Malignant Rhabdoid Tumours (MRT) cell 
lines and colony formation 
MRT cell lines were grown as non-adherent tumourspheres to assess self-renewal 
capacity. The adherent cells were detached from the flask using 1% trypsin and 
centrifuged at 1200rpm for 5 minutes. The cells were washed twice with 1x PBS and were 
dissociated into a single cell suspension by filtering the culture through 70µ cell strainer 
and were grown in tumoursphere complete media (TSM) at density of 10,000 to 20,000 
cells/ml. The spheres were usually formed by day 3-12 and re-fed with TSM media every 
three days.  
Cell line Cell density for culturing Seeding plate/flask
3x106 in 20 ml media T175 flask
1x106 in 10 ml media T75 flask
2 x105 in 2 ml media 6-well plate
3x106 in 20 ml media T175 flask
1x106 in 10 ml media T75 flask
2 x105 in 2 ml media 6-well plate
3.5 x106 in 10 ml media 10 cm2 plate (for lentiviral)
3x106 in 20 ml media T175 flask
1x106 in 10 ml media T75 flask
2 x105 in 2 ml media 6-well plate
3x106 in 20 ml media T175 flask
1x106 in 10 ml media T75 flask
2 x105 in 2 ml media 6-well plate
3x106 in 20 ml media T175 flask
1x106 in 10 ml media T75 flask
2 x105 in 2 ml media 6-well plate
O9-1
NIH3T3, 293T
A204, G401
CHLA-266
BT16
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The tumoursphere completed media (TSM) was made up of 2% B27 supplement, 20 
ng/ml EGF (Peprotech), 30 ng/ml bFGF (Peprotech), 2U/ml heparin (Sigma Aldrich), 0.5 
µg/ml hydrocortisone (Sigma Aldrich), 1% sodium pyruvate (Thermo Fisher Scientific), 
1% penicillin/streptomycin and 1% non-essential amino acid (Thermo Fisher Scientific) 
in DMEM/F12 media. Cells were passed through a cell strainer (70 µ) to produce a single 
cell suspension. The spheres were usually formed by day 3-12. The fresh TS media was 
refreshed in every three days.  
The MRT cells were grown until formation of 100-200 µm spheres to avoid cell 
differentiation, death and cellular attachment associated with larger spheres. To passage 
the cells, the cultures were collected and centrifuged at 800 rpm for 10 minutes. The 
supernatant was gently removed. 500 µl of Accutase solution (Stemcell Technologies) 
was added to the cells and incubated at 37ᵒC for 5 minutes. The spheres were dissociated 
by pipetting up and down at least 20 times and 500 µl of warm TS media was added to 
neutralise the Accutase solution. The culture was centrifuged again at 1200 rpm for 3 min, 
counted and re-plated at appropriate cell density. Viable cells were then determined by 
Trypan blue dye exclusion and counted using Countess II FL automated cell counter 
(Thermo Fisher Scientific). Appropriate numbers of single cells were transferred into 6 
and 24 low attachment well plates (Corning®).  
2.3.2 SDS-PAGE and Western Blot 
2.3.2.1 Protein extraction and quantification 
Total protein extracts were prepared from 1x106 cells using cold RIPA buffer (Sigma 
Aldrich) with 1% cocktail protein inhibitor (Sigma Aldrich). The lysates were kept on ice 
for 15 minutes followed by sonication in a Diagenode Bioruptor (Denville, NJ) for three 
30 second cycles on and three cycles off to ensure complete membrane disruption, and 
then centrifugation at 15 rcf (relative centrifugal force) for 15 minutes at 4ᵒC.  
The protein supernatants were quantified using the BCATM Protein Assay Kit (Pierce) 
according to the manufacturer’s instructions. Briefly, 25 µl of each standard and 5 µl of 
protein lysate were loaded into the well of a 96-well plate containing 200 µl of working 
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reagent.  The series of standard protein concentrations were prepared from mixtures of 
bovine serum albumin (ranging from 2 mg to 0 mg) and 1X PBS according to 
manufacturer protocol. The plate was incubated for 30 minutes at 37 ᵒC followed by 3 
minutes of cooling down at room temperature. The absorbance was measured at 562 nm 
using FLUOstar Omega (BMG Labtech) plate reader and the standard curve generated. 
2.3.2.2 Conventional protein electrophoresis and blotting 
Loading buffer (see Appendix) was mixed with 50 µg of protein lysate and the solution 
was denatured at 99 ᵒC for 5 minutes, briefly centrifuged and kept on ice. The samples 
and molecular weight marker (Movex Sharp protein standard, Invitrogen) were separated 
on 4-20% gradient polyacrylamide Amersham ECL Gel (GE Healthcare, UK). The gel 
was run at a constant 160 mV in Tris-Glycine Running buffer for 60 minutes. The 
electrophoresed protein was transferred onto nitrocellulose membrane (Amersham) using 
a semi-dry electroblotting system for 60 minutes at 100 mV. The membrane was stained 
in Ponceau-S solution 0.1% (Sigma) to check that protein was fully transferred to the 
membrane and washed with dH2O to remove leftover staining solution. All solutions are 
listed in Table 2.6.  
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Buffer  Composition 
 
Running Buffer 
 
0.3% w/v Tris (Sigma Aldrich) 
1.44% w/v Glycine (Sigma Aldrich) 
0.1% w/v SDS (Sigma Aldrich) 
dd H2O 
 
2X Loading Buffer 
2% w/v Bromophenol Blue (Biorad) 
5% v/v 1 M Tris, pH 7 (Sigma Aldrich) 
25% v/v mL 20% SDS (Sigma Aldrich) 
2% v/v β-Mercaptoethanol (Sigma Aldrich) 
ddH2O 
 
Transfer Buffer 
 
0.3 % w/v Tris (Sigma Aldrich) 
1.44 % w/v Glycine (Sigma Aldrich) 
0.1 % w/v SDS (Sigma Aldrich) 
20 % v/v Absolute Ethanol (Sigma Aldrich) 
dH20 
 
Blocking solution 
5% w/v Non-Fat Dry Milk (Sigma Aldrich) 
1X TBS 
1% v/v Tween-20 (Sigma Aldrich) 
dH20 
TBS pH 7.6 0.24% w/v Tris (Sigma Aldrich) 
0.84% w/v NaCl (Sigma Aldrich) 
T-TBS 1X TBS (Sigma Aldrich) 
1% v/v Tween-20 (Sigma Aldrich) 
Table 2.6 Buffers for running Western Blot 
 
The membrane was blocked in 5% skimmed milk in 1% TBST (10 mM Tris-HCl pH 8.0, 
150 mM NaCl, 0.05% Tween 20) overnight at 4°C. The membrane was probed using 
antibodies against BMI1 (1:250, Abcam), SMARCB1 (1:250, BD Biosciences), 
SMARCA4 (1:250, Santa Cruz Biotechnology), histone H2A (1:1000, CST), uH2A 
(1:200, Diagenode), H3 (1: 10,000, ThermoFisher Scientific), RING1A (1:1000, CST) at 
room temperature for 4 hours or 4 °C overnight followed by another one-hour incubation 
with specific secondary antibody (1:5000) at room temperature. After rinsing in dH2O 
three times for 10 minutes, the antibody was detected using enhanced chemiluminescence 
(ECL) kit (Pierce, France). Immediately after visualisation of antibody using GBox 
  
71 
Chemi XL1.4 (Syngene) imaging system, the membranes were washed three times for 5 
minutes with 1x TBST before incubation in Western blot stripping buffer (Thermo Fisher 
Scientific) for 1 hour at 37 ᵒ C. The membranes were washed again as before and incubated 
with β-actin antibody (1:20,000, Abcam) for 30 minutes at room temperature. All 
antibodies are indicated in Table 2.7.  
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Antibody Company Dilution 
Anti-SMARCB1 (BAF47) Cat. No. 612110 BD 
Biosciences 
1:250  
Anti-SMARCA4 (BRG1 G-7) Cat. No. 
sc17796 
Santa Cruz 
Biotechnology 
1:250 
Anti-Beta Actin Cst. No. ab49900 Abcam 1:50000 
Secondary antibody HRP Goat Anti-
Rabbit IgG Cat. No. ab6721 
Abcam 1:5000 
Secondary antibody HRP Rabbit Anti-
Mouse IgG Cat. No. ab6728 
Abcam 1:5000 
Anti-BMI1 ChiP Grade Cat No. ab14389 Abcam 1:250 
Anti-BMI1 XP Rabbit Cat. No. 6964 CST 
Technology 
1:250 
Anti-p16INK4a/CDKN2A Cat. No. 
AF5779 
R&D Systems 1:50 
Anti-CD44 Cat. No. ab157107 Abcam 1:400 
Table 2.7 Antibodies used in Western Blot 
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2.3.2.3 WES simple protein blotting and analysis 
Protein lysate was prepared as previously described in Section 2.2.1. For WES analysis, 
the lysates were separated by an automated capillary-based electrophoresis system (WES, 
Protein Simple, San Jose, CA). All procedures were performed according to 
manufacturer’s recommendations using supplied reagents. Briefly, after quantification of 
protein concentration using similar steps described in section 2.2.1, 4 µl of 0.8 to 1.0 µg 
of protein lysates were mixed with 1 µl of 5x sample fluorescent master mix and were 
denatured at 95ᵒC for 5 minutes. The samples, blocking reagent, wash buffer, primary 
antibodies, secondary antibodies and chemiluminescent substrate were added into 
designated wells in the manufacturer provided microplate. Primary antibodies used as 
listed in Table 2.7. Plate loading, sample separation and immune detection were carried 
out automatically using default settings for 3 hours. The data was analysed using Compass 
software (Protein Simple).  
2.3.3 Expression quantification by real-time PCR (RT-PCR) 
2.3.3.1 DNA/RNA extraction, purification and quantification 
DNA extraction was performed on 1x106 cells using the DNeasy Blood and Tissue Kit 
(Qiagen) according to the manufacturer’s instructions. RNA was extracted from 1x106 
cells using the Total RNA Purification Kit (Norgen Biotek). Briefly, the adherent cells 
were washed twice with 1X PBS and 350 µl of Lysis buffer was added to the cells in a 6-
well plate format. The lysate containing DNA or RNA was fixed with 100% methanol 
and bound to the column. The column was washed twice with a washing buffer followed 
by centrifugation at 14,000 x g for 1 minute. DNA or RNA was eluted in an appropriate 
volume of TE buffer or ddH20 (Invitrogen) respectively. For long-term storage, DNA 
samples were stored at -20 oC and RNA samples at -80 oC. Quantification of DNA and 
RNA was carried out using NanoDrop 1000 (Thermo Scientific). The purity and integrity 
of total RNA was evaluated based on OD ratios at A260/A280 and A260/A230 ranged 
between 1.8 to 2.  
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2.3.3.2 cDNA conversion of RNA samples 
cDNA was synthesised from 2 µg of total RNA using High-Capacity RNA to cDNA kit 
Ô (Applied Biosystem). To prepare 20 µl of cDNA, an appropriate volume of RNA (2 
µg) was added to 10 µl of 2X reverse transcription buffer mix, 1 µl of reverse transcription 
enzyme mix and topped up with nuclease-free H2O. The mixture was incubated at 37 °C 
for 60 minutes, 95 °C for 5 minutes and held at 4°C. The cDNA was stored at -20°C.  
2.3.3.3 Oligonucleotides and Primer design for qRT-PCR 
All oligonucleotides were synthesised either by Sigma Aldrich or Eurofins Genomics and 
re-suspended in nuclease-free H2O (Invitrogen) to a concentration of 100 µg/mol. Primers 
used in qRT-PCR (Table 2.8 and Table 2.9)  were designed using Primer3Plus software 
(version 4.0.0 and previously; http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi/) and Primer Express software version 3. The transcripts 
of the genes were retrieved from the Ensembl (http://www.ensembl.org/index.html). Each 
of the primers was checked for non-specific binding using NCBI blast nucleotides 
(https://blast.ncbi.nlm.nih.gov/) and UCSC In-Silico PCR software 
(https://genome.ucsc.edu/).  
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Table 2.8 Primers for qRT-PCR to evaluate the differential expression in human cell 
lines. 
Primers Species Sequence (5’-3’)
GAPDH Fwd Human CAGGTCATCCATGACAACTTTG
GAPDH Rev Human GTCCACCACCCTGTTGCTGTAG
BMI1 Fwd Human TTCATTGATGCCACAACCAT
BMI1 Rev Human CAGCATCAGCAGAAGGATGA
p16 Fwd Human CCCTCAGACATCCCCGATT
p16 Rev Human TCTAAGTTTCCCGAGGTTTCTCA
p14 Fwd Human CCCTCGTGCTGATGCTACTG 
p14 Rev Human CCATCATCATGACCTGGTCTTCT
p21 Fwd Human GGCAGACCAGCATGACAGATT
p21 Rev Human GCGGATTAGGGCTTCCTCT
CD44 Fwd Human TCCAACACCTCCCAGTATGACA
CD44 Rev Human GGCAGGTCTGTGACTGATGTACA
CCND1 Fwd Human GCCGTCCATGCGGAAGATC
CCND1 Rev Human CCTCCTCCTCGCACTTCTGT
CCND2 Fwd Human CTGTGTGCCACCGACTTTAAGTT
CCND2 Rev Human TGCTCCCACACTTCCAGTTG
CCND3 Fwd Human CAGGCCTTGGTCAAAAAGCA
CCND3 Rev Human GCGGGTACATGGCAAAGGTA
CCNE1 Fwd Human CCAGGAAGAGGAAGGCAAAC
CCNE1 Rev Human CCTGTCGATTTTGGCCATTT
CCNE2 Fwd Human CCTTGTGCCATTTTACCTCCAT
CCNE2 Rev Human CATCCAATCTACACATTCTGAAATACTG
CDK4 Fwd Human TGCAGAGATGTTTCGTCGAAA
CDK4 Rev Human CCCAACTGGTCGGCTTCA
CDK6 Fwd Human CTTCGAGCACCCCAACGT
CDK6 Rev Human GGTTTCTCTGTCTGTTCGTGACACT
GLI2 Ex2 Fwd Human AAGCAAGAAGCCAAAAGTGG
GLI2 Ex3 Rev Human TGGTACCTTCCTTCCTGGTG
GLI3 Ex3 Fwd Human CGAACAGATGTGAGCGAGAA
MYC Fwd Human AATGAAAAGGCCCCCAAGGTAGTTATCC
MYC Rev Human GTCGTTTCCGCAACAAGTCCTCTTC
JARID2 Ex7 Fwd Human GTCACGCAGATTCAGCACAT
JARID2 Ex8 Rev Human TAATCAGCCGGAAAAAGCAG
SOX2 Fwd Human TTGCTGCCTCTTTAAGACTAGGA
SOX2 Rev Human CTGGGGCTCAAACTTCTCTC
OCT3/4 Fwd Human AGCAAAACCCGGAGGAGT
OCT3/4 Rev Human CCACATCGGCCTGTGTATATC
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Table 2.9 Primers for qRT-PCR to evaluate differential expression in mouse cell lines. 
Primers Species Sequence (5’-3’)
Klf4 Fwd Mouse GTACCCCTCTCTCTTCTTC
Klf4 Rev Mouse GGCTGCCTCATTAATGT
Sox2 Fwd Mouse CTGGACTGCGAACTGGAGAAG
Sox2 Rev Mouse TTTGCACCCCTCCCAATTC
Oct4 Fwd Mouse TTCCCTCTGTTCCCGTCACT
Oct4 Rev Mouse TGGTGCCTCAGTTTGAATGC
Myc Fwd Mouse GCAGCTCGCCCAAATCC
Myc Rev Mouse CGAGTCCGAGGAAGGAGAGA
Bmi1 Fwd Mouse CGCTCTTTCCGGGATCTTTT
Bmi1 Rev Mouse GCTCAGTGATCTTGATTCTGGTTGT
Jarid2 Fwd Mouse CAGTAGGTCAGCACGGGAGAA
Jarid2 Rev Mouse CGGAGTGGCCTCTTTGCTT
Gli2 Fwd Mouse CTGCATGCTAGAGGCAAACTTTT
Gli2 Rev Mouse TCCATCTCAGAGGCTCATACTCTTT
Ezh2 Fwd Mouse CGCTCTTCTGTCGACGAT
Ezh2 Rev Mouse CTCTTATATGTGTTGGGTGTTG
P16 Fwd Mouse CTCAACTACGGTGCAGATTCGA
P16 Rev Mouse CACCGGGCGGGAGAAG
P21 Fwd Mouse TTCCGCACAGGAGCAAAGT
P21 Rev Mouse CGGCGCAACTGCTCACT
Ccnd1 Fwd Mouse GTGCGTGCAGAAGGAGATTGT
Ccnd1 Rev Mouse CTCACAGACCTCCAGCATCCA
Ccnd2 Fwd Mouse CCATGAATTACCTGGACCGTTT
Ccnd2 Rev Mouse GGAGCTGAAGATGGGTCTTAGGA
Ccnd3 Fwd Mouse TCCAAGCTGCGCGAAAC
Ccnd3 Rev Mouse GGTCCGTATAGATGCAAAGCTTCT
Ccne1 Fwd Mouse GGTGGCTCCGACCTTTCAG
Ccne1 Rev Mouse GCAAAAACACGGCCACATT
Ccne2 Fwd Mouse CTAAGGCGCTTTATGTTTGCAA
Ccne2 Rev Mouse ATGTTGACACAGTCCTCATCTCATAAT
Cdk4 Fwd Mouse CCTGCCGGTTGAGACCAT
Cdk4 Rev Mouse AAGAAAATCCAGGCCGCTTAG
Cdk6 Fwd Mouse CCTGAAGCCAGCATGGAGAA
Cdk6 Rev Mouse CCACGCACTCATACTGCTGATC
Cd44 Fwd Mouse TTCTCCCCACGACCCTTTT
Cd44 Rev Mouse GGCGTGCTGGATGAAACG
Gapdh Fwd Mouse GTTGTCTCCTGCGACTTCA
Gadh Rev Mouse GGTGGTCCAGGGTTTCTTA 
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2.3.3.4 Quantitative polymerase chain reaction 
The qRT-PCR was performed using a SYBR Green qPCR Supermix-UDG with ROX kit 
(Invitrogen, USA) on a ViiA7 machine (Applied Biosystems, UK). The qRT-PCR was 
carried out in a 10 µl reaction containing 4µl of cDNA (1 ng/µl), 0.2 µl of forward primer 
(100 mM), 0.2 µl of reverse primer (100 mM), 5.1 µl SYBRÒ Select Master Mix and 0.5 
µl dH2O. The master mix provided is composed of AmpliTaq® DNA Polymerase and 
SYBR® Green cyanine dye, resulting in binding to DNA that absorbs blue light (λmax = 
497 nm) and emits green light (λmax = 520 nm). The reactions were performed in 364-
well plate with cycling conditions described in Table 2.10. All qRT-PCR reactions were 
run in triplicate with GAPDH used as internal control.  
 
Table 2.10 qRT- PCR reactions and run conditions 
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2.3.3.5 Analysis of qRT-PCR data by the comparative CT method 
Relative quantification of qRT-PCR data was analysed using 2-ΔΔCT to determine changes 
in gene expression relative to a housekeeping gene, GAPDH. This method is 
advantageous as it does not require a calibration curve. The 2-ΔΔCt method assumes a 
uniform PCR amplification efficiency of 100% across all samples.  
Differential gene expression (fold change) was calculated as follows: 
 
1) ∆Ct = [Ct target gene – Ct reference gene] 
2) ∆∆Ct = [∆Ct target sample – ∆Ct reference sample] 
3) Fold change expression =2-ΔΔCt 
 
 
2.3.4 Immunohistochemistry 
Cells for immunohistochemistry were harvested and embedded on the slide using the 
cytospin method. Briefly, 20 µl cell suspension (at a density of 1 x105 cells) was added 
into a funnel that attached to the slide. The funnels were loaded in a rotor and centrifuged 
at 4000 rpm for 5 minutes using Shandon Cytospin Centrifuge instrument. The cells then 
were fixed in formalin for 10 minutes followed by 95% ethanol for 5 minutes. The cell 
sections were stained for anti-SMARCB1 and anti-CD44 antibodies (Table 2.7) according 
to standard protocol (Judkins et al., 2004, Koh, 2013). The images of sections were 
captured using Aperio Imagescope analysis software.  
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2.3.5 Flow cytometry  
2.3.5.1 Fluorescence-activated cell sorting  
For limiting dilution assay, GFP-, RFP- and Tomato-expressing cells were harvested and 
washed twice with PBS. Cells were centrifuged at 1200 rpm for 5 minutes, re-suspended 
in 100 µl of PBS for sorting.  
For isolation of CD44 high/low cell populations, cells were harvested and washed twice 
with PBS. Cells were transferred to a 5 ml FACS tube and were mixed with 100 µl of 
FACS sorting buffer made up from 0.2% BSA in PBS. 5 µl of mouse monoclonal CD44-
APC-CyÔ7 antibody (BD Pharmingen) was added 1x106 cells and the solution was 
incubated for 30 minutes at room temperature in the dark. 500 µl of sorting buffer was 
added after 3 minutes of centrifugation at 450 rcf.  
Prior to sorting, cells were passed through a 70 µ cell strainer to obtain single suspension 
cells. All samples were sorted using FACSAria sorter. DAPI (Sigma Aldrich, 1 µg/ml) 
was added to exclude dead cells.  
2.3.5.2 Cell cycle analysis with Propidium iodide (PI) 
Cell cycle stages were determined by measuring the cellular DNA content using flow 
cytometry. Cells were harvested, washed twice with PBS and fixed with 70% cold ethanol 
overnight at 4 °C. For cell cycle analysis, the cells were washed twice with cold PBS and 
centrifuged at 800 rpm for 5 minutes. The cells then were incubated with 100 µg/ml 
ribonuclease A, RNase (Sigma Aldrich) for 5 minutes followed by 30 minutes staining 
with 50 µg/ml propidium iodide, PI (Sigma Aldrich). Samples were analysed using a 
FACSCalibur (BD Biosciences) and FlowJo software.  
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2.3.5.3 Assessment of different apoptotic stages using FITC AnnexinV 
For detection of different apoptotic stages following treatment with shRNA and inhibitor, 
cells were harvested, washed twice with cold PBS and resuspended in 1X Binding Buffer 
at a concentration of 1x106 cells/ml. 100 µl of sample was transferred to a 5 ml FACS 
tube and was mixed with 5 µl of FITC Annexin V and 5 µl PI. The solution was incubated 
for 15 minutes at room temperature in the dark. 500 µl of 1X Binding Buffer was added 
to the tube prior to analysing the samples on FACS FortessaX20. The resulting FACS data 
were analysed with FlowJo.  
2.3.6 Lentiviral production, sucrose gradient purification and infection 
For lentiviral production, 3.5 x 106 293T cells were seeded in 10 cm dish and were co-
transfected with 10 µg of expression vector and the packaging vectors 10 µg pCMV-
ΔR8.91 and 5 µg pMD2G using Calcium Phosphate Transfection (Calphos Transfection 
Kit, Clontech). After 12 hours of transfection, media was replaced with fresh media. 
Lentivirus supernatant was collected 72-hours post-transfection, centrifuged at 4°C for 
10 minutes, aliquoted and stored at -80 °C. For transduction of stem cells, the virus was 
concentrated using the sucrose cushion technique. Briefly, 25 ml of lentivirus medium 
was added into 37.5 ml Beckman conical tunes and overlaid with 4 ml of 20% sucrose 
(made in 1X PBS and sterile filtered). The tubes were spun at 26,000 rpm for 2 hours at 
4°C in a Beckman Swingle bucket rotor (SW32Ti). After spin, the supernatant was 
carefully discarded, and the virus pellet was re-suspended with 200 µl of cold 1X PBS.  
2.3.6.1 Determining viral titre 
Titre of virus particles was calculated by infection of 100,000 293T cells with virus stock 
in a serial dilution approach from 10-3 to 10-7. 24-hours post-infection, the media 
containing virus was replaced. For Puromycin resistance vector, the cells were split 1:2. 
Fresh media with 1 µg/ml Puromycin (Invitrogen) was added to all but one well of a 12- 
well plate which had fresh media only and served as a control. The cells were harvested 
after 48 hours of Puromycin selection and the cells viability was counted using Countess 
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II FL automated cell counter (Thermo Fisher Scientific). The virus titer in plaque-forming 
units (PFU/ml) was calculated by firstly determining the slope of the graph generated 
from the percentage of viable cells after Puromycin selection at different virus dilutions 
(with an assumption of MOI 1 = 50%) and then measured PFU/ml according to the 
formula shown below:  
  PFU/ml: (slope (x) of graph) / (number of cells seeded for titer) 
Virus titre for fluorescently labelled viruses (GFP, RFP and Tomato) was determined 
using FACS Calibur and the resulting data was used to measure transduction unit per ml 
(TU/ml) of the virus particle. Briefly, 100,000 of G401 cells was infected with a 10-fold 
serial dilution of stock virus. 24-hours post infection, the virus-containing media was 
replaced with fresh media and the cells were harvested three days after infection. The 
intensity of fluorescence signal for each serial dilution was assessed by FACS and the 
virus titer (TU/ml) was calculated using the formula as below: 
 
TU/ml: (N x P) / (V x D) 
Note: 
N = Cell density seeded for titer 
P = % of fluorescent positive cells (should be <20%) 
V = Virus volume used for infection in each well, in ml 
D = Dilution factor 
 
2.3.6.2 Lentivirus transduction with different multiplicity of infection (MOI) 
Multiplicity of infection (MOI) is described as number of virions affecting each cell 
during infection. Theoretically, if 1 million virions are required to infect 1 million cells, 
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the MOI is one. MOI was determined by infecting the Rhabdoid cell lines with the virus 
at different MOI ranging from 1 to 20. After 24-hours post infection, the spent media was 
replaced with fresh media. Three days post-infection, GFP-, RFP- and Tomato-expressing 
cells were harvested, washed twice with PBS, counted for cell viability using Trypan blue 
dye and analysed on FACS Calibur for fluorescence signal. RNA was extracted from the 
samples and cDNA was synthesized from a total RNA to determine the relative 
quantification of gene expression of p21, p14, p16, BMI1 and CD44 (Table 2.8 and Table 
2.9). Protein was also extracted from similar cell pellet and was evaluated by Western 
Blot. The ideal MOI was determined by considering cell culture condition during 
treatment relative to control and greatest number of infected cells that showed 
downregulation of BMI1 and overexpression of other genes p21, p14, p16 and CD44.  
MOI for lentiCRISPRv2 virus was determined by infecting stem cells, 293T and NIH3T3 
with the unconcentrated or concentrated virus at MOI 1, 3, 5 and 10. Media containing 
virus was removed next day and replaced with fresh media containing puromycin to a 
final concentration of 1 µg/ml. Two days after puromycin selection, the cells were 
harvested, washed twice with PBS and counted for cell viability using Trypan blue 
staining to determine the MOI.  
2.3.7 Bacterial strains 
Bacterial strain used in this study was One Shot Stbl3 Escherichia coli (E.coli) 
(Invitrogen).  
2.3.7.1 Viral vectors 
2.3.7.2 shRNA BMI1 and non-silencing (NS) 
Two independently designed lentiviral BMI1 RNAi knockdown and control short hairpins 
were used. The H1-shRNA-EF-1a-eGFP vector contained shRNA sequences targeting 
BMI1 and the Luciferase was a kind gift from Prof John E. Dick. The second hairpin 
contained pLKO5dSFFVeGFPmiR30n vector (A gift from Prof Olaf T. Heidenreich) 
(Figure 2.3) had shRNA sequence to BMI1 and red fluorescent protein (RFP) used as non-
  
83 
targeting control (NTC). The two BMI1 short hairpin RNA (shRNA) were designed to 
target different regions of the BMI1 transcript.  
 
 
Figure 2.3 Full plasmid map of pLKO5dSFFeGFPmiR30n. This plasmid vector is based 
on a natural human mir-30a backbone. The shRNA sequences were inserted at “shRNA” 
site on the vector. The SFFV is the promoter region for eGFP and mir-30a. The eGFP is 
selection marker for the vector.   
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2.3.7.3 LentiCRISPRv2 plasmid 
LentiCRISPR version 2 (LentiCRISPRv2) was obtained from Addgene (Plasmid #52961) 
contains Puromycin resistant gene as a selectable marker for transfected cells and 
Ampicillin resistant gene for selection of the plasmid in E.coli (Figure 2.4). 
LentiCRISPRv2 vector was digested with restriction enzyme BsmBI (NEB) to insert 
single guide RNA (sgRNA) into the vector.  
 
Figure 2.4 Full sequence map of LentiCRISPRv2 vector. U6 is a promoter for sgRNA. 
The sgRNA sequence was inserted at “sgRNA insert” by removing the stuffer (at similar 
location of sgRNA insert) using BsmBI restriction enzyme. The Cas9 and puromycin 
selection marker are driven by EF-1a promoter. The co-expression of Cas9 and 
Puromycin selection marker is linked by P2A. 
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2.3.7.4 Packaging plasmids for viral production 
Two viral vectors required for generation of lentivirus are packaging plasmid (pCMV-
ΔR8.91) and envelope plasmid (pMD2.G) (kindly donated by Dr Paul Sinclair) along 
with expression vector. The packaging plasmid contains a robust CAG promoter that 
facilitates the efficient expression of packaging protein during virus production whereas 
the envelope plasmid contains VSV-G coding sequence which is required to pseudotype 
the viral envelope.  
2.3.8 Bacterial cloning and transformation 
2.3.8.1 Ligation and cloning PCR amplicons into digested vectors  
Oligo annealing and cloning of the sgRNA into digested LentiCRISPRv2 plasmid was 
performed according to the protocol provided by Zhang lab and Gecko. Briefly, sgRNA 
oligos designed for SMARCB1 and SMARCA4 were phosphorylated and annealed with 
T4 PNK enzyme (NEB) at 37 °C for 30 minutes, 95 °C for 5 minutes and then ramped 
down to 25°C at 5°C /minute in a thermocycler. The annealed oligos were diluted at 1:200 
ratio with sterile water. 10 µl ligation reaction included 2.3 µl BsmBI digested vector (50 
ng from stock), 1µl diluted oligo duplex, 5 µl 2x Quick Ligase buffer (NEB), ddH2O 
water and 1µl Quick Ligase (NEB) was set up and incubated at room temperature for 10 
minutes. 
Primer sequences targeting BMI1 was cloned into pLKO5dSFFVeGFPmiR30n (called 
Plko5d in this thesis) vector according to protocol provided by Thermo Fisher Scientific. 
T4 DNA ligase (Invitrogen) was used according to Table 2.11. The reaction was incubated 
overnight at room temperature. The product was stored at -20 °C (5 µl was used for 
transformation).  
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Table 2.11 Ligation mixture for sticky-end vector 
 
2.3.8.2 Transformation 
Plasmids were transformed into High-Efficiency One Shot Stbl3 Escherichia coli (E.coli) 
bacteria (Invitrogen) according to manufacturer’s protocol. 1µl of pUC19 (Invitrogen) 
and 5 µl of ddH2O were used as positive and negative control respectively. Transformed 
colonies were selected in Luria-Bertani (LB) plates containing 100 µg/ml Ampicillin.  
2.3.8.3 Bacterial cultures  
Bacterial strains were cultured in 10 ml of LB growth medium with antibiotic selection 
from a single colony, overnight on 360° shaker at 37 °C. Microbial LB plate was prepared 
from LB agar containing specific antibiotic selection. Inoculation was performed using a 
metal loop into LB plate or LB media. The stock of bacteria was stored at -80 °C in 50% 
glycerol (v/v) while the LB plates were stored at 4 °C, wrapped in Parafilm.  
  
87 
2.3.8.4 Harvesting of bacteria from LB broth and extraction of nucleic acids 
Bacterial cultures were harvested after 18 hours of incubation on a shaker. The mini-
cultures (< 1.5 ml) were harvested by centrifugation at 13,000 rpm for 3 min whereas the 
culture larger than 200 ml (maxi) were harvested at 9,000 rpm for 15 minutes.  
Plasmids were extracted from mini and maxi cultures using a miniprep plasmid 
purification kit (Invitrogen) and Endo-Free Plasmids Maxi kit (Qiagen) respectively, 
according to manufacturer's protocols. Briefly, the cell pellet was re-suspended in an 
appropriate volume of Lysis buffer with RNAase and the solution passed through 
extraction column, leaving the DNA bound to the membrane. At the elution step, DNA 
was re-suspended first in isopropanol and then in 70% ethanol. The resulting DNA pellets 
were re-suspended in an appropriate volume of TE buffer.  
2.3.8.5 Quantification of nucleic acids by spectroscopy 
Total DNA extracted from the plasmid was measured using NanoDrop ND1000 (Thermo 
Scientific). The purity and integrity of total DNA was evaluated based on OD ratios at 
A260/A280 ranged between 1.8-2.  
2.3.9 DNA manipulation techniques 
2.3.9.1 DNA restriction 
BsmB1 restriction enzyme (NEB) was used to digest 2 kb stuffer on the LentiCRISPRv2 
vector to allow an insertion of sgRNA. Restriction enzyme digests were performed 
according to manufacturer’s instructions. In brief, 5 µg of expression plasmid was 
digested in a 60 µl reaction mixture containing 3 µl of FastDigest BsmBI (NEB), 3 µl 
FastAP (Fermentas), 10X FastDigest Buffer and ddH2O. The digestion reaction was 
incubated for 30 minutes at 37 °C. Similarly, the same digestion enzyme was used to 
digest the Plko5d plasmid to create blunt end insertion site.  
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2.3.9.2 Agarose gel electrophoresis 
Digested plasmids required for downstream experiments were separated by agarose gel 
electrophoresis. The percentage of agarose (Bioline) used in this study varied from 0.8% 
to 1.5% (w/v) depending on the predicted size of DNA fragments. The agarose powder 
was suspended in TBE, heated and supplemented with Red gel (Biotium) at a 
concentration of 0.01% (v/v). Prior to loading the sample into the wells, 5 µl of sample 
was mixed with 1 µl of DNA loading buffer (Promega). Size of DNA bands on agarose 
was evaluated using a PCR marker (Promega) and a DNA marker (Promega) depending 
on the estimated size of the products. The samples were run at constant 100 V for 30 
minutes to 1 hours and the DNA bands were visualised using Syngene G-box. 
2.3.9.3 Gel extraction and purification of digested DNA 
The DNA bands with a correct product size on agarose gel were excised using a clean 
scalpel and purified using a GeneJET™ Gel Extraction Kit (Thermo Fisher) according to 
manufacturer’s instructions. The gel was dissolved with a binding buffer at 1:1 ratio (v/w) 
and heated 50 °C for 10 minutes until the gel was completely dissolved. The solution was 
transferred to column and DNA bound to the membrane. The column was washed twice 
with a wash buffer and the DNA was eluted in TE buffer.  
2.3.9.4 Polymerase chain reaction (PCR) 
Target DNA sequences for colony screening or molecular cloning were amplified using 
PCR (Gene Amp PCR System 9700) thermocycler.  
2.3.9.5 Sequencing 
To confirm the correct BMI1, SMARCB1 and SMARCA4 sequences were cloned into 
various expression vectors and intermediate plasmids, sequencing was carried out using 
the primers listed in Table 2.12. Sequencing was performed by Eurofins Genomics 
(Germany) and resulting traces were analysed using FinchTv.  
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Table 2.12 Sequencing primers to check for insert in plasmid vectors 
 
2.3.10 CRISPR/Cas9 mediated knockout of SMARCB1 and SMARCA4 
2.3.10.1 Construction of CRISPR/Cas9 single guide RNA (sgRNA)  
Single guide RNA (sgRNA) targeting regions in exon 1 and exon 2 of human and murine 
SMARCB1 and SMARCA4 were designed using CRISPR design tool (http://www.e-
crisp.org/E-CRISP/designcrispr.html). Two single guide RNAs for each gene for each 
organism were designed with the least off-target effects that tolerate mismatches and 
fewer hits. The sgRNA sequences used in the construction of lentiCRISPRv2 vectors are 
tabulated in Table 2.13. 
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Table 2.13 List of single guides RNA (sgRNAs) targeting SMARCB1 and SMARCA4 
in Homo sapiens and Mus musculus 
 
2.3.10.2 Non-targeting control single guide RNAs (sgRNA)  
sgRNA for non-targeting control was obtained from the Human GECKOv2 library and 
Mouse GeCKOv2 library (Addgene). The selected 20bp sgRNA was checked for its 
potential binding to the target genes (i.e SMARCB1 and SMARCA4). Six oligonucleotides 
were selected for each organism listed in Table 2.14 and Table 2.15. NTCH6 and NTCM1 
showed high transduction efficiency and therefore were used in all CRISPR experiments. 
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Table 2.14 List of Homo sapiens non-targeting control (NTC) single guide RNAs for 
CRISPR/Cas9 construction. 
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Table 2.15 List of Mus musculus non-targeting control (NTC) single guide RNAs for 
CRISPR/Cas9 construction. 
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2.3.10.3 SURVEYOR PCR primers design  
Primers for surveyor assays were designed near upstream and downstream of the sgRNA. 
Ideally, the cleavage site should create two distinct product sizes on an agarose gel. The 
primers were designed using Primer3web version 4.0.0 website (http://primer3.ut.ee). For 
efficient amplification, the primers were designed to yield the amplicon length between 
400 to 500 bp. The SURVEYOR primers used in CRISPR experiment are listed in Table 
2.16 and Table 2.17. 
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2.3.10.4 SURVEYOR mutagenesis assay 
Detection of InDel mutations generated by CRISPR/Cas9 were validated using the 
SURVEYOR Nuclease Assay. This assay is commonly used to detect single nucleotide 
mismatch that is induced by nuclease, a member of CEL family of mismatch specific 
nucleases. SURVEYOR nuclease recognises and cleaves both strands of a DNA 
heteroduplex on the 3’ side of base substitution or insertion/deletion (InDel), Briefly, there 
are 4 steps in SURVEYOR mutagenesis assay;  PCR amplification of target DNA from 
both mutant and wild-type reference DNA; (ii) hybridization to form heteroduplexes 
between mutant and wild-type reference DNA; (iii) cleave of heteroduplexes with 
Surveyor nuclease to cleave heteroduplexes; and (iv) analysis of digested DNA products 
using the detection/separation on gel electrophoresis.  
 Firstly, PCR amplification was performed for control and test samples. Genomic DNA 
was extracted as described in Section 2.3.3.1 from HEK293T, NIH3T3 and neural crest 
cells (O9-1) after 48 hours of antibiotic selection. 100 ng of genomic DNA was used to 
amplify the regions spanning CRISPR CAS9 mutation sites using specific primers (Table 
2.16) and AmpliTaq Gold Polymerase (Thermofisher Scientific) as per manufacturer’s 
instructions. Control C and G fragment provided in the Transgenomic SURVEYOR 
mutation detection kit (Integrated DNA Technologies) were also amplified in parallel. 
Human male genomic DNA (Promega) and mouse genomic DNA (Promega) were used 
instead of test sample DNA.  
20 µl PCR reactions were prepared as follows; 2µl Gene AmpÒ 10X Gold Buffer (150 
mM Tris-HCl, pH 8.0, 500 mM KCl), 10µl of 10uM forward primer, 10µl of 10uM 
reverse primer, 0.8µl of 5mM dNTP mix (Vh Bio), 0.8µl of 1.5mM of 25mM magnesium 
chloride (MgCl2), 0.2µl of AmpliTaq Gold polymerase, 50ng DNA and deionized water. 
Genomic DNA was substituted with H20 to serve as a negative control. 50 µl PCR reaction 
of the two plasmid DNA, Control C and control G provided by the manufacturer were 
prepared to contain all the PCR components as above except forward primer, reverse 
primer and genomic DNA as the primers are already incorporated with the plasmid 
templates. PCR conditions for each primer are shown in Table 2.18 and Table 2.19. PCR 
products were run on 2% v/w gel electrophoresis with 100bp DNA ladder (Promega) to 
confirm one single band of the product. 
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Table 2.18 PCR amplification condition for SURVEYOR nuclease analysis 
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Table 2.19 Annealing temperature for SURVEYOR primers 
 
After PCR amplification, a DNA hybridisation step was carried out using PCR amplified 
DNA. Reference DNA (C and G, provided by the company) was mixed at an equal 
amount to form a reference control. Briefly, 10µl of each PCR amplified DNA (test 
sample) was mixed with 10µl of negative control (NTC) in 0.2 ml tube. The samples were 
hybridised on a thermocycler according to manufacturer’s protocol. 30 µl of G and C 
alone were placed in separate tubes to serve as negative control for nuclease treatment. 
The hybridised product was digested with 2 µl of 0.15M MgCl2 solution, 1µl of 
SURVEYOR Enhancer S and 1 µl of SURVEYOR Nuclease S. The samples were kept 
on the ice and properly mixed by gentle vortexing followed by incubation for 60 minutes 
at 42°C. The reaction was stopped by adding 2µl of Stop solution into the tubes. Finally, 
the digestion products were analysed by 1.5% w/v agarose gel electrophoresis. 
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2.3.10.5 IncuCyte® live cell count proliferation assay 
Growth curve of cell lines transfected with CRISPR/Cas9 lentivirus was established using 
IncuCyte® live cell imaging system. The images of cells were captured 24-hours post 
infection and 24 hours post CD44 sorting for NIH3T3 and O9-1 cell lines respectively. 
Cell proliferation was measured using an IncuCyte phase only module and the images 
were collected on IncuCyte Zoom for 14 days. A specific processing definition was 
applied using IncuCyte mask (goldenrod) and the percentage cell confluency was 
exported to GraphPad Prism software for statistical analysis. 
2.3.10.6 Immunofluorescence imaging of human Rhabdoid tumour markers  
The effect of SMARCB1 knockout on cell migration and cytoskeleton organisation was 
evaluated using immunofluorescence labelling of phalloidin (F-actin). Additionally, the 
presence of human Rhabdoid IHC characteristics such as positive vimentin and 
cytokeratin 8 were also established using this technique. In brief, 20,000 cells were seeded 
in 8-well chambers (Sigma Aldrich) 24 hours prior to antibody incubation and the cells 
were fixed with formalin for 30 minutes at room temperature. To permeabilise, the cells 
were fixed for 5 minutes with 0.1% v/v Triton in PBS followed by 3 x 5 minutes washing 
steps with PBS. For the evaluation of cytoskeleton organisation, cells were stained with 
100µl of 1X of CytoPainter Phalloidin iFlour-488 for 1 hour in the dark at room 
temperature. Cells were washed with PBS to remove excess conjugate before mounting 
with Prolong Gold antifade reagent with DAPI staining, sealing with nail polish and 
imaging with Leica DM6 microscope. For visualisation of vimentin and cytokeratin, cells 
were incubated with appropriate primary antibodies; anti-rabbit vimentin (CST D21H3) 
and anti-cytokeratin 8 (Life Technologies MA514428) for 1 hour at room temperature 
and washed three times 5 minutes each on the rocker to remove the excess antibodies. 
The cells were then blocked with 1% BSA in PBS for 30 minutes followed by secondary 
antibody incubation using either goat anti-mouse IgG Alexa Fluor 488 (ThermoFisher A-
11001) or goat anti-rabbit IgG Alexa Fluor 568 (ThermoFisher A-11001) for 1 hour in the 
dark at room temperature. Cells were washed with PBS, mounted with DAPI and sealed 
for imaging. 
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2.3.10.7 Cell differentiation 
CD44 sorted NC cells were plated on 6-well plate at 200,000 cell density and were 
cultured in O9-1 media. When the cells reached 90% confluency, the spent media was 
removed, and the cells were washed once with PBS. To induce osteogenic differentiation, 
cells were cultured in differentiation medium made up of DMEM, FBS 10%, 50 µg/ml 
ascorbic acid, 10 mM β-glycerophosphate, 10 nM dexamethasone. The media was 
changed every three days. After 3 weeks in culture, the cells were washed three times 
with 1x PBS, fixed with 10% formalin (room temperature) for 30 minutes followed by 
three times washing step with distilled water. For detection of calcium deposits, alizarin 
red solution was prepared a day prior to cell staining. 2g alizarin red solution (Sigma 
Aldrich) was dissolved in 100 ml of distilled water and the pH was adjusted to 4.1-4.3. 
The dark brown solution was filtered using 0.2 microns and stored in dark at 4°C. To stain 
the cells, 2 ml of Alizarin red was added to the well and the cells were incubated for 10-
15 minutes in dark. Cells were washed with distilled water 3 times. Undifferentiated cells 
were zero to slightly reddish, whereas differentiated osteoblasts with extracellular 
calcium deposits cells were bright red. 
To induce adipogenic differentiation, the cells were cultured in differentiation medium 
made up of a-MEM media supplemented with 10% FBS,1% L-glut 1% Pen-Strep, 1µM 
dexamethasone, 1µM indomethacin, 500 µM 3-isobutyl-1-methylxanthine (IBMX) and 
10 µg/ml human recombinant insulin. The media was changed every three days. After 3 
weeks in culture, the cells were washed three times with 1x PBS, fixed with 10% formalin 
(room temperature) for 30 minutes followed by three times washing step with distilled 
water. Detection of lipid oil droplet was utilized to access adipogenic differentiation. To 
prepare oil-red-o staining, 300 mg of oil-red-o powder (Sigma Aldrich) was mixed with 
100 ml of 99-100% isopropanol. During formalin fixed incubation time, 3 parts of oil-
red-o were mixed with 2 part of deionised water and the mixed solution was allowed to 
sit at room temperature for at least 10 minutes. Prior to staining, oil red o solution was 
filtered through 0.2-micron filter (Thermo Scientific). To stain the cells, 2 ml of oil-red-
o solution was added to the well and the cells were incubated for 10-15 minutes in dark. 
Cells were washed with distilled water 3 times or until the water becomes clear. For 
analysis 1 ml of distilled was added to the well and the presence of lipid droplet was 
assessed by microscope. 
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2.3.11 Therapeutic targeting BMI1 in Malignant Rhabdoid Tumour (MRT) with 
shRNA and small inhibitors 
2.3.11.1 Oligonucleotides and primers 
All oligonucleotides were synthesized and designed as previously described (see section 
2.3.3). The primers used to target BMI1 in Plko5d vector are in Table 2.20. 
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2.3.11.2 shRNA targeting of BMI1 in MRT 
MRT cell lines were transfected with shRNA lentivirus from two different vectors as 
discussed in previous section 2.7.1 at appropriate MOI. Cells were infected with lentivirus 
for 24 hours and media replaced with fresh media the next day. Cells were harvested 96 
hours post infection.  
2.3.11.3 Inhibition of BMI1 in MRT cells lines with PTC209 
To determine the GI50 values, 1000 cells were plated in 96-well plate and 12 different 
concentrations of BMI1 inhibitors ranging from 0 to 5.7 nM were added and DMSO was 
used as a control. The number of visible cells was recorded 96 hours post-transfection in 
triplicate using CellTiter Glo (Promega) and dose-response curves were fitted to data. For 
subsequent experiments using PTC209, cells were treated with sub-lethal dose as follows; 
1 µM and 3.5 µM for G401, A204 and CHLA-266 whereas 5 µM and 10 µM for BT16.  
2.3.11.4 Limiting dilution assay and ELDA analysis 
For in vitro limiting dilution assay (LDA), transduced MRT cell lines were dissociated 
into single cells and diluted serially to an appropriate cell density. Prior to cell 
dissociation, adherent MRT cells were infected with either shRNA lentivirus for 24 hours 
or PTC209 for 96 hours post infection. Cells transfected with PTC209 were allowed to 
recover for 120 hours to enable sphere formation.  
In 96-well plates, cells were plated at following densities; 50,000, 10,000, 5,000, 1,000, 
100, 10 and 1 per well. For each cell density (50,000, 10,000, 5,000), at least 12 wells 
were seeded with cells whereas 96 wells were seeded with cells for low cell density 
(1,000, 100, 10 and 1). Wells containing spheres were scored on day 6 and the positive 
wells were used to measure the frequency of sphere-forming units (SFUs) using the LDA 
software provided by the Walter and Eliza Hall Institute 
(http://bioinf.wehi.edu.au/software/elda/index.html). For shRNA-infected cells, positive 
GFP, RFP and tomato cells were sorted and seeded in the wells.  
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2.3.11.5 Assessment of cell apoptosis using Caspase 3/7 assay  
The effect of BMI1 knockdown using both shRNA and PTC209 on cell apoptosis was 
assessed using Caspase3/7-Glo apoptosis kit (Promega) according to manufacturer’s 
instructions. Briefly, 1000 MRT cells were seeded in 96-well plate in triplicate and the 
reading was taken at 24, 72, 120 hours post treatment with shRNA and BMI1 inhibitors. 
25 µl of Caspase3/7 solution was added to the wells and the plate was incubated at 37°C 
for 30 minutes. The OD at 560 nm was read in a FLUOstar Omega (BMG Labtech) plate 
reader. Fold increase in Caspase 3/7 activity over time course was determined by 
comparing these results with that of the simultaneous controls (DMSO or NTC). The 
background reading from cells and buffers was subtracted from the reading of both MRT-
treated and control samples.  
2.3.11.6 Cell senescence analysis 
To determine senescence following BMI1 knockdown, MRT cells were seeded at a 
density of 1 x 105 in 6-well plate (Corning) and infected with either shRNA lentivirus at 
MOI 5 or PTC209 at two drug concentrations and DMSO (1.0%). For A204, G401 and 
CHLA-266, the cells were treated at 1 and 3.5 µM whereas BT16 cells were treated at 5 
and 10 µM. After 96 hours infection, the b-galactosidase was measured using senescence 
detection kit (Sigma Aldrich) according to manufacturer’s protocols. Positive b-
galactosidase stained cells (green) were manually counted.  
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2.4 Appendix  
Appendix  2.1: Expression profiles of various stem cell types for identification of cell of 
origin for MRT.  
 
Continued 
GEO accession 
number
Stem cell type Source Number of dataset
GSE40751 NPC
Gene Expression 
Omnibus (GEO) NCBI
5
GSE40904 Glioma
Gene Expression 
Omnibus (GEO) NCBI
12
GSE42294 NPC
Gene Expression 
Omnibus (GEO) NCBI
5
GSE44186 MSC
Gene Expression 
Omnibus (GEO) NCBI
1
GSE45899 NSC
Gene Expression 
Omnibus (GEO) NCBI
2
GSE47796 NPC
Gene Expression 
Omnibus (GEO) NCBI
11
GSE47796 Hepatocytes
Gene Expression 
Omnibus (GEO) NCBI
4
GSE47796 NPC
Gene Expression 
Omnibus (GEO) NCBI
10
GSE47796 Neuronal
Gene Expression 
Omnibus (GEO) NCBI
3
GSE47796 PSC
Gene Expression 
Omnibus (GEO) NCBI
12
GSE47796 Endoderm
Gene Expression 
Omnibus (GEO) NCBI
2
GSE48616 Osteogenic
Gene Expression 
Omnibus (GEO) NCBI
4
GSE54186 ESC
Gene Expression 
Omnibus (GEO) NCBI
2
GSE54186 EB
Gene Expression 
Omnibus (GEO) NCBI
2
GSE54186 ESC
Gene Expression 
Omnibus (GEO) NCBI
2
GSE54186 EB
Gene Expression 
Omnibus (GEO) NCBI
2
GSE55679 ESC
Gene Expression 
Omnibus (GEO) NCBI
4
GSE56906 NSC
Gene Expression 
Omnibus (GEO) NCBI
2
Deposited data stem cell expression profiles
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Continued 
GSE56906 ESC
Gene Expression 
Omnibus (GEO) NCBI
2
GSE56906 NPC
Gene Expression 
Omnibus (GEO) NCBI
2
GSE58475 NSC
Gene Expression 
Omnibus (GEO) NCBI
2
GSE60740 MSC
Gene Expression 
Omnibus (GEO) NCBI
2
GSE61050 ESC
Gene Expression 
Omnibus (GEO) NCBI
3
GSE61266 ESC
Gene Expression 
Omnibus (GEO) NCBI
3
GSE61266 NPC
Gene Expression 
Omnibus (GEO) NCBI
3
GSE61842 NPC
Gene Expression 
Omnibus (GEO) NCBI
8
GSE61842 ESC
Gene Expression 
Omnibus (GEO) NCBI
4
GSE61842 EB
Gene Expression 
Omnibus (GEO) NCBI
1
GSE65631 MSC
Gene Expression 
Omnibus (GEO) NCBI
12
GSE67309 NPC
Gene Expression 
Omnibus (GEO) NCBI
1
GSE67338 NBS
Gene Expression 
Omnibus (GEO) NCBI
3
GSE69991 MSC
Gene Expression 
Omnibus (GEO) NCBI
6
GSE7178 NPC
Gene Expression 
Omnibus (GEO) NCBI
9
GSE7179 ESC
Gene Expression 
Omnibus (GEO) NCBI
9
GSE71080 MSC
Gene Expression 
Omnibus (GEO) NCBI
1
GSE7637 MSC
Gene Expression 
Omnibus (GEO) NCBI
30
GSE74358 Neuronal
Gene Expression 
Omnibus (GEO) NCBI
8
GSE74358 NPC
Gene Expression 
Omnibus (GEO) NCBI
3
GSE7896 ESC
Gene Expression 
Omnibus (GEO) NCBI
8
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Continued  
GSE82101 NPC
Gene Expression 
Omnibus (GEO) NCBI
1
GSE24598 MSC
Gene Expression 
Omnibus (GEO) NCBI
3
GSE9940 neural epithelial
Gene Expression 
Omnibus (GEO) NCBI
1
GSE9940 ESC
Gene Expression 
Omnibus (GEO) NCBI
3
GSE9940 EB
Gene Expression 
Omnibus (GEO) NCBI
4
GSE9940 neural epithelial
Gene Expression 
Omnibus (GEO) NCBI
10
GSE10315 MSC
Gene Expression 
Omnibus (GEO) NCBI
3
GSE10315 Chondrogenic
Gene Expression 
Omnibus (GEO) NCBI
24
GSE13307 NPC
Gene Expression 
Omnibus (GEO) NCBI
4
GSE13715 NPC
Gene Expression 
Omnibus (GEO) NCBI
18
GSE15209 NSC
Gene Expression 
Omnibus (GEO) NCBI
5
GSE18043 Osteogenic
Gene Expression 
Omnibus (GEO) NCBI
8
GSE18618 NPC
Gene Expression 
Omnibus (GEO) NCBI
3
GSE18618 iPSC
Gene Expression 
Omnibus (GEO) NCBI
6
GSE18618 ESC
Gene Expression 
Omnibus (GEO) NCBI
6
GSE24530 ESC
Gene Expression 
Omnibus (GEO) NCBI
8
GSE27313 MSC
Gene Expression 
Omnibus (GEO) NCBI
1
GSE28618 Glioma
Gene Expression 
Omnibus (GEO) NCBI
1
GSE29368 Glial
Gene Expression 
Omnibus (GEO) NCBI
5
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GSE29368 Oligodendrocyte
Gene Expression 
Omnibus (GEO) NCBI
5
GSE29625 ESC
Gene Expression 
Omnibus (GEO) NCBI
12
 GSE30807 MSC
Gene Expression 
Omnibus (GEO) NCBI
1
GSE31215 MSC
Gene Expression 
Omnibus (GEO) NCBI
10
GSE34152 NSC
Gene Expression 
Omnibus (GEO) NCBI
4
GSE35546 MSC
Gene Expression 
Omnibus (GEO) NCBI
1
GSE35546 Chondrogenic
Gene Expression 
Omnibus (GEO) NCBI
6
GSE36923 MSC
Gene Expression 
Omnibus (GEO) NCBI
3
GSE36923 Adipogenic
Gene Expression 
Omnibus (GEO) NCBI
3
GSE36923 MSC
Gene Expression 
Omnibus (GEO) NCBI
11
GSE17312 ESC
Gene Expression 
Omnibus (GEO) NCBI
1
GSE17312 iPSC
Gene Expression 
Omnibus (GEO) NCBI
3 
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Chapter 3 An analysis of putative cell of origin for 
Malignant Rhabdoid Tumours (MRT) 
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3.1 Summary 
Malignant Rhabdoid Tumours (MRT) are highly aggressive malignancies which occur 
almost entirely in infants. MRT are caused by biallelic inactivation of SMARCB1, a 
tumour suppressor gene and a core subunit of the SWI/SNF complex (Versteege et al., 
2002, Biegel et al., 2000, Roberts and Biegel, 2009). The tumours are highly 
heterogeneous and can be found at various locations in the body. Knowledge of tumour 
aetiology especially cell of origin and how it relates to different anatomical locations is 
still lacking. A few candidates for cell of origin of MRT have been proposed so far by 
other studies based upon the phenotypic diversity of MRT (Haas et al., 1981, Ota et al., 
1993, Suzuki et al., 1997, Okuno et al., 2010, Kato et al., 2003, Parham et al., 1988). 
However, there is no systematic approach to identify putative cells of origin for MRT as 
the assumptions of cell of origin were made based on the presence of differentiation 
markers from multiple lineages such as neural and mesenchymal in primary tumours. 
Therefore, in this chapter, I seek to shed light on the cell of origin for MRT and whether 
the cell of origin is common for tumours regardless of anatomical locations. This 
hypothesis was challenged by performing a meta-analysis, cross-referencing expression 
profiles from primary MRT (n=119), and functional models in which SMARCB1 was re-
expressed (n=5 lines) with expression profiles from multiple candidate stem cell types 
including epithelial, embryonic, neural, mesenchymal and neural crest (n=446) 
suggesting three putative candidate cell populations within the family of neural crest (NC) 
cells, neural stem cell (NSC) and mesenchymal stem cells (MSC). The extent of 
transcriptional overlap clearly reflects differences in tumour location and molecular 
subgroup. 
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3.2 Introduction 
3.2.1 ATRT and ECRT: are they molecularly distinct?  
Malignant Rhabdoid Tumours (MRT) are stratified as poor prognosis disease. MRT can 
be categorised into Atypical Teratoid Rhabdoid Tumours (ATRT) for which the tumours 
arise in the brain or central nervous system (CNS) (Rorke et al., 1996, Torchia et al., 
2015), and Extra Cranial Rhabdoid Tumours (ECRT) for tumours that are found in the 
soft tissue, kidney, lung, liver, etc (MacDonald, 2008, Beckwith and Palmer, 1978). MRT 
are phenotypically highly heterogeneous. Inter-tumoural heterogeneity in each molecular 
subtype was reported in few studies based on genomic, transcriptomic and epigenomic 
profiling (Johann et al., 2016, Chun et al., 2016, Torchia et al., 2016, Han et al., 2016, 
Torchia et al., 2015). In 2015, Torchia et al. (2015) reported two gene expression 
subgroups within the MRT which correlated with clinical outcome. Their initial study 
was expanded in 91 primary ATRT and 10 ATRT cell lines (Torchia et al., 2016) 
demonstrating that ATRT can be segregated into three epigenetic subgroups with distinct 
epigenomic features, types of SMARCB1 mutation, transcriptional features and specific 
therapeutic sensitivities. Molecularly distinguishable subgroups within ATRT also have 
been reported by Johann et al. (2016), in which ATRT were divided into three subgroups 
with distinct epigenetic and expression profiles.  
Regardless of anatomical location, ATRT and ECRT are caused by biallelic inactivation 
of SMARCB1, a potent tumour suppressor gene and a core subunit of SWI/SNF chromatin 
remodelling complex (Biegel et al., 2002b, Biegel et al., 2000, Roberts and Biegel, 2009). 
The question is then raised whether ATRT and ECRT are a single entity with unique 
genetic and epigenetic expression profiles. To elucidate potential molecular disparities 
between ATRT and ECRT, Grupenmacher et al. (2013) analysed the global gene 
expression and microRNA expression of primary MRT (10 RTK and 13 ATRT) and cell 
lines (G401-RTK and MON-AT/RT) using principal component analysis (PCA). Their 
work showed two subgroups within MRT related to tumour location (Figure 3.1a). 
However, analysis based on microRNA expression failed to separate the primary tumours 
(Figure 3.1b). 
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Figure 3.1 Principal component analysis of two molecular subgroups in MRT; ATRT 
and ECRT. Square represented ATRT whereas circle represented RTK (ECRT).  (a) The 
plot shows the separation of two subgroups using unsupervised gene expression analysis. 
Cell lines clustered as a group and separated from the primary tumour. (b) PCA using 
microRNA expression showed a major cluster of tumours. The figures were reproduced 
from Grupenmacher et al. (2013).  
 
The extent to which ATRT and ECRT overlap also has been studied by PBTG group at 
NICR (unpublished). RNA-Seq of primary MRT (10 ATRT, 13 ECRT) was compared 
with 228 paediatric medulloblastoma (MB) and analysed using non-negative matrix 
factorisation (NMF). Gene expression analysis showed five distinct subgroups consisting 
of four MB subgroups and one MRT subgroup (irrespective of tumour origin) (Figure 
3.2). This finding illustrates that two subgroups within MRT share a closer expression 
profile than that of the MB subgroups. Additionally, to gain more insight whether there 
is a common molecular subgroup for MRT, 23 primary MRT RNA-seq (10 ATRT, 13 
ECRT) was analysed using NMF. Unsupervised NMF analysis (k=2) of these tumours 
confirmed the existence of two metagenes associated with primary tumour location, one 
that broadly but not exclusively defined a group of ECRT while the other group described 
entirely ATRT (Figure 3.3).  
(a) (b) 
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Figure 3.2 A t-SNE plot of cross platform projection of consensus NMF metagene 
expression (k=5) in primary MRT (n=23) vs MB (n=228) showing MRT is a single 
entity regardless of anatomical location. The figure was reproduced from PBTG group 
(unpublished). 
 
Taken together, Grupenmacher et al. (2013) and the PBTG group demonstrated consistent 
findings in which MRT encompasses two subgroups namely ATRT and ECRT. Of note, a 
cross-platform projection of 2 metagenes onto four independent published datasets 
showed a transition of expression profiles from neural (i.e. GFAP, MAP2, SOX1/2) to 
mesenchymal phenotype (H19, HOXC5/6/8/9/10) (work done by PBTG group, 
unpublished) (Figure 3.4). This finding was corroborated by gene set enrichment analysis 
(GSEA) of these metagenes which showed significant enrichment of neural and 
mesenchymal genesets e.g. those describing mesenchymal (Normalized Enrichment 
Score (NES) = 3.48, p<0.001) and proneural (NES = 3.09, p<0.001) glioblastoma 
phenotypes respectively. These metagenes are correlated with three subgroups that were 
previously described by (Johann et al., 2016) as ATRT-MYC which demonstrated a 
mesenchymal gene signature, ATRT-TYR signifies an intermediate state and ATRT-SHH 
which associated with a neural signature. These findings, therefore, raise the question as 
MRT vs MB
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to whether MRT regardless of tumour location originate from a common type of 
progenitor cell or if there is more than one cell of origin in MRT. 
 
 
Figure 3.3 A heatmap of unsupervised NMF consensus clustering (k=2) of primary 
MRT RNA-seq (n=23) shows two metagenes within MRT related to primary tumour 
locations. Cross-platform projection into previously published dataset that are 
associated with clinicopathological profiles and gene expression of 58 genes identified 
within the top 100 genes that related with this metagene and present in all platforms.  
 
3.2.2 Introduction to cell of origin  
3.2.2.1 Cell of origin of CNS embryonal tumours 
For many cancer types, the precise identification of cell of origin remains unknown. The 
cell of origin can be described as normal cells that have undergone oncogenic 
transformation due to genetic mutations (Rycaj and Tang, 2015). In childhood cancer, 
cancer may arise as a result of mutation in the embryonal cells or when the mature 
prenatal cells acquire embryonal properties which favour the survival pre- or post-natal 
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environment (Marshall et al., 2014). Prenatal oncogenic mutations may occur in early 
progenitor or stem cells which have extensive self-renewal capacity that is essential for 
in utero development. Therefore, the identification of a cell of origin will allow a better 
understanding of childhood cancers in terms of why the tumours develop, how to prevent 
them and what is the best way to treat them. 
Several childhood cancers such as infant acute lymphoblastic leukaemia (ALL) and MRT  
are thought to have an embryonal cell of origin (Marshall et al., 2014). However, there is 
no clear evidence whether the embryonal tumours arise from the embryonal cells in utero 
or because of mutation in more mature prenatal cells which have the capacity to rapidly 
evolve towards tumour development.  
Neuroblastoma (NB) is also thought to originate from prenatal embryonal cells. Clinical 
presentations of Neuroblastoma (NB) such as young age at time of diagnosis (<5 years) 
(Maris, 2010) and multifocal and bilateral tumours in tissue derived from embryonic 
neural crest cells (Brodeur, 2003) provided evidence of a prenatal origin for this 
embryonal malignancy. Besides that, normal foetal neuroblasts resemble tumours that 
derived from neuroblastoma, thus providing an evidence for prenatal origin. NB occurs 
predominantly in infancy and young children (Brodeur, 2003, Maris, 2010). Analysis of 
differentiation markers suggests the earliest cell of origin for NB is neural crest cells. 
Transgenic expression of Mycn or Alk in JoMa1, a multipotent neural crest progenitor cell 
line resulted in neuroblastoma like tumours in vivo in contrast to wild-type  JoMa1 cells 
(Schulte et al., 2013). Additionally, high expression of Myc in under the control of the rat 
tyrosine hydroxylase (Th) promoter in Th-MYCN transgenic mice led to NB 
tumourigenesis (Hansford et al., 2004).  
Another type of an embryonal tumour, Medulloblastoma (MB) which consists of four 
molecular subgroups (Wnt, Shh, Grp3 and Grp4), is thought to have a different type cell 
of origin for each subgroup. Activation of b-catenin and mutation in Wnt signalling 
pathway in BLBP+, Olig3+ neural precursor that present in the brainstem of embryonic 
mice initiated tumour formation which in line with radiological analysis of Wnt MB 
tumours often found within the fourth ventricle, infiltrating the dorsal surface of the 
brainstem (Gibson et al., 2010, Takebayashi et al., 2002). Activation of Shh in granule 
neural progenitor cells predisposed MB at 3 months of age of mice (Yang et al., 2008). 
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Notably, mutation of Ptch (Shh effector) in neural stem cells led to rapid development of 
MB with 100% of mice formed tumours by 3-4 weeks. In short, these studies demonstrate 
that deregulation of Shh in neural progenitor and neural stem cells can serve as origin for 
Shh subtype of MB. 
3.2.3 Cell of origin for Malignant Rhabdoid Tumours 
3.2.3.1 Cell of origin for MRT: what we know so far? 
MRT are highly heterogeneous tumours however the histological origin of MRT still 
remains elusive. Nevertheless, significant progress was made to identify the cells of 
origin that are capable of initiating MRT tumourigenesis. The cell morphology and the 
presence of multilineage differentiation markers in MRT have led to speculation that the 
tumours originate from neuroectodermal (Haas et al., 1981, Ota et al., 1993, Suzuki et al., 
1997, Okuno et al., 2010), neural (Higashino et al., 2003, Bonnin et al., 1984), epithelial 
(Parham et al., 1988), or myogenic (Sugimoto et al., 1999). Recent genome-wide analysis 
of primary MRT (Chun et al., 2016, Torchia et al., 2016) and mouse model experiments 
(Han et al., 2016, Vitte et al., 2017) point towards mesenchymal, neural crest cells and 
neural stem cells as potential cells of origin for MRT.   
As previously mentioned in section 3.2.1, gene expression analysis of primary MRT 
(ATRT and ECRT) by the PBTG group demonstrated the transition in gene expression 
pattern from mesenchymal to neural (Figure 3.4). Transcriptional analysis by Torchia et 
al. (2016) reported that two genesets related to neural and mesenchymal cell development 
were highly enriched in ATRT. This raises the possibility that MRT originate from 
mesenchymal and/or neural stem cells. In support of this view, MRT also exhibit markers 
involved in myogenesis such as skeletal b-tropomyosin, neutral calponin, NFAT3, and 
myosin regulatory light chain thus illustrating a  mesenchymal stem cell origin of tumours 
(Pomeroy et al., 2002).  
MRT are also postulated to originate from neural crest cells (Chun et al., 2016, Han et al., 
2016, Vitte et al., 2017, Gadd et al., 2010). Comparison of 10 MRT with 12 cellular 
mesoblastic nephromas, 16 clear cell sarcomas of the kidney, and 15 Wilms tumours using 
RNA-seq showed downregulation of differentially expressed genes associated with 
neural crest cell and neural development (Gadd et al., 2010). Likewise, a recent genome 
 
117 
study by Chun et al. (2016) in primary ECRT reported significant enrichment of genes 
expressed during various stages in neural crest development such as neural plate border 
formation, neural crest cell specification and migration and also neural crest 
differentiation into various lineages such as  cardiac neural crest (Card), myoblast (Myo), 
and sympathetic neurons (SN). Tamoxifen injection at a specific developmental window 
(E6-E7) in Smarcb1flox/flox; Rosa26-CreERT2  mice gave rise to tumours at various locations 
such as soft tissues that phenotypically resembled human MRT (Han et al., 2016). Gene 
expression analysis of Smarcb1-deficient tumours shared closer expression profiles with 
the expression profiles of neuron progenitors and ectomesenchyme; a cephalic neural 
crest cell-derived mesoderm. Following this study, Vitte et al. (2017) have reported that 
conditional knockout of Smarcb1 at protein zero (P0) in neural crest cells using Cre 
recombinase expression led to tumour formation in cranial nerves and meninges that 
exhibited histological characteristics and molecular profiles mimicking human MRT.  
Although analysis of cell morphology, differentiation markers and gene expression of 
primary tumours provide clues as to the cell of origin of MRT, such studies have 
limitations. Expression of specific markers in tumour cells may not reflect the expression 
at an early developmental stage. Current mouse model experiments by Vitte et al. (2017) 
and Han et al. (2016) provide the closest clue for cell of origin for MRT, however so far, 
no tumours were found in CNS. The majority of tumours were developed in meninges, 
which is a rare location for ATRT (El-Nabbout et al., 2010, Mondal et al., 2011), eyes and 
head (Vitte et al., 2017). In short, the potential cell of origin and how it can correlate with 
the location of the primary tumours should be further explored as it will allow 
development of better mouse models and invention of new targeted therapy for MRT. 
Having said this, definitive evidence of a cell of origin for each molecular subgroup is 
critically needed. Here I apply a more systematic approach to accurately identify and 
characterise potential cells of origin for MRT and the possibility of subgroup-specific 
cells of origin.  
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Figure 3.4  Transition from neural to mesenchymal geneset observed in primary MRT. 
GSEA analysis of pre-ranked genes based on correlation with MRT metagenes (k=2) 
demonstrated significant gene set enrichment associated with neural (on right of plot) 
and mesenchymal (on the left of plot). Each tick represents the gene within the geneset 
whereas the height represents the expression score (ES). The loess curve shows 
enrichment trend. Pink, blue and grey shading represents genes significantly positively 
negatively, and non-significantly correlated respectively. The figure is adapted from 
PBTG group (unpublished).  
 
3.2.3.2 Analysis of expression profiles of MRT cell lines following SMARCB1 re-
expression shows resemblance to expression profiles associated with adult 
multipotent stem cells 
Gene expression analysis of SMARCB1 re-expression profiles in 5 MRT cell lines (A204, 
G401, KD, SWOH and LM) provides an early indication of potential cell of origin within 
MRT (Figure 3.5). These expression profiles were generated from time course experiment 
in which SMARCB1 expression was forcibly re-expressed in 5 MRT cell lines (Table 3.1) 
using lentiviral transfection of pCDH-EF1-PURO-SMARCB1 plasmid (INI1). The MRT 
cell lines were also transfected with lentiviral PCDH-CMV-MSC-EF1-Puro plasmid to 
create control cells (Control). The cell pellets were collected on day 1, 3, 7 and 14 post-
transfection and RNA extraction was performed for RNA-sequencing analysis. The initial 
gene expression analysis using Affymetrix HGU133plus2 array was performed by selecting 
the genes that were differentially expressed initially between each cell line in the absence of 
SMARCB1 expression. The profiles were then projected onto the first three components of a 
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principle component analysis (Dr Dan Williamson, unpublished). Interestingly, following 
SMARCB1 expression over time, the gene expression of all five cell lines converges towards 
one point in space which resembles most closely that of the cells derived from adult 
multipotent stem cells. This result provides an insight that MRT, regardless of anatomical 
origin may possibly originate from the similar cell population. This preliminary analysis was 
re-evaluated further in this study with addition of a much greater number and range of stem 
cell profiles and MRT primary tumours.  
 
Table 3.1 MRT cell lines used in SMARCB1 re-expression experiment 
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Figure 3.5 Analysis of expression profiles of MRT cells from 5 different MRT cell lines 
following SMARCB1 re-expression after Day 1, 3, 7 and 14. A principal components 
analysis of genes, which are differentially expressed in response to SMARCB1 re-
expression, shows that expression profiles converge over time to a point in expression 
space, which most closely resemble adult multipotent stem cells. Included are expression 
profiles from a variety of multipotent cell types (i.e. neural stem cells, human embryonic 
stem cells, induced pluripotent stem cells, etc). Expression of these genes separates the 
adult multipotent stem cells from the other stem cell types. 
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3.3 Aims 
The study reported in this chapter aimed to identify potential cells of origin within 
Malignant Rhabdoid Tumours (MRT). 
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3.4 Results 
3.4.1 Transcriptome analysis of primary Malignant Rhabdoid Tumours (MRT) 
identifies MRT subgroups and provides an insight into potential cell of origin 
MRT can be found at various location in the body including CNS, soft tissues, liver, 
kidney, etc. Recent genome-wide studies of primary MRT illustrated the existence of 
molecular subgroups in MRT (Chun et al., 2016, Johann et al., 2016). Transcriptomic 
analysis of primary MRT (10 ATRT, 13 ECRT) (see detail in section 3.2.1) demonstrated 
two molecular subgroups within MRT related to bodily location. This finding implies that 
the cell of origin for each subgroup is distinct. This has led me to hypothesise that MRT 
have different cells of origin that are linked to primary tumour origin. To explore the 
molecular subgroups within MRT and how their tumour location correlates to cell of 
origin, unsupervised cluster analysis was performed on HGU133p2 primary MRT 
consisting of 113 ATRT and 37 ECRT. All the MRT HGU133p2 profiles were pre-filtered 
to remove genes for which fold change < 3-fold and/or the range < 300 between maximum 
and minimum values (with the top/bottom 5% most extreme values removed). t-
Distributed Stochastic Neighbour Embedding (t-SNE) showed that despite harbouring a 
common genetic mutation in SMARCB1, MRT are segregated into two subgroups related 
to tumour location; ECRT and ATRT (Figure 3.7a). The bodily location related to the 
subgroup in MRT provides the first indication that the cell of origin for MRT is not 
common and there is a possibility of at least two cellular origins that are specific for each 
subgroup.  
The existence of two subgroups in MRT was further corroborated using t-SNE analysis 
of the top 1000 most differentially expressed genes between ECRT and ATRT. This t-
SNE analysis separated the primary MRT into two distinct subgroups (Figure 3.7b), 
mainly related to primary tumour location, except for a few ATRT profiles clustered 
among ECRT. These datasets were from GSE28026  microarray analysis of 18 ATRT 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28026) which showed 
upregulation of bone morphogenetic protein (BMP), (Birks et al., 2011), a pathway 
commonly associated with mesenchymal stem cell (MSC) (Beederman et al., 2013) and 
embryonic stem cell (ESC) differentiation (Zhang et al., 2010). 
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Initial analysis suggests two different cells of origin for MRT related to the bodily location 
of primary tumours. To examine the pathways or genes that are specific to the bodily 
location of each molecular subgroup in MRT, the previously supervised RT HGU133p2 
expression profiles were used as the basis for pre-defined gene ranking. The genes were 
ranked based on ECRT and ATRT related genes. Gene set enrichment analysis (GSEA) 
was performed on these pre-ranked genes to identify gene signatures that represent well-
defined biological states or processes for each subgroup. The pre-ranked genes were 
analysed against hallmark gene sets (H) and gene ontology gene sets (C5) (both taken 
from MSigDB) (http://www.broadinstitute.org/gsea/index.jsp). 
GSEA analysis against Hallmark MSigDB identified 14 gene sets that were positively 
enriched (FDR of <25%, 8 of which had a NOM (nominal) p-value of < 1%) in ECRT vs 
ATRT (cohort of 13 primary ECRT) and 8 gene sets that were negatively enriched (FDR 
of < 25%; 4 p<1%). Of 14 gene sets identified in this analysis, “hallmark adipogenesis”, 
a subgroup of genes that involve in mesenchymal cell differentiation was positively 
enriched in ECRT (enrichment score (ES) of 0.22, normalised enrichment score (NES) of 
1.17). The adipogenesis associated genes that were upregulated in ECRT includes FABP4, 
CD36, SLC1A5, etc. Fatty acid binding protein 4 (FABP4, also known as aP2) is a 
cytoplasmic fatty acid chaperone which expressed primarily in adipocytes cells. This 
gene has been widely used as a marker for adipocyte cell differentiation (Shan et al., 
2013).  
GSEA analysis was also performed against Gene Ontology MSigDB to identify biological 
signalling pathways associated with two subgroups in MRT; ATRT and ECRT. This 
analysis has identified 107 gene sets that were positively enriched (FDR of <25%, 66 of 
which had a NOM (nominal) p-value of < 1%) in ECRT vs ATRT (cohort of 13 primary 
ECRT) and 45 gene sets that were negatively enriched (FDR of < 25%; 4 p<0.01). These 
45 gene sets negatively enriched in ECRT but positively enriched in ATRT are related to 
brain development and neuronal differentiation. The genesets include “GO neuron 
differentiation”, “neurite development”, “neurogenesis”, etc. Genes that were 
upregulated in ATRT includes Thy1 and SOX2.  
Both GSEA analyses indicate the enrichment of gene sets related to the anatomical 
location of the primary tumours; whereby the ECRT subgroup showed enrichment in 
mesenchymal cell differentiation and ATRT demonstrated upregulation of gene sets 
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associated with neural cell development. More importantly, results from this study 
corroborated previous reports whereby the authors identified transitions between neural 
and mesenchymal gene set in primary MRT (Chun et al., 2016, Torchia et al., 2016). In 
short, two subgroups differed in genes regulating cell lineage and developmental 
signalling depending on their primary tumour location. This finding indicates that two 
cells of origins for MRT are potentially neural for ATRT and mesenchymal for ECRT.  
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Figure 3.7  Bodily location of primary MRT related to molecular subgroups within 
MRT suggests two possible cells of origin. t-SNE analysis of HGU133p2 array 
expression profiles of primary MRT showing two subgroups in MRT known as ATRT (in 
red) and ECRT (in blue) positively related to bodily location. The genes were pre-filtered 
in an (a) unsupervised and (b) supervised manner. (c) Example GSEA enrichment plots 
from the hallmark and gene ontology MSIgDB gene set libraries indicating those 
positively or negatively enriched in either ECRT or ATRT genesets. The enrichment score 
(ES) indicates the degree to which the genesets are overrepresented at the top or bottom 
of the ranked gene list. Positive ES represents the geneset enrichment at the top of the 
ranked list while negative ES illustrates the geneset enrichment at the bottom of the 
ranked list. The ranked list that was used in this analysis was ECRT at the top and ATRT 
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at the bottom. The leading-edge subset is represented by the vertical line, and it indicates 
the genes that contribute most to enrichment score within the gene set. Gene set 
enrichment analysis (GSEA) of pre-ranked data of ECRT vs ATRT shows enrichment of 
genes linked to adipogenesis in ECRT while genes involved in neural were enriched in 
ATRT (neurogenesis).  
 
3.4.2 Unsupervised gene expression profiles of various stem cell types  
Gene expression analysis in primary MRT provides an initial indication of the possibility 
of two different cells of origin for MRT; neural stem cell and mesenchymal stem cells 
(see section 3.4.1). Additionally, gene signatures for neural crest cells and embryonic 
stem cells have been reported in primary ECRT and ATRT (Richer et al., 2017, Chun et 
al., 2016, Deisch et al., 2011). To identify putative cells of origin for MRT by considering 
other stem cell phenotypes that have been reported in MRT such as epithelial, 
mesenchymal, neuroectodermal, neural etc, the published Affymetrix HGU133Plus2 
expression array datasets for various stem cell types were searched using terms “RNA 
signature” and “non-cancerous stem cells” on NCBI GEO 
(https://www.ncbi.nlm.nih.gov/geo/)(details of the dataset are presented in Chapter 2, 
section 2.2.1). These datasets were further filtered to restrict to human expression profiles 
and the HGU133plus2 platform. The final expression profiles that were retained after the 
filtering process consists of several progenitor and stem cells. These include embryoid 
bodies (EB), progenitor stem cells (PSC), embryonic stem cells (ESC), induced 
pluripotent stem cells (iPSC), mesenchymal stem cells (MSC), stromal (STR), 
mesodermal cells, epithelial stem cells, hepatocytes, keratinocytes, adipocytes, 
chondrogenic, osteogenic, neural crest (NC), endoderm, neural epithelial, neurons, neural 
progenitor cells (NPC) and neural stem cells (NSC).  
To identify potential cells of origin for MRT from these various stem cell types, the 
published HGU133p2 stem cell profiles were initially pre-filtered to remove genes for 
which fold change < 3-fold and/or the range < 300 between maximum and minimum 
values (with the top/bottom 5% most extreme values removed) and the data analysed 
using a principle component analysis (PCA). PCA was performed using the filtered data 
sets to visualise the clustering of stem cells expression profiles (Figure 3.8). The analysis 
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showed the tendency of data sets to cluster into three broad groups: neural and its 
derivates which includes neural epithelia, neuronal stem cell, neuron and neural 
progenitor cells (in grey), embryonic stem cells (in blue) and mesenchymal with its 
derivatives which includes stromal, adipocytes, chondrogenic and osteogenic (in orange, 
yellow and red). (Figure 3.8a). 3D visualisation of PCA shows distinct groups of 
embryonic/totipotent stem cells separately from neural stem cell profiles. In brief, 3 major 
groups of stem cell profiles showed in this plot were mesenchymal (MSC) and its 
derivatives with neural crest (NC), neural stem cells (NSC) and embryonic stem cells 
(ESC).  
 
Figure 3.8 Unsupervised principle component analysis (PCA) showing HGU133p2 
array expression of various stem cell populations. Colours and shapes are labelled 
according to broad stem cell types. Black represents group of neuroglia cells of CNS, 
grey represents neuronal, orange represents stromal, yellow represents mesenchymal 
stem cells (MSC), red represents MSC derivatives, blue represents embryonic stem cells 
(ESC) and totipotent progenitor cells. ESC = embryonic stem cells, NSC = neural stem 
cells, NPC = neural progenitor cells, EB = embryoid bodies, iPSC = induced pluripotent 
stem cells, MSC = mesenchymal stem cells.  
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3.4.3 Unsupervised expression analysis reveals similarities between primary MRT 
and various stem cell types 
In keeping with early onset nature of MRT, SMARCB1 occurs in the cell of origin for 
MRT is most likely to be multipotent stem cells. Transcriptomic analysis of primary MRT 
(113 ATRT and 37 ECRT) shows that MRT are related to the bodily location with 
enrichment of genes linked to neural (ATRT) and mesenchymal (ECRT) expression 
phenotype (see section 3.4.1). Hence, the possibility of two cells of origin for MRT. 
Additionally, various opinions on cells of origin were made based on the presence of 
differentiation markers (Okuno et al., 2010, Suzuki et al., 1997, Parham et al., 1988), cell 
morphology (Gonzalez-Crussi et al., 1982, Haas et al., 1981), omics analysis of primary 
MRT (Torchia et al., 2016, Johann et al., 2016, Chun et al., 2016) and also MRT mouse 
models (Han et al., 2016, Vitte et al., 2017). I thus sought to explore which stem cell type 
could give rise to two molecular subgroups in MRT. Transcriptome profiles from stem or 
progenitor cells that are publicly available (Section 3.4.2) were cross-referenced with 
primary MRT tumours profiles (Section 3.4.1). Genes were pre-filtered to remove non-
varying probes (fold change < 300, absolute delta = 300, after excluding the top 5% most 
extreme values) in an unsupervised manner and the combined stem cell profiles and 
primary MRT underwent PCA analysis. The 3D PCA plot shows that primary MRT 
profiles were located in between NSC, MSC and derivatives; and NSC and derivatives 
expression profiles (Figure 3.9). The PCA plot demonstrates ECRT clustered close to 
MSC and NC profiles whereas ATRT clustered close to NSC. This finding corroborated 
the gene expression analysis of primary MRT mentioned in section 3.4.1. Notably, 
embryonic stem cell (ESC) profiles formed a distinct cluster separately from other stem 
cell populations (NSC, NC and MSC). The expression profiles of primary MRT did not 
overlap with ESC and totipotent stem cells (endoderm, epithelial, hepatocytes, 
keratinocytes and iPSC). Collectively, the location of primary MRT broadly overlaps with 
three stem expression profile namely NC, NSC and MSC, indicating that MRT may share 
a closer expression profiles with these stem cell populations thus possibly cell of origin 
(Figure 3.9). Secondly, ATRT located close to NSC suggests the potential of similar 
expression profiles shared between ATRT and NSC, thus the possibility of ATRT 
originating from NSC. Likewise, ECRT clustered closer to MSC and its derivatives. It is 
noteworthy that integration of expression profiles of primary MRT with broad stem cell 
populations in this analysis demonstrates ECRT grouped close to NC (“neural crest” on 
the PCA). These findings point to the possibility of shared expression profiles between 
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ECRT and MSC and NC thereby the probability of ECRT to originate either from NC or 
MSC. The results show consistency with previous analysis in section 3.4.1 that MRT 
originate from different cell of origin depending on the bodily location of primary 
tumours.  
 
 
Figure 3.9 3D PCA showing unsupervised HGU133p2 array expression of primary 
MRT clustered close to stem cell profiles of mesenchymal and derivatives (orange, red 
and yellow), neural (grey) and neural crest cells (grey). The stem cell profiles and 
primary MRT were coloured and labelled according to rough type of stem cell. 
Embryonic stem cells (blue), endoderm (green) and totipotent progenitor cells (pink) 
made up a group, away from the primary MRT. This analysis demonstrates primary MRT 
may share closer expression profiles with stem cell populations (mesenchymal and 
derivatives; neural and derivatives, and neural crest cells). Notably, ECRT clustered 
close to neural crest cells and mesenchymal stem cell with its derivatives. Whilst, ATRT 
were located near neural stem cells and its derivatives. ESC = embryonic stem cells, NSC 
= neural stem cells, NPC = neural progenitor cells, EB = embryoid bodies, iPSC = 
induced pluripotent stem cells, MSC = mesenchymal stem cells. 
All Stem Cells + RT: PCA, fold = 3, delta = 300
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Figure 3.10 Hierarchy of stem cell differentiation to support discovery of cell of origin 
for MRT that are possibly subgroup related. 
 
3.4.4 Meta-analysis of primary tumour with stem cell profiles suggest three 
possible cells of origin in MRT 
Integration of transcriptome profiles of primary MRT with various stem cell profiles as 
previously discussed indicates possible three cells of origin in MRT, which related to the 
location of primary tumours in the body (section 3.4.1, Figure 3.7 and section 3.4.3, 
Figure 3.9). The findings to this point suggest NSC, NC and MSC as potential cells of 
origin for MRT. Therefore, the previous stem cell profiles including derivatives were 
simplified into three groups. EB, PSC, ESC and iPSC were grouped as ESC; MSC, 
stromal, and endoderm derivatives were clustered as MSC; NPC, NSC and neural 
epithelial were classified as NSC; and neural crest cells as NC. To further characterise 
those three potential cells of origin in MRT and how they correlate with the bodily 
location for each molecular subgroup in MRT, the top 1000 most variably expressed genes 
between four stem cell profiles ESC, MSC, NSC and NC were selected using limma 
analysis. Expression of these genes was then integrated into primary MRT. t-SNE analysis 
showed separation of three stem cell profiles within the family of ESC, NSC and, NC and 
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MSC (Figure 3.11a). Notably, cross-referencing of genes differentially enriched in stem 
cell populations (ESC, NSC, NC and MSC) with primary MRT illustrates primary ECRT 
overlapped with NC and MSC while ATRT overlapped with NSC analysed using PCA 
(Figure 3.11b). It signifies that primary ECRT may enrich expression of genes that 
regulate NS and MSC developmental pathway. Likewise, genes that highly expressed in 
ATRT relative to ECRT tend to relatively highly expressed in NSC compared to other 
stem cell types.  
The presence of MSC and NSC gene signatures in primary MRT have been demonstrated 
previously in omics studies by Chun et al. (2016), Torchia et al. (2016) and PBTG group 
(unpublished) in which the authors illustrated the transition between NSC and MSC 
expression phenotypes in two subgroups of MRT, based on significant enrichment of gene 
sets that regulate these two pathways as determined by Gene Set Enrichment Analysis. 
Therefore, it is of interest to examine if similar findings can be achieved using my stem 
cells cohorts as results point towards MSC and NSC as potential cells of origin for MRT. 
To achieve this aim, non-negative matrix factorisation (NMF) was applied to MRT 
primary and stem cell populations; NSC, NC and MSC (STR and MSC) (k = 2) (Figure 
3.11c). The consensus NMF clustering identifies two metagenes which broadly describe 
the transition between MSC to NSC. This finding is corroborated by a boxplot of one 
these metagenes which show ATRT splits into two groups, one group showing expression 
overlap with NSC and while the remaining ATRT profiles show correlation with MSC 
and lie on top of an NSC-MSC continuum (Figure 3.11d). These results are compatible 
with previous observations of MSC-NSC transition in MRT from studies by Chun et al. 
(2016), Torchia et al. (2016) and PBTG group (unpublished). Two metagenes are broadly 
related to two subgroups in MRT linked to the location of primary tumours in the body. 
Consistently, Pearson correlation matrix of genes significantly expressed in either ATRT 
or ECRT demonstrated ATRT strongly correlated with NSC (Figure 3.11e), while the 
ECRT correlated with NC and MSC (Figure 3.11f). 
Altogether, the analyses further validated three potential cells of origin for MRT; NSC, 
NC and MSC. The extent of transcriptional overlap between stem cell profiles and 
primary MRT suggests closer sharing of expression profile that may reflect the occurrence 
of MRT at different anatomical location. 
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Figure 3.11 Degree of transcriptional overlap between primary MRT and stem cell 
profiles illustrates MRT share a closer expression profile with MSC, NC and NSC thus 
reflecting different bodily location for subgroups in MRT. (a) t-SNE showing broad 
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grouping of stem cell populations consisting of NSC (grey), MSC (orange and yellow), 
NC (black) and ESC (green). (b) PCA analysis of integrated expression of top 1000 
discriminatory genes between each stem cell population with primary MRT, showing 
ECRT (blue) clustered close to expression profiles of NC and MSC, while ATRT (red) 
clustered around NSC. This plot shows the majority of MRT lie in between MSC and NSC. 
(c) Heatmap showing supervised NMF consensus clustering (k=2) of primary MRT RNA-
seq expression profiles and stem cell expression profiles (MSC, STR, NC and NSC) 
confirming the transition between MSC and NSC. (d) Boxplot of one of the metagenes 
showing the primary MRT lie on the continuum between MSC and NSC. Also, the boxplot 
depicts how the SMARCB1 re-expression in the cell lines move the expression profiles 
towards the mesenchymal. (e and f) Pearson correlation matrix showing genes that are 
significantly highly expressed in ATRT or ECRT. The boxplot represents the mean 
pearson correlation between a given sample (f) and all other expression data and the 
boxplot shows types of stem cells with the greatest correlation with primary MRT. ATRT 
shows a greatest correlation with NSC (e) relative to other stem cell types, whereas ECRT 
shows the greatest correlation with MSC and NC (f) relative to NSC. INI1 denotes 
SMARCB1 re-expressing MRT cells, PCDH denotes SMARCB1-deficient MRT cells. ESC 
= embryonic stem cells, NSC = neural stem cells, MSC= mesenchymal stem cells, STR = 
stromal, NC = neural crest cells. 
 
3.4.5 Re-expression of SMARCB1 in MRT cell lines provokes cell differentiation 
ATP-dependent SWI/SNF chromatin remodelling complex has a role in a variety of 
cellular processes including cell differentiation (Roberts and Orkin, 2004). Particularly 
for MRT, experimental studies demonstrated a requirement for SMARCB1 in hepatocyte 
(Gresh et al., 2005) and adipocyte (Caramel et al., 2008) cell differentiation. These studies 
illustrate that mutation of SMARCB1 in specific cell types has the capacity to block 
normal cell differentiation. Evidently, MRT are associated with an undifferentiated 
phenotype and the differentiation process was restored upon SMARCB1 re-expression 
(Caramel et al., 2008). Initial analysis from Dr Dan Williamson manipulating the cell 
expression models provided the basis for identifying potential cells of origin for MRT 
(Figure 3.5). The role of SMARCB1 in cell differentiation as demonstrated in previous 
studies prompted me to investigate whether SMARCB1 re-expression in MRT cell lines 
 
135 
will also provide clues to discovery of cell of origin. With this aim, expression profiles of 
SMARCB1 re-expressing MRT cell lines (SWOH, KD, A204, G401, WT1) at day 1,3,7 
and 14 were analysed. The genes that were differentially expressed amongst cell lines 
were identified (delta > 6) using supervised clustering analysis of gene expression data 
and compared against stem cell profiles.  In MRT cells in which SMARCB1 was forcibly 
re-expressed, cells became gradually more differentiated over time and their expression 
profile altered from that of an early neural crest to a more differentiated mesenchymal 
pattern (Figure 3.12). Most of the cell lines were derived from ECRT (A204, G401, WT1, 
KD) (Table 3.1) and this finding is in agreement with my comparison of expression 
profiles of primary ECRT with stem cell profiles which illustrated the possibility of MSC 
or NC origin for ECRT. In addition, my assumption that cell line models originate from 
NC or MSC was corroborated by Pearson correlation matrix which demonstrated 
SMARCB1 re-expressing cell lines (denotes as INI1 in Figure 3.11f) correlated most 
strongly with NC and MSC, as determined by expression of genes that significantly 
highly expressed in ATRT or ECRT (Figure 3.11f). Comparison of gene expression 
analysis of MRT cell lines against stem cell profiles indicates that SMARCB1 expression 
provokes the cells to differentiate towards NC and MSC, thus confirming that NC or MSC 
is a potential cell of origin for ECRT.  
 
13
6 
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Figure 3.12 PCA of stem cells, primary MRT and SMARCB1 re-expressing cell lines 
using only genes which were different amongst the cell lines (delta > 6). The PCA plot 
showing that re-expression of SMARCB1 in MRT cells gradually changed the cells to 
become more differentiated over time (from day 0, 3, 7 to 14) and their expression profile 
altered from an early neural crest cells (NC) to more differentiated mesenchymal stem 
cells (MSC). INI1 represents the RNA-seq data of SMARCB1 re-expression in MRT cell 
lines while PCDH represents the RNA-seq of SMARCB1-deleted MRT cells. ESC = 
embryonic stem cells, NSC = neural stem cells, MSC= mesenchymal stem cells, STR = 
stromal, NC = neural crest cells. 
 
3.4.6 Expression of stem cell type signature genes illustrates subgroup specific cell 
of origins within MRT 
Integrated gene expression analysis demonstrates the transcription overlap between 
primary MRT and stem cell types. For instance, ATRT shows a close similarity with NSC, 
while ECRT illustrates a close expression profile with MSC and NC (Figure 3.11). This 
may reflect how each subgroup enriches expression of the genes that regulate different 
biological process. Therefore, I next defined molecular and cellular features of the 
subgroups, ATRT and ECRT and to what extent these subgroups correlate with a 
suggested cell of origins i.e NSC for ATRT and MSC/NC for ECRT in order to provide 
the evidence of bodily location related subgroup. Genes that were significantly 
differentially expressed in each stem type were selected and compared against primary 
MRT and cell lines; and other stem cell types. A heatmap of genes differentially expressed 
in NSC compared to MSC and ESC (defined by discriminatory statistical coefficient >2 
between ESC and NSC, and MSC and NSC) illustrates high expression of these genes in 
ATRT in relative to ECRT (Figure 3.14a). An attempt to examine similarity in gene 
expression between MRT and NC (defined by a coefficient greater than 2 compared to 
MSC cells) was unsuccessful due to small number of expression profiles for NC collected 
in this study (Figure 3.14b). To circumvent this problem, the genes that were linked with 
NC were manually curated from previously published studies (Chun et al., 2016, Ishii et 
al., 2012) and compared with expression profiles of other stem cell population (ESC, NSC 
and MSC), MRT primary (ECRT and ATRT) and cell lines. Additionally, genes that were 
downregulated in NC were identified and compared against primary MRT, cell model and 
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other stem cell types. Notably, these gene sets were highly enriched in ATRT (data not 
shown). Consistently, genes differentially expressed in MSC compared to NSC and ESC 
(discriminatory statistical coefficient >3 between ESC and NSC) were highly enriched in 
ECRT relative to ATRT, thus giving strong evidence of MSC as cell of origin for ECRT 
(Figure 3.13c). In line with these results, genes that are significantly highly expressed in 
each two subgroups have the greatest correlation with ATRT, while NC and MSC have 
the greatest correlation with ECRT (Figure 3.11e-f). This analysis demonstrates a degree 
of similarity in expression profiles between stem cell populations and MRT. High 
expression of NSC specific genes in ATRT may reflect the possibility of NSC as cell of 
origin for ATRT subgroup. Likewise, few MSC specific genes are enriched in ECRT, thus 
describing the incidence of ECRT in mesenchymal metabolically active organ such as 
liver or kidney.  
The initial differential gene expression analysis between ATRT and ECRT in primary 
MRT cohort (113 ATRT and 37 ECRT) describes two potential cells of origin; NSC and 
MSC. However, following integrated analysis of transcriptome profiles of these primary 
MRT with various stem cell expression profiles, I have discovered NC as a potential cell 
of origin in addition to NSC and MSC. The subsequent analysis illustrates NC and MSC 
as potential ECRT cells of origin as opposed to NSC for ATRT. To further confirm the 
subgroup-specific cell of origin from three stem cell types, genes most differentially 
enriched in each subgroup (ATRT and ECRT) were identified using a supervised analysis 
of gene expression as previously discussed in section 3.4.1 The heatmap showing 
expression of ATRT related genes was enriched in NSC (Figure 3.14a). By contrast, 
expression of ECRT related genes was significantly enriched in NC and MSC (Figure 
3.14b). Furthermore, SMARCB1 re-expressing MRT cell lines (INI1) shared closer 
expression profiles with ECRT and NC, thereby further corroborating the observations in 
primary ECRT. Taken together, as demonstrated by consistent gene expression results 
discussed above, ATRT potentially originates from NSC while ECRT possibly originates 
either from NC or MSC. Figure 3.14a clearly illustrates two possible cells of origin in 
MRT which correlate to the bodily location of primary tumours.  
To address the relevance of NSC, NC and MSC as candidate cells of origin for MRT, I 
then sought the examine the expression of SMARCB1-dependent genes in these stem cell 
types. The heatmap illustrates high expression of SMARCB1-dependent genes in NSC, 
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NC and MSC stem cell populations (Figure 3.14b). SMARCB1 dependent genes which 
are often associated with ATRT subgroup including SOX2 and MYCN were highly 
expressed in NSC. Notably, NC and MSC also demonstrate enrichment of SMARCB1 
dependent genes such as MYC, CDKN2A, CCND1 (Figure 3.14b).  
Altogether, the three differential gene expression analyses that were performed in a 
supervised analysis manner show a positive correlation between ECRT and MSC or NC, 
and between ATRT and NSC. This finding supports my hypothesis of a subgroup-specific 
cell of origin in MRT. Importantly, results from this study provide an insight that 
SMARCB1 mutation in specific cell types can obstruct normal cell development i.e neural 
cell differentiation eventually leading to tumour formation in the brain. It may explain the 
different bodily location associated with each subgroup. 
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Figure 3.13 MRT primary and cell lines share closer expression profiles with MSC, NC 
and NSC. (a) Heatmap showing NSC specific genes (grey) that are highly expressed in 
ATRT (crimson), (b) expression of NC specific genes failed to identify in MRT primary 
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and cell lines due to limited number of NC specific genes (c) while few MSC (yellow and 
orange) specific genes are enriched in ECRT (red). ESC = embryonic stem cells, NSC = 
neural stem cells, MSC= mesenchymal stem cells, STR = stromal, NC = neural crest 
cells. 
 
 
Figure 3.14 Heatmap analysis of differential gene expression of MRT primary and cells 
compared to several stem cell types. (a)Heatmap analysis of genes significant different 
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between ATRT and ECRT illustrates ATRT related genes are enriched in NSC, while 
ECRT related genes are enriched in MSC and NC, suggesting cell of origin associated 
with bodily location. (b) Heatmap showing SMARCB1 dependent genes are enriched in 
MSC, NC and NSC. These genes are associated with two subgroups in MRT. ESC = 
embryonic stem cells, NSC = neural stem cells, MSC= mesenchymal stem cells, STR = 
stromal, NC = neural crest cells. 
 
3.4.7 Embryonic stem cells (ESC) are not a cell of origin candidate for MRT 
Immunohistochemistry studies and genome-wide analysis of primary MRT have shown 
the presence of ESC expression markers such as OCT4, NANOG, SOX2, etc thus leading 
to an assumption that MRT may originate from ESC (Richer et al., 2017, Chun et al., 
2016, Deisch et al., 2011). However, the meta-analysis performed in this part of study 
showed no overlap in expression of ESC with either primary MRT and MRT cell lines 
(Figure 3.11b, e and f). To confirm these results, genes that were linked with ESC were 
selected in a supervised manner and were analysed against MRT primary and cell lines. 
The heatmap shown in Figure 3.13 shows that the expression of ESC specific genes was 
minimal in MRT primary and cell lines (Figure 3.15), as opposed to the large amount of 
expression of genes involved in MSC and NSC (Figure 3.13 and Figure 3.14a). The 
minimal transcriptional overlap between ESC with MRT suggests that ESC is not likely 
a potential cell of origin for MRT. 
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Figure 3.15 Heatmap showing expression of embryonic stem cell specific genes are 
diminished in MRT primary and cell lines signifying that ESC is not likely a cell of 
origin for MRT. ESC = embryonic stem cells, NSC = neural stem cells, MSC= 
mesenchymal stem cells, STR = stromal, NC = neural crest cells 
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3.5 Discussion 
3.5.1 Gene expression analysis reveals candidates’ cell of origin in MRT 
MRT can be found at various location in the body but the true cell of origin still remains 
unknown. Studies reported in this chapter attempted to shed light on the mechanism that 
leads to MRT occurrence at multiple anatomical sites through identification of putative 
cells of origin for MRT. I postulated in this chapter that the tumours arise from distinct 
cell types that serve as a cell of origin and originate from early progenitor cells that have 
extensive self-renewal capacity due to highly aggressive and early onset nature of MRT 
(Rorke et al., 1996). Recent genomic studies (Johann et al., 2016, Chun et al., 2016) and 
mouse model experiments (Vitte et al., 2017, Han et al., 2016) suggest the possibility of 
neural crest (NC) cell or neural stem cells (NSC) as potential candidates for MRT cell of 
origin as determined by gene expression profiling and the potential of SMARCB1 
knockout mouse models to develop tumours that molecularly and phenotypically 
resembling to human MRT. Knockout of SMARCB1 at specific developmental window 
(E7-10) in vivo is capable of initiating tumourigenesis (Han et al., 2016). In their study, 
cross-referencing of transcriptome profiles of MRT mouse and human tumours with stem 
cell expression profiles including embryonic stem cell (GSE44175), neural progenitor 
(GSE44175 and GSE44175), neuron (GSE46150), oligodendrocytes derived from neural 
stem cells (GSE9566), astrocytes derived from neural stem cells (GSE9566), 
ectomesodermal tissue from the palate (GSE9566) and neural crest (GSE11149) suggests 
neural progenitor and NC as potential cell of origin for MRT. Therefore, their findings 
are in agreement with results presented in this chapter which demonstrate NSC or NC as 
possible cell of origin.  
Comprehensive gene expression analysis presented in this chapter demonstrated three 
probable cells of origin which are either NSC, NC or MSC. However, NC is the top 
candidate for MRT cell of origin in this study as NC progenitors are the earlier migrating 
cells with multi-lineage differentiation potential. In theory, NC shows the embryonic 
structural characteristics of vertebrates. It is originally found in the neural plate border 
region, between presumptive neural epithelium and epidermis. NC possess a high 
capacity for migration and multipotency (Liu and Cheung, 2016). The cells exhibit stem-
like features such as self-renewal and can differentiate into a variety of cell types ranging 
from craniofacial skeletal tissues to the trunk peripheral nervous system (Dupin and 
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Coelho-Aguiar, 2013). NC cells that populate in sympathetic, parasympathetic, enteric 
and partly sensory ganglia can give rise to neurons and glial cells whereas NC cells that 
reside at head and neck structure can give rise to diversity of mesenchymal cell types. 
Taken together, NC cells fit the criteria for early onset of MRT and multipotency hence 
this stem cell type was further studied in Chapter 4 as a potential cell of origin for MRT.  
3.5.2 Gene expression analysis indicates the possibility of subgroup specific cell of 
origin for MRT  
Integrated gene expression analysis of primary MRT, cell lines and various stem cell types 
indicated different cell of origin in MRT related to tumour location of primary tumours. 
GSEA performed on primary MRT showed enrichment of different biological process in 
each subgroup found in MRT. In line with previous genome-wide profiling studies (Chun 
et al., 2016, Johann et al., 2016), ATRT showed enrichment of genes specific for neuronal 
development whereas ECRT demonstrated upregulation of genes associated with 
mesenchymal cell processes. These findings are in line with unsupervised analysis of 
stem cell and primary MRT expression profiles presented in section 3.4.3 which showed 
a high degree of overlapping expression between ATRT and NSC, and  ECRT with NC 
and MSC as shown in Figure 3.11.  
Supervised analysis of differentially expressed genes between ECRT and ATRT 
confirmed that ATRT shared similar expression profile with NSC whereas ECRT shared 
a closer expression profiles with NC and MSC. Also, in the absence of SMARCB1, the 
expression profiles of MRT cell lines clustered closely with primary ECRT. However, 
their expression altered from that of an early NC to a more differentiated MSC pattern 
upon SMARCB1 re-expression thus suggesting that ECRT probably originates either from 
NC or MSC. Transcriptome profiles of primary MRT and mouse models are fully 
consistent with this finding of potential subgroup-specific origins within MRT (Chun et 
al., 2016, Han et al., 2016). Previously, Han et al. (2016) profiled tumours developed from 
their mouse models and compared the transcriptome profiles of these tumours and 
expression profiles of human MRT with various stem cell profiles. Their analysis of these 
datasets using Pearson correlation matrix analysis showed mouse and human ATRT were 
highly correlated with neural progenitor while ECRT were correlated with NC. It was 
shown that each subgroup enriched different gene sets as shown in genome-wide analysis. 
ATRT showed enrichment of genes associated with neural such as OTX2, a neural 
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progenitor marker. In contrast, ECRT did not show expression of neural-specific genes 
but demonstrated enrichment of mesoderm signature genes such as HOXA/C and TXB2. 
Taken these as a whole, their results also imply the possibility of subgroup-specific cell 
of origin which correlated with anatomical location of primary tumours.  
Altogether, my study and Han et al. (2016) establish that the cell of origin is subgroup-
specific and related to bodily location. The occurrence of MRT at various locations in the 
body may be due to mutation of SMARCB1 in a specific cell population that is capable of 
hijacking normal cell differentiation processes during cell development which leads to 
tumour development. 
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Chapter 4 Somatic CRISPR/Cas9 mediated knockout of 
SMARCB1 in a putative cell of origin: A 
system for the development of Malignant 
Rhabdoid Tumours (MRT) models and 
identification of potential therapeutic targets 
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4.1 Summary 
The poor survival rate of patients with Malignant Rhabdoid Tumours (MRT) who receive 
conventional chemotherapy or radiotherapy treatment, highlights the need for new 
targeted therapies. MRT are teratoid in nature and can occur almost anywhere in the body. 
The development of MRT, in particular, the cell(s) of origin and their relationship to 
tumour location and molecular subtype is largely unknown. Although biallelic loss of 
SMARCB1 is minimally sufficient to initiate tumourigenesis, I hypothesised that this is 
dependent upon mutation in a particular type of cell; most likely an early pluripotent cell. 
To provide an effective method for investigating somatic loss of function of SMARCB1 
in a putative cell of origin, CRISPR/Cas9 vectors were generated to target human and 
mouse SMARCB1. Using a lentiviral approach, the phenotype associated with SMARCB1 
mutation in my hypothesised candidate cell of origin, namely neural crest (NC) cells was 
investigated. Somatic Smarcb1 loss in NC cells gave rise to cells which resembled human 
MRT at a histological, immunohistochemical and molecular level, indicating the possible 
cell of origin for MRT. These studies will pave the way for the development of mouse 
modelling of MRT and identification of novel therapeutic approaches for treatment of this 
aggressive childhood cancer. 
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4.2 Introduction 
4.2.1 Loss of SMARCB1 hijacks normal cell proliferation and differentiation thus 
initiates tumourigenesis 
The mechanism by which SMARCB1 loss contributes to tumourigenesis is complex due 
to its role as a tumour suppressor gene coding for a core subunit of the SWI/SNF 
chromatin remodelling complex, which is involved in many normal cellular activities 
such as differentiation and proliferation. The mechanism by which SMARCB1 loss 
promotes cell survival and proliferation is through its interaction with pathways such as 
the p16(CDKN2A)-Rb-E2F pathway, Wnt signalling pathway, Sonic Hedgehog 
signalling pathway  and the Polycomb group system (Jagani et al., 2010, Knutson et al., 
2013, Mora-Blanco et al., 2014, Rimkus et al., 2016, Wilson et al., 2010a, Yang et al., 
2016). Several studies have demonstrated the role of SMARCB1 in cell cycle progression, 
the re-expression of SMARCB1 in SMARCB1-deficient MRT cells leads to G1 cell cycle 
arrest, cell senescence and apoptosis (Betz et al., 2002, Versteege et al., 2002)(Figure 4.1). 
These results are due to the transcriptional activation of p16 by SMARCB1 which in turn 
leads to the phosphorylation of Rb through the repression of cyclin D1-CDK4 activity. 
Hyper-phosphorylated Rb (pRb) disassociates from E2F thus impeding its anti-
proliferative activity. E2F also regulates genes that are involved in apoptosis and 
differentiation. In short, SMARCB1 plays a significant role in regulating cell cycle 
progression through activation of p16 and repression of Rb pathways.  
In addition to being highly aggressive and rapidly proliferating, MRT are teratoid in 
nature i.e. containing cells with multiple lineages. This phenotype suggests a role for 
SMARCB1 in cell differentiation. In Caramel et al. (2008)'s study, the authors reported 
the re-introduction of SMARCB1 in MRT cell lines caused the cells to differentiate into 
adipocytes as measured by Oil-Red-O staining of lipid droplets. To corroborate this 
finding, qPCR was performed to measure the expression of adipogenic markers LPL, 
AP2, C/EBPα and PPARg2 which showed a strong upregulation of these markers in 
SMARCB1 re-expressing MRT cells relative to control. These results illustrate the 
requirement for SMARCB1 expression in adipogenesis. Additionally, knockdown of 
SMARCB1 in hepatoblast-hepatocyte lineage model of cell differentiation impeded 
glycogen storage and epithelial morphogenesis, which are the criteria of hepatocyte 
differentiation (Gresh et al., 2005). Besides that, the authors found downregulation of 
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nearly 70% of genes that are normally upregulated during liver development as assessed 
from transcriptomic datasets of these cells (Gresh et al., 2005). Results from Gresh et al. 
(2005) and Caramel et al. (2008) emphasises the role of SMARCB1 and the SWI/SNF 
chromatin remodelling complex in the activation of cell-type specific machinery and cell 
differentiation. In other studies, the SWI/SNF complex is shown to interact with C/EBPb 
to regulate the expression of genes specific to the myeloid or adipocyte lineage (Kowenz-
Leutz and Leutz, 1999, Pedersen et al., 2001) and MyoD to regulate muscle cell 
determination (Ivana et al., 2001).   
The undifferentiated phenotype of MRT and its high proliferation rate suggest that it is 
the disruption of the delicate balance between cell proliferation and differentiation that 
drives MRT tumourigenesis. 
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Figure 4.1 Role of SMARCB1 in cell differentiation and proliferation. Re-introduction 
of SMARCB1 expression in MRT cell lines induces cell differentiation through activation 
of E2F pathway and decrease cell migration as a result of activation of cell cycle 
inhibitors; p21 and p16. It also triggers cell cycle arrest and apoptosis via Rb pathway. 
 
4.1.1 Development of MRT murine disease models: challenges and history 
The aggressive nature of MRT and the essential role of SMARCB1 in multiple pathways 
poses a major challenge for the development of a disease model. Homozygous deletion 
of Smarcb1 in mice results in early embryonic lethality (3.5 – 6.5 days post coitum) (Guidi 
et al., 2001). To circumvent the problem, mouse models were developed in which 
Smarcb1 was heterozygously deleted or subject to conditional deletion. However, these 
models developed highly aggressive cancers which resembled rhabdoid like tumours and 
T-cell lymphomas with a median age of onset of 11 months or 3-4 months of age, 
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depending on the model (Roberts et al., 2000, Roberts et al., 2002, Roberts and Orkin, 
2004). Additionally, Han et al. (2016) have developed a Smarcb1/flox; Rosa26-CreERT2 
mouse model for MRT by temporal control of tamoxifen injection. Their mouse model 
showed that tamoxifen injection before E6 in pregnant mice, at the time of birth of the 
mice, or at 2 months of age of newborn mice were embryonic lethal and these results 
mimic the embryonic lethality observed in previous mouse models. More importantly, 
their mouse model demonstrates the appropriate window for injection that leads to a high 
penetrance of tumours with a median onset of 3 months. Further to this work, comparison 
of transcriptomic analysis of intra- and inter-species datasets (including data from this 
mouse model) suggested the possibility of a variety of cells of origin for MRT. A recent 
mouse model study by (Vitte et al., 2017) exploited the Smarcb1 deletion in neural crest 
cells using the Cre recombinase vector which was expressed under the control of the P0 
promoter. Homozygous deletion of Smarcb1 in this mouse model leads to the formation 
of tumours that phenotypically resemble human MRT with an overall median survival of 
3.2 months and onset of 1.5-5 months of age.  
In general, recent mouse models developed for MRT are promising and able to 
circumvent embryonic lethality. However, it is worth noting that, while most of the 
tumours formed resemble human MRT, none of the models was able to provide evidence 
of tumour formation in other anatomical sites aside from head and brain. These mouse 
models bear similarities to ATRT tumours, the formation of tumours in extracranial sites 
such as the kidneys are so far not apparent. To gain a better understanding of MRT disease 
especially disease arising in different anatomical locations, development of a disease 
model that represents each molecular subtype within MRT is greatly needed.  
4.1.2 CRISPR/Cas9 mediated genome editing technology 
CRISPR/Cas9 technology provides a powerful tool for genome editing that has been used 
widely for functional screenings both in vivo and in vitro. CRISPR is an acronym for 
clustered regularly interspaced short palindromic repeats and is associated with Cas9 
which functions as a nuclease enzyme. CRISPR/Cas9 forms irregular genetic loci in many 
bacteria and archaea to provide immunity against viruses and plasmids. Three types of 
CRISPR/Cas9 system (I-III) have been identified in both bacteria and archaea so far but 
the CRISPR/Cas9 type II from Streptococcus thermophilus or Streptococcus pyogenes is 
the most widely adapted in genome engineering technology (Makarova et al., 2011, Rath 
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et al., 2015, Li et al., 2015). The system works through co-expression of the bacterial 
endonuclease Cas9 and short guide RNA molecules (sgRNA) (Figure 4.2). The sgRNA 
directs Cas9 nuclease to the complementary region in the genome. At the recognition site 
which is usually at the 5' end of gRNA followed by an NGG sequence which is known as 
protospacer-adjacent motif (PAM), Cas9 nuclease will create double-strand break (DSB) 
that can be repaired by non-homologous end joining (NHEJ) which often introduces small 
insertions or deletions (indels) (Figure 4.1). The resulting indels shift the open reading 
frame, thus leading to loss of function of the gene of interest. CRISPR/Cas9 systems can 
also be used for gain of function purpose through a homology-directed recombination 
(HDR) mechanism at the targeted region in the presence of exogenous donor DNA. This 
can be achieved through introduction of precise DNA mutation or insertion of specific 
DNA sequence in the targeted site in the genome. However, Cas9 can tolerate the 
mismatches between sgRNA and complementary region in the genome only up to a 
certain limit. 3 or more adjacent mismatches at the 5’ end of sgRNA can reduce its activity 
(Anderson et al., 2015), and will produce off-target effects if the mismatch is beyond this 
threshold. These undesirable effects of the CRISPR/Cas9 system necessitate fresh 
strategies to reduce the potential for off-target effects.  
 
 
 
Figure 4.2 Schematic diagram of double strand break (DSB) created by Cas9 adapted 
from (Ran et al., 2013). The DSB can be repaired either by NHEJ or HDR. NHEJ will 
often create indel mutations. 
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4.2.2 Aims 
In this chapter, I aimed to: 
• construct a CRISPR/Cas9 system targeting SMARCB1 and SMARCA4 
• isolate sub-populations cells that will tolerate Smarcb1 deletion and still 
retain capacity for prolonged proliferation 
• characterise Smarcb1-deficient neural crest (NC) cells 
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4.3 Results 
4.3.1 Generation of single guide RNA (sgRNA) for CRISPR/Cas9 genome editing 
Four single guide RNA (sgRNA) were designed that specifically target the region in either 
exon 1 or 2 of Homo sapiens (HS) and Mus musculus (MM) SMARCB1 and SMARCA4 
using either optimised CRISPR (http://crispr.mit.edu/) or CRISPR design  (http://www.e-
crisp.org/E-CRISP/designcrispr.html) web tools. The list of guide RNA generated by the 
E-CRISPR website is displayed only if the number off-target effect does not exceed a 
user-specified threshold. The output guide RNA is ranked based on off- and on-target 
efficiency if more than one design is found in the target locus. On-target efficiency was 
optimised for 20bp guide with NGG protospacer-adjacent motif (PAM) (Doench et al., 
2016)  which improved on-target efficiency.  
In this study, the 20 nucleotide (nt) sgRNAs were selected due to their specific location 
near to NGG PAM on 5’ sequence, their low off-target effects and high on-target 
efficiency scores (E-scores). The target sequences should be complementary to the gRNA 
ending in a NGG 5’ (PAM) as this is required to recruit Cas9 nuclease to cut both strands 
of the DNA (Figure 4.3a). To increase the specificity of Cas9, the location of PAM was 
specified as a minimum of 8bp and maximum of 12bp of the target sequence  (Figure 
4.3a)(Hsu et al., 2013). To further optimise the specificity of Cas9 for SMARCB1 and 
SMARCA4 gene editing, the potential off-target effects were considered when choosing 
the guide RNA. The E-CRISPR website tool was used to evaluate the off-target effects 
and target site homology using the alignment program Bowtie2 (Heigwer et al., 2014). In 
addition to this, the guide RNA was not selected if the target sequence with genomic off-
target had less than three mismatches. Besides that, the guide RNA sequence was 
designed to exclude intronic regions, CpG islands and UTRs. A total of 8 guide RNAs 
were designed in this study (Figure 4.3b). Homo sapiens GeCKO (HSG) or mus musculus 
GeCKO (MMG) guide RNAs were obtained from human/mouse GeCKO V2 genome-
wide library (https://www.addgene.org/pooled-library/#crispr). Whilst, the remaining 
four guides were designed using the E-CRISPR website and were named as either homo 
sapiens E-CRISPR (HSE) or mus musculus E-CRISPR (MME). The eight CRISPR 
constructs were designed to target SMARCB1 and SMARCA4 expression in the potential 
cells of origin for MRT, either from human or mouse  derived cell lines.  
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Figure 4.3 sgRNA targeting SMARCB1 and SMARCA4 in human and mouse. (a) 
schematic of target sequence with NGG PAM in CRISPR/Cas9 construct. (b) The target 
region of sgRNA for SMARCB1 and SMARCA4. Four sgRNA were manually designed in 
this study using E-CRISPR website tool here denoted as HSE or MME inducing indels in 
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exon 1 for SMARCB1 and exon 2 for SMARCA4. Whilst four sgRNAs were obtained from 
CRISPR/Cas9 GeCKO library denoted as HSG or MMG. 
 
4.3.2 Optimisation of CRISPR/Cas9 constructs in HEK293T and NIH3T3 
To evaluate the efficiency of CRISPR/Cas9 in generating somatic knockout of SMARCB1 
and SMARCA4, HEK293T and NIH3T3 cell lines were first infected with the 
lentiCRISPRV2 virus. Three MOIs initially tested on 293T and NIH3T3 were 1, 5 and 10 
using CRISPR SMARCB1 HSE and SMARCA4 HSE. The mutation created by 
CRISPR/Cas9 was detected using the SURVEYOR nuclease assay which uses 
endonuclease to cleave DNA with high specificity at sites of base-substitution mismatch 
(Figure 4.4a). Following infection, the morphologies of SMARCB1- and SMARCA4- 
deficient cells differed from the non-targeting control cells. SMARCB1 knockdown 
induced cell death 48 hours post puromycin selection and the cutting efficiency increased 
as the multiplicity of infection (MOI) increased. Cleavage intensity of each PCR 
amplicon and cleaved bands from SURVEYOR analysis was measured using Image J 
according to the formula below: 
"#$% = (( + *)/(- + ( + *) 
indel (%) = 100 × 11 − 3(1 − "*45)6 
 
where a = integrated intensity undigested band, b + c = intensity of cleaved product, the 
formula adapted from (Ran et al., 2013) 
 
CRISPR/Cas9 targeting SMARCB1 using CRISPR SMARCB1 HSE construct at MOI 5 
and 10 in HEK293T yielded 61% of cleavage efficiency in the surveyor mutation 
detection assay (Figure 4.4b). Lentivirus transfection was less effective at MOI 1 which 
has 46% cleavage efficiency only. On the other hand, editing (insertion/deletion) 
efficiency of CRISPR SMARCA4 HSE in 293T cells was more efficient at MOI 10 than 
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MOI 1 and 5. The cleavage efficiency for MOI 10 was 67% while MOI 1 and 5 have only 
35% and 48% cutting efficiency respectively (Figure 4.4b). From this initial surveyor 
mutation detection analysis, both CRISPR constructs have cleavage activities and the 
cleavage efficiency is better at MOI 10 for CRISPR SMARCA4 and MOI 5 or MOI 10 
for CRISPR SMARCB1 (MOI 5). Hence, the experiments were repeated to examine the 
cleavage efficiency for other CRISPR sgRNA constructs. Lentivirus transfection at MOI 
5 was used for CRISPR SMARCB1 (HSE, HSG. MME and MMG) while MOI 10 was 
used for CRISPR SMARCA4 (HSE, HSG. MME and MMG) on 293T and NIH3T3 cells. 
Transfection of 293T and NIH3T3 with CRISPR SMARCB1 at MOI 5 resulted in ~60% 
cleavage efficiency (Figure 4.4c). Similarly, CRISPR mediated SMARCA4 knockout in 
293T and NIH3T3 at MOI 10 resulted in ~60% cleavage efficiency (Figure 4.4c).  
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Figure 4.4 Efficiency of CRISPR/Cas9 in creating indels in SMARCB1 and SMARCA4 
measured by SURVEYOR assay. (a) Illustration of SURVEYOR mutagenesis assay. Blue 
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band represents single strand DNA and indel denotes the mutation created by 
CRISPR/Cas9 system. First, the genomic DNA from 48 hours post transfection were 
amplified by PCR. During the hybridisation step, the homoduplex and heteroduplex DNA 
strands are formed. The assay uses a nuclease enzyme to cut the DNA strand that has 
mismatch mutation. The CRISPR indel frequency was calculated using the formula and 
presented above. (b) Optimisation of CRISPR lentivirus infection on 293T cells using two 
CRISPR construct targeting SMARCB1 and SMARCA4 at MOI 1, 5 and 10. Percentage 
of Indel represents the cutting efficiency of each CRISPR. (c) Electrophoresis gels showed 
two cleaved products (indicates with red arrow of). The percentage of indel mutation was 
calculated using the formula mentioned in the paragraph. C – CRISPR, NTC –No 
Template Control. 
 
4.3.3 CRISPR/Cas9 can efficiently generate knockout of SMARCB1 and 
SMARCA4 in HEK293T and NIH3T3 
To further analyse the effectiveness of CRISPR/Cas9 in mediating SMARCB1 and 
SMARCA4 knockout, the effect of SMARCB1 and SMARCA4 mutation on protein 
production was studied by an automated western system known as WES and by 
immunohistochemistry. The HEK293T and NIH3T3 cells were infected with 
unconcentrated lentiCRISPRv2 virus at MOI of 5 and 10 respectively and the cells were 
harvested 48 hours post puromycin selection. For detection of SMARCB1 and 
SMARCA4 protein, the total protein lysate was analysed with anti-SMARCB1 (BAF47) 
(BD Bioscience, Cat. No. 612110) and anti-SMARCA4 (BRG1 G-7) (Santa Cruz 
Technology, Cat. No. sc17796) in WES. The band was quantified using the densitometric 
program on ImageJ, and the percentage of protein loss was calculated using the formula 
below: 
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7 = 89:;<=1>?@*4A?@  
B = CD<>?@*4A?@ 
%F@G*FHGI@ = 7J ∗ 100 
 
As shown in Figure 4.5a, western blotting illustrated that CRISPR/Cas9 knockout leads 
to loss of 75%  and 44% SMARCB1 protein expression in HEK293T cells infected with 
HSE and HSG respectively while 88%  and 61% SMARCB1 protein  loss was observed 
in NIH3T3 cells  infected with MMG and MME respectively as compared to NTC wild-
type (WT) (Figure 4.5a). In contrast, WES analysis revealed a loss of 54% and 56% of 
SMARCA4 protein in HSE and HSG HEK239T cell respectively while 64% and 70% 
SMARCA4 loss was achieved in MME and MSG NIH3T3 respectively relative to NTC 
(WT).  
 
To confirm the WES results, immunohistochemical (IHC) staining of SMARCB1 and 
SMARCA4 deletion was performed in NIH3T3 and HEK293T cells. The cells were 
stained with anti-SMARCB1 antibody and anti-SMARCA4 antibody at 1:100 and 1:400 
dilution respectively. The nuclear staining analysis was performed using Aperio 
Imagescope software (using nuclear staining algorithm). Loss of nuclear SMARCB1 
protein by immunohistochemistry was seen in 60% of SMARCB1-deficient HEK293T 
cells compared to 8.5% of control cells in which the Aperio Imagescope scored them as 
negative (SMARCA4-HSE cells was used as control for SMARCB1 staining) (Figure 
4.5b). In contrast, 71% of cells were scored positive (+3 and +2) for SMARCA4 staining 
in SMARCA4-HSE transfected cells, as analysed using Aperio Imagescope. This result 
was not comparable with western blot which showed loss of 56% of SMARCA4 protein 
expression in HEK293T- deleted SMARCA4A HSE cells. This may be due to   
SMARCA4 antibody not being optimised for immunohistochemistry analysis. Also, this 
experiment was performed once only.  
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Altogether, initial experiments in HEK293T and NIH3T3 showed good knockout was 
efficiently achieved using CRISPR/Cas9 to target SMARCB1 and SMARCA4 as 
determined by surveyor mutation detection assay, western blot and 
immunohistochemistry analysis. The CRISPR/Cas9 system containing eight guide RNAs 
was optimised for ideal MOI and cell density; MOI of 5 for all human and mouse CRISPR 
SMARCB1 and MOI of 10 for all human and mouse CRISPR SMARCA4.  
The following experiments presented in this chapter utilised CRISPR/Cas9 mediated 
SMARCB1 knockout in appropriate cells of origin. Although the efficiency of remaining 
six CRISPR/Cas9 constructs that target human SMARCB1 and SMARCA4, and mouse 
SMARCA4 was reported in this chapter, I was unable to perform any experiments using 
these constructs in other candidates’ cells of origin due to the time constraints.  
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Figure 4.5 Validation of SMARCB1 and SMARCA4 protein knockout using 
CRISPR/Cas9 by western blot and immunohistochemistry. (a) 0.8 µg of protein lysate 
was run on WES simple protein western blot for detection of SMARCB1 and SMARCA4 
protein. Vinculin antibody serves as loading control. (b) Representative image of 
immunohistochemistry analysis to further examine the efficiency of CRISPR/Cas9 
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knockout system on protein production. Only 293T cells were infected with lentivirus 
SMARCA4-HSE (MOI 10) and SMARCB1-HSE (MOI 5) were analysed by 
immunohistochemistry using SMARCB1 (1:100) and SMARCA4 (1:400) antibodies. 
Knockout using SMARCA4-HSE cells were used as a negative control for SMARCB1 
staining whereas SMARCB1-HSE was utilised as a negative control for SMARCA4 
staining. The scale bar is 200 µM.  
 
4.3.4 Generation of SMARCB1 knockout in a candidate cell of origin for MRT 
using CRISPR/Cas9 system 
The work in this part of the chapter was performed based on the hypothesis that 
SMARCB1 loss in the appropriate cell of origin could provoke genome-wide chromatin 
remodelling to initiate tumourigenesis and interrupt normal cell differentiation. The aim 
was to examine whether loss of SMARCB1 in a putative cell of origin could mimic the 
phenotype of primary MRT. Previous studies to identify potential cells of origin for MRT 
(Han et al., 2016, Vitte et al., 2017) and our bioinformatics analysis suggested neural crest 
(NC) cells as a possible cell of origin for MRT. Therefore, I performed functional studies 
to create a knockout of Smarcb1 in this cell population using the CRISPR/Cas9 system. 
For this project, the NIH3T3 cell line was used as a cell line control and NTC was used 
as a vector control. Two mouse CRISPRs targeting Smarcb1 were used and designated as 
CRISPR SMARCB1 MMG and CRISPR SMARCB1 MME. 
4.3.4.1 Validation of CRISPR/Cas9 mediated Smarcb1 knockout in neural crest 
cells at the protein level  
In this study, either exon 1 or 2 of Smarcb1 was targeted in neural crest (NC) cells using 
CRISPR/Cas9 (designated CRISPR SMARCB1 MMG and CRISPR SMARCB1 MME 
respectively) based genome engineering via a lentiviral approach. The NC cells obtained 
from E8.5 mouse embryos were labelled with Wnt1-Cre; R26R-GFP (Ishii et al., 2012). 
The cells were obtained from Merck Milipore. The cells exhibited neural crest properties 
including differentiation capacity, multipotency and expression of neural cell markers. 
The NC cells were able to differentiate into chondrocyte, osteoblast, smooth muscle cell 
and glial cells when cultured in specific differentiation media. Furthermore, the cells 
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exhibited multipotency markers such as CD44, nestin and sca-1 and also showed presence 
of neural crest markers such as AP-2α, Twist1, and Snail1, as determined by reverse 
transcriptase polymerase chain reaction (RT-PCR).  
For this project, the NC cells were cultured in specialised media supplemented with 
bFGF, on matrigel and were seeded on a coated plate at a density of 200,000 cells 
(methods described in Chapter 2, section 2.3.1.2). To determine the appropriate MOI of 
CRISPR/Cas9 lentivirus, NC cells were infected with lentivirus at MOI 3 and MOI 5. 
The cell growth was monitored using an EVOS microscope on day 1, 3 and 9 post 
puromycin selection. Visual inspection revealed a large proportion of dead cells following 
Smarcb1 knockout 24 hours post puromycin selection, particularly in CRISPR 
SMARCB1 MME knocked-out NC cells relative to non-targeting control (NTC) cells 
(Figure 4.6 and Figure 4.7), however, cell growth was recovered on day 3 and 9. To 
quantitatively confirm this result, the number of viable cells was counted using the cell 
images taken using EVOS microscope. The cell images were analysed using Image J 
analysis software to measure the viable cells. Briefly, the image was converted to 16-bit 
greyscale and the binary image was analysed using the "analyse particle" programme. 
The resulting outcome showed the count (number of cells in the image), average size and 
total area. The bar graph was plotted based on counts for each cell line treated with 
CRISPR-SMARCB1 or control. Knockout of Smarcb1 decreased the number of viable 
cells after 24 hours of puromycin selection. However, the number of cells gradually 
increased on day 3 and 9. Strikingly, the cell growth was recovered on day 3 for both 
SMARCB1 MMG and SMARCB1 MME infected cells.  
To determine the efficiency of CRISPR SMARCB1 knockout in NC cells and also to gain 
an insight that growth recovery was not due to overgrown cells with Smarcb1 expression, 
formalin fixed cell blocks were prepared using the cells harvested on day 9. 
Immunohistochemical staining of sections prepared from these cell blocks allows the 
assessment of nuclear Smarcb1 protein expression within the NC cell population. The 
nuclear staining of Smarcb1 in NC cells transfected with CRISPR SMARCB1 MMG and 
CRISPR SMARCB1 MME at MOI 3 show 92% and 80% of the cells had reduced or 
negative staining for Smarcb1 expression respectively (Figure 4.9). In contrast, lentivirus 
transfection at MOI 5 was less efficient for CRISPR SMARCB1 MME where only 40% 
of cells have lost Smarcb1 expression relative to 81% of cells for CRISPR SMARCB1 
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MMG. Therefore, MOI 3 was selected for downstream experiments. Notably, Aperio 
staining failed to detect Smarcb1 expression in 3% of NTC cells and 7% of primary 
cerebellum tissue section (Figure 4.8).  
Importantly, the IHC result of Smarcb1-deficient NC cells provides evidence that these 
cell populations were able to proliferate in the absence of Smarcb1 expression.  
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Figure 4.6 Optimisation of CRISPR/Cas9 knockout of Smarcb1 in neural crest (NC) 
cells at MOI 3. The NC cells were seeded at 200,000 cell density in 6 well plate and were 
infected with concentrated lentivirus CRISPR SMARCB1 MMG and SMARCB1 MME at 
MOI 3. The images were taken on day 1, 3 and 9 post transfections using an EVOS 
microscope and the number of viable cells was measured using Image J software. Bar 
graph showing small number of viable cells counted in CRISPR SMARCB1 MME cells 
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using automated cell counter on Image J after 24-hour of puromycin selection (D1 on 
graph). The growth for SMARCB1 MME and SMARCB1 MMG transfected cells was 
recovered on the following days. 
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Figure 4.7 Optimisation of CRISPR/Cas9 knockout of Smarcb1 in neural crest (NC) 
cells at MOI 5. The NC cells were seeded at 200,000 cell density in 6 well plate and were 
infected with concentrated lentivirus CRISPR SMARCB1 MMG and SMARCB1 MME at 
MOI 5. The images were taken on day 1, 3 and 9 post puromycin selection using EVOS 
microscope and the number of viable cells was measured using Image J software. Bar 
graph showing small number of cells counted in CRISPR SMARCB1 MME transfected 
cells using automated cell counter on Image J after 24-hour of puromycin selection (D1 
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on graph). However, the growth for SMARCB1 MME and SMARCB1 MMG transfected 
cells was recovered on the following days.  
 
 
Figure 4.8 Immunohistochemical staining of Smarcb1 expression in neural crest (NC) 
cells and primary tissue. NC cells used in this analysis were harvested from CRISPR-
NTC infected at two different MOIs; MOI 3 and MOI 5. The appropriate MOI to be used 
in the downstream experiment was selected based on protein knockout efficiency as 
determined by immunohistochemistry (IHC) analysis. Control primary tissue from 
cerebellum was included as positive Smarcb1 staining. The percentage of Smarcb1 
negative staining cells refers to number of cells in which the Aperio imagescope failed to 
detect nuclear Smarcb1 staining (algorithm nuclear = 0). 
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Figure 4.9 Immunohistochemical staining of Smarcb1 expression in neural crest (NC) 
cells and primary tissue. NC cells used in this analysis were harvested from 
CRISPR/Cas9 knockout of Smarcb1 at two different MOIs; MOI 3 and MOI 5. The 
appropriate MOI to be used in the downstream experiment was selected based on protein 
knockout efficiency as determined by immunohistochemistry (IHC) analysis. Control 
primary tissue from cerebellum was included as positive Smarcb1 staining.  
 
4.3.4.2  Selection of the Smarcb1 negative population using CD44 surface marker 
by FACS sorting 
The aim of this study was to establish the characteristics of Smarcb1-deficient NC cells. 
However, IHC analysis of CRISPR SMARCB1 knockout in NC cells demonstrated 
50.6% of NC cells were Smarcb1 positive (Figure 4.10a). It was crucial to ensure there 
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was no masking of effect from Smarcb1 expressing cells, therefore, we sought to isolate 
a pure population of Smarcb1-deficient cells.  
Smarcb1 is a nuclear protein and its expression was knocked out using CRISPR/Cas9 
vectors. Thus, it confers a challenge for sampling Smarcb1 negative cell population. To 
overcome the problem, I examined the cell surface marker that present in MRT to enrich 
Smarcb1 negative cells. In primary MRT, the expression of BAF-SWI/SNF responsive 
cell surface protein, CD44 was either low or absent (Singhal et al., 2010, Biegel et al., 
2002a). Hence, the expression of the Cd44 surface marker protein was exploited to enrich 
Smarcb1 negative NC cells by separating the cell population into two groups; Cd44 high 
(positive Smarcb1 expression) and Cd44 low (negative Smarcb1 expression). To achieve 
this aim, the percentage of Cd44 expression was measured using fluorescence-activated 
cell sorting (FACS). Briefly, NC cells were transfected with concentrated CRISPR and 
control (NTC) lentiviruses at MOI 3 and the transfected cells were harvested on day 6, 
11 and 13 post-transfections. For sorting, the cells were incubated with CD44-APC-
CyÔ7 antibody (BD Pharmingen). NC wild-type (WT) cells were used as negative or 
low Cd44 expression. To enrich the Cd44 low cell population, the gating strategy was 
defined as Cd44 high, Cd44 low-high and Cd44 low based on fluorescence intensity of 
Cd44 protein expression (Figure 4.10b). Analysis of FACS using FlowJo software shows 
time window for expression of Cd44 cell surface protein expression over time (day 6, 11 
and 13) after transfection with the lowest expression recorded on day 13. To examine 
characteristics of Smarcb1 negative cells i.e growth, phenotype, etc, Smarcb1 positive 
cells (from Cd44 high cell population) were utilised as a control. For comparison between 
Smarcb1 negative cells and Smarcb1 positive cells, cells were sampled based on Cd44 
high from Cd44 high gate and Cd44 low from Cd44 high-low and Cd44 low gates. The 
cut-offs for Cd44 low gating strategy was made as CD44 expression is still present at low 
percentage in primary MRT (particularly in ECRT) and to maximise sampling of Smarcb1 
negative cells can be obtained from Cd44 low gate. 
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Figure 4.10 The optimisation of Cd44 surface marker using FACS for sampling 
Smarcb1-deficient NC cells. (a) Immunohistochemistry (IHC) showing mixture of 
Smarcb1 positive and negative cells in NC cells transfected with Smarcb1 (SMARCB1 
MMG) CRISPR lentivirus while NTC cells showed total Smarcb1 positive cells. To obtain 
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pure Smarcb1-deficient cells, FACS was used to sample cells using Cd44 surface marker. 
(b) Gating strategy for sorting Cd44 surface marker cells. Three gates were drawn as 
enrichment strategy to obtain pure Smarcb1-deficient cells, grey denotes Cd44 low, 
purple denotes Cd44 high-low while green represents Cd44 high. Cells were coloured 
red for NC wild type, orange for CRISPR targeted cells and blue for NTC. The cells were 
sorted based on Cd44 high from Cd44 high gate, and Cd44 low from Cd44 low and Cd44 
low-high gates. The sorted cells were cultured in 6-well plate for 14 days and were 
analysed for Smarcb1 and Cd44 expression by IHC.  
 
As I wished to assess the functional relevance of Smarcb1-deficient NC cells (Cd44 low) 
compared to Smarcb1 positive cells (Cd44 high) in downstream experiments, it was 
critical to establish that these two cell populations show two distinct Smarcb1 expressions 
i.e low/high. To this end, NC cells were transfected with CRISPR SMARCB1 and the 
cells were sorted based on Cd44 expression on day 13 post-transfection. FACS purified 
Cd44 low and high were cultured for 14 days and the cells harvested for IHC analysis. 
Figure 4.11 shows 75% and 77% of NC cells have lost Smarcb1 protein expression 
obtained from Cd44 low cell populations treated with SMARCB1 MMG and SMARCB1 
MME respectively, in comparison to 13% and 13.2% of cells cultured from SMARCB1 
MMG and SMARCB1 MME CD44 high respectively. Cells from NTC were included as 
a positive control of Smarcb1 and Cd44 expression. A totally “pure” population of 
Smarcb1 negative cells from Cd44 low gate was unobtainable as a small proportion of 
cells (~25%) still showed positive nuclear Smarcb1 staining. However, Cd44 high 
population could still be a useful comparison in the downstream experiment as the two 
populations showed a 5-fold difference in Smarcb1 protein expression. IHC analysis of 
Cd44 cytoplasmic staining validated FACS analysis in which Cd44 low demonstrated a 
low percentage of cells with CD44 staining while Cd44 high showed high proportion of 
cells with CD44 staining (Figure 4.12). In summary, sorting against the Cd44 surface 
marker was able to increase the proportion of Smarcb1 negative cells. More importantly, 
this experiment indicates that the Smarcb1 knocked out cells were able to proliferate for 
13 days prior sorting and the proliferation persists for a further of 14 days following Cd44 
cell sorting (Figure 4.11).  
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Figure 4.11 Immunohistochemical staining for Smarcb1 expression in NC cells to 
establish positive and negative Smarcb1 cell population from Cd44 surface sorting. 
FACS sorted cells were evaluated for by IHC. Pure Smarcb1-deficient cells from Cd44 
low sorted cells could not be achieved as a small proportion of cells showed Smarcb1 
positive staining. However, there is a marked difference in percentage of positive 
Smarcb1 cells between Cd44 low and high. Notably, Aperio Imagescope failed to detect 
nuclear Smarcb1 staining (algorithm nuclear = 0) in 1.4% of NTC cells. 
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Figure 4.12 Immunohistochemical staining for Cd44 expression in NC cells to establish 
positive and negative Smarcb1 cell population from Cd44 surface sorting. FACS sorted 
cells were evaluated for Cd44 cytoplasmic protein expression by IHC. Loss of Cd44 
cytoplasmic cells was shown by red arrow. Expression of Cd44 protein was low in Cd44 
low and high in Cd44 high, validating FACS analysis. Notably, Aperio Imagescope failed 
to detect cytoplasmic Cd44 staining (algorithm nuclear = 0) in 2% of NTC cells. 
 
4.3.4.3 Cell proliferation is sustained in Smarcb1-deficient NC cells 
SMARCB1 is ubiquitously expressed in non-cancerous cells and mutation of this gene is 
not well tolerated in most cell types, consequently, Smarcb1 loss in mice leads to early 
embryonic lethality (Roberts et al., 2000, Klochendler-Yeivin et al., 2000, Guidi et al., 
2001). To test the hypothesis that loss of Smarcb1 in neural crest cells leads to MRT 
tumourigenesis, it was necessary to determine if the NC cells could retain proliferative 
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capacity without functional Smarcb1. The cell growth of transfected cells was monitored 
pre- and post- Cd44 sorting. The cell density pre-Cd44 sorting was measured using trypan 
blue whereas post-CD44 sorting was measured using INCUCYTE live imaging 
microscope.  
Prior to Cd44 sorting, 200,000 NC cells were transfected with lentiviral CRISPR targeting 
Smarcb1 (SMARCB1 MMG and SMARCB1 MME) and NTC. The number of viable 
cells was counted on day 2, 4, 7, 9 and 13 post-infection. Although only a small number 
of viable cells were recorded 48 hours post-transfection, the number was expanded to 2–
3 x 106 cells by day 13 (Figure 4.13a). Notably, there is no significant difference in 
number of viable cells measured between Smarcb1 -deficient cells and NTC. By contrast, 
Smarcb1 knockout in NIH3T3 led to cell death as the number of viable cells declined 
from day 4 onwards. WES analysis on nuclear-extracted samples confirmed the loss of 
functional Smarcb1 protein expression in NIH3T3 and NC cells (Figure 4.13b). 
In short, increased number of viable Smarcb1-deficient cells demonstrated that these cells 
were able to proliferate without functional Smarcb1. Furthermore, it indicates that 
mutation of Smarcb1 in NC cells does not impede cell survival. More importantly, this 
experiment established that the effect of Smarcb1 loss is context dependent as 
demonstrated by NIH3T3 cells which showed a marked decrease in cell growth and 
proliferation.  
 
 
178 
 
 
Figure 4.13 Smarcb1-deficient NC cells retained proliferative capacity. Loss of 
Smarcb1 in NTC demonstrated an increase in cell viability over time. In contrast, loss 
of Smarcb1 in NIH3T3 has a major impact on the growth rate as cell viability was 
decreased four days after transfection suggesting this cell type does not tolerate Smarcb1 
loss. The results are shown as mean ± SEM of two independent experiments and the 
significance was determined by unpaired Student’s t-test (**p< 0.005 and ****p< 
0.0001 vs control of appropriate culture). (b) Automated western blot (WES) analysis of 
total protein extracted from CRISPR Smarcb1 knockout NC cells confirmed Smarcb1 
knockdown in these cells. Smarcb1 knockdown by CRISPR/Cas9 resulted in Smarcb1 
protein loss in NC cells and NIH3T3. Beta-actin serves as loading control.  
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To gain a better understanding of the growth characteristics of Smarcb1-deficient NC 
cells, I then compared two sorted populations Cd44 low and Cd44 high as these cells 
exhibited a remarkable difference, more than 50% of cells have lost Smarcb1 expression 
as shown in Figure 4.11. The cells were sorted on day 13 post-transfection according to 
Cd44 expression and were cultured for three further passages. The cell growth was 
monitored using INCUCYTE ZOOM live imaging microscope. Data from INCUCYTE 
was recorded based on percentage cell confluency and the reading was analysed relative 
to day 0 of each CRISPR construct i.e. NTC. During passage 1, the cell number of Cd44 
high was higher than that of Cd44 low for individual CRISPR (Figure 4.14b). However, 
Cd44 low cells grew faster than Cd44 high cells in passage 2 for SMARCB1-MME 
construct as illustrated by percentage of cell confluency in culture (Figure 4.14b). 
Nevertheless, this was not statistically significant. The increase in proliferation rate was 
also seen in SMARCB1 MMG Cd44 low and Cd44 high, however, the difference in 
proliferation rate between these two cell populations was only observed after day 3 
(Figure 4.14b). However, during the third passage, SMARCB1 MMG Cd44 low has 
gained more proliferative capacity than Cd44 high as Cd44 low cells reached 
approximately 14% cell confluency compared to 7% cell confluency seen in Cd44 high 
by day 4 (Figure 4.14c). Strikingly, in passage 3, NTC cells showed a decline in 
proliferation capacity as illustrated by decreased in cell confluency on day 4, compared 
to SMARCB1 MME CD44 high and low; and SMARCB1 MMG CD44 low (Figure 
4.14c). The resulting confluency data indicates Smarcb1-deficient cells maintained the 
cell proliferation and tolerated Smarcb1 loss.  
In short, Smarcb1 knocked out in NC cells maintained the cell proliferation as seen in all 
Smarcb1-deficient cell populations. To further understand the role of Smarcb1, its effect 
on cell cycle and self-renewal were assessed in NC Smarcb1 knockout cells. 
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Figure 4.14 Time course study of effect of Smarcb1 loss on cell confluency. (a) Cell 
confluency was measured using INCUCYTE live imaging microscope for three 
passages. The confluency curves showing Smarcb1-deficient cells maintained cell growth 
as indicated by cell confluency. (a) Smarcb1 knockout in NC cells increased the 
proliferation rate as the percentage of cell confluency was higher than that of NTC, with 
the exception of SMARCB1 MMG Cd44 low. (b) Similar to Passage 1, SMARCB1 Cd44 
low cells from CRISPR SMARCB1 MME construct gained proliferative capacity as the 
percentage of cell confluency was higher than their counterpart in passage 2. Notably, 
NTC also regained the proliferation rate. (3) The Smarcb1-deficient cells in passage 3 
continued to increase the proliferation rate relative to NTC after day 3 in culture. A 
significant increase in the percentage of cell confluency was seen on day 4 in SMARCB1 
MME Cd44 low relative to NTC. There was no statistical different between Cd44 low vs 
Cd44 high and Smarcb1-deficient NC cells vs NTC. The results are shown as mean ± 
SEM of two independent experiments and the significance was determined by unpaired 
Student’s t-test (*p< 0.05, **p< 0.005 vs NTC). 
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4.3.4.4 Smarcb1 inactivation in neural crest cells dysregulates molecules involved 
in cell cycle progression and demonstrates the opposite transcriptional 
effect to that of SMARCB1 re-expression in MRT cells 
Smarcb1-deficient NC cells were still able to maintain the proliferation capacity after 26 
days of transfection This result suggests a growth suppressive role for SMARCB1 and 
supports a causative role of SMARCB1 loss in MRT tumourigenesis. To elucidate the 
mechanism by which Smarcb1 loss in NC drives cellular growth, the effect of Smarcb1 
loss was studied (Figure 4.14) on cell cycle-related genes by qPCR. The cell pellets were 
harvested from the Smarcb1-deficient NC- and NTC cells after day 7 of Cd44 expression 
sorting. qPCR analysis revealed a significant increase in the expression of genes coding 
for proteins promoting G1/S phase transition including Ccnd1, Ccnd3, Ccne1, Cdk4 and 
Cdk6. Of note, expression of Ccnd2 and Cdk4 is higher in Smarcb1-deficient NC cells 
compared to expression in MRT primary and cell lines which expressed lower CCND1 
and CDK6. By contrast, the expression of G1-phase inhibitors such as p16 and p21 was 
downregulated (Figure 4.16) and this mimics the expression level in MRT primary and 
cell lines. Notably, there were no marked differences in the expression of cell cycle-
related genes between Cd44 high and Cd44 low cell populations. 
Previous studies have shown reintroduction of SMARCB1 leads to cell cycle arrest (Betz 
et al., 2002, Kuwahara et al., 2010). Therefore, in this study, a similar approach was 
utilised to determine how Smarcb1 loss drives proliferation in the NC cells. Briefly, MRT 
cells were transfected with SMARCB1 WT lentivirus containing pCDH-EF1-PURO-
SMARCB1 plasmid or PCDH lentivirus carrying pCDH-CMV-MCS-EF1-Puro plasmid. 
MRT cells were harvested 5 days after puromycin selection and RNA was extracted using 
the protocol described in 2.3.3.1. Restoration of SMARCB1 in MRT cells caused 
downregulation of cell cycle promoting genes such as CCND1, CCND2, CDK4 and 
CDK6 accompanied by decreased expression of p21 and p16 (Figure 4.17). By contrast, 
the transcriptional effects of these genes in Smarcb1-deficient NC cells were the reverse. 
This indicates that Smarcb1 expression exerts regulation on the cell cycle machinery and 
its loss increases the proliferative capacity in NC cells. Up to this point, assessment of 
cell proliferation in Figure 4.13 and the qPCR analysis of cell cycle-related genes did not 
demonstrate significant differences in transcriptional expression between Cd44 low and 
Cd44 high of Smarcb1 -deficient cell populations although more than 50% of cells have 
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lost SMARCB1 expression as shown in Figure 4.11. Therefore, I sought to examine 
another mechanism that could provide explanation for similar growth characteristic and 
transcriptional expression seen in CRISPR SMARCB1 MMG Cd44 high and Cd44 low 
cell populations. 
 
 
Figure 4.15 Percentage of NC cells that have lost Smarcb1 expression measured on day 
11 post CD44 sorting by immunohistochemistry analysis (see section 4.2.2). These cells 
were harvested on day 7 post CD44 sorting for gene expression analysis of cell cycle 
related genes.   
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Figure 4.16 Smarcb1 loss in neural crest (NC) cells caused deregulation of the 
expression of cell cycle related genes. Expression analysis of Smarcb1-deficient NC cells 
demonstrates downregulation of cell cycle inhibitor genes accompanied by upregulation 
of cell cycle promoting genes, supporting the effect of Smarcb1 loss on cell proliferation 
of NC cells. Inactivation of Smarcb1 caused upregulation of cell cycle promoting genes 
including Ccnd1, Ccnd2, Ccnd3, Ccne1, Ccne2, Cdk4 and Cdk6 concomitantly with 
decreased in expression of two protein inhibitors; p21 and p16. mRNA expression of each 
genes was normalised to Gapdh. The results are shown as mean ± SEM of two 
independent experiments. 
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Figure 4.17 SMARCB1 re-expression in MRT cells shows the opposite transcriptional 
effect to that of Smarcb1 loss in NC cells. RNA was extracted from MRT cells with and 
without SMARCB1 expression. The mRNA expression of each gene was normalised 
against GAPDH of MRT cells without SMARCB1. The expression of genes in Smarcb1-
deficient NC cells was included for comparison purpose and the mRNA expression was 
normalised to Gapdh and the expression was presented as relative to control (NTC NC 
cells for CRISPR and Smarcb1-deficient MRT cells for MRT cells). The bar graph showed 
SMARCB1 inactivation in human MRT cells caused downregulation of cell cycle 
promoting genes (CCND1, CCND2, CDK4 and CDK6) along with upregulation of cell 
cycle inhibitors (p21 and p16). The results are shown as mean ± SEM of two independent 
experiments. 
 
4.3.4.5 Mutation of Smarcb1 in neural crest cells causes dysregulation of self-
renewal machinery 
Primary MRT have a high proliferative rate and Smarcb1 knockout using CRISPR/Cas9 
maintained the proliferation rate of NC cells, the postulated candidate cell of origin. I 
next examined if Smarcb1 loss in NC cells impacted self-renewal using a tumoursphere 
assay. Post Cd44 sorting Smarcb1-deficient NC cells were harvested on day 4 and the 
cells were washed twice with PBS and cultured at a density of 10,000 cells in 
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tumoursphere media made up of 2% B27 supplement, 20 ng/ml EGF (Peprotech), 30 
ng/ml bFGF (Peprotech), 2U/ml heparin (Sigma Aldrich), 0.5 µg/ml hydrocortisone 
(Sigma Aldrich), 1% sodium pyruvate (Thermo Fisher Scientific), 1% 
penicillin/streptomycin and 1% non-essential amino acid (Thermo Fisher Scientific) in 
DMEM/F12 media. The cells were allowed to form spheres for 12 days. Loss of Smarcb1 
in NC cells increased the number of primary tumourspheres as opposed to NTC (Mean ± 
SEM, 4 ± 1, n=2 technical replicates) (Table 4.1). In short, tumorsphere forming 
efficiency was not statistically different between Cd44 high and low cell populations 
although the trend of increase can be observed for Cd44 high cells in two tumoursphere 
cultures (Figure 4.18).  
To further examine the sphere forming efficiency, the secondary tumoursphere cultures 
derived from primary tumourspheres were established. Briefly, the primary 
tumourspheres were dissociated into single cells and re-plated in tumoursphere medium 
at 10,000 cell density and the cells grown in these culture conditions for 12 days. Figure 
4.18 shows that Smarcb1 knockout in NC cells resulted in increased self-renewal potential 
as illustrated by an increase in the number of secondary tumoursphere when compared to 
NTC. SMARCB1 MMG Cd44 low cells produced 12.5 tumourspheres while SMARCB1 
MMG Cd44 high cells produced 16.5 tumourspheres (n= 2 technical replicates) (Table 
4.1). By contrast, seven tumourspheres were counted in NTC culture. The increase in the 
number of tumoursphere was also seen in SMARCB1 MME Cd44 low and SMARCB1 
MME Cd44 high measuring for 11 and 15 respectively. A significant increase of 
secondary tumoursphere formation was seen in SMARCB1 MMG Cd44 high cell 
populations only. In line with the formation of primary tumourspheres, the Cd44 high cell 
population generated more tumourspheres than the Cd44 low cell population, but the data 
was not significant. CD44 expression has been widely used as cancer stem cell (CSC) 
marker (Bahena-Ocampo et al., 2016). Thus, selecting for loss of Cd44 expression may 
be a confounding factor influencing self-renewal mechanisms.  
In short, culturing Smarcb1-deficient NC cells as tumourspheres demonstrates the 
capacity of these cells to self-renew as illustrated by an increase in the number of 
tumourspheres. Intriguingly, the Smarcb1-deficient NC cells display increased self-
renewal potential as the number of secondary tumourspheres were higher than previously 
described in primary tumoursphere. More importantly, the proportion of self-renewing 
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cells within the Cd44 low and Cd44 populations varied, as Cd44 high cell population 
consistently demonstrated more tumoursphere than Cd44 low, in both primary and 
secondary tumoursphere assay, although the data were not statistically different.  
  
Figure 4.18 Smarcb1 loss in NC cells caused dysregulation of self-renewal machinery. 
To assess the self-renewal potential of these cells, tumoursphere assay was implemented 
as a self-renewal readout for Smarcb1-deficient cells. Primary tumourspheres were 
formed from single cells of adherent NC cells (at 10,000 cell density) when cultured in 
tumoursphere media for 12 days. To further assess self-renewal capacity, the primary 
tumoursphere was dissociated into single cells and re-plated at 10,000 for formation of 
secondary tumoursphere. The number of tumourspheres was counted on day 12. Self-
renewal capacity of Smarcb1-deficient cells was increased over two serial passage 
tumoursphere assays, with notable differences in the proportion of self-renewing cells 
between Cd44 high and Cd44 low. The results are shown as means ± SEM of two 
independent experiments and the significance was determined by unpaired student’s t-
test (* p<0.05 vs NTC). 
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Table 4.1 Effect of Smarcb1 knockout on formation of tumourspheres. Results are 
shown as Mean ± SEM and the significance of the results was determined by unpaired 
student’s t-test.  
 
To gain further insight into the effect of Smarcb1 loss on self-renewal mechanism and 
how two cell populations; Cd44 high and Cd44 low showed differences in self-renewal 
potential, evaluation of the expression of genes involved in self-renewal pathways was 
carried out using qPCR analysis. The self-renewal genes used in this analysis were 
selected based on the evidence from published expression profiles of primary MRT 
(Johann et al., 2016, Deisch et al., 2011, Venneti et al., 2011b) and also SMARCB1 re-
expression cell model (PBTG).   
This analysis demonstrated that loss of functional Smarcb1 in NC cells caused 
upregulation of the expression of self-renewal genes such as Sox2, Klf4, Oct4, Bmi1, Gli2 
and Jarid2 by approximately 1.1 to 7 -fold change (Figure 4.19). A small decrease of 0.8-
fold in the expression of Klf4 in CRISPR SMARCB1 MMG Cd44 low was also seen. 
Although gene expression of self-renewal related genes was broadly similar between 
Cd44 high and Cd44 low cell populations, a few genes are more highly upregulated in 
Cd44 high than Cd44 low thus possibly supporting the observation of a higher number of 
tumourspheres in Cd44 high than Cd44 low cell populations. For instance, expression of 
Ezh2 and Sox2 which have clear roles in self-renewal and pluripotency was significantly 
higher in Cd44 high cells.  
 
188 
Overall, an increase in expression of self-renewal related genes such as Sox2, Klf4, Oct4, 
Bni1, Gli2 and Jarid2 in Smarcb1-deficient NC cells mimics the enrichment of these 
genes in our expression-profiling of primary MRT (PBTG). In summary, knockout of 
Smarcb1 using a CRISPR/Cas9 system in NC cells is associated with an increase in the 
number of tumourspheres and expression of self-renewal related genes.  
 
Figure 4.19 Increase in the number of tumourspheres is associated with increased 
expression of self-renewal genes demonstrated by qPCR analysis. RNA was extracted 
from NC cells infected with NTC and two different CRISPR constructs targeting Smarcb1 
expression in cells. mRNA expression was normalized against Gapdh of NTC NC cells. 
The expression of self-renewal genes in all Smarcb1 cell populations (CD44 high/low) is 
largely comparable with the exception of Sox2, Ezh2 and Cd44 which were highly 
expressed in Cd44 high for both CRISPR construct. The results are shown as means ± 
SEM of two individual experiments. 
4.3.4.6 Defective cytoskeleton organisation in Smarcb1-deficient NC cells 
Knockout of Smarcb1 in NC cells led to a modification in cell phenotype and morphology. 
The original spindle shape of NC cells changed upon Smarcb1 knockdown. In general, 
the cells demonstrated fibroblastic features. However, this is not obvious from the images 
taken using phase contrast microscope (Figure 4.20). F-actin distribution can provide an 
indication of cell morphology (Silveira e Souza et al., 2011, Fernández-Segura et al., 
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1995). Hence, the cytoskeleton of cells was examined by immunofluorescence (IF) 
imaging using phalloidin staining of F-actin filament. Overall, Smarcb1 knockout in NC 
cells was associated with dramatic alteration of cell shape including loss of original 
spindle shape and high cytoplasmic area. Besides that, Smarcb1-deficient cells also 
demonstrated a remarkable increase of the cell size relative to NTC cells, for instance, 
the area per object measured using ImageJ software for NTC was 4.64 mm2 whereas 
SMARCB1 MMG Cd44 low was 19.2 mm2. The diameter of a nucleus for Smarcb1-
deficient cells was also bigger than that of NTC cells. The mean size of nucleus for NTC 
cells was 10.31 ± 0.6988 mm2 (n = 10 nuclei, n = 4 technical replicates). On the other 
hand, the mean size of nucleus measured in SMARCB1 MMG Cd44 low was 17.72 ± 
1.127 mm2 (n = 10 nuclei, n = 4 technical replicates, p-value = 0.0014), SMARCB1 MMG 
Cd44 high was 17.92 ± 0.6864 mm2 (n = 10 nuclei, n = 4 technical replicates, p-value = 
0.0002), SMARCB1 MME Cd44 low was 20.21 ± 1.736 mm2 (n = 10 nuclei, n = 4 
technical replicates, p-value = 0.0018) and  SMARCB1 MME Cd44 high was 17.97 ± 
0.8892 mm2 (n = 10 nuclei, n = 4 technical replicates, p-value = 0.0005). The large 
nucleus seen in Smarcb1-deficient NC cells is comparable with morphologic features of 
proliferating MRT cells which usually show a large nucleus relative to non-cancerous 
cells. The MRT cells have eccentric nuclei and the cell sometimes may contain two nuclei 
(Hayat, 2012). 
Immunofluorescence imaging of NTC cells showed the majority of F-actin filaments 
were evenly distributed in the cytoplasm as dense bundles (spindle shape). By contrast, 
Smarcb1 knockout in NC cells greatly altered the organisation and distribution of F-actin 
filaments as seen in CRISPR SMARCB1 MMG Cd44 low Smarcb1-deficient NC cells, 
relative to Cd44 high for the same CRISPR construct, NTC NC cells and NIH3T3 cells 
(Figure 4.21 and Figure 4.22). CRISPR SMARCB1 MMG Cd44 low cells demonstrated 
a clear disruption in the cytoskeletal organisation as the F-actin filaments were crossed 
on top of each other forming a filamentous network within cells. Likewise, NC cells 
treated with CRISPR SMARCB1 MME also showed disordered distribution of 
cytoskeletal structures that can be seen in phalloidin staining cells. However, there is no 
obvious difference in F-actin organisation between Cd44 high and low cells population 
for the CRISPR SMARCB1 MME construct. Two MRT cell lines; A204 and G401 also 
showed disruption of the actin organisation compared to NIH3T3, a control cell line 
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(Figure 4.22) thus supporting observation of F-actin filament arrangement in Smarcb1-
deficient NC cells.  
Smarcb1-deficient cells immunostained with phalloidin antibody also showed 
localisation of cells within filopodium (Fp) and actin-rich protrusion, microspike. 
Notably, prominent stress fibre (Sf) was observed in Smarcb1-deficient cells and this 
figure was absent in NTC. The presence of stress fibres in MRT has been reported by  
(Medjkane et al., 2004). In this study, the authors found that the organisation of stress 
fibres which were initially present in MRT cell lines was disrupted upon reintroduction 
of Smarcb, causing the change in cell shape. Staining of Smarcb1-deficient NC cells with 
phalloidin antibody also demonstrated the presence of other actin filaments usually 
involved in cancer progression including diagonal meshwork lamellipodium and 
filopodium (Arjonen et al., 2011). In summary, these findings suggest that Smarcb1 loss 
leads to the alteration in the organisation of actin cytoskeleton and size of cells.  
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Figure 4.20 Smarcb1 loss in NC cells is associated with changes in cell morphology. 
The sorted cells were cultured in an incubator installed with using INCUCYTE live cell 
imaging microscope (scale: 200 um). Image of Smarcb1-deficient and NTC cells taken 
on day 25 post transfection. A phase contrast microscopy showing modification of cell 
shape of Smarcb1-deficient cells and loss of spindle cell shape, as seen in NTC cells.  
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Figure 4.21 Smarcb1 loss in NC cells affects the cytoskeletal structure of cells. The 
representative fields showing NTC and Smarcb1-deficient NC cells stained for F-actin 
using fluorescently conjugated phalloidin antibody (in green) and the nuclei were stained 
with DAPI (in blue). The images were taken using the 40X objective on the Zeiss Leica 
DM6 microscope. The images showed prominent stress fibre (Sf), diagonal meschwork 
lamellipodium (Lp) and filopodium (Fp). 
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Figure 4.22 Smarcb1 loss in NC cells affects the cytoskeletal structure of cells. The 
representative fields showing a negative control cells; NIH3T3 and two positive control 
cells from MRT cell lines; A204 and BT16 stained for F-actin using fluorescently 
conjugated phalloidin antibody (in green) and the nuclei was stained with DAPI (in blue). 
The images were taken using the 40X objective on the Zeiss Leica DM6 microscope. The 
images show prominent stress fibre (Sf), actin protusion microspike (Ms), diagonal 
meschwork lamellipodium (Lp) and filopodium (Fp). 
 
4.3.4.7 Smarcb1 loss in early neural crest cells displays human MRT features 
Taking all the findings to this point together, Smarcb1 loss in NC cells has demonstrated 
strong evidence supporting the NC cells as a possible cell of origin for MRT. To assess 
whether Smarcb1-deficient NC can phenotypically resemble human MRT, formalin fixed 
adherent cell were prepared to analyse the typical MRT features such as inclusion bodies 
and prominent nucleoli in Smarcb1-deficient NC cells from day 11 of post Cd44 sorting 
and control NTC cells using H&E (Haemotoxylin and Eosin) staining (Figure 4.24). The 
IHC staining of the sections from the cell block could not identify the presence of 
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prominent nucleoli and inclusion bodies in any Smarcb1-deficient NC cells extracted 
from day 11 post Cd44 sorting (Figure 4.24a), although 91% and 87% of SMARCB1 
MMG CD44 low and SMARCB1 MME CD44 low cells respectively have lost Smarcb1 
expression (Figure 4.24b).  
To further examine if Smarcb1 loss in NC cells can mimic human MRT, the important 
markers that are commonly used in MRT diagnosis were examined in knocked out and 
control NC cells. Human MRT can demonstrate wide-ranging immunoreactivity due to 
heterogeneous histologic features. For this study, I evaluated the expression of vimentin 
and cytokeratin 8 (CK8) using immunofluorescence. The immunofluorescence staining 
revealed positive staining for vimentin in all Smarcb1-deficient cells compared to NTC 
NC cells (Figure 4.26). Notably, the expression of vimentin was stronger in Cd44 low 
relative to Cd44 high population of cells infected by both CRISPR SMARCB1 MMG and 
SMARCB1 MME constructs (Figure 4.26). The expression of vimentin was also detected 
in MRT cell lines; A204 and BT16, thus illustrating the similarity with Smarcb1-deficient 
NC cells (Figure 4.28). 
Cytokeratin staining is also used for MRT diagnosis and its expression is usually detected 
in focal loci of ATRT (Vitte et al., 2017). Therefore, cytokeratin 8 expression was 
examined in Smarcb1-deficient NC cells, MRT cell lines (A204 and BT16) and NTC NC 
cells. Immunofluorescence staining showed a modest CK8 expression in CRISPR 
SMARCB1 MME Cd44 low (Figure 4.28). The expression of CK8 was weak in CRISPR 
SMARCB1 MMG Cd44 low and CRISPR SMARCB1 MME Cd44 high cells. By 
contrast, expression was absent in NTC NC and NIH3T3, suggesting that Smarcb1 
knockout induces the expression of keratins in cells (Figure 4.28). Furthermore, the 
modest cytokeratin 8 expression could also be identified in A204 and the expression of 
cytokeratin 8 was stronger in the BT16 cell line.  
Attempt was also made to identify perinuclear inclusion bodies using dual 
immunofluorescence staining of vimentin and cytokeratin 8 in BT16 cells and 
SMARCB1-deficient MME Cd44 low cells, however the presence of inclusion bodies 
was difficult to detect as co-localisation of two intermediate filaments form packed and 
elongated filaments (Figure 4.29). In summary, Smarcb1 -deficient NC displayed typical 
histological and immunophenotype that resemble those found in human MRT but further 
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work (i.e mice engrafment) should be done to identify the presence of typical rhabdoid 
cells such as inclusion bodies.  
 
Figure 4.23 Identification of human MRT phenotypes in NC cells. The H&E staining 
was performed on adherent Smarcb1-deficient cells in a chamber of 6 well to identify 
common phenotypes that are associated with human MRT including eosinophilic 
inclusion and prominent nuclei.  
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Figure 4.24 Immunohistochemical staining for Smarcb1 protein expression in NC 
cells. The Smarcb1 staining was performed on adherent Smarcb1- deficient cells and 
NTC cells in a chamber of 6 well. NC cells used in this analysis were harvested 11 days 
after of Cd44 sorting. Nuclear Smarcb1 staining was scored using Aperio Imagescope 
using nuclear algorithm. The nuclei were scored negative if algorithm readings were 0 
and +1. The nuclei were scored positive if the readings were +2 and +3. 
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Figure 4.25 Smarcb1-deficient cells demonstrates human MRT phenotype. The 
representative fields showing Smarcb1-deficient NC cells and NTC cells stained for 
intermediate filament III using fluorescently conjugated vimentin antibody (in red) and 
the nuclei were stained with DAPI (in blue). The images were taken using the 40X 
objective on the Zeiss Leica DM6 microscope. 
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Figure 4.26 Smarcb1-deficient cells demonstrates human MRT phenotype. The 
representative fields showing a negative control cell; NIH3T3 and two positive control 
cells from MRT cell lines; A204 and BT16 stained for intermediate filament III using 
fluorescently conjugated vimentin antibody (in red) and the nuclei were stained with 
DAPI (in blue). The images were taken using the 40X objective on the Zeiss Leica DM6 
microscope.  
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Figure 4.27 Smarcb1-deficient cells demonstrates human MRT phenotype. The 
representative fields showing Smarcb1-deficient NC cells and NTC cells stained for 
intermediate filament type II keratin using fluorescently conjugated cytokeratin 8 
antibody (in green) and the nuclei were stained with DAPI (in blue). The images were 
taken using the 40X objective on the Zeiss Leica DM6 microscope.  
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Figure 4.28 Smarcb1-deficient cells demonstrates human MRT phenotype. The 
representative fields showing a negative control cells;, NIH3T3 and two positive control 
cells from MRT cell lines; A204 and BT16 stained for intermediate filament type II keratin 
using fluorescently conjugated cytokeratin 8 antibody (in green) and the nuclei were 
stained with DAPI (in blue). The images were taken using the 40X objective on the Zeiss 
Leica DM6 microscope.  
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Figure 4.29 Immunofluorescence imaging of dual staining of cytokeratin 8 (green) and 
vimentin (red). Co-localisation of cytokeratin 8 and vimentin was seen in two cells; BT16 
and Smarcb1-deficient MME CD44 low cells. However, the perinuclear inclusion bodies 
could not be detected within the cells. The nuclei were stained with DAPI (in blue). The 
images were taken using the 40X objective on the Zeiss Leica DM6 microscope. 
 
4.3.4.8 The effect of Smarcb1 loss on cellular differentiation in neural crest cells  
In a previous study, re-expression of SMARCB1 in MRT cell lines provoked adipogenic 
cell differentiation (Caramel et al., 2008). Another study showed that loss Smarcb1  in 
developing liver impairs the formation of hepatic epithelium accompanied by 
downregulation of 70% of genes that involve during liver development, thus indicating 
the requirement of Smarcb1 for hepatocyte differentiation (Gresh et al., 2005). 
Furthermore, primary MRT are often associated with an undifferentiated phenotype, thus 
implying a significant role of SMARCB1 in cell differentiation. 
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Figure 4.30 Experimental model for cell differentiation. It is predicted in this study that 
SMARCB1 loss could cause defects in cell differentiation. An Experimental study by 
Caramel et al., (2008) demonstrated that re-expression of SMARCB1 in some MRT cell 
lines provoked cell differentiation into the adipocyte lineage. 
 
To investigate this further, Smarcb1-deficient NC cells and NTC cells were cultured in 
two types of differentiation media; adipogenic and osteogenic after 9 days of Cd44 
sorting. To induce the cell differentiation, cells were cultured in differentiation media for 
3 weeks and the media was changed every two days. In osteogenic cell differentiation, 
the formation of mineralised nodules in osteogenic cells cultures offers a tool to assess 
the mature osteoblast cells in culture. Alizarin Red solution was used to stain mineralised 
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nodules after three weeks in culture. In contrast to the hypothesis of this study that the 
loss of functional Smarcb1 in the appropriate cell of origin has the ability to block lineage-
specific differentiation, Smarcb1-deficient NC cells exhibited osteogenic potential in 
comparison to NTC cells. Alizarin Red staining showed nearly 70-85% of Cd44 high 
cells in 6-well plate were stained with Alizarin Red relative to approximately 3-5% of 
cells in Cd44 high well (Figure 4.31a). Notably, only one mineralised nodule was seen in 
NTC well.  
Likewise, Smarcb1-deficient NC cells also differentiated towards an adipogenic lineage 
when cultured in adipogenic differentiation media (Figure 4.31b). The cells were stained 
with Oil Red O solution and were analysed for the presence of lipid droplet in the 
cytoplasm. Figure 4.2b showed the accumulation of lipid droplets in Smarcb1-deficient 
NC cells as well as control NTC. A mean of 38 ± 7 lipid droplets was counted in NTC 
cells, 52.5 ± 7.5 lipid droplets in SMARCB1 MMG Cd44 high cells, 10 ± 2 lipid droplets 
in SMARCB1 MMG Cd44 low cells, 68.5 ± 10.5 lipid droplets in SMARCB1 MME 
Cd44 high and 9.5 ± 4.5 lipid droplets in SMARCB1 MME Cd44 low.  
The observations from current study did not support the hypothesis of this study. More 
repeats should be performed before completely rejecting this hypothesis however it seems 
from these first experiments that Smarcb1 loss does not discriminately block cells from 
differentiating into osteocytes and adipocytes.  
 
 
 
 
 
 
 
 
204 
  
 
 
Figure 4.31 Osteogenic and adipogenic differentiation experiments to study the 
potential of Smarcb1-deficient cells to differentiate. Cells were grown in differentiation 
media (osteogenic and adipogenic) for three weeks before the staining step. (a) Alizarin 
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red staining was used to detect accumulation of calcium compounds containing 
osteocytes in differentiated culture (in red). (b) Oil red O was used to demonstrate the 
presence of lipid droplet (in red). 
 
4.3.4.9 Summary of the results 
 
 
Figure 4.32 Timeline of experiments performed in this project. 
 
Overall, CRISPR/Cas9 can efficiently knock out Smarcb1 expression in NC cells. The 
timeline in Figure 4.32 shows the timings of the experiments performed in this project. 
Smarcb1 expression was checked following the Cd44 cell sorting using IHC analyses on 
day 13 post-transfection prior to CD44 sorting, day 11 post CD44 sorting and day 13 post 
Cd44 sorting (Table 4.2 and Table 4.4). IHC analysis of Smarcb1 nuclear expression in 
Smarcb1-deficient NC cells from a second replicate, after 11 days of Cd44 sorting could 
not be determined accurately due to few problems which I will discuss in detail in Section 
4.4.3. Differentiation assays (osteogenic and adipogenic) demonstrated that Smarcb1-
deficient cells were still capable to differentiate into adipocyte and osteocytes. This is 
probably due to the fact that small proportion of cells within Smarcb1-deficient cells were 
Smarcb1 positive. Also, it is worth to note that, there is no significant difference between 
Cd44 high and Cd44 low cell populations in terms of expression of cell cycle genes, self-
renewal potential and growth capacity. The practicability of using Cd44 expression 
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marker in sampling Smarcb1 negative cells is further discussed in Section 4.4.2. The 
summary of results was presented in the table below: 
 
 
Table 4.2 Summary of results pre CD44 sorting. ND = not determined 
 
 
Table 4.3 Summary of results post CD44 sorting. ND = not determined 
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Table 4.4 Summary of results post CD44 sorting. ND = not determined 
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Table 4.5 Summary of results post CD44 sorting. ND = not determined 
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4.4 Discussion 
4.4.1 CRISPR/Cas9 mediated Smarcb1 genome editing in neural crest cells 
provides a tool to study MRT tumourigenesis 
The early onset of MRT provides an indication of the requirement for a mutational event 
in early development resulting in tumourigenesis. Loss of Smarcb1 in granule cell 
precursors demonstrates a lack of tumourigenic phenotype in Smarcb1flox/flox, Atoh-Cre 
mice model, indicating tumourigenesis of ATRT does not arise from granule cell 
precursor (Moreno et al., 2014). These observations narrow down the developmental 
window and the potential candidates for the cell of origin of MRT. Results from the 
bioinformatics analysis of different cell types (Chapter 3) suggested neural crest (NC) 
cells as a potential MRT cell of origin, especially for ECRT. This observation is in line 
with a growing number of reports based on histological, genomics and mouse studies in 
MRT (Chun et al., 2016, Han et al., 2016, Vitte et al., 2017).  
In a MRT mouse model study by Han et al. (2016), the authors found the high penetrance 
of tumour, mainly intracranial after tamoxifen injection into Rosa26-CreERT2; 
Smarcb1flox/flox mice were observed between E6 and E10. Injection of tamoxifen after E10 
failed to develop tumours. Although their mouse model experiments provides an 
important piece of information regarding the developmental window at which cells are 
susceptible to Smarcb1 loss for the initiation of tumourigenesis, the authors did not 
specifically perform the injection in specific type of cells to speculate the cell of origin 
for MRT. Following this study, Vitte et al. (2017) developed P0-CreC; Smarcb1flox/flox 
mice to study the cell of origin for MRT. In this study, the authors performed deletion of 
Smarcb1 in early NC cells at protein zero promoter and reported the tumours 
demonstrating immunohistological and molecular profiles resemble human MRT. Their 
mouse model demonstrated loss of Smarcb1 at a developmental window of E9.5 in early 
neural crest cells is required for MRT oncogenesis (Vitte et al., 2017). Knockout of 
Smarcb1 at a later developmental stage such as E12.5 or E13.5 failed to induce 
tumourigenesis. However, their hypothesis that early NC cells at P0 is a potential cell of 
origin raised a question as to whether these cell populations are true cell of origin for 
MRT since they also speculated that these cell populations are a cell of origin for 
schwannoma and eventually concluded that some MRT may originate from meninges as 
most tumours were formed in this region. Furthermore, the authors did not explicitly time 
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the induction of Smarcb1 mutation in mice except by inference through the expression of 
protein zero (P0), which is an active promoter in early NC cells.  
In this study, an early NC cell that was derived from the mouse at E8.5 was used as a 
potential cell of origin for MRT. Previous mouse model studies utilised Cre recombinase 
constructs to specially target Smarcb1. Here, I report another technique to knockout 
Smarcb1 in cells using CRISPR/Cas9 technology. Inhibition of expression using 
CRISPR/Cas9 is highly efficient as shown by approximately 80-90% loss of Smarcb1 
protein after 27 days of transfection (Figure 4.11). In particular, two CRISPR/Cas9 
constructs that targeted different regions in mouse Smarcb1 has been successfully 
generated with comparable knockout efficiency. Moreover, the off-target effects were 
reduced further by choosing the guide RNAs that were distinctive from any other sites in 
the genome by at least three nucleotides and by adding extra guanines (Kim et al., 2017). 
Given that, both constructs demonstrated similar results which were distinct from the 
control (NTC), off-target effects are unlikely to have influenced the findings generated in 
this part of the study. 
This cell model is suitable as a tool to study MRT tumourigenesis and to identify potential 
therapeutic targets. Transfection of sgRNA and Cas9 plasmid into neural crest cells 
resulted in high-level expression of these two components, leading to efficient genome 
editing. Importantly, Smarcb1-deficient NC cells could maintain cell proliferation and 
demonstrated histological and gene expression that resembles human MRT.  
4.4.2 The practicality of selecting pure Smarcb1-negative population using Cd44 
surface marker 
CD44 is a ubiquitously expressed glycoprotein adhesion molecule derived from a gene 
that contained 18 exons (Shigeishi et al., 2013). CD44 is also known as a SWI/SNF 
responsive surface protein CD44 (Banine et al., 2005). The expression of CD44 can 
influence stem cell characteristics through a wide range of mechanism and interaction 
with its main ligand, hyaluronan can also activate many cell signalling pathways 
associated with tumour growth and progression (Shigeishi et al., 2013). Particularly in 
MRT, expression of CD44 is either absent (in ATRT) or low (in ECRT). Hence, its 
expression was exploited to increase the percentage of pure Smarcb1-negative cells. 
However, a pure Smarcb1 negative cell population was unobtainable as there were 
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roughly ~30% Smarcb1 knocked out cells which were positively stained with Smarcb1 
antibody (Figure 4.11). This may explain why Smarcb1 -deficient cells were still able to 
differentiate into mesenchymal lineages i.e adipocytes (Figure 4.31). Besides that, there 
was no significant difference in growth characteristics between Cd44 high and Cd44 low 
cell population measured for 11 days post Cd44 sorting (Figure 4.13). Moreover, gene 
expression analysis of cell cycle-related genes also showed no statistical difference 
between these two cell populations. Hence, the difference in growth characteristics 
between Cd44 high and Cd44 low cell populations could not clearly be outlined in this 
project. Failure to obtain Smarcb1-negative CD44 cell population may also due to the fact 
the stability of Cd44 expression following sorting has not been determined in this study. 
Expression of Cd44 should be re-examined after the first sorting by FACS to ensure Cd44 
expression is low in Cd44 low cell population than Cd44 high cell population and 
therefore may increase significance of the results.  
Sampling Smarcb1-negative cells using Cd44 expression also presents difficulties as 
deregulation of Cd44 expression interferes with expression of other stemness genes and 
capacity of the cells to form tumourspheres. Although the difference in the number of 
tumourspheres between Cd44 high and Cd44 low cells was not statistically significant, 
the results can be confounded by Cd44 expression. C44 has a role in stem cell self-
renewal. Expression of this gene has been widely used as a cancer stem cell (CSC) marker 
(Li et al., 2017). High expression of CD44 has been correlated with cell proliferation and 
tumourigenesis of breast cancer as determined by mammospheres formation and 
tumourigenesis in xenotransplanted mice experiments. The authors found that the number 
of mammospheres was higher in CD44 high cell population relative to CD44 low cell 
population. Their result illustrates the significance of CD44 expression in CSC self-
renewal. Furthermore, they found that high expression of CD44 coupled with a high 
expression of ALDH was capable to increase the cell metastasis thus signifying the 
positive correlation of CD44 with other stemness genes in regulating tumourigenesis.  
Given the problems encountered when using Cd44 expression to sample Smarcb1 
negative cells, it is, therefore, necessary to identify other surface markers that can increase 
the percentage of Smarcb1 negative cells. 
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4.4.3 Feasibility of the techniques used to analyse the percentage of Smarcb1-
negative NC cells  
In this chapter, immunohistochemistry was used to analyse Smarcb1-deficient cells in NC 
cell populations. This technique is commonly used to detect SMARCB1 expression in 
MRT patient material using anti-SMARCB1 antibody (BD Biosciences). IHC is a useful 
tool to measure the proportion of Smarcb1-deficient NC cells. However, it also confers 
challenges for image analysis. For instance, the nuclear expression of Smarcb1 was 
difficult to interpret when the formalin cell blocks were prepared from the monolayer 
cells (Figure 4.24) as opposed to cytospin cells (Figure 4.8). The cells which grew as 
monolayers tend to grow on top of each other and were not uniformly spread in the wells, 
which hindered antigen retrieval and thus antibody staining. The images presented in 
Figure 4.24 also highlights edge effects which creates challenges to the accuracy of image 
quantitation and analysis. Thus, preparation of the cell block using cytospin would 
provide a useful method in evaluating Smarcb1 expression in cells.  
4.4.4 Smarcb1 loss in NC cells maintains cell survival and causes deregulation of 
cell cycle-related genes 
Loss of functional Smarcb1 in other cell lines is often associated with cell death and 
growth arrest. Knockout of Smarcb1 using CRISPR/Cas9 resulted in decreased cell 
proliferation and count after 48 hours of puromycin selection in NIH3T3. However, the 
proliferative capacity of NC cells was maintained following the loss of Smarcb1. 
Smarcb1 loss in NC cells also caused dysregulation of cell cycle-related genes. The 
findings of this study implicating SMARCB1 in cell cycle regulation in MRT is supported 
by numerous other studies (Betz et al., 2002, Versteege et al., 2002, Isakoff et al., 2005, 
Roberts and Biegel, 2009).  A study of the role of SMARCB1 as a tumour suppressor gene 
in the development of MRT reveals the effect of SMARCB1 loss on cycle progression 
through downregulation of p16 expression and upregulation of E2F and CCND1 
expression. Here, I showed that Smarcb1 knockout reduced the expression of p16 and 
p21 genes concomitantly with an increase in expression of cell cycle promoting genes 
such as Ccnd1, Cccnd2 and Ccnd3 in NC cells, as determined by qPCR analysis. Hence, 
the effect of Smarcb1 knockout on cell cycle regulation in NC cells mimics the 
observations collected from previous studies and also from primary and cell data 
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available in the group. It is worth noting that the expression of Ccnd2, Ccnd3, Cdk6 is 
higher in Smarcb1- deficient cells compared to MRT primary and cell lines. 
4.4.5 Smarcb1-deficient cells exhibit phenotypes resembling human features 
A few studies have demonstrated that SMARCB1 re-expression causes a dramatic change 
in the cell shape such flat cell formation (Dunaief et al., 1994)  due to disruption of actin 
stress fibre organisation associated with increased in expression of genes involved in actin 
cytoskeleton (Medjkane et al., 2004). A study by Medjkane et al. (2004) provides 
evidence of Smarcb1’s role in cytoskeleton organisation. CRISPR knockout of Smarcb1 
also caused dramatic modifications of cell shape in NC cells and the mechanism that 
contributes to change in cell shape was investigated using phalloidin antibody staining. 
This antibody selectively binds to actin filament known as F-actin. Actin is the 
monomeric subunit of two types of filaments in cells which are microfilaments and thin 
filaments (Cooper, 2000). It is involved in many cellular activities including cell motility, 
cell division, cell shape and many more. Indeed, Smarcb1 knockout in NC cells greatly 
altered the actin cytoskeleton organisation compared to NTC. Knockout of Smarcb1 in 
NC cells also caused the formation of many stress fibres (contractile bundles of actin) 
within cells. This observation can explain the change in cell shape. Also, the presence of 
many filopodia, a feature of cell motility, in Smarcb1-deficient NC cells relative to the 
control suggests improved cell propagation in these cells. In the absence of SMARCB1 
expression, many stress fibres were found in the MRT cell line (Medjkane et al., 2004). 
However, they were diminished upon SMARCB1 re-expression, thus resulting in a more 
rounded cell shape. The specific pathway by which SMARCB1 regulates cytoskeletal 
arrangement in NC cells can be elucidated through gene expression analysis, though it 
has been proposed to occur through the Rho pathway in MRT cell line (MON) (Medjkane 
et al., 2004).  
Smarcb1-deficient cells also demonstrated strong positive staining of the intermediate 
filament vimentin. The immunoreactivity of MRT primary and cell lines with vimentin 
has been reported in few studies and it serves as a diagnostic marker for MRT (Sugimoto 
et al., 2016, Itakura et al., 2001). Vimentin usually forms a filamentous network that can 
vary in size and it can be found at the rim of the cytoplasm or the cell periphery. In some 
MRT cells, vimentin can co-localise with cytokeratin 8. In this study, Smarcb1 knocked 
out in NC cells resulted in weak expression of cytokeratin 8 making it difficult to identify 
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co-localisation of these two types of intermediate filaments. Nevertheless, the presence 
of cytokeratin 8 expression still provides the evidence that Smarcb1-deficient cells can 
immunophenotypically resemble human MRT as its expression was absent in NTC NC 
cells. 
Collectively, Smarcb1 loss altered the cell shape and size and is associated with actin 
cytoskeleton organisation. Smarcb1 -deficient cells showed immunoreactivity with two 
MRT markers; vimentin and cytokeratin 8. In short, data from this study recapitulates the 
findings from previous studies and human MRT tissue.  
4.4.6 Histological characteristics of “Rhabdoid” cells are absent in Smarcb1-
deficient NC cells 
An attempt was made to identify the main histological characteristics of rhabdoid cells 
such as prominent nuclei and cytoplasmic inclusion bodies using conventional H&E 
staining. However, these figures were not detected in Smarcb1-deficient NC cells. Of 
note, classic morphological features and the identification of the rhabdoid cells with 
characteristics of nuclear and cytoplasmic aspects were also challenging in the primary 
MRT cells (Bourdeaut et al., 2007). The inclusion bodies and prominent nucleoli can be 
seen in cells when engrafted in mice. To circumvent the problem mentioned above with 
immunohistochemistry, the presence of inclusion bodies was further examined using 
immunofluorescence staining. These inclusions are ultrastructurally characterised by the 
presence of agglomerates of two intermediate filaments; cytokeratin (CK) or vimentin 
(Raymond and Leong, 1989, Waelter et al., 2001, Itakura et al., 2001, Parker et al., 2002). 
The presence of cytokeratin in an MRT cell line, Tm86-16 was described as clusters of 
globules or clumps if located at the cell periphery (Itakura et al., 2001). 
Immunofluorescence staining showed weak expression of cytokeratin 8 (CK8) in 
majority Smarcb1-deficient cells which limits the ability to detect inclusion bodies. In 
this analysis, BT16 and Smarcb1-deficient MME Cd44 low cells demonstrated strong 
positive CK8 and vimentin staining. Hence, dual immunofluorescence staining was 
performed in these cells to identify perinuclear inclusion bodies (Figure 4.29). The 
immunofluorescence assessment revealed clear co-localisation of two intermediate 
filaments in the same area, and CK8 formed packed and elongated filaments. Therefore, 
it was very difficult to distinguish the inclusion bodies in the cells. Shiratsuchi et al. 
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(2001) also reported the difficulty to detect inclusions in cells as the filamentous 
inclusions can vary in size and arrangement from cell to cell. 
 In short, although classic histological features of rhabdoid cells were not established 
from these experiments, this may be a result of lack of interaction with a more complex 
dynamic tissue microenvironment. Thus, establishing a mouse xenograft model with the 
Smarcb1-deficient NC cells will provide a better context to assess histological features 
and increasing interaction with a more dynamic and complex microenvironment, and 
potential of NC cells as a cell of origin for MRT.  
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Chapter 5 Establishing tumoursphere assay of Malignant 
Rhabdoid Tumours (MRT) cell lines for self-
renewal identification and analysis 
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5.1 Summary 
Malignant Rhabdoid Tumours (MRT) are characterised by a biallelic mutation in 
SMARCB1, a component of the SWI/SNF chromatin remodelling complex (Versteege et 
al., 1998, Biegel et al., 2002b). MRT are aggressive and present a poor disease prognosis 
(Reinhard et al., 2008, Brennan et al., 2013a). Work done within my group has shown 
strong overexpression of a large number of “self-renewal/stemness” genes in primary 
MRT, as determined by gene expression analysis. Other studies also have shown that a 
number of these genes are deregulated by loss of SMARCB1 and/or the larger SWI/SNF 
complex (Deisch et al., 2011, Venneti et al., 2011b, Johann et al., 2016). Therefore, I 
assume that SMARCB1 loss is capable of hijacking self-renewal mechanisms and could 
potentially contribute towards disease aggressiveness. To investigate the mechanism of 
self-renewal in MRT and to access its potential as a targetable element of MRT 
tumourigenesis, I have piloted the use of plate-based assays to measure the tumoursphere 
formation in MRT cells, as a self-renewal readout. The tumourspheres were generated 
from two MRT cell lines; A204 and G401 in various plating formats. I aimed to identify 
minimum cell density required to form tumourspheres in order to avoid fusion cells and 
to determine the conditions for tumoursphere culturing media. Notably, across serial 
passaging of tumoursphere, MRT cells are able to form tumourspheres and the efficiency 
of tumoursphere formation is remarkably improved with increased passage number. 
Identification of cells within MRT that are capable of sustaining multipotency and self-
renewal will provide a critical insight into the discovery of tumour origins and the 
mechanisms that underpin tumourigenic potential.  
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5.2 Introduction 
5.2.1 Malignant Rhabdoid Tumours (MRT) share common biology properties with 
stem cells 
Malignant Rhabdoid Tumours (MRT) are a highly aggressive disease with a poor survival 
rate (Madigan et al., 2007, Kordes et al., 2010, Reinhard et al., 2008). MRT are 
heterogeneous tumours consisting of multiple phenotypes such as primitive 
neuroectodermal, mesenchymal and epithelial features even within the same tumours 
(Biggs et al., 1987, Tsokos et al., 1989, Kato et al., 2003). In line with this, experimental 
findings demonstrated the ability of MRT cells to differentiate into adipogenic lineages 
upon SMARCB1 re-expression (Caramel et al., 2008) and inhibition of SMARCB1 with 
RNAi interference (RNAi) impaired neuronal differentiation in vivo (Albanese et al., 
2006a). These observations have led to an assumption that MRT originates from 
multipotent stem cells. Studies to understand MRT biology illustrated a number of stem 
cell related genes shared between MRT and embryonic stem cells (Deisch et al., 2011). 
These genes include SALL4, SOX2, OCT4, NANOG and KLF4 which regulate the self-
renewal pathway. The stem cell-associated gene network often involves the interaction of 
genes to regulate self-renewal and differentiation. For instance, SALL4 regulates the 
expression of OCT4, which in turn activates the expression of other genes such as UTF1, 
TCL1 and ZFP206. Of note, UTF1 and TCL1 markers were highly expressed in MRT. In 
line with this, Venneti et al. (2011b) also identified stem cell markers such as NANOG, 
SOX2, SALL4, MUSASHI, KLF4, T-cell leukaemia/lymphoma 1, undifferentiated 
embryonic cell transcription factor and ZFP209 in primary MRT using 
immunohistochemistry analysis. Altogether, the results illustrate the stem cell properties 
shared between MRT and stem cells.  
5.2.2 Tumoursphere assay as in vitro stem cell assay 
Tumoursphere assays or sphere-forming assays are a widely used technique to identify 
stem cells based on their ability to undergo self-renewal and differentiation from a single 
cell in vitro. Tumourspheres are also known in other studies as spheroids, neurospheres 
(a brain tumour) or mammospheres. Tumourspheres originating from a small number of 
cells with stem cell characteristics are capable of growing in suspension culture and can 
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form tumours in vivo. They grow as floating clusters of undifferentiated and proliferating 
cells.  
The assay was initially described by Reynolds and Weiss (1992) following the discovery 
of multipotent precursor from the adult brain. The strial tissue from the periventricular 
area of the subventricular zone (SVZ) was cultured as tumourspheres (known as 
neurospheres in their study) in the presence of epidermal growth factor (EGF) in culture 
(Reynolds and Weiss, 1992, Pastrana et al., 2011). The formed spheres expressed 
NESTIN which is commonly found in neuroepithelial stem cells in the embryonic brain. 
Intriguingly, cells differentiated into both neurons and glial cells when cultured in 
adherent media. Subsequent studies have shown that cells within the SVZ can be cultured 
as spheres in vivo. Use of the tumoursphere assay has led to a breakthrough of surface 
markers to isolate putative stem cells and to purify stem cells and their progeny for 
functional studies both in vitro and in vivo. 
Following this study, Dontu et al. (2003) have tailored the neurosphere assay to propagate 
mammary epithelial stem cells (MaSC) in vitro. This assay was later utilised as a 
surrogate reporter of stem cell activity in the mammary gland (Diaz-Guerra et al., 2012). 
The assay works based on the principle that only undifferentiated cells derived from 
mammalian epithelium cells will survive and form tumourspheres while other cell types 
die from anoikis. The in vitro tumoursphere assay also has been used as a tool to select 
and propagate tumourigenic breast cancer cells from the primary tumours using the 
surface markers CD44 and CD24 (Ponti et al., 2005).  
In addition to the function of tumoursphere as a surrogate tool to measure stem cells 
within a population, this assay has been used to screen new drugs that target cancer stem 
cells in tumours (Cioce et al., 2010). Cancer stem cells (CSC) are a subpopulation within 
the tumours which possess self-renewal and multi-lineage differentiation capacity to 
maintain the tumourigenicity of cancer cells (Ajani et al., 2015). CSC have been 
implicated in cancer recurrence and resistance to therapy. CSC are protected from 
chemotherapy agents through different mechanisms including proficiency in DNA repair 
machinery, high expression of ATP-binding cassette drug transporters and also activation 
of signalling pathways such as PI3K/AKT and Wnt (Maugeri-Saccà et al., 2011). In 
glioblastoma, ionizing radiation caused the inhibition of P13K or AKT which in turn leads 
to activation of DNA repair, as demonstrated by the delayed clearance of γ-H2AX foci 
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(Kao et al., 2007).  Accordingly, use of an Akt inhibitor can efficiently target glioblastoma 
stem-like cells, determined by a decrease in the number of viable cells and reduced 
neurosphere forming efficiency (Eyler et al., 2008). Therefore, development of CSC 
targeted therapy is considered key for successful cancer treatment with increased cancer 
recurrence rate and chemoresistance.  
To this end, the tumoursphere assay has been used to facilitate the identification of agents 
that selectively kill CSC. A high throughput screening was performed in a 384-well plate 
format to identify agents with a strong selective toxicity for breast CSC (Gupta et al., 
2009). Using this assay, the authors have identified salinomycin which has the ability to 
reduce the CSC population by more than 100-fold more than that of paclitaxel, a 
commonly used breast cancer chemotherapeutic drug. Tumoursphere assays also have 
been used to screen for chemical compounds that target CSC in triple negative breast 
cancer cells (Fitzpatrick et al., 2017). Of 989 FDA-approved drugs, three therapeutic 
compounds with the ability to reduce the breast CSC population of cells in triple-negative 
breast cancer cell line MDA-MB-231 were identified. This study highlights the 
practicality of a tumoursphere assay in facilitating the identification of potent anti-cancers 
for this lethal cancer.  Overall, the tumoursphere assay offers a simple, efficient and low-
cost culture system and can be widely used in varying types of stem cell research.   
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5.3 Aims 
In this chapter, I aimed to:  
1. establish tumoursphere assays from Malignant Rhabdoid Tumours (MRT) to be 
utilised for identification of self-renewing cells in MRT 
2. evaluate stem cell activity in Malignant Rhabdoid Tumours (MRT) cell lines 
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5.4 Results 
5.4.1 Optimisation of tumoursphere assay media composition for culturing 
adherent MRT cell lines 
MRT cell lines are usually grown in adherent culture. This will limit the capacity to 
identify stem cell properties of these cell lines including self-renewal. As there is 
currently no publicly available protocol to culture MRT cell lines as tumourspheres, the 
technique and media condition that are commonly used to culture neurospheres were 
adapted for this project (Louis and Reynolds, 2009). To establish the tumoursphere 
condition for MRT, two MRT cell lines that were available at that time (A204 and G401) 
were cultured on two types of media; homemade media and commercial media, 
StemXVivo serum-free media from R&D systems which acted as a control. The 
homemade media was made up from 0.4% BSA, 5 µg/ml Insulin, 1% PenStrep, 1% B27 
supplement, 20 ng/ml bFGF and 20 ng/ml EGF in DMEM/F12 medium plus Glutamax. 
The tumourspheres were allowed to form for 9 days and images were taken every three 
days using EVOS Cell Imaging microscope (Life Technology).  
Overall, there was no statistical difference in the number of tumoursphere between two 
types of culture media at specific time points, for A204 and G401 cell lines (Figure 
5.1,Table 5.1, Figure 5.2). Notably, the number of tumoursphere derived from A204 was 
significantly increased between day 6 and 9 at a density of 4000 cells per well in 
homemade media (Figure 5.1 and Figure 5.2). There was no significant increase in the 
number of tumourspheres in commercial media. Notably, only 20 tumourspheres were 
counted on day 9 in commercial media as many spheres exceeded the appropriate size for 
tumoursphere which is no smaller than 50 µm and no larger than 200 µm. This is probably 
due to the fact the cells proliferated better on 3D Matrigel culture (commercial) in 
comparison to 2D culture (homemade). The shape of tumourspheres cultured in 
commercial media was more defined as the cells grew in a tight cluster (Figure 5.2 and 
Figure 5.3). 
 For the G401 cell line, the number of tumoursphere was statistically different as 
measured between day 6 and 9 for homemade media (p = 0.0248). The number of 
tumourspheres increased from 8 to 25 (Figure 5.1 and Figure 5.3). There were marginal 
differences in the number of tumourspheres on day 6 between a starting density of 4000 
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and 8000 which recorded for 11 and 8 tumourspheres respectively. In general, the number 
of tumourspheres was similar between commercial and homemade media suggesting the 
homemade media can be used for culturing tumoursphere.  
Notably, the number of A204 viable cells measured using trypan blue staining on day 9 
also increased in homemade culture, as the plating cell density increased. This increase 
was also seen in the G401 cell line, with the exception of an initial plating cell density of 
4000 which recorded a cell count of more than 8000 on day 9 (383000 for 4000 cell 
density vs 344000 cells for 8000 cell density). The cell count in commercial media could 
not be measured as the tumourspheres were cultured on sticky methylcellulose which was 
hard to dissolve in PBS. Overall, although the A204 cell line recorded more cell viability 
than G401 cell line throughout 9 days of culturing, more tumourspheres were observed 
with less single cells in G401 cell line compared to A204 cell line. For the future 
experiment (detailed in Chapter 6), homemade media was used to culture tumoursphere 
as it was more cost-effective and allows the measurement of viable cells as this could not 
be achieved when using commercial media. More importantly, tumoursphere forming 
efficiency measured in this media was almost comparable with commercial media. The 
culture media was slightly modified with the addition of 4 µg/ml Heparin and 0.5 µg/ml 
Hydrocortisone. Heparin was added as it helps to stabilise the binding of FGF to its 
receptor, while hydrocortisone is known to improve cell proliferation (Weiswald et al., 
2015).  
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Table 5.1 Average number of tumourspheres for two MRT cell lines cultured in two 
different tumoursphere media (n= 2). 
 
 
 
 
 
Cell line Day Commercial Homemade Commercial Homemade
0 2000 2000 0 0
6 NA NA 6 3
9 NA 244000 21 15
0 4000 4000 0 0
6 NA NA 10 6
9 NA 586000 25 23
0 8000 8000 0 0
6 NA NA 21 18
9 NA 751000 20 27
0 2000 2000 0 0
6 NA NA 2 5
9 NA 154000 7 9
0 4000 4000 0 0
6 NA NA 7 11
9 NA 383000 13 21
0 8000 8000 0 0
6 NA NA 8 8
9 NA 344000 20 25
A204
G401
Number of viable cells Number of tumourspheres
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Figure 5.1 Culturing tumourspheres from MRT cell lines in two tumoursphere culture 
medias. The homemade media was adapted from neurosphere assay with modification 
and addition of reagent to improve the tumoursphere formation. Adherent MRT cells were 
dissociated into single cells and seeded at 2000, 4000 and 8000 cell density per well. Bar 
graph showing the number of tumourspheres measured on day 0,6, and 9 for both media. 
There was no statistically different in the number of tumourspheres between two cultures 
at all initial cell seeding density.  
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Figure 5.2 Phase contrast of tumourspheres from A204 cell lines in two different 
culture media; homemade and commercial. The cells were seeded at 2000, 4000 and 
8000 per well. The number of tumourspheres was counted on day 0, 6 and 9. The images 
were taken using EVOS microscope. Row represents day of counting the tumourspheres 
whereas column represent starting initial density of cells in culture. 
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Figure 5.3 Example Phase contrast of tumourspheres from G401 cell lines in two 
different culture media: homemade and commercial. The cells were seeded at 2000, 
4000 and 8000 per well. The number of tumourspheres was counted on day 0, 6 and 9. 
The images were taken using EVOS microscope. Row represents day of counting the 
tumourspheres whereas column represent starting initial density of cells in culture. 
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5.4.2 Cell density and surface area of the culture: Critical parameters when 
designing tumoursphere assay 
Experimental procedures for culturing tumoursphere have undergone a lot of 
modifications over the years and might be varied between research groups. The 
modifications include the medium composition, cell density, surface area of culture dish 
as well as culture length. Amongst all, cell density is the most critical element for the 
development of clonality of tumoursphere (Pastrana et al., 2011). Since the final readouts 
of tumoursphere assay are number and size of tumoursphere, it is critical to ensure that 
the tumourspheres are formed from clonal expansion (proliferation) and not due to cell 
aggregation. Ideally, each of the tumourspheres is derived from a single cell to become a 
clone. To examine the ideal cell density for the formation of tumoursphere from MRT cell 
lines, a range of cell densities were tested in a different surface area of culture plate/flask. 
Initially, MRT cells were grown in the non-adherent medium at a density of 500 to 8000 
cells per ml in a 24-well plate (Figure 5.2 and Figure 5.3).  However, the number of 
tumourspheres obtained at a high cell density was hard to determine due to the fusion of 
tumourspheres hence false positive results. Likewise, culturing the cells at low density 
was also problematic as a small number of tumourspheres were observed in the well and 
the size of clusters of cells did not meet the standard. For tumoursphere assay 
experiments, the cluster of cells was considered as a tumoursphere if there were at least 
10 cells contained within it and the size is no smaller than 50 µM and no larger than 200 
µM.  
To identify if an increase in surface area of cell dish could improve the number of 
tumoursphere and avert the problem with tumoursphere fusion, I tried culturing MRT 
cells in two plating formats; 6-well and T-25 flask for three passages. The number of 
tumourspheres calculated on day 9 for each passage in a 6-well and T-25 flask was 
tabulated in Table 5.2. The number of tumourspheres was increased over subsequent 
passages in both plating formats suggesting a selective increase in self-renewal capacity 
of MRT cells or at least a greater proportion of spheres initiating cells in culture. The 
number of tumourspheres was also presented in bar graphs (Figure 5.4).  
High-density seeded cultures produced high numbers of tumourspheres when culturing 
in these two formats (Figure 5.4). Culturing cells in T25 is more practical than plate 
format as the movement of the plate leads to the cells aggregations either at the centre of 
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the plate or attached to the wall despite the cells being grown in a low attachment plate. 
The spheres forming efficiency was significantly increased between passages for both 
cell lines as indicated by an increase in the number of tumoursphere when culturing in a 
T25 flask (Figure 5.4a). In A204 cells culture, the formation of tumourspheres was 
increased by 2 times between passage 0 and 1, and the production of tumourspheres 5 
times more between passage 1 and 2 (Figure 5.4a and Table 5.2). Likewise, the number 
of tumoursphere derived from G401 cells in passage 2 was 5 times higher than that of 
passage 1 (Figure 5.4a). These results indicate high surface area of T25 flask provided 
more room for cells to continue to expand without producing cell fusions or aggregations. 
Nevertheless, production of tumourspheres is also reasonably high in 6-well plates 
(Figure 5.4c) and the number of tumourspheres continued to increase by 3.4- and 2.8-
times between passage 1-2 for A204 and G401 respectively (Figure 5.4c).  
In short, high numbers of tumourspheres were achieved when culturing in T25 flask 
format and the problem with cell aggregation can be avoided if culturing using this 
format. However, it requires more volume of media than a 6-well plate. On the other hand, 
the culture of tumoursphere in a 6-well plate can be problematic due to cell aggregation 
if initial seeding density is high. However, the problem was not pronounced at an initial 
seeding density of 8000 cells. The presence of tumourspheres can be distinguished from 
the irregular clump of cells by careful interpretation of size and shape of spheres. The 
size of tumourspheres is no smaller than 50 µM and no larger than 200 µM and the shape 
is nearly round.  
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(b) 
(a) 
Passage Number of tumoursphere per 10,000 cells 
A204 G401 
Replicate 1 Replicate 
2 
Replicate 1 Replicate 2 
0 8 12 6 5 
1 24 32 35 26 
2 156 174 166 159 
 
Passage Number of tumoursphere per 8,000 cells 
A204 G401 
Replicate 1 Replicate 2 Replicate 1 Replicate 2 
0 7 10 11 14 
1 19 15 23 28 
2 65 57 77 64 
 
Table 5.2 Number of tumourspheres per initial cell density of 10,000 and 8,000 counted 
in (a) T25 flask and (b) 6-well plate respectively. The tumourspheres were counted from 
two replicates. 
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Figure 5.4 Tumoursphere formation in T25 flask and 6-well plate. (a) Significant 
increase in the number of tumourspheres was observed in two MRT cell lines in 3 
passages when culturing in T25 flask format. The production of tumourspheres was 
higher in passage 2 (b) Number of tumoursphere also increased in passage 1 for 6-well 
plate, but this did not reach statistical significance for both cell lines. Significant increase 
in number of tumourspheres was observed between passage 1 and 2. The results are 
shown as means ± SEM of two independent experiments and the significance was 
determined by unpaired student’s t-test (* p< 0.05, ** p<0.01, *** p<0.001, vs plating 
format in appropriate culture). 
 
5.4.3 Characterisation of stem cell potential of MRT cell lines 
The tumoursphere assay was designed in this study to characterise and define the stem 
cell potential of MRT cell lines such as self-renewal. This assay will be used in limiting 
dilution assay (Chapter 6). Ideally, the cells should be plated at an extremely low cell 
density to investigate self-renewal potential of cells. An attempt was made to culture the 
MRT cells by plating a single cell per well in 96-well plate by FACS sorting, however, 
the experiment was not successful. There was no tumoursphere observed when cultured 
under these conditions. Hence, the cell density was increased to identify minimum cell 
density that is required to form tumoursphere. MRT cells were plated at 10, 50, 100 per 
well in triplicate. Three-weeks after FACS sorting in 96-well plate, the tumourspheres 
were observed in the 96-well plate when cultured under this condition, illustrating that 
minimum of 10 cells is required to form tumourspheres from MRT cells. 
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Primary MRT have been shown to express stem cell markers such as SOX2, NANOG, 
OCT4 and Nestin as determined by immunohistochemistry, genomic and gene expression 
analyses (Deisch et al., 2011, Venneti et al., 2011b). Therefore, it is of interest to examine 
if an increase in the number of tumourspheres is correlated with an increase in expression 
of stem cell markers. To this end, RNA was extracted from the tumourspheres at days 0, 
3 and 9. However, due to low numbers of spheres obtained on each harvesting day, it was 
impossible to perform qPCR to examine the expression of self-renewal genes. The 
experiment would have to be repeated in the future to identify mechanisms that underly 
the increase in tumoursphere formation efficiency.  
Additionally, the serial passaging assay was performed to examine the self-renewal 
potential of cells and sphere-forming capacity. The primary tumourspheres were 
dissociated into a single cell and 8000 cells were plated into a non-adherent medium. 
After 9 days in culture, the secondary tumourspheres were dissociated and 8000 cells 
were added to the well for tertiary tumoursphere formation. Of note, MRT cell lines can 
be passaged up to 4 times (the experiment was purposely stopped at passage 4) (Figure 
5.5). The number of tumourspheres was counted on day 9 for passage 1 to 3 and day 5 
for passage 4. Of note, the number of tumourspheres was greatly increased accompanied 
by bigger size of tumoursphere (within the range of preferable diameter) after passage 2 
for G401 and A204 cell line cultured in homemade media (Figure 5.5a and b). 
Interestingly over passages, the time for single cells to form tumourspheres was 
decreased. For instance, big tumourspheres were observed in culture at passage 4 as early 
as day 3 but the measurement was performed on day 5.  
In theory, during the passaging of the tumourspheres, the majority of the cells do not have 
the capacity to proliferate and therefore die. A small portion of surviving cells can then 
expand the progeny and form tumoursphere. I hypothesised that the number of cells that 
survived and can form tumourspheres increases with passage number. To test the 
hypothesis, the fold expansion of surviving cells that generated tumourspheres in culture 
was measured using this formula; initial cell density/end cell density (Deleyrolle et al., 
2011). In this study, fold expansion increased over passage time and this finding indicates 
that tumourspheres possess the self-renewal capacity and display a significant increase in 
proliferation potential (a characteristic of stem cells) in MRT cells (Figure 5.5c).  
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Altogether, increase in the number of tumourspheres and the ability of the cells to form 
tumourspheres in a shorter time (day 3 in passage 4) as opposed to day 9 for earlier 
passages illustrates an increase in self-renewal capacity of the MRT cells. The number of 
viable cells was also increased over four passages indicating that tumourspheres possess 
the self-renewal and proliferation capacity to form clonal.  
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Figure 5.5 Increase in self-renewal capacity observed in MRT cell lines is correlated 
with increase in number of tumourspheres over passages. (a) Cell images taken on day 
9 (except day 5 for P4) showed number and size of tumourspheres. (b) Self-renewal 
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capacity increased over passages as indicated by the number of tumourspheres derived 
from 8000 cells. (c) Fold expansion of cells showed increased cell number (between day 
5/9 with day 0) and this finding demonstrated proliferation capacity of tumoursphere. 
The results are shown as means ± SEM of three individual experiments and the 
significance was determined by unpaired student’s t-test (* p< 0.05, ** p<0.01, *** 
p<0.001, ****p<0.0001 vs earlier passage (i.e passage 2 vs passage 1).    
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5.5 Discussion 
5.5.1 Practicality of tumoursphere assay as a tool to assess self-renewal capacity of 
cells 
Several immunohistochemistry studies of primary MRT showed that MRT exhibit stem 
cells markers such as OCT4, NANOG, SOX2 and others (Deisch et al., 2011, Venneti et 
al., 2011b).  Transcriptomic analysis of MRT primary and cells showed upregulation of 
stem cell self-renewal genes such as BCL6, BMI1, GLI12 etc (PBTG, unpublished). The 
discovery of these stem cell-associated genes in the MRT primary and cells has led me to 
the hypothesis that the aggressiveness of MRT is linked to deregulation of stem cell 
properties such as self-renewal and pluripotency. Investigation of this hypothesis required 
a method to understand if MRT possess self-renewal capacity and to what extent self-
renewal in MRT cells can drive tumourigenesis. Here, the use of the classic tumoursphere 
assay or spheroid formation assay to assess the ability of MRT cells to self-renew and 
pluripotent was reported.  This technique has been shown to be practical for stem cells 
and cancer stem cell studies and is widely used in other types of human cancers including 
leukaemia, breast cancer, brain tumour and others (Ponti et al., 2005, Dontu et al., 2003, 
Ignatova et al., 2002, Singh et al., 2004). The majority of published studies utilise this 
method to study cancer stem cells within tumours which commonly rely on specific 
surface markers to isolate the population of cells of interest. Through a series of 
experiments presented in this chapter, I have demonstrated that the tumoursphere assay 
can be used as a MRT self-renewal assay thus allowing the assessment of shRNA and 
inhibitor that target specific self-renewal pathway in limiting dilution and clonal assay 
format (Chapter 6).  
Although tumourspheres can be generated from MRT cell lines using homemade media 
and can be grown on non-methylcellulose coated wells, there are a few aspects that need 
to be considered when using this culture system. Firstly, the size of tumourspheres is 
inconsistent among different cell lines and there are non-uniform criteria for the size of 
tumoursphere (Johnson et al., 2013). As this is the first study to culture tumoursphere 
from MRT cell lines, the size range was determined based on an average of tumoursphere 
across all cell lines and from previously established protocols (Reynolds and Weiss, 1992, 
Shaheen et al., 2016). Furthermore, the size can reflect the responsiveness of the cells to 
growth factor and stage of proliferation/differentiation of parental tumourspheres 
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(Deleyrolle et al., 2011). This observation is common in the highly heterogeneous tumour 
as the mixed population of cells at several stages of development can give rise to a 
different size of tumoursphere. The problem can be solved by growing the cells on an 
adherent format and by assessing the tumoursphere behaviour based on bulk population 
analysis (Deleyrolle et al., 2011).  Moreover, other confounding factors such as cells that 
are used to generate tumourspheres should be put into consideration (i.e immediately after 
thawing vs a week after thawing) as it will interfere with efficiency of the cells to form 
tumourspheres and growth rate of tumourspheres.  
MRT are highly heterogeneous tumours and may be considered as "stem-like" tumours 
due to the expression of stem cells markers such as NANOG, SOX2, OCT3/4 etc. They 
possess the ability to differentiate along to multiple stem cell lineages such as adipocytes 
(Deisch et al., 2011, Okuno et al., 2010, Venneti et al., 2011b, Caramel et al., 2008). 
Therefore, there is a possibility that a heterogeneous population of cells are composed of 
cells with (stem-like) and without (progenitor cells) self-renewal potential. The 
progenitor cells may still have limited proliferation capacity to form tumourspheres, 
hence leading to underestimation of the number of tumourspheres in culture. This 
problem, however, can be overcome through serial passaging of tumourspheres as 
theoretically, only self-renewing cells can form tumoursphere where the other cells 
cannot. Based on retrospective studies of neurospheres formation, only 6% of all cells 
can be passaged more than 7 times while the rest of the cells cannot, thus suggesting that 
a small number of cells have increased the self-renewal capacity (Louis et al., 2008).  
Overall, tumourspheres were successfully derived from MRT cell lines grown in 
homemade media in vitro. This assay can be used for self-renewal identification and 
analysis as serial passaging of tumourspheres demonstrated the increased ability of cells 
to form tumourspheres. Though more advanced studies such as qPCR, 
immunofluorescence or sequencing should be done to check the expansion in the 
expression of self-renewal genes over passing time, serial passaging of tumoursphere 
assay is able to illustrate a selective increase of self-renewal ability. To establish stem cell 
properties of MRT, genome-wide studies such as RNA-seq should be performed as it will 
allow selection of particular genes that govern self-renewal in MRT. 
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Chapter 6 Therapeutic targeting of the self-renewal 
machinery as a novel Malignant Rhabdoid 
Tumour cancer therapy strategy 
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6.1 Summary 
Malignant Rhabdoid Tumours (MRT) are rare paediatric brain tumours caused by 
mutation of SMARCB1 which encodes for chromatin remodelling protein (Versteege et 
al., 2002, Biegel et al., 2000, Roberts and Biegel, 2009). MRT present a challenge for 
clinical management due to the early onset and highly aggressive nature. Despite 
intensive multimodal therapy for MRT, overall survival rates are still poor (Reinhard et 
al., 2008). There is a lack of curative therapeutic interventions available for these patients. 
To identify potential therapeutic targets for MRT, the mechanisms that may contribute 
towards MRT aggressiveness were explored in this project. Gene enrichment analysis 
(GSEA) of integrated functional genomics with primary and cell model MRT identifies 
stemness as a “less-well evidenced” SMARCB1-dependent or MRT tumourigenesis-
related pathway as this theme has not previously been studied in detail for MRT. To 
examine to what extent mutation in stemness/self-renewal pathways/genes can contribute 
to MRT tumourigenesis, the genes which are highly expressed in MRT and whose 
expression is SMARCB1-dependent were identified by cross-referencing the curated 
stemness/self-renewal genes with transcriptome profiling of MRT primary and cell lines 
along with whole-genome CRISPR/Cas9 screening of MRT cell lines (details of the 
method are described in Chapter 2).  This analysis revealed that of 54 curated 
stemness/self-renewal genes, BMI1 is highly expressed in primary MRT and its 
expression is downregulated upon SMARCB1-reexpression in MRT cells illustrating its 
SMARCB1 dependency. BMI1 plays a role in the self-renewal machinery for both stem 
cells and cancer stem cells (Bhattacharya et al., 2015). The function of BMI1 was studied 
using shRNA and a small molecular inhibitor (PTC209). Knockdown of BMI1 using 
shRNA or PTC209 strongly impairs MRT cell growth, induces apoptosis and cell 
senescence and provokes cell cycle arrest. In addition, PTC209 treatment caused 
impairment of self-renewal in MRT cells. In short, targeting BMI1 offers a new strategy 
for therapeutic targeting in MRT.  
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6.2 Introduction 
6.2.1 Malignant Rhabdoid Tumour (MRT) aggressiveness: potentially linked to 
stem cell characteristics of tumour 
Malignant Rhabdoid Tumours (MRT) are rare, early onset tumours with a median age of 
diagnosis of ~18 months (Benesch et al., 2014, Varambally et al., 2002). The young age 
of patients at the time of diagnosis and the aggressive behaviour of the disease provides 
a real challenge for treatment of the patients. The aggressive behaviour of the malignancy 
is evidenced by poor patient survival and early onset of disease. The overall survival is 
less than 25% in infants (≤10 months) and young patients (≤24 months) (Bourdeaut et al., 
2008). MRT present immune markers from multiple lineages exhibiting a teratoid 
phenotype and contains cells with heterogeneous morphology within the same tumour 
leading to speculation that MRT may arise from multipotent stem cells (Gadd et al., 2010, 
Deisch et al., 2011, Caramel et al., 2008). Stem-like characteristics of MRT were 
demonstrated by an immunohistochemistry study showing that MRT primary tumours 
expressed important stem cell markers such as KLF4, SOX2, NANOG, Mushashi-1 and 
SALL4 (Deisch et al., 2011). High expression of EZH2, a factor that regulates cell 
proliferation and differentiation has also been found in MRT. Gene expression analysis 
of primary MRT and SMARCB1-deficient mouse embryonic fibroblast (MEF) tumours 
from a conditional mouse model showed that SMARCB1 loss caused upregulation of 
EZH2 expression which in turn led to increased expression of stem cell-associated genes 
such as DNMT3A, FGFR1, JARID2, POU5F1, etc. (Wilson et al., 2010a). However, the 
expression of these genes was downregulated in SMARCB1 and EZH2 double conditional 
knockdown in MEF mouse model. Furthermore, recent studies suggest that SMARCB1 
mediates MRT tumourigenesis dependency on EZH2 (Knutson et al., 2013, Alimova et 
al., 2012). Their studies showed that inhibition of EZH2 using siRNA and chemical 
inhibitors suppressed tumour self-renewal and impaired MRT tumour growth. 
Collectively, their observations suggested the role of SMARCB1 in stem cell regulation 
and when mutated can cause the aberrant function of self-renewal and pluripotency 
machinery.  
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6.2.2 Role of BMI1 and the impact of its negative regulation in cancer 
development 
The B-cell specific Moloney murine leukaemia virus integration site 1 (BMI1) gene in 
humans is located on the short arm of chromosome 10 (10p11.23) and the protein is 
universally expressed in almost all tissues, with a tendency to be highly expressed in the 
brain, kidney, bone marrow, placenta, lungs, blood and oesophagus (Siddique and 
Saleem, 2012).  Studies have demonstrated the role of BMI1 in a various cellular process 
such as proliferation, senescence, differentiation and also contributes to the embryonic 
development and stem cell self-renewal machinery (Cao et al., 2011, Park et al., 2003) 
(details in Chapter 1). BMI1 has been shown to exert its role in cell proliferation and 
senescence by acting as a transcriptional repressor at the INK4a-Arf locus (Jacobs et al., 
1999a). An experimental study showed that knockdown of BMI1 in mouse embryonic 
fibroblasts (MEF) impaired the cell cycle entry to S phase and led to premature cell 
senescence. Western blot analysis of the tumour cells obtained from this Bmi1-deficient 
MEF demonstrated upregulation of p19 (Arf) and p16 protein expression. BMI1 also has 
the capacity to block cell senescence and immortalisation as overexpression of BMI1 has 
been shown to activate human telomerase reverse transcriptase (hTERT) transcription and 
induction of telomerase activity (Dimri et al., 2002). BMI1 is also required for self-
renewal and maintenance of post-natal haematopoiesis (Park et al., 2003) and neural stem 
cells (NSC) in the central nervous system and peripheral nervous systems (Molofsky et 
al., 2005). The number of stem cells present was reported as normal as was cell 
differentiation in each tissue obtained from Bmi1-/- mice (at time of birth), however, a 
self-renewal defect was apparent in post-natal Bmi1-/- mice as the number of stem cells 
was reduced by early adulthood.  
Overexpression of BMI1 and its role in oncogenesis has been reported in several types of 
human cancers including cervical, breast and ovarian cancers (Gavrilescu et al., 2012). 
Some studies have also shown a positive correlation between overexpression of BMI1 
with aggressive disease progression and poor prognosis. For instance, overexpression of 
BMI1 was reported in 38.7% (29/75) cases of nasopharyngeal carcinoma, in which the 5 
year OS was higher in the BMI1 control group patients  (normal expression of BMI1) than 
the BMI1 overexpression patients (84.2% vs.47.6%)(Song et al., 2006). Similarly, 
survival analysis of patients with hepatocellular carcinoma also demonstrated short OS 
in patients with BMI1 overexpression relative to BMI1 low expression (p < 0.0001) (Zhai 
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et al., 2016). Furthermore, Yang et al. (2010) also reported a correlation between 
overexpression of BMI1 with survival of 179 patients presenting with ovarian carcinoma. 
The survival of patients with high BMI1 expression was greatly reduced (mean 49 
months) compared to patients with low BMI1 expression (mean 100 months). 
Overexpression of BMI1 has also been associated with paediatric brain tumours (Farivar 
et al., 2013). qPCR analysis of a cohort of 59 paediatric brain tumours including 20% 
medulloblastoma, 34% astrocytomas, 28% ependymomas, and 18% others (Primitive 
Neuro Ectodermal Tumours (PNET), gangliogliomas, and oligodendrogliomas) showed 
BMI1 gene expression was 4.85 times higher than normal brain tissue. The univariate 
survival analysis demonstrated that mean survival time for patients with high BMI1 
expression was 20.3 months compared to 39.6 months in patients with low BMI1 
expression. Furthermore, BMI1 high expression provided a significant independent 
prognostic factor determined by multivariate Cox regression analysis.  
Altogether, BMI1 exerts its role in cellular activities including cell proliferation, 
senescence and self-renewal through transcriptional repression of the Ink4a/Arf locus. In 
summary, overexpression of BMI1 has been implicated in the development of various 
cancers and confers poor disease prognosis.  
6.2.3 Specific targeting of BMI1 using PTC209 
Recently, a small inhibitor molecule PTC209 that decreases the translation of BMI1, was 
developed using a drug discovery platform technology called GEMS (Gene Expression 
Modulation by Small Molecule) by Kreso et al. (2014) and PTC Therapeutics company. 
In theory, the BMI1 3’ UTR contains multiple A-U rich elements that significantly 
upregulate expression of the reporter gene whilst its 5’ UTR consists of a strong IRES 
activity. Therefore, this high throughput technology was employed to selectively identify 
the compound that could inhibit both 3’ and 5’ UTR mediated BMI1 reporter expression.  
Evidence has shown that small population of cells within the primary colorectal tumours 
have the capacity to initiate new tumours and sustain the formation of tumours in 
transplant experiments. These cells are known as cancer-initiating cells (CICs) and 
possess the stemness properties including self-renewal. Kreso et al. (2014) found that 
those CICs functions are dependent on BMI1, a self-renewal gene. Thus, the efficacy of 
PTC209 in inhibiting BMI1 expression was studied in CICs cell lines. They showed that 
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PTC209 can effectively inhibit expression of endogenous BMI1 in human colorectal 
HCT116 and human fibrosarcoma HT1080 tumour cells in a dose-dependent manner. 
Incubation of HEK293 and HT1080 cells with PTC209 overnight and for 48 hours 
respectively, had no effect upon cell growth or viability. Downregulation of BMI1 using 
PTC209 inhibits the self-renewal capacity of colorectal cancer initiating cells determined 
by limiting dilution assay (LDA) in-vitro and impaired the ability of these cells to form 
tumour in-vivo long-term, reducing the tumour burden illustrating the potential of 
targeting self-renewal regulator as means of therapeutic intervention.  
The inhibitor has also been tested in other types of cancer such as acute myeloid 
leukaemia (AML) (Nishida et al., 2015), biliary tract cancer  (Mayr et al., 2016) and 
multiple myeloma (Bolomsky et al., 2016) which also demonstrate similar findings. 
These authors showed that inhibition of BMI1 using PTC209 reduced cell growth, 
induced cell apoptosis, senescence and self-renewal defects. Therefore, the therapeutic 
targeting of BMI1, if achieved, would provide an attractive strategy for the development 
of cancer therapies for MRT.   
This chapter is focused upon exploiting the innate stem cell characteristics of MRT using 
bioinformatics analysis (detailed in Chapter 2) to identify potential self-renewal genes 
which are active in MRT and whose activity is SMARCB1 dependent. Also, in this study, 
the expression of BMI1 and the effect of a BMI1 inhibitor, PTC209 in MRT were 
investigated. 
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6.3 Aims 
In this chapter, I aimed to:  
3. Identify self-renewal genes that are active and whose activity is SMARCB1-
dependent  
4. Investigate the effect of targeting BMI1 and how its expression changes 
following treatment with shRNA and the small molecular inhibitor, PTC209 
5. Understand the role of BMI1 as self-renewal gene in MRT tumourigenesis 
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6.4 Results 
6.4.1 Bioinformatic analysis of candidate self-renewal/stemness genes that drive 
tumourigenesis in SMARCB1-deficient MRT 
Previous studies on MRT presented the consequence of SMARCB1 loss which included 
disruption to cycle cell regulation (Betz et al., 2002), aberrant activation of the sonic 
hedgehog (Shh)-Gli pathway (Jagani et al., 2010), Wnt signalling pathway (Mora-Blanco 
et al., 2014) etc. Work within my group was performed to further examine other pathways 
that are deregulated following SMARCB1 loss and are implicated in SMARCB1-
dependent tumourigenesis, pathway analysis was performed on RNA-seq data from 
SMARCB1 re-expressing, and 5-aza treated MRT cells using Ingenuity (IPA) canonical 
and upstream regulator analysis. This identifies key regulatory effectors likely to produce 
the observed changes in expression and Gene Enrichment Analysis (GSEA) using 
MSigDB libraries C2 (Curated), C3 (Motif), C6 (Oncogenic) and H (Hallmark). The 
outputs were manually characterised in curated pathway themes (Figure 6.1). Pathway 
analysis was also performed on CRISPR/Cas9 GeCKO screen data from MRT cell lines 
with and without SMARCB1 using Model-based Analysis of Genome-wide 
CRISPR/Cas9 Knockout (MAGeCK) method. Differentially essential (DEss) genes were 
identified by comparing per-gene sgRNA abundance at time points across MRT cell lines. 
For instance, SMARCB1 Day7/14 vs Day0, control Day7/14 vs Day0, SMARCB1 vs 
control at Day7/14. Pathway analysis was then performed with the ranking and p-value 
calculated by MAGeCK using IPA analysis and GSEA analysis (MSigDB Hallmarks). To 
identify genes or pathways that have therapeutic potential to counteract MRT 
tumourigenesis, functional genomic cell lines and primary tumour data was integrated, 
and the genes/pathways were prioritized based on these criteria: expression/activation 
dependent on SMARCB1 and/or 5-aza, characteristic of primary MRT and essential to cell 
fitness (GeCKO); preferably in a SMARCB1-dependent manner. The data that were 
functionally analysed using GSEA and IPA included whole genome CRISPR screen 
including all comparisons as above plus MRT vs MB Day14 (a GeCKO screen 
comparison of MRT to a panel of 4 medulloblastoma cell lines included as a cell type 
control), SMARCB1 re-expression vs control, 5-aza vs control, primary MRT vs MB or 
ET (embryonic tumour). Pathway analysis of integrated data illustrates pathways that are 
SMARCB1-dependent or associated with MRT tumourigenesis (Paediatric Brain Tumour 
Group (PBTG) at Newcastle University, unpublished)  including MYC/Let7 targets, 
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Interferon, PLK1, Polycomb (Kim and Roberts, 2014) (Figure 6.1). Amongst these, 
pathways that have not been recognised as SMARCB1 related pathways such as stemness 
were also present in the analysis. Stemness can be defined as the potential of stem cell 
niches to possess pluripotency and undergo self-renewal and differentiation (Anton et al., 
2007, Leychkis et al., 2009). 
 
 
 
 
Figure 6.1 The multiplatform cross-referencing strategy to identify pathways with 
potential as therapeutic target to counteract MRT tumourigenesis.(a) The bubble plot 
demonstrating the pathway themes that were ranked and prioritized by average score of 
constituent pathway analyses calculated by rational selection algorithm (strength of 
evidence. The themes were clustered as processes, those well evidence or poorly evidence 
to SMARCB1/MRT related pathways. The size of bubble represents number of pathway 
analyses. (b) Heatmap showing the stemness and polycomb pathways identified by cross-
referencing with CRISPR GeCKo screening (D7/D14 Control vs Day 0, D7/D14 
SMARCB1 vs Day 0, D7/D14 Control vs D7/D14 SMARCB1 & MRT vs MB Day14), 
model expression (5-aza vs control, SMARCB1 vs control) and primary expression 
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analyses (Primary MRT vs MB, Primary MRT vs Embryonal). Row represents the top 3 
events from MSigDB library or analysis type. The heatmaps are colored by normalized 
enrichment (GSEA) or z-activation score (IPA). Grey shows a non-significant score. Type 
indicates analysis: blue = GSEA, green = IPA, C2=curated gene sets (GSEA), 
C4=computational gene sets (GSEA), C6=Oncogenic signatures (GSEA), H=Hallmark 
gene sets, C=Canonical Pathways (IPA) and U=Upstream regulators (IPA). The figures 
were reproduced from PTBG (unpublished).  
 
Integrated data analysis of cell line and primary MRT identified stemness as a potential 
therapeutic target with SMARCB1-dependent/related tumourigenesis. However, there has 
been no systematic genome-wide analysis of how this occurs and which self-renewal 
pathways are altered by SMARCB1 mutation and contribute to tumourigenesis. To this 
end, I implemented a systems biology approach to analyse RNA-Seq data of primary and 
cell line model data provided by my group (unpublished) to identify the self-
renewal/stemness pathways or genes directly affected by the loss of SMARCB1. The 
potential stemness/self-renewal genes were compiled through prior knowledge (canonical 
pathways and ontology (Kegg and gene ontology (GO)), IPA knowledgebase by searching 
genes that regulate “stemness”, “self-renewal” and “pluripotency” pathways. The 
stemness/self-renewal genes were also manually profiled from the published literature 
(Ramalho-Santos et al., 2002, Koeva et al., 2011). The total number of genes that were 
profiled in this analysis was 210 genes. The stemness genes identified from the 
aforementioned analysis include SOX2, POU5F1, TP53 etc while the self-renewal genes 
include BMI1, ARID1A, BCL6, CD44, etc. The pluripotency genes that were listed 
include FOXO1, KLF4, SMARCA4 etc. A full list of genes is presented in Appendix 6.1.  
To identify which stemness/self-renewal genes are functionally relevant to SMARCB1, I 
next performed integrated data analysis of custom stemness/self-renewal genes with 
RNA-seq data of primary and cell line MRT using R and IPA analysis. The RNA-seq data 
that underwent the analysis were; primary MRT (n = 23) vs MB (n = 228), SMARCB1 re-
expression vs control (PCDH) (n = 4), and ATRT (n = 10) vs ECRT (n = 13). 
Medulloblastoma (MB) was included as a comparison for embryonal tumours. Cross-
referencing of stemness gene lists with RNA-seq data of MRT primary and SMARCB1 
re-expression cell model, and embryonal tumours revealed 54 genes that are functionally 
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relevant to SMARCB1 expression (stemness genes = 30, self-renewal genes = 25, 
pluripotency genes = 9). The list of genes is tabulated in Appendix 6.2. The boxplot 
showing the representation of genes present in three analyses between stemness/self-
renewal genes with embryonal tumours, primary MRT and SMARCB1 re-expression cell 
models. Cross-referencing of stemness/self-renewal genes with MRT and MB indicates 
five stemness/self-renewal genes that are activated in these two types of embryonal 
tumours (Figure 6.2). Similarly, a gene list was also identified when cross-referencing 
stemness/self-renewal genes with RNAseq of MRT subgroups; ATRT and ECRT. 
However, of the five genes listed in MRT subgroups, there were only two genes that 
showed transcriptional activation in response to SMARCB1 loss and re-expression in 
MRT cells; JARID2 and BMI1. Expression of BMI1 was upregulated in the absence of 
SMARCB1 (represented by PCDH in boxplot analysis) and its expression was 
downregulated in response to SMARCB1 re-expression in MRT cells (denoted by 
SMARCB1 boxplot). In contrast, the expression of JARID2 was upregulated in 
SMARCB1-deficient MRT cells and upon restoration of SMARCB1, its expression was 
downregulated.  
The genes were described as “functionally relevant to SMARCB1” if the gene showed 
transcriptional evidence of activation in response to SMARCB1 loss and downregulation 
in response to SMARCB1 re-expression in MRT cells and similarly showed high 
expression in primary MRT. The aforementioned cross-referencing analysis of RNA-seq 
data from SMARCB1 re-expression cell model (n = 4) and primary MRT (10 ATRT and 
13 ECRT) with the custom stemness/self-renewal gene list revealed two genes that are 
activated in primary MRT and whose expression is SMARCB1-dependent which are BMI1 
and JARID2. 
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Figure 6.2 Boxplots showing representative expression of self-renewal genes in primary 
tumour and MRT cells. Integrated analysis between RNA-seq with candidate self-
renewal genes showed at least two genes whose expressions are significant in MRT 
primary and cell models. In cell models, SMARCB1 on the plot represents SMARCB1 re-
expression in MRT cells, while PCDH represents MRT cells (without SMARCB1 
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expression. Y-axis shows log2 fold expression of gene. The square box denotes 
interquartile (IQR). Upper whiskers of the boxplot represent the 75% percentile + 1.5 x 
interquartile (IQR) while lower whiskers represent the 25% percentile – 1.5 x 
interquartile (IQR). MB = Medulloblastoma. 
 
To further validate the functional relevance of SMARCB1-dependent self-
renewal/stemness genes, integrated data analysis was performed on 54 self-
renewal/stemness genes with a genome-wide CRISPR/Cas9 knockout screen data of 4 
MRT cell lines (G401, STA-WT1, A204 & CHLA266) with and without re-expression of 
SMARCB1 (PBTG, unpublished). Briefly, CRISPR/Cas9 screening was performed using 
a GeCKOv2 lentiviral library and the cells were infected with lentivCRISPRv2 virus 2 
days before SMARCB1 (INI1) or control lentivirus infection on day 0 (Figure 6.3a). Cells 
were harvested at days 0, 7 and 14 followed by amplification, sequencing and counting 
to estimate abundance of integrated sgRNAs. CRISPR/cas9 screening data at day 7 
concomitantly with RNA-seq of MRT cells (SMARCB1 re-expression cell model) were 
analysed using Ingenuity Pathway Analysis (IPA). The analysis was performed based on 
upstream regulator analysis (which recognizes key regulatory effectors likely to generate 
the observed changes in expression) and the result is presented in Figure 6.3b. The 
upstream regulator analysis showed 31 significant SMARCB1-dependent upstream genes 
at day 7 SMARCB1 vs control (x-axis) and SMARCB1 re-expression cell models. Genes 
that were appeared in two experimental arms includes CDKN1A, BMI1, etc.  
To identify candidate genes that will be used in a functional stemness/self-renewal 
experiment for MRT, the genes were prioritised and selected based on their functional 
significance, establishing SMARCB1-dependency in both integrated data analyses (RNA-
seq of primary and cell line, and CRISPR/Cas9 GeCKO) and their ability to target non-
actionable mutation. Therefore, of 54 genes, BMI1 was selected as a self-
renewal/stemness target as it is druggable, showed SMARCB1-dependency and has been 
implicated in other embryonal tumours such as Medulloblastoma (MB). Furthermore, 
Bmi expression was upregulated following Smarcb1 loss in candidate cell of origin for 
MRT, neural crest (NC) cells (details in Chapter 4). 
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Figure 6.3 Stemness/self-renewal genes whose expression are SMARCB1 dependent 
analysed using CRISPR/Cas9 GeCKO screening. (a) The experimental set up for whole 
genome CRISPR/Cas9 screening in 4 MRT cell lines. The cells were infected with 
GeCKOv2 lentiviral two days prior to SMARCB1 (INI1) or control lentivirus infection on 
day 0. Cells were collected on day 3, 7 and 14. (b) CRISPR data in combination with 
RNA seq data of MRT cell model were analysed using IPA based on upstream regulator. 
The x-axis here represents the dependent knock out in CRISPR screening on Day 7 
whereas the Y-axis represent SMARCB1 re-expression model. The figure shows 
SMARCB1 dependent genes in which SMARCB1 had a clear effect on their expression 
either by inhibition or activation.  
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6.4.2 BMI1 expression in a subset of MRT patient samples and cell lines 
Overexpression of BMI1 has been found in many types of cancers such as 
Medulloblastoma (MB) (Wang et al., 2012), prostate cancer (Mimeault and Batra, 2011), 
bladder cancer (Qin et al., 2009) amongst others. BMI1 overexpression induces cell 
proliferation, metastasis and has demonstrated significant correlation with poor overall 
survival of patients (see details in Section 6.2.2) (Wang et al., 2015). As there is no study 
demonstrating the expression of BMI1 in MRT, its expression was first evaluated in MRT 
primary tumours and cell lines; and compared with expression in normal paediatric brain 
(cortex and cerebellum) using RNA-seq data. As shown in Figure 6.4a, there is no 
significant difference between primary MRT and normal tissue transcription profiles. 
Likewise, transcriptional profiling data of human MRT revealed the expression of BMI1 
did not significantly differ between ECRT and ATRT (Figure 6.4a). However, RNA-seq 
analysis of SMARCB1 re-expression in MRT cell models demonstrated significant 
overexpression of BMI1 in MRT cells (Control vector) and the expression was 
downregulated upon restoration of SMARCB1 (SMARCB1+vector) (Figure 6.4). 
I next examined the expression of BMI1 in primary tumour tissue at the protein level. 
The primary MRT tissues (2 ECRT and 1 ATRT) were stained with antibody Anti-BMI1 
antibody (Abcam. Cat No. ab14389) for immunohistochemistry analysis. The samples 
were then analysed for nuclear staining using APERIO Imagescope. 
Immunohistochemistry analysis demonstrated significant upregulation of BMI1 
expression. IHC staining showed BMI1 was highly expressed in ATRT compared to 
healthy tissues controls extracted from the cerebellum (Figure 6.4b). Of note, BMI1 
expression is present at a low level in normal kidney tissue and expression elevated in its 
corresponding tumour (RTK). To confirm the IHC result, a western blot was performed 
on total protein lysate to examine the expression of BMI1 in MRT cell lines. The 
membrane was probed with anti-BMI1 antibody for detection of BMI1 protein. Western 
blot analysis showed that expression of BMI1 protein was higher in absence of 
SMARCB1 (control) and the protein was diminished upon SMARCB1 re-expression 
(IN1) in MRT cells (Figure 6.4c). Protein lysate from HDMB03, a Medulloblastoma cell 
line was included as a positive control of BMI1 overexpression as BMI1 has been 
reported to be upregulated in this tumour (Wang et al., 2012).  
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Altogether, analyses of MRT primary tissue and cell lines at protein demonstrate 
overexpression of BMI1 thus indicating the possible involvement of this gene in MRT 
tumourigenesis. To further elucidate the role of BMI1 in MRT, the expression of this gene 
was studied using shRNA gene knockdown and pharmacological inhibition of BMI1 
inhibitor, PTC209. 
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Figure 6.4 BMI1 expression in MRT primary tumours and cells. (a) Boxplot of BMI1 
expression in MRT primary, compared with normal tissue from various origins in the 
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human body. Data from MRT experimental model was also included (control vector, 
PCDH) and was compared with SMARCB1 re-expression cells and 5-Azacytidine. 
Transcriptomic expression of BMI1 is not significantly different between primary MRT 
and controls. However, high expression of BMI1 was seen in MRT cell lines (control 
vector) and upon SMARCB1 re-expression in MRT cells, BMI1 expression was reduced. 
(b) Expression of BMI1 was examined in primary tissue by immunohistochemistry (IHC). 
Primary MRT tissues consist of two ECRT samples (RTK and ECRT) and one ATRT was 
analysed for the presence of BMI1 protein using anti-BMI1 antibody. Cerebellum and 
kidney serve as control. High expression of BMI1 was seen in ATRT tissue compared to 
cerebellum. Low BMI1 protein expression was observed in control kidney, however the 
expression level was elevated in RTK tissue, illustrating overexpression of BMI1 in MRT. 
Overexpression of BMI1 was also seen in ECRT sample (from liver). (c) The BMI1 
expression was also examined in MRT cell lines by western blot anlysis. High expression 
of BMI1 in MRT cell lines (PCDH) compared to control (SMARCB1 re-expression cells, 
INI1 on figure). Beta-actin serves as a loading control and HDMBO3, a medulloblastoma 
(MB) cell line was used for comparison as MB has been shown to have high expression 
of BMI1.  
 
6.4.3 shRNA-mediated knockdown of BMI1 in MRT cells 
A few studies illustrated strong association between upregulation of BMI1 in comparison 
to normal tissue with rapid tumour progression in other human tumours including 
Medulloblastoma and Neuroblastoma (Leung et al., 2004, Dahmane and Ruiz-i-Altaba, 
1999, Calao et al., 2013). However, there is no study to report the role of BMI1 in MRT 
tumourigenesis. To address this question, I examined whether the expression of BMI1 has 
a functional impact in MRT using two different short hairpin RNA (shRNA) that target 
different regions of the BMI1 gene, namely shRNA GFP and shRNA RFP. Two shRNA 
constructs targeting luciferase (LUC) and a non-silencing (NS) were utilised as controls.  
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6.4.3.1 Confirmation of BMI1 knockdown at the protein and mRNA level using 
shRNA 
Before exploring the possible biological effect of BMI1 knockdown in MRT, I first 
examined the efficiency of shRNA lentivirus in mediating knockdown of BMI1 at the 
RNA and protein level. To this end, MRT cells were seeded at a density of 200,000 cells 
in a 6-well plate and were infected with shRNA lentiviral at MOI 5. This MOI was 
initially determined by the transfection efficiency analysis of GFP/RFP lentivirus 
evaluated by flow cytometry (FACS) (data not shown). After 48 hours of shRNA 
transfection, positive GFP/RFP cells (usually 80-90% cells) were harvested, and RNA 
and protein were extracted for measurement of the mRNA levels by quantitative RT-PCR 
and analysis of BMI1 protein by immunoblotting against the BMI1 antibody (methods 
described in Chapter 2). In 4 MRT cell lines, the qPCR analysis showed more than 3 times 
reduction in BMI1 transcript was achieved for shRNA-RFP relative to control whereas 
BMI1 expression was reduced by 1.5-2.5-fold in shRNA-GFP treated cells compared to 
control construct.  
The automated western blot (WES) analysis also demonstrated efficient knockdown of 
BMI1 by two shRNA constructs; shRNA-GFP and shRNA-RFP. For shRNA-GFP 
construct, 25% of BMI1 protein expression reduction was observed in CHLA-266 cell 
line. In the G401 cell line, about 70% BMI1 protein reduction was achieved. 
Approximately 60% BMI1 protein knockdown was achieved in A204 and BT16 cell 
lines. By contrast, shRNA-RFP transfection in A204 and G401 cell lines resulted in 
minimal BMI1 protein knockdown measured as 26% and 28% respectively. Whilst, 40% 
BMI1 protein reduction was observed in the CHLA-266 cell line 48 hours post infection. 
In BT16 cells, more than 50% protein knockdown were achieved. 
In short, both qPCR and western blot analyses showed that two shRNA constructs 
targeting BMI1; GFP and RFP can efficiently knockdown BMI1 in at least three MRT 
cell lines (A204, G401 and BT16) as demonstrated by a decrease in RNA and protein 
expression in BMI1-deficient MRT cells in relative to control (LUC/NS) (Figure 6.5a-b). 
For the rest of the chapter, I present results from shRNA-GFP lentivirus only and any 
experimental work using shRNA-RFP is included in the appendix.  
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Figure 6.5 shRNA can efficiently knockdown BMI1 at RNA and protein level. Cells 
were transfected with shRNA lentivirus carrying GFP or RFP construct at MOI 5. (a) 
BMI1 mRNA level measured by real time qPCR and normalised for GAPDH. The results 
are shown as mean ± SEM of three independent experiments. (b) Automated western blot 
(WES) analysis of BMI1 expression in A204, G401, CHLA-266 and BT16 cell line after 
48 hours of transfection at MOI 5. b-actin was used as loading control. (c) Densitometry 
result of WES analysis of A204, G401, CHLA-266 and BT16 cell line following BMI1 
knockdown with two shRNA constructs. Densitometry results were normalised to b-actin. 
 
6.4.3.2 BMI1 is required for MRT cell survival 
BMI1 expression has been associated with tumour development and progression 
(Sparmann and van Lohuizen, 2006). The expression of BMI1 alone or coupled with other 
molecules such as Hras, MYC, etc has been shown to initiate tumourigenesis in several 
types of non-tumourigenic immortalised cells lines through the p16Ink4a mechanism 
(Chiba et al., 2007, Datta et al., 2007, Jacobs et al., 1999b). BMI1 has been shown to 
involve in normal stem cell proliferation via its role as stemness gene. Elevated 
expression of BMI1 has been observed in many types of cancers including leukaemia, 
medulloblastoma, gliomas and cancer from other tissues (He et al., 2009). Moreover, 
overexpression of BMI1 in culture increased the expression of p16Ink4a and p19Arf 
which in turn promoted cell proliferation. In line with this, Liu et al. (2006a) have shown 
that BMI1 knockdown by RNA interference (RNAi) in both normal and malignant human 
cells reduced the survival cancer cells but not of normal cells. Taken as a whole, it raises 
the question of whether the elevated BMI1 expression in human malignancies is sufficient 
to enhance self-renewal activity of cancer cells and therefore increase cell proliferation, 
I next sought to examine whether BMI1 loss has an effect on MRT cell growth and 
proliferation. For this experiment, the MTS based assay, CellTiter96 Aqueous one was 
used to measure cell proliferation following BMI1 knockdown with shRNA. The 
assessment of proliferation was performed 24, 48, 96 and 120 hours post-transfection. 
Absorbance readings for each time and each condition (BMI1 vs LUC) were normalised 
to the t0 absorbance, which was set to 0. The absorbance differences at each time interval 
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reflect the proliferation rate for each culture, measured by subtraction of normalised 
absorbance values.  
BMI1 knockdown significantly decreased the proliferation rate in all MRT cell lines 
(Figure 6.6 and Figure 6.7). In A204, transfected with shRNA BMI1, the proliferation rate 
showed a slight decrease, but statistically significant difference was seen relative to LUC 
at 120 hours post transfection (Figure 6.6a and Figure 6.7a). By contrast, a significant 
decrease in cell proliferation rate was observed in G401 and CHLA-266 cell lines from 
96 hours onwards (Figure 6.6b and Figure 6.7b). BMI1 knockdown also decreased cell 
proliferation in the BT16 cell line and significant differences relative to LUC were only 
observed at 120 hours post-transfection (Figure 6.6a and Figure 6.7b). In all MRT cell 
lines transfected with shRNA-BMI1, the proliferation rate was significantly slower 
between 96-120 hours relative to LUC transfected cells (Figure 6.7). Similarly, BMI1 
knockdown with shRNA RFP in four MRT cell lines also reduced the cell proliferation 
and the proliferation rate was statistically significant between 96 and 120 hours when 
compared with control NS (Appendix 6.4).  
To corroborate the reduced proliferation rate between 96-120 hours, I seeded the 
transfected cells in a 6-well plate and images of the cells were taken 96 hours after 
transfection using the EVOS microscope. The cell images were analysed using Image J 
analysis software to measure the viable cells. Briefly, the image was converted to 16-bit 
greyscale and the binary image was analysed using the “analyse particle” programme. 
The resulting outcome showed the count (number of cells in the image), average size and 
total area. The bar graph was plotted based on the count for each cell line treated with 
BMI1 or control. Image J analysis measuring the viable cells of four cell lines is in 
agreement with this finding which demonstrated significantly less viable cells 
(approximately 75-80% reduction) measured in BMI1-knocked down cells 96 hours post-
transfection compared to control (LUC) (Figure 6.8). Knockdown of BMI1 in G401 and 
CHLA-266 cells caused a significant reduction in the number of viable cells (Figure 6.8). 
A small number of viable cells was also observed in A204 and BT16 cell lines following 
BMI1 knockdown accounting for 1570 and 1551 cells respectively, compared to 12710 
and 12596 respectively for LUC transfected cells. Combining the dataset for all cell lines 
(n=4 biological replicates) showed a significant reduction in the number of viable cells 
for BMI1 knocked down cells relative to LUC control cells (paired t-test: p-value < 
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0.0001, SEM ± 1396). In short, BMI1 knockdown impaired the MRT cell proliferation 
implying a role in regulating MRT growth. 
 
 
Figure 6.6 The effect of BMI1 knockdown on MRT cell proliferation (a) Lentiviral 
transfection of shRNA significantly reduced the cell proliferation in all MRT cell lines in 
relative to control (LUC vector) measured using MTS CellTiter Aqueous one solution. 
The reading was measured 24, 48, 96 and 120 hours post infection. Luminescence unit 
(RLU): x 10,000. Knockdown of BMI1 reduced the proliferation rate in all MRT cell lines 
and the readings were more significant at 120 hours post transfection. The results are 
shown as means ± SEM of three individual experiments and the significance was 
determined by unpaired student’s t-test (* p< 0.05, ** p<0.01, *** p<0.001, 
****p<0.0001 vs LUC). 
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Figure 6.7 Knockdown of BMI1 halts MRT cellular growth. MTS proliferation assay of 
four MRT cells following transfection with shRNA-BMI1(BMI1) and shRNA-LUC (LUC). 
(a) Knockdown of BMI1 slows down the cell proliferation in A204 cell lines and more 
pronounced between 96 – 120 hours relative to LUC. (b-c) BMI1 knockdown in G401 
and CHLA-266 resulted in significant of inhibition of proliferation when compared to 
LUC between 48-96 hours and 96-120 hours time interval. (d) BMI1 knockdown also 
reduces the growth rate in BT16, however the effect is not statistically different between 
LUC for three-time intervals; 0.24, 24-48 and 48-96 hours. A significant reduction in cell 
proliferation was seen only between 96-120 hours. Altogether, these findings suggest 
BMI1 knockdown slows down the growth rate of four MRT cell lines and the effect is 
more pronounced at later times (between 96-120 hours). The results are shown as means 
± SEM of three individual experiments and the significance was determined by unpaired 
student’s t-test (** p<0.01, *** p<0.001, ****p<0.0001 vs LUC). 
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Figure 6.8 Phase contrast images of A204, G401, CHLA-266 and BT16 cell lines at 96 
hours after transfection with shRNA-BMI1 and shRNA-LUC. The scale bar is 200 um. 
Cell images taken at 96 post infection from two independent experiment was analysed 
using ImageJ software to measure number of viable cells. The image was analysed using 
“analyse particle” programme and the bar graph was plotted based on outcome from 
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“analyse particle” analysis. The bar graph showing decreased in number of viable cells 
for shRNA BMI compared to LUC) at 96 hours. The results are shown as means ± SEM 
of two individual experiments and the significance was determined by unpaired student’s 
t-test (* p< 0.05 vs LUC). 
 
6.4.3.3 BMI1 knockdown with shRNA did not significantly induce cell apoptosis but 
it caused cell senescence  
To identify the possible mechanisms by which BMI1 knockdown slows down cell 
proliferation, the effect of BMI1 on cell apoptosis and cell senescence was evaluated. 
BMI1 has been associated with enhanced anti-apoptotic ability in many cancers (Teshima 
et al., 2014, Siddique et al., 2013). To test the induction of apoptosis following BMI1 loss, 
the Caspase-Glo 3/7 luminescence assay was used to measure caspase 3- and 7- activities. 
The reagent has been optimised for measuring caspase activity, luciferase activity and 
cell lysis. Luminescence was proportional to the amount of caspase activity present in the 
cells (Promega Corporation). For the apoptosis assay, the MRT cells transfected with 
shRNA lentivirus were initially seeded in a 6-well plate and were transferred to a 96-well 
plate after 24 hours of transfection (1000 cells/well).  
BMI1 knockdown increased cell apoptosis in G401 cells significantly at 96 and 120 hours 
post-transfection (> 2-fold increase) (Figure 6.9b). However, no significant increase was 
seen in two MRT cell lines, A204 and CHLA-266 at similar time points (Figure 6.9a, c 
and d). A significant increase in apoptosis was observed in BT16 cell line at 120 hours 
only (approximately 2.5-fold increased over LUC) (Figure 6.9d). The effect of BMI1 
knockdown on cell apoptosis was similar to the effect of BMI1 knockdown on cell 
proliferation, i.e. more pronounced from 96 hours onwards. However, combining the 
datasets from 4 cell lines (n = 4 biological replicates, n= 2 technical replicates each cell 
lines) demonstrated a significant induction of apoptosis activity as early as 24 hours (24 
hours: p-value = 0.0024, SEM ± 0.3587, 48 hours: p-value = 0.045, SEM ± 0.5609, 96 
hours: p-value = 0.00279, SEM ± 0.3587, 120 hours: p-value = 0.0526, SEM ± 3.085).  
Transfection of MRT cells with shRNA-RFP also induced cell apoptosis at a later time 
point in the experiment. BMI1 knockdown significantly caused an increase in apoptosis 
activity in A204 at 72 and 120 hours when compared to NS (Appendix 6.5). Knockdown 
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of BMI1 in G401 resulted in a significant increase in cell apoptosis at 120 hours relative 
to control. BMI1 knockdown significantly increased apoptosis in G401, CHLA-266 and 
BT16 relative to control when measured at 120 hours. A significant increase in apoptosis 
was observed for all time points; 24, 72 and 120 hours when combining all biological 
repeats (4 cell lines, 2 technical replicates each cell line) (24 hours: p-value = 0.0022, 
SEM ± 0.6443, 72 hours: p-value = 0.0042, SEM ± 2.305, 120 hours: p-value = 9.265).  
Given the variability in apoptosis data for both shRNA constructs, more technical 
replicates are needed to demonstrate the significance of the datasets. 
To fully ascertain whether BMI1 knockdown can cause significant induction of apoptosis 
in MRT cells, I, next compared the luminescence reading from BMI1 knockdown 
experiment with luminescence reading from Staurosporine-induced apoptosis treatment 
in MRT cell line (Dr Selby, unpublished). Dr Selby demonstrated that Staurosporine 
treatment increased apoptosis significantly in G401 cells (n = 2 technical repeats, p-value 
< 0.0001). The mean luminescence reading was measured at 113,068 (n = 2 technical 
repeats, SD ± 15,119) Thus, 113,068 was set as a reference point for the massive amount 
of apoptotic cells in MRT. Comparison of his apoptosis reading with BMI1 experiment 
showed that BMI1 knockdown did not cause massive apoptosis activity in MRT cells. In 
line with this, later result of cell cycle analysis (Figure 6.11) showed that following BMI1 
knockdown only 2.1% cells accumulated in sub-G0 phase. Thus, supporting the notion 
that the effect of BMI1 knockdown on cell apoptosis is less pronounced in MRT cells.  
Given the inconsiderable amount of apoptosis in BMI1 knocked-down cells, I next 
examined another mechanism that contributes to slow growth rate following BMI1 
knockdown. To further determine if the inhibition of proliferation due to BMI1 
knockdown was also a result of cell senescence, the effect of BMI1 inhibition by shRNA 
on cell senescence was studied. A b-galactosidase assay was used to identify senescent 
cells in culture. One day prior to staining cells with b-galactosidase (staining at 120 hours 
post-transfection), cells transfected with shRNA-BMI1 and shRNA-LUC were harvested 
and re-plated at 10,000 cells in a 6-well plate. The senescent cells (in green) were 
manually counted from 5 random regions per well (6-well plate, 9 cm2/well) and the mean 
± SEM of senescent cells from two independent experiments was presented in Figure 
6.10. The senescence-associated b-galactosidase assay showed a high level of b-
galactosidase activity in BMI1 knocked out A204 cell lines accounting for 465 positive 
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b-galactosidase staining compared to 15 positive b-galactosidase staining in LUC 
transfected cells (Figure 6.10). This result was the highest among other MRT cell lines. 
In BT16 cells, 300.5 b-galactosidase stained cells were measured for shRNA BMI1, 
relative to 20 stained cells for shRNA LUC. BMI1 knockdown in G401 cell line also 
caused cell senescence, I counted an average of 201 stained cells relative to 24 stained 
cells for LUC transfection. In contrast, BMI1 knockdown modestly induced senescence 
in CHLA cells in which I counted only 105 cells compared to 5 stained cells for LUC. 
Altogether, BMI1 knockdown by shRNA did not massive induction of apoptosis, it is 
however, significantly caused senescence in MRT cells. 
 
 
Figure 6.9 Effect of BMI1 knockdown on apoptosis in MRT cells. Time dependent effect 
of BMI1 knockdown on caspase 3/7 activity in four MRT cell lines (a) A204, (b) G401, 
(c) CHLA-266 and (d) BT16. BMI1 knockdown did not cause massive apoptosis activity 
in MRT cells although the trend of increase can be observed in four MRT cell lines.The 
results are shown as means ± SEM of three individual experiments and the significance 
was determined by unpaired student’s t-test (** p<0.01, *** p<0.001, ****p<0.0001 vs 
LUC). Luminescence unit (RLU): x 1,000.  
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Figure 6.10 Silencing of BMI1 using shRNA induced cell senescence in MRT cells. 
The presence of senescent cells in culture was identified using senescence associated b-
galactosidase staining after 120 hours of lentiviral transfection. The microscopic images 
represent a region in the well for each culture. Senescent cells shown by red arrows. The 
number of senescent cells (green coloured cells) was presented as percentage of 
senescent cells (from a total of 550 cells per well. The bar graph showing the number of 
senescent cells in each culture measured from two independent experiments. The results 
are shown as means ± SEM of two independent experiments and the significance was 
determined by unpaired student’s t-test (* p< 0.05 vs control of the appropriate sample). 
A204
LUC BMI1
CHLA G401
BT16
a
b
200 um 200 um 200 um 200 um
200 um200 um200 um200 um
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6.4.3.4 BMI1 knockdown leads to cell accumulation in G1/G0 phase and alters 
expression of cell cycle related genes.  
Knockdown of BMI1 in MRT impairs cell growth (section 6.4.3.2). To identify the 
mechanism that is associated with a reduction in cell proliferation (Figure 6.6), analysis 
of the cell cycle was performed by flow cytometry (FACS). Analysis of cell cycle 
distribution was performed on 1x 106 BMI1 knockdown (BMI1-KD) cells and control 
samples collected at 24 hours and 120 hours post-transfection.  
Average accumulation of 2.1% of cells in sub-G0 phase was observed at 120 hours across 
four cell lines; A204, G401, CHLA-266 and BT16 (2.1 ± 1.3, mean ± SD) (Figure 6.11). 
BMI1 knockdown in A204, G401, CHLA-266 and BT16 caused a small but statistically 
significant increase in the number of cells in G0/G1 phase compared with the control 
which recorded a significant decrease (Figure 6.11a and b, Appendix 6.10 and 6.11). In 
G401, CHLA-266 and BT16 cell lines, BMI1 knockdown resulted in a significant 
decreased in cell count in S and G2/M phases at 120 hours, compared with LUC (Figure 
6.11a and b, Appendix 6.10 and 6.11). The decrease in cell count in G2/M phase was also 
observed as early as 24 hours but in only two cell lines transfected with shBMI1, G401 
(p-value = 0.0007, mean ± SEM: 27.13 ± 2.02) and A204 (p-value = 0.0022, mean ± 
SEM: 14.9 ± 0.7034). A signification reduction of cells entering S phase was seen in 
CHLA-266 transfected cells compared with LUC at 24 hours (p-value = 0.0045, mean ± 
SEM BMI1: 24.8 ± 0.8888, mean ± SEM LUC: 34.23 ± 1.369). Altogether, knockdown 
of BMI1 with shRNA disrupts normal cell cycle progression and reduced the fraction of 
proliferating cells. Notably, a significant accumulation of cells was seen in G0/G1 phase 
at 120 hours when cell cycle datasets for four cell lines were combined (p < 0.0001, n = 
4 biological replicates, n = 2 technical replicates, SEM ± 4.186) (Figure 6.12b). Moreover, 
fraction of cells was significantly reduced in S and G2/M phases for BMI1 transfected 
cells relative to control LUC cells (n = 4 biological replicates, n = 2 technical replicates, 
S phase (p-value < 0.0008, SEM ± 2.982), G2/M phase (p-value < 0.0001, SEM ± 1.608).  
To further investigate the effect of BMI1 inhibition on cell cycle regulatory gene 
expression, I next performed qPCR analysis to evaluate the change in expression level of 
seven cell cycle-related genes 96 hours post-transfection with shRNA lentivirus (Figure 
6.13). Across four cell lines, the cell cycle promoting G1-S phase genes CCND1, CCND3, 
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CDK4, CDK6, CCNE1 and CCNE2 were downregulated at an average of 0.81-, 0.91-, 
0.79-, 0.88-, 0.89-, 0.61-fold change (Figure 6.13). As expected, BMI1 knockdown 
caused upregulation of cell cycle inhibitors including p21 (an average of 1.67-fold 
change) and two tumour suppressor genes regulated by BMI1 which are p14 and p16 (an 
average of 1.49 and 1.33-fold change). This data indicates that BMI1 plays a role in cell 
cycle regulation. Furthermore, it is worth noting that the expression of CCND1 was 
slightly lower than CCND2 following BMI1 knockdown in MRT cells. The expression of 
CCND1 is higher than CCND2 in wild type MRT cells and primary (data not shown). 
This result may indicate the possible role of BMI1 on cell cycle regulation through 
regulating CCND1 expression.  
In short, PI staining shows that knockdown of BMI1 caused growth arrest in G1/G0 phase. 
Furthermore, the qPCR analysis demonstrated increased expression of cell cycle inhibitor 
genes; p21 and p16 accompanied by downregulation of cell cycle promoting genes. These 
results may explain the slow proliferation rate in BMI1 knocked-down MRT cells. 
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Figure 6.11 shRNA mediated silencing of BMI1 resulted in G0/G1 cell cycle arrest in 
MRT cells. Cell cycle analysis of MRT cell lines transfected with shRNA-BMI1 and 
shRNA-LUC. The cells were harvested 24- and 120-hours post transfection, fixed in cold 
70% ethanol and stained with propidium iodide (PI). A total number of 15,000 events 
were counted for each sample and the data were analysed using FlowJo software. Cell 
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cycle distribution of BMI1 knocked down cells compared to LUC after (a) 24 hours and 
(b) 120 hours of transfection. Sub-G0 represents cells with a DNA content less than 2N, 
G0/G1 represents cells with DNA content 2N, cells in S phase with DNA content more 
than 2N while G2/M cells with DNA content of 4N. The results are shown as means ± 
SEM of three individual experiments and the significance was determined by unpaired 
student’s t-test (* p< 0.05 ** p<0.01, *** p<0.001, ****p<0.0001 vs LUC). 
 
 
Figure 6.12 A significant effect of BMI1 knockdown in cell cycle when datasets were 
combined. Cell cycle distribution of BMI1 and LUC transfected cells at (a) 24 and (b) 
120 hours post lentiviral transfection. The data was presented as combination of four 
biological replicates (4 MRT cell lines) at two time points. The results are shown as 
means ± SEM of three independent experiments and the significance was determined by 
paired student’s t-test (** p<0.01, ****p<0.0001 vs LUC). 
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Figure 6.13 BMI1 knockdown alters the expression of cell cycle regulatory genes in 
MRT cells. Accumulation of BMI1-deficient cells in G0/G1 phase was further confirmed 
with increased in expression of cell cycle inhibitors (p21 and p16) and decreased in cell 
cycle promoting genes (CCND1, CCCND2, CDK4, CDK6, CCND3 and CCNE1) as 
determined by qPCR analysis. The expression was presented as relative to control 
(control is set as 0). The mRNA expression as normalised to GAPDH. Data are presented 
as mean ± SEM of three independent experiments.  
 
6.4.3.5 Knockdown of BMI1 depletes the self-renewing cell population in MRT cell 
lines 
The role of BMI1 as a critical component of the self-renewal machinery has been 
comprehensively described in many studies (Park et al., 2003, Kreso et al., 2014, 
Molofsky et al., 2005, Molofsky et al., 2003). I next determined if BMI1 knockdown 
could deplete the self-renewing cell population in MRT, which I hypothesised could 
contribute to MRT tumourigenesis.  
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As the self-renewal process itself is a complex mechanism to measure, one method that 
is widely used as self-renewal readout in vitro was employed, namely the sphere initiation 
assay. Briefly, in this assay, the cells are cultured as non-adherent spherical clusters of 
cells (known as tumourspheres hereafter), which can be dissociated and re-plated to 
reinitiate the tumourspheres. The self-renewal capacity of cells was studied using a 
limiting dilution assay (LDA) and re-plating tumourspheres. The adherent MRT cell lines 
were transfected with shRNA lentivirus for 24 hours and the cells were cultured in 
appropriate adherent culture media (Details of the media is described in Chapter 2) for 
another 48 hours. After 72 hours post-transfection, the cells were trypsinised, washed 
with 1X PBS (3 times) and mechanically dissociated into single cells by pipetting the 
cells up and down in 1ml PBS. The cells were then passed through a 40 µm filter. The 
cells were seeded either in a limiting dilution assay format down to one cell per well or 
10, 100 and 1000 cells in 6-well plates for serial plating of tumoursphere experiment. At 
lower cell density, 1 and 10 the cells were seeded in 96-well plate or 6-well plate using 
FACS while serial dilution was performed to seed cells at cell densities ranging from 
50,000 cells to 10 cells per well. The cells were cultured in tumoursphere media for 120 
hours.  
In the LDA experiment, the wells that contained tumourspheres were recorded as positive. 
Results from LDA shows no significant difference between shBMI1 and shLUC 
transfection at a cell density of 1,000 to 50,000 cells as tumourspheres were seen in all 
12 wells seeded with control and BMI1 knocked-down cells (Appendix 6.3). The effect 
of BMI1 knockdown on tumoursphere initiating efficiency was significant at a seeding 
density of 10 and 100 cells per well compared to control (Figure 6.14a). Therefore, these 
data underwent ELDA analysis (http://bioinf.wehi.edu.au/software/elda/) to measure the 
frequency of active self-renewal cells in MRT cultures following BMI1 knockdown using 
shRNA GFP. ELDA limiting dilution analysis from tumoursphere cultures estimated that 
1 in 4.69 A204 cells transfected with shLUC lentivirus possessed self-renewal capacity 
whereas 1 in 58.11 BMI1 knocked-down A204 cells have this ability (p-value= 2.42 x 10-
48, n= 3 technical replicates)  (Table 6.1, Figure 6.14b). Knockdown of BMI1 in A204 
reduced the self-renewing cells approximately 12 times more than shLUC A204 cells. 
BMI1 knockdown also significantly decreased tumoursphere initiating efficiency in BT16 
cells by 9-fold. ELDA analysis demonstrated that the proportion of self-renewing cells in 
BT16 knocked down cells was 1 in 42.69 cells compared to 1 in 4.69 cells for shLUC 
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construct (p-value= 1.95 x 10-40, n= 3 technical replicates) (Figure 6.14b). BMI1 
knockdown in CHLA-266 and G401 cell lines significantly reduced the self-renewal 
capacity of cells by approximately 13.5 times relative to shLUC transfected cells. For 
G401 cell line, cells that retained self-renewal capacity after transfection with shBMI1 
was 1 in 63.15 relative to 1 in 4.69 for shLUC transfected cells (p-value= 2.98 x 10-51, n= 
3 technical replicates). This observation was comparable with CHLA-266 cell line in 
which ELDA analysis estimated 1 in 63.32 self-renewing cells in BMI1 knocked-down 
cells compared to 1 in 4.69 in control LUC cells (p-value= 6.90 x 10-55, n= 3 technical 
replicates). Altogether, these results illustrate that targeting BMI1 caused self-renewal 
defects in all MRT cells as the shBMI1 transfected cells have lost the ability to form 
tumourspheres at an average reduction of 12.25 times compared to shLUC transfected 
cells, when four datasets from four biological replicates were combined.  
BMI1 knockdown using shRNA-RFP also impairs the self-renewal capacity of MRT cells, 
determined using LDA (Appendix 6.8). Tumourspheres were observed at a plating cell 
seeding density of 1,000 to 50,000 cells per well for both cells transfected with shRNA-
BMI1 and shRNA-NS. The effect of BMI1 knockdown on tumoursphere forming 
efficiency was statistically significant at a cell density of 10 and 100 cells per well only 
for BMI1-knocked down cells relative to control NS cells. The ELDA analysis also 
demonstrated a significant decrease in sphere-forming efficiency following BMI1 
knockdown in four MRT cell lines compared with NS (Appendix 6.7). The analysis 
provided an estimate of 1 in 81.77 self-renewing cells in BMI1-knocked-down A204 cells 
relative to 1 in 4.69 cells for NS transfected cells (p-value= 2.42 x 10-48, n= 3 technical 
replicates). This observation was comparable with G401 cells line in which the ELDA 
analysis estimated 1 in 88.68 active self-renewing cells for BMI1 transfected cells 
compared to 1 in 4.69 for NS transfected cells (p-value= 2.98 x 10-51, n= 3 technical 
replicates). The number of cells with self-renewal capacity was also small in BMI1 
knocked-down BT16 cells, measured for 1 in 90.11 cells relative to 1 in 4.60 for NS 
transfected cells (p-value= 1.95 x 10-40, n= 3 technical replicates). In the CHLA266 cell 
line, BMI1 knockdown reduced the active self-renewing cells, estimated at 1 in 75.92 
cells for BMI1 knocked-down cells compared to 1 in 4.69 for NS control cells (p-value= 
6.90 x 10-55, n= 3 technical replicates). These results indicate that BMI1 knockdown in 
four MRT cell lines reduced self-renewing population cells at an average reduction of 18 
times (mean of four biological replicates).  
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To fully ascertain the effect of BMI1 knockdown on self-renewal capacity of MRT cells, 
I next assessed the tumoursphere forming capacity in MRT cell lines following BMI1 loss 
in a re-plating tumoursphere assay. The adherent MRT cells were transfected with 
shRNA-GFP lentivirus for 24 hours and were dissociated into single cells on the same 
day. The single cells were seeded in 6-well plate at a density of 1000 cells per well in 
tumoursphere culture. Formation of primary tumourspheres was counted after 120 hours 
in culture. Primary tumourspheres were harvested and dissociated into single cells and 
the cells were re-seeded at 1000 cell per well in tumoursphere culture. Secondary 
tumourspheres were allowed to form for 120 hours. Results from the serial tumoursphere 
assay showed that BMI1 knockdown significantly reduced the mean number of primary 
tumourspheres in CHLA-266 cells (n = 2 technical replicates, number of tumoursphere 
=8, p-value = 0.00422) compared with LUC (mean ± SEM: 16.5 ± 1.50) (Figure 6.14c, 
Appendix 6.15). A decrease was also observed in G401, A204 and BT16 cells transfected 
with shBMI1, however the number was not statistically different with LUC transfected 
cells (G401[p-value = 0.1153, mean ± SEM: 9 ± 2], A204 [p-value = 0.4117, mean ± 
SEM: 10.5 ± 2.50], BT16 [p-value = 0.1425, mean ± SEM: 9.5 ± 1.50].  
Knockdown of BMI1 resulted in a significant reduction in the number of secondary 
tumourspheres in all MRT cell lines (Figure 6.14c). Formation of secondary 
tumourspheres was greatly reduced in BT16 cells transfected with shBMI1 (p-value = 
0.0068, mean ± SEM: 6.5 ± 0.5). A significant decrease in the number of tumourspheres 
was also observed in G401, CHLA-266 and A204 (p-value = 0.004). Notably, the number 
of tumourspheres was not statistically significant over two cultures for all cell lines 
although the fewer tumourspheres were found in secondary culture than initial primary 
culture (Figure 6.14 and Appendix 6.15). Combining the datasets from four cell lines (n 
= 4 biological replicates, n = 2 technical repeats) demonstrated a significant reduction in 
the number of both primary and secondary tumourspheres in BMI1 knocked-down cells 
relative to LUC control cells (primary [p-value < 0.0001)(Figure 6.14d and  Table 6.2). 
A similar reduction trend was also observed in the formation of secondary tumourspheres 
as the mean number of tumourspheres across four cell lines was smaller than that of 
primary tumourspheres for shBMI1 (p-value = 0.0028, mean difference = 2.625, SEM = 
± 0.9149). This result indicates that BMI1 knockdown depletes the self-renewing cells 
thus corroborating results from ELDA analysis. On the other hand, transfection of shLUC 
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demonstrated upward trajectory in the formation of tumourspheres (p-value = 0.0006, 
mean difference = 4.5, SEM = ± 1.065). In conclusion, the reduced number of 
tumourspheres and abrogation of long-term self-renewal capacity in BMI1-deficient cells 
illustrate the role of BMI1 in controlling self-renewal in MRT. 
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Figure 6.14 BMI1 knock-down using shRNA impairs self-renewal capacity of MRT 
cells. (a) The effect of BMI1 loss on primary tumourspheres was measured using limiting 
dilution assay (LDA). The shRNA infected cells were cultured in tumourspheres media at 
density of 50,000 cells down to one cell per well and tumourspheres were allowed to form 
for 120h. Knockdown of BMI1 caused significant reduction in the number of 
tumourspheres at cell density of 10 and 100 cell per well. These results were further 
b 
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analysed using ELDA to measure active self-renewing cells in BMI1-deficient cells. (b) 
ELDA analysis demonstrates significant decrease in sphere forming efficiency following 
BMI1 knockdown in four MRT cell lines compared with LUC. The results are shown as 
means ± SEM of three independent experiments and the significance was determined by 
unpaired student’s t-test (****p<0.0001 vs LUC). (c) BMI1 loss affects the tumoursphere 
forming efficiency observed in certain MRT cell lines. Knockdown of BMI1 reduced the 
formation secondary tumourspheres in all MRT cell lines when compared with LUC. The 
results are shown as means ± SEM of three independent experiments and the significance 
was determined by paired student’s t-test (** p<0.01, *** p<0.001, ****p<0.0001 vs 
LUC/ primary tumoursphere). (d) Despites a decrease in formation of tumourspheres 
over two cultures for BMI1 transfected cells, the reading was not statistically significant 
in all cell lines. (e and f) Number of tumourspheres from four cell lines were combined 
and paired student t-test analysis was performed on these datasets (n= 4 biological 
repeats, n= 2 technical repeats,** p<0.01, *** p<0.001, ****p<0.0001 vs LUC/ primary 
tumoursphere).  
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6.4.4 Targeting self-renewal machinery of BMI1 using small molecule inhibitor, 
PTC209 
Knockdown of BMI1 mediated by shRNA shows significant effects on MRT cell 
progression as well as self-renewal potential. These findings imply the value of targeting 
self-renewal machinery through the therapeutic targeting of BMI1. PTC209, a small 
molecule inhibitor was originally identified by Kreso et al. (2014) in her studies to 
regulate the survival of colon cancer through inhibition of BMI1 expression. Recent 
studies reported potent effects of PTC209 in targeting self-renewing cells in other types 
of cancer (Bolomsky et al., 2016, Mayr et al., 2016, Alzrigat et al., 2017) which led me 
to explore the pre-clinical activity of PTC209 in MRT cell lines.  
 
6.4.4.1 PTC209 is a potent anti-MRT agent in vitro 
To identify the effect of pharmacological inhibition of BMI1 using PTC209 on cell 
proliferation, the MRT cell lines (A204, G401, CHLA-266 and BT16) were treated with 
a concentration ranging from 0.001 to 250 µM. Briefly, the cells were seeded in a 96-well 
plate (1000 cells/well) in triplicate. The number of viable cells was determined using 
CelTiter glo and the plate was read at 560 nm in a FLUOstar Omega (BMG Labtech) 
plate reader. To determine the GI50 of PTC209 for each cell line, the reading underwent 
analysis using GraphPad PRISM to generate a dose-response inhibition curve that fits a 
non-linear regression model. The curve was presented as log(concentration) vs response. 
The analysis showed that PTC209 inhibited the growth of four MRT cell lines in a dose-
dependent manner (GI50). The effect of PTC209 on the overall cell viability of MRT cell 
lines after 96 hours was illustrated in a dose-dependent manner as shown in Figure 6.16a. 
Notably, MRT cell lines showed different responses to PTC209 concentrations as 
measured by GI50. A204, G401 and CHLA displayed greater sensitivity to the inhibitor 
(3, 4 and 4.6 µM respectively) in comparison to BT16 (10µM). Altogether, PTC209 
mediated a potent anti-MRT activity, reducing the viability of MRT cell lines at 
concentrations ranging from 1-10 µM and this range is almost equivalent to the study by  
Mayr et al. (2016) in which the authors reported GI50 ranging from 0.52 – 8.33 µM in five 
biliary tract cancer cell lines. Treatment of PTC209 in eight human myeloma cell lines 
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showed the different sensitivity of the cell lines to inhibitor with GI50 ranging from 0.21 
– 5.68 µM (Bolomsky et al., 2016). The GI50  reported in eight AML and five ALL cell 
lines ranging from  0.21 – 0.77 µM to  0.32 – 0.86 µM respectively (Nishida et al., 2015).  
To further examine the effect on BMI1 inhibition using PTC209 on cell proliferation, two 
drug concentrations (sub-lethal dose and GI50 dose) were tested in each cell line. For 
A204, G401 and CHLA, the cells were treated at 1 and 3.5 µM whereas the BT16 cell 
line was treated at 5 and 10 µM. The cell images were taken after 48 hours of treatment 
with DMSO and PTC209 using the EVOS microscope. The images then underwent viable 
cells analysis using ImageJ software. As shown in Figure 6.16c, inhibition of BMI1 by 
PTC209 reduced the number of viable cells compared with DMSO. PTC209 treatment at 
the highest concentration tested in this experiment (3.5 and 10 µM) resulted in significant 
reduction in the number of viable cells seen in all MRT cell lines compared to DMSO. 
Treatment of PTC209 at 3.5 µM in A204 resulted in a 10 times reduction in the number 
of cells relative to DMSO (Figure 6.16c). Similarly, the number of viable cells in BT16 
treated with 10 µM of PTC209 decreased by 3 times compared with DMSO. The change 
in the number of viable cells suggests the deficiency in proliferation compared to control 
DMSO treatment as early as 48 hours (Figure 6.16c).  
In the following experiments, two drug concentrations (sub-lethal dose and GI50 dose) 
were tested in each cell line. For A204, G401 and CHLA, the cells were treated at 1 and 
3.5 µM whereas the BT16 cell line was treated at 5 and 10 µM. 
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Figure 6.15 MRT cells demonstrate different responses to concentrations of PTC209. 
The GI50 of PTC209 in each MRT cell lines was determined using CellTiterGlo assay at 
96 hours post treatment and the luminescence readings were analysed using PRISM to 
generate log(concentration) vs response curve. PTC209 significantly inhibited 4 MRT 
cell lines in a dose dependent manner ranging from 3.5 to 10 µM.  
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Figure 6.16 Pharmacological inhibition of BMI1 reduced cell proliferation (a) Phase 
contrast images of A204, G401, CHLA-266 and BT16 cell lines at 48 hours after 
treatment with two concentrations of PTC209 (GI50  and sub GI50). The GI50  for A204, 
G401, CHLA-266 was 3.5 µM while BT16 was 10 µM. The sub-GI50  for A204, G401, 
CHLA-266 was 1 µM while BT16 was 5 µM. The cell images were taken using EVOS cell 
imaging microscope 48hours post treatment. The scale bar is 400um. The images 
showing the BMI1 inhibition impedes the cell growth as early as 48 hours. Row 
represents cell lines whereas column represents concentration of drug (b) ImageJ 
analysis to measure the number of viable cells following treatment with PTC209. To 
count the viable cells, the images underwent cell count scoring using ImageJ analysis 
and the number of viable cells was presented in a bar graph. The bar graph showing 
decreased in cell number of viable cells in PTC209 treated cells compared with DMSO, 
which serves as control. The results are shown as means ± SEM of two individual 
experiments and the significance was determined by unpaired student’s t-test (* p< 0.05, 
** p<0.01, *** p<0.001 vs DMSO). 
 
6.4.4.2 Pharmacological inhibition of BMI1 did not significantly induce cell 
apoptosis in MRT cell lines 
Treatment of PTC209 in four MRT cell lines impaired cell proliferation as indicated by 
slow growth rate after PTC209 treatment (Figure 6.16). I next sought to examine other 
possible mechanisms by which pharmacological inhibition of BMI1 slows down the cell 
growth. To this end, the effect of BMI1 inhibition by PTC209 on cell apoptosis was 
studied using a Caspase-Glo 3/7 luminescence assay. This assay measures the caspase 3- 
and caspase 7- activity within the cells as an indicator for cell apoptosis. BMI1 
knockdown by PTC209 did not cause a significant induction of apoptosis in the three 
MRT cell lines (A204, CHLA-266 and BT16) in a dose-dependent manner, as the 
apoptosis activity was not statistically significant compared with DMSO (Figure 6.17). A 
significant increase in apoptosis activity was only seen in G401 cell line at 3.5 µM relative 
to DMSO treatment. Although apoptosis reading from G401 cell line showed significant 
apoptosis activity, the luminescence reading was lower than the reference point from Dr 
Selby’s apoptosis dataset (Refer 6.4.3.3). Comparison of the luminescence reading from 
PTC209 treatment with datasets from Staurosporine treatment in MRT cell lines (Dr 
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Selby, PhD thesis) indicates that pharmacological inhibition by PTC209 did not cause 
massive induction of apoptosis in MRT cells. This result was further corroborated by the 
later result of cell cycle analysis which did not significantly demonstrate accumulation of 
cells in sub-G0 phase. 
To gain more insight into the effect of PTC209 treatment on cell apoptosis, FITC 
AnnexinV-PI assay was used. In the apoptotic cell, the membrane phospholipid 
phosphatidylserine (PS) is transported from the inner to the outer space of the plasma 
membrane, hence showing PS to the external cellular environment. The FITC AnnexinV-
PI assay incorporates the AnnexinV, which is a 35-36 kDa Ca2+ dependent phospholipid-
binding protein that has a high affinity for phospholipid phosphatidylserine (PS) and 
binds to cells with exposed PS. AnnexinV is conjugated to FITC for flow cytometry 
analysis. This assay is used in conjunction with propidium iodide (PI) to identify stages 
of cell death i.e necrosis. To measure apoptosis using this assay, the cells were harvested 
72 hours after the treatment with either DMSO or PTC209) and incubated with FITC 
Annexin V and PI solution (Details of the method is described in Chapter 2). The cells 
were analysed using the FACS Canto and measurements were analysed using FlowJo 
software. Figure 6.18 showing a quadrant plot that represents stages of cell death. The Q4 
square represents the viable cells (FITC Annexin V and PI negative), the Q3 square 
represents the cells in the early apoptosis (FITC Annexin V positive and PI negative. The 
Q1 and Q2 denote the cells in late apoptosis or already dead.  
After 72 hours treatment with PTC209 at 1 and 3.5 µM in A204 cell line, BMI1 inhibition 
caused accumulation of 2.42% and 10.2% of apoptotic cells in early apoptosis (Q3) stage 
respectively, and 1.06% and 3.13% of cells in late apoptosis (Q2) stage respectively 
(Figure 6.18). In the G401 cell line, PTC209 treatment at 1 and 3.5 µM caused less than 
1.1% of apoptotic cells in early apoptosis stage. Whilst, 0.93% and 2,13% of cells in late 
apoptosis stage respectively were measured in G401 cells treated with PTC209 at 1 and 
3.5 µM respectively. Similarly, PTC209 treatment at two drug concentrations in other cell 
CHLA-266 resulted in less than 4% of apoptotic cells measured from late apoptosis Q3 
square and less than 1% of apoptotic cells in early apoptosis Q2 square (Figure 6.18). 
PTC209 treatment in BT16 cells with 1 and 3.5 µM caused 0.81% and 1.12% apoptotic 
cells in Q2 square respectively whereas less than 2.5% of apoptotic cells were measured 
in the Q3 square for 1 and 3.5 µM treated cells respectively. Notable, less than 1% of 
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apoptotic cells were observed in Q2and Q3 squares for DMSO treatment in three MRT 
cell lines; G401, CHLA-266 and BT16 with an exception of A204 cell line in which 
2.09% of apoptotic cells were measured in Q3.  
Both apoptosis assays utilised in this study demonstrated that treatment with PTC209 did 
not significantly induce cell apoptosis in MRT cell lines, although the trend of increase 
in cell apoptosis can be observed in Caspase-Glo 3/7 luminescence assay. Analysis of cell 
apoptosis using the Caspase-Glo 3/7 showed a significant increase in apoptosis activity, 
observed in G401 cells following PTC209 treatment. However, AnnexinV FITC-PI assay 
showed that pharmacological inhibition of BMI1 only resulted in less than 6% of 
apoptotic cells. Likewise, PTC209 treatment in A204 at 3.5 µM did not cause significant 
induction of cell apoptosis as determined by the Caspase-Glo 3/7. However, 
approximately ~13.77% of apoptotic cells were measured using the Annexin V FITC-PI 
staining (Figure 6.18). Given the discrepancy in results between two apoptosis assays, 
more technical replicates are needed to increase the significance of results. 
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Figure 6.17 Pharmacological inhibition of BMI1 on apoptosis in MRT cells after 72 
hours treatment with PTC209. The Caspase-Glo 3/7 assay was used to measure caspase 
3- and caspase 7-acitivity within the cells. The luminescence reading was normalised to 
blank and the measurement was presented as relative to cell only (without any treatment). 
The results are shown as mean ± SEM of three individual experiments and the 
significance was determined by unpaired student’s t-test (** p<0.01 vs DMSO). 
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Figure 6.18 FITC Annexin V-PI assay measuring the cell apoptosis in PTC209 treated 
cells. Cells treated with PTC209 and DMSO were incubated with FITC Annexin V and 
PI to analyse the percentage of apoptotic cells. Q1 represents necrotic cells (already 
dead), while Q2 represents late apoptosis. Q3 represents early apoptosis stage. 
Combination of three squares denotes the apoptotic cells and the number of cells in these 
squares were combined to generate a bar graph of percentage of apoptotic cells in four 
MRT cell lines. Statistical analysis could not be performed as the experiment was 
performed once only.  
 
To study another mechanism that contributes to inhibition of cell proliferation, I next 
examined the effect of pharmacological inhibition of PTC209 on cell senescence in four 
MRT cell lines after 96 hours of treatment. The senescent cells were detected using b-
galactosidase staining. The senescent cells (in green) were manually counted from 5 
random regions per well (6-well plate, 9 cm2/well) and the mean ± SEM of senescent 
cells from two independent experiments was presented in Figure 6.20. The senescence-
associated b-galactosidase assay showed a significant effect of BMI1 inhibition in A204 
cells treated at 1 µM relative to DMSO (mean 1 µM: 300 cells, mean DMSO: 4, p-value= 
0.0019, n= 2 technical replicates) relative to DMSO. PTC209 treatment at 3.5 µM in 
A204 cell lines also caused significant cell senescence relative to DMSO (mean 3.5 µM: 
419 cells, mean DMSO: 4, p-value= 0.0002, n= 2 technical replicates)(Figure 6.20 and 
Figure 6.20). In BT16 cells, 267.5 and 378 senescent cells were counted for 1 µM and 
3.5 µM respectively. These datasets were significant relative to 23.5 senescent cells for 
DMSO (p-value 5 µM = 0.0051, p-value 10 µM = 0.0026, n= 2 technical replicates). 
Pharmacological inhibition of BMI1 also caused cell senescence in G401 cell line. 101 
and 263.5 senescent cells were measured in PTC209 treated cells at 1 µM  and  3.5 µM  
respectively, relative to 9 senescent cells for DMSO treatment (p-value 1 µM = 0.0144, 
p-value 3.5 µM = 0.0009, n= 2 technical replicates) (Figure 6.20 and Figure 6.20). In 
contrast, BMI1 knockdown by PTC209 at 1 µM modestly induced senescence in CHLA-
266 cell line recorded for 132.5 senescent cells compared to 6 senescent cells for DMSO 
(p-value: 0.0253, n= 2 technical replicates) (Figure 6.20). Strikingly, PTC209 treatment 
at 3.5 µM in CHLA-266 produced less senescent cells than 1 µM (mean 3.5 µM: 94 
senescent cells, p-value= 0.0064, n= 2 technical replicates  (Figure 6.20 and Figure 6.20). 
 
290 
In short, pharmacological inhibition of BMI1 significantly caused cell senescence in MRT 
cell lines in a dose-dependent manner, with an exception of CHLA-266 cell lines. More 
technical replicates are required for CHLA-266 cell line to demonstrate the real effect of 
BMI1 knockdown on cell senescence at two different drug concentrations. 
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Figure 6.19 Pharmacological BMI1 inhibition by PTC209 induces cell senescence in 
MRT. The presence of senescent cells in culture was identified using senescence 
associated b-galactosidase staining after 96 hours of treatment. The microscopic images 
represent a region in the well for each culture of one technical replicate. Senescent cells 
shown by red arrows. 
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Figure 6.20 Pharmacological BMI1 inhibition by PTC209 induces cell senescence in 
MRT. Knockdown of BMI1 in A204 resulted in significant accumulation of senescent 
cells at both concentrations (1 and 3.5 µM) after 96 hours of treatment. The number of 
senescent cells (green coloured cells) was presented as percentage of senescent cells 
(from a total of 550 cells per wel.. The bar graph showing the number of senescent cells 
in each culture measured from two independent experiments. The results are shown as 
means ± SEM of two independent experiments and the significance was determined by 
unpaired student’s t-test (****p<0.0001 vs DMSO). 
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Table 6.3 The effect of BMI1 inhibition by PTC209 on cell senescence. Results show 
average senescent cells from 5 random regions per well (6-well plate, 9 cm2/well). The 
significance was determined using unpaired student t-test.  
 
6.4.4.3 Targeting BMI1 using PTC209 disrupts normal cell cycle progression 
Analysis of senescence-associated b-galactosidase demonstrates the accumulation of 
senescent cells following treatment with PTC209. This finding may explain the reduced 
proliferation rate in PTC209 treated cells compared with DMSO. To better understand if 
slow cell growth is due to cell arrest, cell cycle analysis using Flow Cytometry was 
performed. The cell cycle analysis was performed to examine if BMI1 inhibition using 
PTC209 causes a G0/G1 cell cycle arrest. MRT cell lines (1 x 106) were treated with 
PTC209 at two drug concentrations; 1 µM and 3.5 µM for A204, G401 and CHLA-266; 
and 5 µM and 10 µM for BT16. DMSO was included as a control.  
In general, BMI1 knockdown by PTC209 in four MRT cell lines; A204, G401 and CHLA-
266 did not alter cell cycle distribution at 24 hours post-treatment (Figure 6.21a-d, Figure 
6.22a). A significant result was only measured in BT16. The changes were more 
pronounced at 72 and 120 hours. There were no fraction of cells in sub-G0 phase for both 
cell lines when treated at 1 µM. PTC209 treatment in BT16 did not result in an increase 
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in the number of cells in this phase for two drug concentrations at two-time points (data 
cannot be clearly seen on the graph due to the small percentage).  
Pharmacological inhibition of BMI1 resulted in an increase in the number of cells in the 
G0/G1 phase for all MRT cell lines. More significant induction of percentage of cells in 
this phase seen in BT16 measured at 120 hours when compared to DMSO (5 µM [p-value 
= 0.0129], 10 µM [p-value = 0.0115], n= 2 technical replicates) (Figure 6.21d, Appendix 
6.13 and 6.14). The significant increase in the number of cells in G0/G1 phase was also 
observed in A204 treated with 1 and 3.5 µM, measured at 72 and 120 hours post-treatment 
(Figure 6.21a, Appendix 6.13 and 6.14). BMI1 inhibition in G401 and CHLA cells also 
resulted in an increase in the number of cells count in this phase, however, the reading 
was statistically significant when examined at 120 hours relative to DMSO only (Figure 
6.21b-c). When the data were analysed at 120 hours, the increase in the G0/G1 phase of 
the cycle was more significant suggesting the late effect of PTC209 on cell cycle in these 
cell lines.  
BMI1 inhibition by PTC209 also caused a reduction of cells in S and G2/M phase in all 
cell lines, A204, G401, CHLA-266 and BT16 (Figure 6.21a-d). The effect of BMI1 
knockdown on cell count in these two phases was more significant in BT16, A204 and 
G401 at two points; 72 and 120 hours. Accumulation of cells in G0/G1 phase was more 
significant when the data were combined for all cell lines at 72 and 120 hours (Figure 
6.22b-c). Furthermore, BMI1 inhibition by PTC209 also resulted in a more significant 
decrease in the number of cells in the G2/M and S phases. Of note, there were no 
significant changes observed in cell cycle distribution at 24 hours (Figure 6.22a).  
Overall, cell cycle distribution for all MRT cell lines shows that PTC209 treatment causes 
induction of cells in G0/G1 cell and blocks the cell cycle entry to S and G2/M phases 
when compared with DMSO. The cell cycle analysis suggests that pharmacological 
inhibition of BMI1 causes a G1/G0 cell cycle arrest and supports the findings from the 
cell the senescence analysis.  
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Figure 6.21 Pharmacological inhibition of BMI1 causes cell cycle arrest in MRT cell 
lines. The time dependent effect of PTC209 on cell cycle distributions of four 4 MRT cell 
line;s (a) A204, (b) G401, (c) CHLA-266 and (d) BT16, after 24, 72 and 120 hours of 
treatment.. A total number of 15,000 events were counted for each sample and the data 
were analysed using FlowJo software. Sub-G0 represents cells with a DNA content less 
than 2N, G0/G1 represents cells with DNA content 2N, cells in S phase with DNA content 
more than 2N while G2/M cells with DNA content of 4N The results are shown as means 
± SEM of two independent experiments and the significance was determined by unpaired 
student’s t-test (* p<0.05, ** p<0.01, *** p<0.001, ****p<0.0001 vs DMSO). 
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Figure 6.22 Effect of BMI1 knockdown on cell cycle seen in MRT cells. BMI1 
knockdown significantly increased cell counts in G0/G1 phase when four datasets (from 
4 cell lines) were combined. The decrease in the number of cells in the S and G2/M phase 
was also observed when datasets were combined for four cell lines. The results are shown 
as means ± SEM of three independent experiments and the significance was determined 
by paired student’s t-test (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 vs DMSO). 
 
6.4.4.4 BMI1 inhibition by PTC209 dysregulates the expression of cell cycle 
regulatory genes. 
Flow cytometry analysis of PTC209 treated MRT cells demonstrates cell cycle arrest in 
which the effect on cell cycle more pronounced from 72 hours onwards. Therefore, the 
effect of PTC209 on cell cycle regulation was further studied using qPCR analysis of cell 
cycle-related genes following 96-hours post-treatment with PTC209. Inhibition of BMI1 
 
297 
using PTC209 also caused downregulation of cell cycle promoting G1-phase including 
CCND1, CCND3, CCNE1, CDK4 and CDK6 (Figure 6.23). Changes in mRNA 
expression of these genes were accompanied by increased expression of G1-phase 
inhibitors such as CDKN1A (p21), CDKN2A (p16 and p14). The gene expression analysis 
confirms the effect of PTC209 treatment on cell cycle regulation in MRT cell lines.  
 
 
Figure 6.23 PTC209 causes deregulation of the expression of cell cycle related genes 
in MRT cells. qPCR analysis of PTC209 treated samples show deregulation of cell cycle 
related genes in relation to the DMSO control. Cells were harvested 96 hours post 
treatment. Pharmacologic inhibition of PTC209 induces expression of cell cycle 
inhibitors (p14, p16 and p21) accompanied by repression of cell cycle activating genes 
(CCND1, CCND3, CCNE1, CCNE2, CDK4 and CDK6). The expression was presented 
relative to DMSO only treatment. Data are presented as mean ± SEM of three 
independent experiments. 
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6.4.4.5 PTC209 effectively depletes MRT self-renewing cells and impairs long-term 
tumoursphere formation efficiency 
To further explore the mechanism by which PTC209 slows down the growth of MRT 
cells, I continued to examine the pharmacological inhibition of BMI1 on self-renewal. To 
this end, the limiting dilution assay (LDA) and re-plating tumoursphere experiments were 
utilised. For the LDA experiment, MRT cell lines were treated with PTC209 at two drug 
concentrations as adherent cells for 96 hours followed by removal of the drug from the 
culture. The cells were allowed to recover for 120 hours in an adherent state in culture 
media that specific for each cell line. The cells were seeded for a limiting dilution assay 
from 50,000 cells to 1 cell per well in a 96-well plate. Similar to the shRNA experiment, 
LDA demonstrates no significant difference between DMSO and PTC209 treatment at 
cell density from 50,000 to 1000 cells as the tumourspheres were observed in all 12 wells 
for both treatments. The tumourspheres were seen in all 12-wells seeded with the treated 
cells (Details in Appendix). The effect of BMI1 knockdown on the tumoursphere 
initiating efficiency was statistically significant at a seeding density of 100 and 10 cell 
per well relative to DMSO (Figure 6.24a). To estimate the frequency of active self-
renewal cells in MRT cells following BMI1 knockdown by PTC209, the number of 
positive well-containing tumourspheres for 1, 10, 100 and 1000 cells per well underwent 
ELDA analysis (http://bioinf.wehi.edu.au/software/elda/).  
BMI1 inhibition by PTC209 caused a significant reduction in frequency of active self-
renewing cells in MRT as shown in Figure 6.24b and Table 6.4. ELDA limiting dilution 
analysis from tumoursphere culture showed that PTC209 pre-treatment of A204 cells at 
1 and 3.5 µM significantly reduced the frequency of self-renewing cells (1 in 32.41 and 
1 in 107/36 respectively) when compared to DMSO (1 in 4.69) (p-value = 1.32 x 10-72, 
technical replicates, n= 3). The self-renewal capacity of PTC209 treated cells was 
decreased by 6.9- and 22.8-fold relative to DMSO. The significant reduction of active 
self-renewal cells following treatment with PTC209 at 1µM was also seen in G401 cell 
line which shows 1 in 13.3 of frequency active self-renewal compared to 1 in 4.81 for 
DMSO treatment (p-value = 4.93 x 10-71, technical replicates, n= 3) (The frequency of 
active self-renewal cells was more significantly reduced in G401 treated with 3.5 µM of 
PTC209 (1: 80.48) (p-value = 4.93 x 10-71, technical replicates, n= 3). 
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A comparable result was seen in BT16 which shows an active self-renewing cell 
frequency of 1 in 27.12 and 1 in 81.92 for 5 and 10 µM of PTC209 respectively relative 
to only 1 in 4.69 cells treated with DMSO (p-value = 1.80 x 10-61, technical replicates, n= 
3). ELDA analysis estimated the active self-renewing cells in CHLA-266 was 1 in 31.22 
and 1 in 100.3 for 1 and 3.5  µM of PTC209 respectively compared to 1 in 5.03 in DMSO 
treated cells (p-value = 2.20 x 10-66, technical replicates, n= 3) (Figure 6.24b). The result 
illustrates that targeting BMI1 caused self-renewal deficiency in MRT cells as the BMI1 
infected cells have lost the ability to form tumourspheres by approximately 5 to 23-fold 
in relative to DMSO. 
To confirm the effect of BMI1 knockdown on the self-renewal capacity of MRT cells, I 
next assessed the effect of PTC209 in four MRT cell lines; A204, G401, CHLA-266 and 
BT16 in the re-plating tumourspheres assay. The serial re-plating assay reflects the self-
renewing cells in culture. To set up this experiment, adherent MRT cells were treated with 
either DMSO or PTC209 for 96 hours and were dissociated into single cells on the same 
day (96 hours). The single cells were seeded in 6-well plate at a density of 1000 cells per 
well in tumoursphere culture. Formation of primary tumoursphere was counted after 120 
hours in culture. Primary tumourspheres were harvested and dissociated into single cells, 
re-seeded at 1000 cells per well in tumoursphere culture. Secondary tumourspheres were 
allowed to form for 72 hours.  
PTC209 treatment caused significant reduction in the mean number of primary 
tumoursphere at highest concentration tested for this project (3.5 and 10 µM) relative to 
DMSO (n =2 technical repeats, p-value A204 3.5 µM = 0.0541, p-value G401 3.5 µM = 
0.0198, p-value CHLA-266 1 µM = 0.0094, p-value BT16 10 µM = 0.0041) (Figure 
6.25a, Appendix 6.5a). A decrease in number of primary tumourspheres also observed in 
sub-lethal doses (1 and 5 µM), however the number of tumourspheres was significant 
only in BT16, G401 and CHLA-266 cell lines when compared to DMSO (n =2 technical 
repeats, p-value BT16 5 µM = 0.0541, p-value G401 1 µM = 0.0282, p-value CHLA-266 
1 µM = 0.0077). Pharmacological inhibition of BMI1 at 1 µM in A204 cells also the 
number of primary tumourspheres, however the data was not significant when compared 
with DMSO (n = 2 technical repeats, p-value = 0.0541) (Figure 6.25a, Appendix 6.5a). 
Similarly, formation of secondary tumourspheres was significantly impaired MRT cells 
treated at GI50 and sub-lethal doses of PTC209. (PTC209 GI50 doses: n =2 technical 
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repeats, p-value A204 3.5 µM = 0.0185, p-value G401 3.5 µM = 0.0162, p-value CHLA-
266 1 µM = 0.0059, p-value BT16 10 µM = 0.0017, PTC209 sub-lethal doses: n =2 
technical repeats, p-value A204 1 µM = 0.0231, p-value G401 1 µM = 0.0233, p-value 
CHLA-266 1 µM = 0.0081, p-value BT16 5 µM = 0.025).)(Figure 6.25a, Appendix 6.5a).  
The effect of BMI1 inhibition by PTC209 on the tumourspheres forming efficiency was 
more significant when the data for four cell lines were combined. PTC209 treatment 
caused a significant decrease in the formation of primary tumourspheres (p-value DMSO 
vs 1/5 µM < 0.0001, SEM 1/5 µM = ± 1.267, p-value DMSO vs 3.5/10 µM < 0.0001, 
SEM 3.5/10 µM = ± 1.133) and secondary tumourspheres (p-value DMSO vs 1/5 µM < 
0.0001, SEM 1/5 µM = ± 1.946, p-value DMSO vs 3.5/10 µM < 0.0001, SEM 3.5/10 µM 
= ± 2.133) (n = 4 biological replicates, n= 2 technical repeats) (Table 6.5, Figure 6.26). A 
significant decrease in tumoursphere number was observed in PTC209 treated cells over 
two passages (n = 4 biological replicates, n= 2 technical repeats, p-value 1/5 µM = 0.0006, 
SEM 1/5 µM = ± 1.065, p-value 3.5/10 µM < 0.0028, SEM 3.5/10 µM = ± 1.946).   
Taken all together my results show that PTC209 can efficiently reduce the self-renewing 
capability in MRT cell lines. Besides that, self-renewal capacity of MRT cells was 
sustained following 120 hours recovery period even only with a sub-lethal dose. In the 
serial re-plating experiment, pharmacological inhibition of PTC209 caused a persistent 
decrease in the number of tumourspheres suggesting self-renewal defects. The effect of 
BMI1 knockdown on tumoursphere forming efficiency is more significant when the 
datasets for individual cell line were combined. 
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Figure 6.24 BMI1 silencing using PTC209 impairs self-renewal capacity of MRT cells. 
(a) The effect of BMI1 loss on primary tumoursphere was measured using LDA. The 
PTC209 and DMSO treated cells were cultured in tumourspheres media at density of 
50,000 cells down to one cell per well after 120 hours of recovery time (after removal of 
drug) and tumoursphere were allowed to form for 72h. Knockdown of BMI1 caused 
significant reduction in the number of tumourspheres at cell density of 10 and 100 cell 
per well. These results were further analysed using ELDA to measure active self-
renewing cells in BMI1-deficient cells (b) ELDA analysis demonstrated significant 
decrease in sphere forming efficiency following BMI1 knockdown in four MRT cell lines 
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compared with LUC. The results are shown as means ± SEM of three independent 
experiments and the significance was determined by unpaired student’s t-test 
(****p<0.0001 vs DMSO or primary tumourspheres in appropriate culture). 
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Figure 6.25 The effect of PTC209 on self-renewal is corroborated by re-plating assay. 
Knockdown of BMI1 significantly reduced the formation of primary and secondary 
tumourspheres in four MRT cell lines in comparison to control (DMSO). The results are 
shown as means ± SEM of two independent experiments and the significance was 
determined by unpaired student’s t-test (* p< 0.05, ****p<0.0001 vs DMSO or primary 
tumourspheres in appropriate culture). 
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Figure 6.26 Significant effect of BMI1 knockdown on formation of tumourspheres. The 
decrease in the number of tumourspheres over two passages was more significant when 
the data was combined. The results are shown as means ± SEM of two independent 
experiments and the significance was determined by unpaired student’s t-test (* p< 0.05, 
****p<0.0001 vs DMSO or primary tumourspheres in appropriate culture). 
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Table 6.5 The effect of BMI1 knockdown on tumoursphere formation efficiency. The 
number of tumourspheres for each MRT cell line were combined to access whether BMI1 
knockdown on four biological replicates was statistically significant. The results are 
shown as means ± SEM of two independent experiments and the significance was 
determined by paired student’s t-test.  
 
6.4.4.6 PTC209 reduces the expression of BMI1 possibly through protein 
degradation 
PTC209 treatment in MRT cell lines reduces cell viability, induces cell senescence and 
cycle arrest in G0/G1 phase, and attenuates self-renewal potential. However, the 
underlying mechanism of the drug action is not fully understood. Gene expression 
analysis of BMI1 in PTC209 treated cells shows that PTC209 treatment did not reduce 
the mRNA expression of BMI1 but rather caused upregulation of BMI1 expression 
(Figure 6.27a). However, significant protein expression reduction was observed 
following treatment with PTC209 (Figure 6.27b). Conversely, shRNA-mediated 
knockdown of BMI1 shows significant downregulation of expression at both RNA and 
protein levels (Figure 6.27a and c). These data suggest PTC209 pharmacologically 
inhibited BMI1 expression presumably through post-transcriptional repression 
(ubiquitination). These findings are comparable with studies by Mayr et al. (2016) and 
Alzrigat et al. (2017) in which the authors also reported increased expression of BMI1 at 
the RNA level and reduced BMI1 protein expression in western blot analysis following 
PTC209 treatment. The authors further showed that downregulation of BMI1 protein 
expression was accompanied by decreased in H2AK119ub protein levels in multiple 
myeloma cells. Their findings illustrate that PTC209 pharmacologically inhibited BMI1 
expression presumably through post-transcriptional repression and protein degradation.  
.  
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Figure 6.27 PTC209 inhibits the BMI1 expression in MRT cells through protein 
degradation. (a) Treatment with PTC209 increased the transcript level of BMI1 but 
resulted in degradation of BMI1 protein 48 hours post treatment (b). The expression was 
normalised to DMSO (control) and each bar represents the expression of BMI1 at IC50 
concentration (3.5 µM for A204, G401 and CHLA-266 whilst 5 µM for BT16). On the 
other hand, (a-c) shRNA mediated knockdown of BMI1 showed downregulation at both 
transcript and protein level thus suggesting degradation of BMI1 using PTC209 possibly 
through protein degradation. Beta-actin serves as control in western blot analysis.  
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6.4.4.7  BMI1 knockdown using shRNA and BMI1-inhibitor, PTC209 mimics the 
effects of SMARCB1 re-expression in MRT cell lines: criteria for an 
attractive drug target 
BMI1 regulates the cell survival, proliferation and expression of stem cells associated 
genes. In many human cancers, expression of BMI1 enhances tumour survival through 
alteration of cell cycle regulatory protein expression. With respect to MRT 
tumourigenesis, loss of SMARCB1 is associated with deregulation of cell cycle-related 
genes such as p21, p16 and CCND1 and re-expression of SMARCB1 caused G1 cell cycle 
arrest (Zhang et al., 2002, Reincke et al., 2003). Since SMARCB1 is not directly 
targetable, it is of interest to examine if targeting BMI1 could mimic the effect of 
SMARCB1 re-expression on cell cycle regulation. The expression of BMI1 downstream 
genes associated with cell cycle was examined in the qPCR analysis. Kuwahara et al. 
(2010), Betz et al. (2002) and Versteege et al. (2002) have shown in their studies that 
reintroduction of SMARCB1 in MRT cells caused upregulation of CD44, p21 and p16. 
Therefore, the qPCR analysis was performed in MRT cells to identify if BMI1 knockdown 
can recapitulate their results.  
BMI1 regulates the expression of p16, which is a critical gene associated with MRT 
tumourigenesis. Analysis of gene expression by qPCR showed an elevation of p16 mRNA 
expression in BMI1-deficient MRT cells. Additionally, knockdown of BMI1 by PTC209 
increased the expression of SMARCB1 related genes including p21 and CD44. The 
findings recapitulate the effect of SMARCB1 re-expression in MRT cells. In line with this, 
both pharmacologic inhibition and gene silencing of BMI1 also demonstrated 
commonalities in cell phenotype i.e. growth and cell cycle pattern. Taking the 
observations as a whole, BMI1 presents a new avenue in pharmacological targeting for 
MRT.  
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Figure 6.28 Knocking down BMI1 transcriptionally activates the expression of critical 
genes for MRT and recapitulates the effect of SMARCB1 re-expression in MRT cell 
lines. (a) qPCR analysis of SMARCB1 related genes in SMARCB1 re-expression MRT 
cells. The expressions of CD44, p21 and p16 were upregulated following SMARCB1 re-
introduction in cells. The mRNA expression was normalised to GAPDH and was 
presented as relative to PCDH. (b) qPCR analysis of SMARCB1 related genes CDK2A 
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(p16), CDKN1A (p21) and CD44 was performed to validate the effect of BMI1 inhibition 
on expression of these genes in MRT. The bar graph showing p16, p21 and CD44 were 
following PTC209 treatment. The mRNA expression was normalised to GAPDH and the 
data was presented as relative to DMSO (which was set at 0). Data are presented as 
mean ± SEM of three independent experiments.  
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6.5 Discussion 
6.5.1 Effects of BMI1 knockdown in MRT using shRNA and PTC209 
For this project, selection of candidate self-renewal gene was performed through a cross-
referencing analysis of curated stemness/self-renewal genes with the available genomics 
within the group which included RNA-seq of MRT primary and cells and CRISPR 
GeCKO screening of MRT cells with and without SMARCB1. Through this systematic 
biological approach, BMI1 was selected from 54 stemness/self-renewal genes as it shows 
SMARCB1 dependency, has been implicated in cancer development and is druggable.  
To explore the therapeutic potential of BMI1 as a means to counteract MRT 
tumourigenesis, the effect of BMI1 knockdown was studied in four MRT cell lines using 
shRNA and small molecule inhibitor, PTC209.  shRNA targeting BMI1 inhibited the 
expression of BMI1 at both RNA and protein levels which significantly impaired cell 
proliferation 72 hours post-transfection. Treatment with PTC209 reduced BMI1 
expression at protein level only and which reflects to the mode of action of PTC209 as 
post-translational modificator. Nevertheless, BMI1 knockdown using shRNA and 
PTC209 resulted in an induction of senescence in MRT cell lines. The slow proliferation 
rate was seen after 72 hours and increase in the number of b-galactosidase senescent cells 
after 120 hours were correlated with G0/G1 cell cycle arrest. SMARCB1 loss is also 
associated with deregulation of key cell cycle regulatory proteins. Experimental studies 
by (Kuwahara et al., 2010) and (Betz et al., 2002) showed that re-expression of SMARCB1 
in MRT cell lines leads to G0/G1 cell cycle arrest accompanied by increased  expression 
of cell cycle inhibitors; p21 and p16. RNA inhibition of these genes reversed the cycle 
arrest (Kuwahara et al., 2010). In this study, BMI1 knockdown caused cell cycle arrest 
associated with upregulation of p16 and p21 gene expression, thus mimicking the effect 
of SMARCB1 re-expression in MRT cells. It is worth noting that, apoptosis was low in 
PTC209 treated cells and shRNA knocked down cells, and this almost comparable with 
DMSO. These results are corroborated by small percentage of cells in sub-G0 phase. Of 
note, previous studies have demonstrated some variable effects of PTC209 on cell 
apoptosis. Mayr et al. (2016) observed a slight increase in caspase activity in biliary tract 
cancer cells. However, in additional PTC209 studies by Alzrigat et al. (2017) and 
Bolomsky et al. (2016) a high level of induction of apoptosis in PTC209 treated multiple 
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myeloma cells was observed. Thus, the effect of PTC209 on apoptosis is likely context 
dependent. 
For this project, I hypothesised that MRT tumourigenesis and aggressiveness is correlated 
with its stemness/self-renewal properties. In order to investigate the stemness properties 
within MRT and how it could be exploited to counteract MRT tumourigenesis, it was 
critical to determine if knocking down BMI1 has a significant effect on self-renewal 
machinery. Limiting dilution assay (LDA) and re-plating tumourspheres experiments 
showed that inhibition of BMI1 expression using shRNA and PTC209 significantly 
reduced the self-renewing cell population within MRT. This result is comparable with 
previous observations made by Kreso et al. (2014) on the effect of BMI1 knockdown in 
reducing self-renewal potential in colorectal cancer cells. 
Taking all the data together, results from shRNA and PTC209 studies indicate the 
potential of BMI1 as a future therapeutic target in MRT. Since BMI1 inhibition using 
PTC209 shows the transcriptional results mimicking the effect of SMARCB1 re-
expression in cells, PTC209 deserves further evaluation in organoids or in vivo for its 
potential as an anti-MRT therapy.   
6.5.2 PTC209 modulates post-translational modification of BMI1 expression 
PTC209 was primarily described to reduce the BMI1 expression in a human colorectal 
cancer cell line (Kreso et al., 2014). Subsequent pre-clinical studies tested PTC209 as a 
means to inhibit self-renewal capacity (Bolomsky et al., 2016, Alzrigat et al., 2017, Mayr 
et al., 2016, Nishida et al., 2015). I show that PTC209 treatment in MRT cell lines resulted 
in significant protein loss while elevating the transcript level. The findings were in 
contrast with shRNA mediated BMI1 knockout where I achieved downregulation at both 
RNA and protein levels. Studies of PTC209 in multiple myeloma and biliary tract cancers 
also showed the downregulation of BMI1 at the protein level only but expression at the 
RNA level was not affected (Bolomsky et al., 2016, Mayr et al., 2016). Therefore, it was 
postulated that PTC209 possibly alters post-translational expression of BMI1. BMI1 
inhibition using another BMI1 inhibitor, PTC596 in Acute Myeloid Leukaemia (AML) 
proposed that protein degradation is the principal mechanism of drug action (Nishida et 
al., 2017). The role of BMI1 and other subunits of PRC1 namely RING1A in 
ubiquitination was previously studied by Cao et al. (2005) in which the authors reported 
 
315 
the role of BMI1 and RING1A in HOX gene silencing. Knock out of these two genes 
resulted in reduced expression of HOX as determined by qPCR analysis. Additionally, 
ChIP analysis showed knock out of BMI1 caused significant reduction of H2A 
ubiquitination at the HOX promoter region relative to wild-type cells. Thus, their findings 
illustrate the PTC209 inhibits expression of BMI1 through ubiquitination process. 
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Appendix 6.2 Genes that are functionally relevant to SMARCB1. Integrated data 
analysis of curated gene list in Appendix 6.1 with RNA-seq data of MRT primary, MB 
primary and SMARCB1 re-expression in MRT cell model revealed 54 genes whose 
expression are active in MRT. 
CKS2 STAT3 FKBP9
MCM2 P53 ITGA6
CDT1 MCM4 ITGB1
PCNA HELLS LAPTM4A
TOP2A COL18A1 MSH2
CSRP2 SFRS3 MTMR10
ACAT2 BUB1  FGF2
CBR3 SHROOM3  FGFR1
CCND1 CDC6  HES1
EIF4EBP1 TTK  LIF
 CD44  GLI1 BCL6
 CDKN2A  GLI2 BMI1
 EXT1  IGF1R JARID2
 FOXO4  ITGB3 JARID1B
 FZD4 KLF4 CDKN1A
 DUSP2  MYC  TET1
 FN1 NOTCH2  TGFBR1
 JAK1  SPP1  MED12
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Appendix 6.3 In-vitro limiting dilution assay of BMI1-deficient MRT cells and control 
(LUC) measured on day 5 (120 h) post-lentiviral transfection. 
 
 
Cell density/well Number of wells LUC BMI1
50,000 15 15 15
10,000 15 30 30
5,000 30 30 30
1,000 96 96 96
100 96 96 67
10 96 96 40
1 96 0 0
50,000 15 15 15
10,000 15 30 30
5,000 30 30 30
1,000 96 96 96
100 96 96 62
10 96 96 41
1 96 0 0
50,000 15 15 15
10,000 15 30 30
5,000 30 30 30
1,000 96 96 96
100 96 96 63
10 96 96 40
1 96 0 0
50,000 15 15 15
10,000 15 30 30
5,000 30 30 30
1,000 96 96 96
100 96 96 74
10 96 96 51
1 96 0 0
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Appendix 6.4 The effect of BMI1 knockdown on MRT cell proliferation. Lentiviral 
transfection of shRNA significantly reduced the cell proliferation in all MRT cell lines 
relative to control (Non-silencing (NS) vector) measured using MTS CellTiter Aqueous 
one solution. The reading was measured 24, 48, 96 and 120 hours post infection (a). 
Knockdown of BMI1 significantly reduced the proliferation rate in A204 from 96 hours 
onwards compared to NS. (b-c) Similarly, BMI1 knockdown in G401 and CHLA-266 cells 
resulted in significant decrease in cell proliferation at 96 and 120 hours post transfection 
when compared to NS. (a) A decrease in proliferate rate was also observed in BT16 and 
significant decrease was seen at 120 hours relative to NS. The results are shown as means 
± SEM of three individual experiments and the significance was determined by unpaired 
student’s t-test (* p< 0.05, ****p<0.0001 vs NS). 
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Appendix 6.5 Effect of BMI1 silencing on apoptosis in MRT cells. (a) BMI1 knockdown 
significantly induced the apoptosis activity in A204 at 72 and 120 hours when compared 
to NS. (b) Knockdown of BMI1 in G401 resulted in significant increase in cell apoptosis 
at 120 hours relative to control. (c) Similarly to G401, BMI1 knockdown caused apoptosis 
in CHLA-266 and statistically different with NS was measured at 120 hours. (d) BMI1 
knockdown in BT16 resulted in an induction of apoptosis activity and more significant at 
120 post transfection when compared to control. The results are shown as means ± SEM 
of two individual experiments and the significance was determined by unpaired student’s 
t-test (* p< 0.05, ** p<0.01, *** p<0.001, ****p<0.0001 vs NS of appropriate sample). 
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Appendix 6.6 In-vitro limiting dilution assay of BMI1-deficient MRT cells and control 
(NS) measured on day 5 (120 h) post-lentiviral transfection. 
Cell density/well Number of wells NS BMI1
50,000 15 15 15
10,000 15 30 30
5,000 30 30 30
1,000 96 96 96
100 96 96 58
10 96 96 28
1 96 0 0
50,000 15 15 15
10,000 15 30 30
5,000 30 30 30
1,000 96 96 96
100 96 96 52
10 96 96 32
1 96 0 0
50,000 15 15 15
10,000 15 30 30
5,000 30 30 30
1,000 96 96 96
100 96 96 55
10 96 96 39
1 96 0 0
50,000 15 15 15
10,000 15 30 30
5,000 30 30 30
1,000 96 96 96
100 96 96 53
10 96 96 29
1 96 0 0
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Appendix 6.7 Average frequency of sphere forming measured using limiting dilution 
assay (LDA) in MRT cells transfected with shRNA-RFP from three independent 
experiments. Data was generated using a limdl software provided by Walter and Eliza 
Hall Institute. P-value represents overall difference in frequency of self-renewing cells 
between BMI1 and NS. Active self-renewing cell frequency reflects the cloning efficiency 
of the cultures to generate spheres. 
 
 
Appendix 6.8 BMI1 knock-down using shRNA impairs self-renewal capacity of MRT 
cells. (a) The effect of BMI1 loss on primary tumoursphere was measured using limiting 
dilution assay (LDA). The shRNA infected cells were cultured in tumourspheres media at 
density of 50,000 cells down to one cell per well and tumourspheres were allowed to form 
for 120h. Knockdown of BMI1 caused significant reduction in the number of 
tumourspheres at cell density of 10 and 100 cell per well. These results were further 
analysed using ELDA to measure active self-renewing cells in BMI1-deficient cells. (b) 
ELDA analysis demonstrate significant decrease in sphere forming efficiency following 
BMI1 knockdown in four MRT cell lines compared with NS. The results are shown as 
means ± SEM of three individual experiments and the significance was determined by 
unpaired student’s t-test (****p<0.0001 vs NS of appropriate sample). 
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Appendix 6.9 In-vitro limiting dilution assay of BMI1-deficient MRT cells and control 
(DMSO) measured on day 5 (120 h) after recovery time of PTC209 treatment. 
 
Cell density/well Number of wells DMSO 1/5 µM 3.5/10 µM
50,000 15 15 15 15
10,000 15 15 15 15
5,000 30 30 30 30
1,000 96 96 96 96
100 96 96 80 46
10 96 96 59 27
1 96 0 0 0
50,000 15 15 15 15
10,000 15 15 15 15
5,000 30 30 30 30
1,000 96 96 96 96
100 96 96 90 53
10 96 95 86 37
1 96 0 0 0
50,000 15 15 15 15
10,000 15 15 15 15
5,000 30 30 30 30
1,000 96 96 96 96
100 96 96 81 57
10 96 96 74 30
1 96 0 0 0
50,000 15 15 15 15
10,000 15 15 15 15
5,000 30 30 30 30
1,000 96 96 96 96
100 96 96 81 50
10 96 96 62 26
1 96 0 0 0
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Chapter 7 Conclusion 
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7.1 Introduction 
Malignant Rhabdoid Tumours (MRT) are rare and aggressive cancers that occur primarily 
in infants and children less than 3 years old (Woehrer et al., 2010). These tumours are not 
restricted to one anatomical location but can be found almost everywhere in the body. MRT 
that arise in soft tissue and outside of the brain are known as extra-cranial rhabdoid tumour 
(ECRT) whereas the tumours that occur in the brain and spinal cord are called Atypical 
Teratoid Rhabdoid Tumour (ATRT) (Biggs et al., 1987, Parham et al., 1994, Rorke et al., 
1996). MRT present a unique feature which is often described as “simple genome” due to 
the one recurrent genomic alteration which is characteristic of these tumours type regardless 
of tumour origins (Lee et al., 2012, Hasselblatt et al., 2013, Johann et al., 2016). Histological 
and genome-wide studies report a consistent biallelic inactivation at chromosome 22 of 
SMARCB1 (Versteege et al., 1998, Biegel et al., 2002a). Patients with MRT are treated with 
multimodal therapies which involve the combination of few treatments including surgery, 
radiotherapy and chemotherapy. Despite the advancement in cancer therapy, patients with 
MRT have very poor prognosis due to inefficacious treatment, most patients survived less 
than 1 year after treatment (Chi et al., 2009, Hilden et al., 2004, Tekautz et al., 2005).  
The role of SMARCB1 has been previously established both in vivo and in vitro. Several 
studies have illustrated the tumourigenic effects of SMARCB1 loss in MRT on various 
pathways such as cell cycle, epigenetic mechanism, and lineage-specific cell development 
and differentiation (Wilson and Roberts, 2011, Betz et al., 2002). Additionally, the effect of 
SMARCB1 loss in tumourigenesis was previously studied in a limited number of MRT mouse 
models (Roberts et al., 2000, Roberts et al., 2002, Han et al., 2016). Although SMARCB1 
loss can initiate tumour formation, there is little evidence as to how this single genomic 
abnormality results in a highly aggressive disease which is almost exclusive to very young 
children. 
Despite having little genetic variability, MRT vary histologically containing cells with 
different morphology and differentiation markers from multiple lineages even 
intratumourally (Okuno et al., 2010, Fischer et al., 1989, Harris et al., 1987, Kato et al., 
2003). Various cell of origin has been suggested due to the phenotypic diversity of MRT 
such as neural, neural crest cells, mesenchymal, etc (Harris et al., 1987, Fischer et al., 1989, 
Ota et al., 1993, Parham et al., 1988). The aetiology of MRT regarding its cell of origin and 
how this relates to tumour location and molecular subtype is largely unknown. Attempts to 
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identify cellular origins for MRT showed variable findings. Deletion of either Smarcb1 or 
Smarca4 in granule neurons and their progenitors; which had been postulated to be the origin 
of ATRT, failed to generate tumours in vivo (Moreno et al., 2014). Genome-wide analyses 
suggested neural crest (NC) cells or neural stem cells (NSC)  as cells of origin for MRT 
based on deregulation of many genes involved in development of these two cell types 
following SMARCB1 loss (Chun et al., 2016, Johann et al., 2016, Gadd et al., 2010). MRT 
are characterised as an early onset disease, with a peak incidence at 0-3 years of age (Margol 
and Judkins, 2014). Also in rare circumstances MRT have been reported occurring as a 
congenital subcutaneous mass (White et al., 1999, Toth et al., 2011). Hence, it is more likely 
that SMARCB1 loss occurs in early progenitor cells which are later transformed into MRT.  
As a member of the SWI/SNF chromatin remodelling complex and tumour suppressor gene, 
expression of SMARCB1 is associated with deregulation of pathways that are involved in 
stem cell regulation and maintenance (Gadd et al., 2010). MRT have been proposed to have 
“stem-like cells” within the tumours due to expression of various stem cell markers and also 
phenotypes that resemble mesenchymal, neural and epithelial stem cells (Hollmann and 
Hornick, 2011, Kohashi et al., 2016, Okuno et al., 2010, Biswas et al., 2016, Venneti et al., 
2011b, Deisch et al., 2011). Genome-wide analyses of primary MRT patient samples also 
demonstrated overexpression of genes that regulate self-renewal and pluripotency which are 
common features of stem cells. Collectively, these findings suggest that deregulated stem 
cell processes may significantly impact upon MRT tumourigenesis.  
This research study was performed to provide a better understanding of MRT tumourigenesis 
through identification of cell of origin and stem cell self-renewal pathways/genes that drive 
disease aggressiveness. Given the lack of appropriate MRT mouse models, the data collected 
from cell of origin study were analysed in such a way as to understand which stem cell types 
are potentially the cell of origin of MRT and whether knocking down SMARCB1 in the 
putative cell of origin can be a strategy for the development of a more disease appropriate 
mouse model. My research study also aimed to investigate the stemness/self-renewal 
properties of MRT and its potential to counteract MRT tumourigenesis. To examine the effect 
of manipulating stemness/self-renewal genes/proteins in MRT and to what extent their role 
in MRT can be manipulated for development of new therapeutic targets for MRT. 
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7.2 Summary 
7.2.1 Identification of cell of origin for MRT  
7.2.1.1 Integrated bioinformatics analysis reveals potentially different cell of origin(s) 
for each subtype within MRT  
For many cancer types, the precise identification of tumour initiating cells remains unknown. 
Unlike other human cancers which can be found locally, MRT can arise almost anywhere in 
the body and exhibit multiple phenotypes, thus posing challenges for specific discovery of 
cell of origin for this childhood malignancy. Few studies have tried to establish the potential 
cell of origin for MRT (Harris et al., 1987, Fischer et al., 1989, Ota et al., 1993, Parham et 
al., 1988) and the subtypes within MRT (Chun et al., 2016, Johann et al., 2016, Torchia et 
al., 2016). However, these studies showed several technical limitations in which the findings 
were concluded solely based on either gene expression profiles of primary tumours or 
existence of stem cell surface markers. Preliminary bioinformatic analysis of MRT cell 
models performed by Dr Williamson suggested that MRT possibly originate from early 
pluripotent stem cells. However, this analysis had a limited number of stem cell expression 
profiles and no primary MRT profiles were included. This result was studied further in this 
project.  
To shed light on a potential cell of origin for MRT, a system for ranking putative cells of 
origin was described in chapter 3 through the integrated bioinformatics analysis of 
expression profiles of various stem cells types that were publicly available on the GEO NCBI 
database with primary and model data of MRT. Expression profiles from neural, neural crest, 
stromal, mesenchymal and embryonic stem cells, as well as iPSC, were included (n=446). 
Additionally, a time course experiment in which SMARCB1 was re-expressed in MRT cell 
lines, was utilised in the analysis. This data provided extra information on the potential cell 
of origin for MRT as restoration of SMARCB1 in MRT cells caused the expression profiles 
to converge over time to a point that was closer to neural crest (NC) cells and mesenchymal 
stem cell (MSC) expression profiles. The data were analysed based on differential gene 
expression between MRT primary and SMARCB1 re-expression cell model with various 
stem cell expression profiles using NMF, heatmap and PCA clustering analyses.  
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Results from this study indicate that three candidate cells of origin within the family of neural 
crest (NC), neural (NSC) and mesenchymal stem (MSC) cells. Expression profiles of ATRT 
resemble NSC whilst ECRT resembles NC and MSC. The results were further interrogated 
to understand the possibility of subtype-specific cell of origin in MRT. Gene expression 
profiling characterised three potential cells of origin within MRT based on developmental 
gene expression that related to the bodily location of primary tumours. ATRT showed 
significant enrichment of genes associated with neuronal development while ECRT 
demonstrated upregulation of genes associated with mesenchymal cell type development. 
These findings were in line with previous studies (Chun et al., 2016, Gadd et al., 2010) in 
which the authors reported the expression of genes associated with MSC and NSC in primary 
MRT. Additionally, the extent of transcriptional overlap clearly reflects differences in 
tumour location and molecular subgroup. Of note, embryonic stem cells demonstrated a very 
small similarity with expression profiles of MRT subtypes.  
In conclusion, the bioinformatics analysis performed in this study illustrated that MRT might 
not arise from the same progenitor cells. Consistent with other previous studies (Chun et al., 
2016, Gadd et al., 2010, Han et al., 2016, Vitte et al., 2017), MRT possibly derive either from 
NSC, NC or MSC. Notably, the current study shows that there are possible subtype specific 
cells of origin within MRT which should be explored further as it can feed on current 
knowledge of clinicopathological features and the development of disease models.  
7.2.1.2 CRISPR/Cas9 mediated knockout of Smarcb1 in putative cell of origin: A tool 
for future development of MRT mouse models and identification of therapeutic 
targets ex-vivo 
To develop targeted therapies for MRT, more knowledge is required about the cellular origin 
of these tumours and how SMARCB1 loss results in malignant transformation of these cells. 
Such studies should be first conducted in vivo or ex vivo as it is challenging to isolate the 
cell of origin from patient material. A previous MRT mouse model used in a cell of origin 
study relied on multiple stages of chemically induced Smarcb1 knockdown (Han et al., 
2016).  Although this study presented high penetrance, the standard dose of tamoxifen also 
led to embryonic lethality due to excessive Smarcb1 deletion. Besides that, the authors did 
not perform the knockout Smarcb1 in a specific cell type in mice to provide evidence of cell 
of origin as the chemical tamoxifen were present everywhere in the mice’s body. In the 
second cell of origin mouse model study, Smarcb1 was inactivated in protein zero (P0) of 
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NC cells using Cre recombinase system which resulted in tumour development which 
molecularly, phenotypically and immunohistochemically mimics to human MRT (Vitte et 
al., 2017). However, the majority of tumours resemble meningeal tumours and developed in 
the head, and the authors also speculated that protein zero of NC as a cell of origin for 
Schwannomas. Hence, their results raise a question to which extent neural crest cells is a 
cell of origin for MRT as the authors did not explicitly time the induction of Smarcb1 
knockout except through P0. Besides that, their results did not link to particular subgroups 
within MRT.  
For this project, the NC cells derived from an E8.5 mice embryo was used to investigate the 
prospect of these cells as an MRT cell of origin, as it has been postulated by many studies 
(Vitte et al., 2017, Han et al., 2016, Johann et al., 2016). The expression of Smaarcb1 was 
targeted using CRISPR/Cas9 technology in NC cells.  Here, the effect Smarcb1 knockdown 
was studied in ex vivo before evaluating its tumourigenic capacity in vivo. Although the 
findings generated from this part of the study are insufficient to establish neural crest cell as 
the cell of origin for MRT specifically ECRT, this study demonstrates that CRISPR/Cas9 
system is proficient to inactivate nuclear expression of Smarcb1 and with a very small 
discrepancy between two CRISPR/Cas9 constructs. Here, we show the CRISPR/Cas9 
mediated Smarcb1 gene editing achieves over 85% efficiency of generating NC cells that do 
not express Smarcb1 protein. In this study, stable cell line that permanently knockout of 
Smarcb1 expression was successfully created thus circumventing the limitations found in 
aforementioned mouse models. The CRISPR/Cas9 system is often associated with 
unfavourable off-target events. Such effects were not pronounced as both constructs 
generated almost similar findings in the current studies.  
Data generated from current study demonstrated that Smarcb1 loss in NC cells was able to 
maintain the proliferation capacity even one month after lentiviral transfection, differing 
from studies in other cell types such as NIH3T3 (Detailed in Chapter 4, Section 4.4.4.3). 
Furthermore, in this study, Smarcb1-deficient cells were shown to gain the self-renewal 
capacity when growing as tumoursphere under clonogenic conditions and the findings were 
corroborated by qPCR analysis of self-renewal gene expression (Detailed in Chapter 4, 
Section 4.4.4.5). Strikingly, genetically modified NC cells presented in this study revealed 
gene expression and phenotypes that resemble human MRT. Most importantly, most of the 
data generated from in this cell model including the presence of vimentin and cytokeratin 8 
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protein expression are in line with previous findings from the in vivo study of targeting 
Smarcb1 in early NC cells (Vitte et al., 2017). Besides that, Smarcb1 knockout in NC cells 
resulted in opposing gene expression profiles i.e cell cycle to that of SMARCB1 re-
expression in MRT cells. This result implies that functional NC cells are a potential cell of 
origin for MRT.  
Though this cell model still requires further validation, it will pave a path to development of 
a model system in which the disease is initially originated. In summary, this study reported 
a system to efficiently knock down Smarcb1 in NC cells as a potential cell of origin for MRT. 
This will be useful for researchers aiming to utilise gene editing in NC cell applications. 
Also, researchers will be able to study how MRT tumourigenesis could be linked to tumour 
origin ex vivo. The ex vivo model can allow one to investigate the role of specific gene 
alterations in disease initiation and progression. Such knowledge can provide the basis for 
an improved subgrouping of MRT and for identification of targeted therapies for patients 
with MRT. Furthermore, utilizing CRISPR/Cas9 mediated genome knockout can rapidly 
induce mutation in the gene of interest and has been shown to create higher gene inactivation 
in many in vivo studies.  
7.2.2 Self-renewal genes as potential therapeutic targets in Malignant Rhabdoid 
Tumours (MRT)  
Malignant Rhabdoid Tumours (MRT) are genetically defined by inactivation of SMARCB1 
which has a role as a tumour suppressor gene and a member of the SWI/SNF chromatin 
remodelling complex (Biegel et al., 2002a, Versteege et al., 1998). In experimental systems, 
SMARCB1 re-expression leads to activation of the p16 and p21 pathway leading to cell cycle 
arrest. SMARCB1 expression in the cells restricts the activity of cyclin D-CDK4/6 through 
transcriptional repression of CCND1 accompanied by increase in the expression of cell cycle 
inhibitors; p21 and p16. Therefore, efficacy of targeting CDK4/6 expression in MRT was 
studied in few pre-clinical studies using CDK4/6 inhibitor, Ribociclib (Infante et al., 2016) 
and PD 0332991, a potent inhibitor for CDK4 (Katsumi et al., 2011). Treatment with PD in 
MRT cell lines impaired cell proliferation and induced cell arrest. Phase I clinical trial of 
Ribociclib demonstrated single agent treatment was well tolerated in mrt patients, with a 
similar safety profiles observed in adult patients. Nevertheless, the authors suggested 
combination of ribociclib agent with other targeted therapies such as MAPK/ERK inhibitors 
should be considered in future trials. 
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Recent study showed that cell cycle alteration is not a sole driver in MRT tumourigenesis. It 
has been postulated that MRT tumourigenesis is not only driven by alteration in SMARCB1 
but dependency on Enhancer of Zeste 2 (EZH2), an enzymatic subunit of the Polycomb 
Repressive Complex 2 (PRC2) (Knutson et al., 2013). EZH2 has been implicated in invasive 
tumour growth and poor prognosis in many types of human cancers (Bracken et al., 2003, 
Kleer et al., 2003, Varambally et al., 2002). The role of EZH2 in stem cell maintenance such 
as self-renewal and differentiation in MRT was studied in few chemical inhibition studies in 
vivo and in vitro (Knutson et al., 2013, Alimova et al., 2012). These studies investigated the 
pharmacological properties of different EZH2 inhibitors such as EPZ-6438 and DZNep in 
MRT cell lines and the authors showed comparable results that EPZ-6438 and DZNep 
treatment in MRT cells induced cell apoptosis, altered cell cycle regulatory and also 
abrogated sphere formations. These studies illustrated deregulation of stem cell genes that 
regulate self-renewal and differentiation and may have a critical impact on MRT 
tumourigenesis.  
The impact of targeting self-renewal machinery as a revenue for future MRT therapies was 
also studied by Shabab et al., 2018. In this study, the authors inhibit the expression of Lin28 
which is also a known regulator for the let-7 family of miRNAs. The expression of Lin28 
was found to be upregulated following SMARCB1 loss in MRT samples and the authors 
found that knockdown of Lin28 in two MRT cell lines increased the cell apoptosis and 
impaired cell growth.   
To gain more insight into the impact of targeting self-renewal machinery to counteract MRT 
tumourigenesis, I aimed to identify and assess the stemness/self-renewal genes as new 
therapeutic targets for MRT. Firstly, the self-renewal genes which are active and whose 
activity is SMARCB1 dependent in models and primary MRT samples were assessed by 
comparing of transcriptomic data with a list of self-renewal genes generated from Ingenuity 
Pathway Analysis (IPA). In particular, the stemness/self-renewal genes whose expression 
was commonly implicated in brain tumour progression were identified including BMI1 and 
JARID2. Overexpression of these genes is required to mediate tumourigenesis for the 
hedgehog (Hh) subgroup of Medulloblastoma (Wang et al., 2012).  Through cross-
referencing analysis between stemness/self-renewal candidate genes with RNA-seq and 
CRISPR screening data, BMI1 was selected as a target gene. Although the mechanism of 
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BMI1 in stem cell self-renewal has been established in other human cancers, its role in MRT 
is still not clear.  
The expression of BMI1 in MRT was studied in this project using shRNA constructs and the 
small molecule inhibitor, PTC209. As MRT occur predominantly in infants and children, the 
administration of anti-cancer agents at low dose is desirable. Here, we identified sub-lethal, 
low doses of PTC209 as a potent inhibitor of cell proliferation and self-renewal in MRT. 
Treatment of MRT cell lines with sub-lethal doses of PTC209 inhibits cell growth, induces 
cell cycle arrest and senescence and more importantly impairs long-term MRT self-renewal 
capacity as assessed by limiting dilution assay. Notably, knockdown of BMI1 using shRNA 
and an inhibitor in MRT cell lines generated data such as cell cycle profiles, gene expression 
and cell senescence that recapitulates the findings from SMARCB1 re-expressing cell studies 
(PBTG, unpublished).  
Targeting BMI1 using PTC209 significantly impedes protein production while maintaining 
RNA expression. This suggests the possible effect of PTC209 on BMI1 post-translation 
modification thus conferring its attractive therapeutic effect.  Here, this study reports the 
potential of BMI1 to act as a therapeutic target for MRT and the efficacy of PTC209 in 
inhibiting BMI1 expression. While the cytotoxic effect of PTC209 and detailed mechanism 
by which this inhibitor can impair cell growth and self-renewal capacity at low doses need 
to be determined in vivo, it may offer an effective and well-tolerated therapeutic option for 
young patients diagnosed with MRT and possibly other types of tumours as well. Besides 
that, BMI1 which is also a component of Polycomb Repressive Complex 1 (PRC1) has been 
reported to have a synergetic role with EZH2 in modulating transcriptional silencing. 
Therefore, it can offer a new drug combination for MRT treatment.  
 
 
 
342 
7.3 Limitations 
7.3.1 Identification of cell of origin for MRT 
The initial aim of the study was to identify the cell of origin for MRT through knock out of 
SMARCB1 and SMARCA4 using CRISPR/Cas9 system in candidate cells. Meta-analysis of 
RNA-seq data of primary and cell line model with various stem cell profiles revealed three 
possible cells of origin for MRT related to location of primary tumours; neural stem cell 
(NSC) for ATRT whilst neural crest (NC) cells and mesenchymal stem cells (MSC) for 
ECRT. It is worth noting that gene expression analysis performed to identify cell of origin 
for MRT and how it correlates with bodily location may confound the results as niche 
environment may influence the tumour cell growth and variable activities (i.e expression of 
the genes). Genes may be expressed in one microenvironment, but not in another, therefore 
will lead to false positive results. Therefore, analysis of other datasets that have less variance 
(i.e effect of tumour microenvironment such as paracrine) such as genome wide DNA 
methylation profiles may provide clues for  cell of origin for MRT. Our detailed methylation 
profiles of primary tumours (work done by Yura Grabvoska) revealed differences in 
methylation status i.e hypomethylation among different regions of CpG island. Although use 
of methylation profiles may be of limited value as the data can also show hypo- or hyper-
methylated status, the difference seen in our primary and cell lines may reflect different cell 
of origin for MRT and further work should be done to identify a cohort of developmentally 
regulated sequence elements i.e CpG island to uncover transcriptional regulators in lineage 
differentiation.  
From the bioinformatics analysis, three potential cells of origin were identified from a family 
of neural crest (NC) cells, mesenchymal stem cells (MSC) and neural stem cells (NSC). 
However, due to time constraint, the effect of SMARCB1 knockdown in neural crest cells 
was only reported in this study. Although Smarcb1-deficient NC cells demonstrated 
phenotypic similarities with human MRT, they cannot be definitively stated as the only cell 
of origin for MRT and particularly ECRT, since experiments were not carried out on the 
other candidates. Besides, though qPCR analysis and tumoursphere assay showed an 
increase in cell cycle regulation and self-renewal capacity in Smarcb1 knockout cells, this 
study has not provided definitive evidence that deletion of Smarcb1 in this cell type confers 
tumourigenesis. Xenograft of Smarcb1-deficient cells may provide an insight into 
SMARCB1 driven MRT tumourigenesis dependency on cell of origin, though previous 
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mouse model study illustrates Smarcb1 loss in P0 expressing cells is tumourigenic and 
capable to initiate tumour formation (Vitte et al., 2017).  
Attempts were made to characterise Smarcb1-deficient NC cells based on histological 
characteristics of rhabdoid cells such as abundance of mitotic figure, inclusion bodies and 
prominent nuclei. However, I failed to detect cells with these characteristics. One possible 
explanation is most studies which have previously demonstrated the MRT phenotypes have 
done so using tissue sections. Hence, in vivo study of Smarcb1-deficient NC cells may 
provide better assessment of MRT histological phenotypes if the tumours are successfully 
formed.  
7.3.2 Self-renewal genes as potential therapeutic targets in Malignant Rhabdoid 
Tumours (MRT)  
Current therapies for infants and children with MRT are still ineffective. Hence, this part of 
the project aimed to discover therapeutically targetable self-renewal pathways/genes 
downstream of SMARCB1 mutation as the most efficient means to counteract MRT 
tumourigenesis and induce differentiation/growth arrest in MRT cells. Reduced expression 
of BMI1 using small inhibitor, PTC209 was able to demonstrate remarkable findings that 
mimic the effect of SMARCB1 re-expression in MRT cell lines. However, further 
investigation of this inhibitor should be performed to identify the utility of BMI1 inhibitor 
for MRT treatment. The cytotoxicity and efficacy of PTC209 in inhibiting MRT 
tumourigenesis in vivo cannot be established as the effect of this small inhibitor was only 
studied in vitro. Besides that, data for self-renewal efficiency was generated from in vitro 
limiting dilution assay. Though inhibition of BMI1 with PTC209 and shRNAs demonstrated 
impairment of long-term self-renewal capacity of MRT cells growing in 3D tumoursphere, 
such effect should be studied further in vivo. 
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7.4 Future work 
7.4.1 Molecular profiling of Smarcb1-deficient cells on cell of origin within MRT  
The present study attempted to identify potential cells of origin for MRT. Bioinformatics 
analysis suggests that the cell of origin for MRT is potentially molecular subtype specific. 
Despite comprehensive bioinformatics analysis, further investigation is required to support 
this finding. Besides that, results from bioinformatics analysis showed neural crest (NC) 
cells as one of the potential cells of origin for MRT. To further investigate if NC cells are the 
cell of origin in MRT, CRISPR/Cas9 knock out of Smarcb1 was performed in NC cells. 
However, due to time constraint, the experiment was performed only in neural crest cells 
and non-stem cells (NIH3T3 cell line) was used as a control. Knockout of SMARCB1 should 
also be performed in other candidates of cell of origin; neural stem cells and mesenchymal 
stem cells. Furthermore, from the bioinformatics analysis, embryonic stem cells (ESC) 
showed no potential as cell of origin for MRT. Use of ESC as control may be useful to 
validate this result. To determine if there is a common or specific cell of origin for MRT, 
RNA-seq and 450K methylation of SMARCB1-deficient cells will be performed and 
compared with human MRT and previous mouse model data. Though SMARCB1 loss led to 
tumour formation in previous mouse models of MRT, the majority of the tumours were 
observed in head or meninges (Vitte et al., 2017). For this project, I hypothesised that cell of 
origin for MRT in subtype-specific which related to the bodily location of primary tumours. 
Therefore, it is necessary to determine if tumours or Smarcb1-deficient NC cells (if 
Smarcb1-deficient cells can transform into tumours) can preferentially recapitulate 
molecular subgroups seen in primary human tumours. To this end, across species 
comparative genome-wide studies between Smarcb1-deficient NC cells with published 
expression profiles of human and mouse MRT tumours (Han et al., 2016, Vitte et al., 2017, 
Chun et al., 2016, Johann et al., 2016) can be done to examine their molecular analogy.  
7.4.2 Characterisation of cell of origin for development of MRT mouse models and 
therapeutic intervention 
Recent mouse models have shown the potency to develop tumours that mimicking human 
MRT (Han et al., 2016, Vitte et al., 2017). However, majority of the tumours were found in 
the rare regions such as meninges. To date, there is no study that reported the occurrence of 
the tumours in other parts of mice's body including kidney. To address this issue, 
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development of mouse model that can represent each molecular subgroup is anticipated 
through identification of cell of origin. To this end, Smarcb1 knock out was performed in a 
candidate cell of origin for ECRT using CRISPR/Cas9 technology. The ex vivo study of 
Smarcb1 loss in early NC cells suggests that Smarcb1 inactivation is sufficient to promote 
cell proliferation and induce phenotypes that resemble human MRT Hence, xenograft of 
Smarcb1-deficient cells in mice will provide a better model for understanding the role of cell 
of origin in mediating MRT tumourigenesis and aggressive behaviour of MRT. Besides that, 
transcriptomic profiling of Smarcb1-deficient cells obtained from mouse model will be 
performed by RNAseq and the data will be integrated with primary human and mouse model 
data to investigate the potential of NC cells as the cell of origin for MRT before the attempts 
to translate the functional cell of origin as relevant mouse model for pre-clinical drug testing 
for MRT. 
This study demonstrates the phenotype of Smarcb1-deficient NC cells mimicking human 
MRT based on the presence of two commonly associated markers in MRT; vimentin and 
cytokeratin. It is important to note that, SMARCB1 loss can also be found in other types of 
tumours such as Schwanomma. Therefore, staining the cells preferably tumour cells with 
S100, epithelial membrane antigen, or smooth muscle will differentiate MRT cells from non-
rhabdoid tumours. Characterisation of SMARCB1 loss in cells of origin will uncover the 
molecular factors within the cell of origin that supports the mutation in SMARCB1 is 
transforming particular cells to become cancerous.   
Our ultimate goal of studying cell of origin is to discover new therapeutic targets that could 
effectively cure MRT. To develop effective therapies for MRT, there is a need to understand 
better how the cell of origin can affect the characteristics and behaviour of MRT cells. 
Analysis of differential gene expression between primary human tumours with candidate 
cell of origin and normal cells should be implemented to identify “gene signature” that 
associated with cancer transformation and drug sensitivity. The identification of the genes 
that implicated in MRT tumourigenesis will facilitate the development of new targeted 
therapies for MRT. 
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7.4.3 Understanding the role of BMI1 as histone m.odification protein in MRT as 
potential therapeutic target for MRT 
Post-translation modifications (PTM) of core histone protein of chromatin play a critical role 
in controlling the dependability of transcription regulatory machinery in cells. PTM includes 
methylation, acetylation, ubiquitination, phosphorylation, lipidation, SUMOylation, 
hydroxylation, glycosylation and disulphide bonds (Witze et al., 2007, Liddy et al., 2013). 
Studies have illustrated aberrant function of PTM can cause disruption in normal biological 
process such as cell signalling, DNA repairs, cell differentiation, cell proliferation which 
eventually can lead to tumour progression and drug resistance (Chandrasekaran et al., 2017, 
Okamoto and Lipton, 2015, Eisenberg-Lerner et al., 2016, Khan et al., 2015). Post-
translation modifiers have demonstrated the potential as therapeutic target for human cancers 
in several studies (Lu et al., 2016, Krueger and Srivastava, 2006, Martín-Bernabé et al., 
2017). The most common type of modifications is methylation processes which are catalysed 
by histone methyltransferase. The most common gene that is linked to methylation events 
on histone modification is EZH2, which is a member of Polycomb Repressive Complex 2 
(PRC2).  
It has been shown that histone modifications are also regulated by SWI/SNF complexes 
(Alver et al., 2017). Deregulation of enzymes that regulate the epigenome often results in 
global consequences on chromatin. For instance, experimental studies have illustrated 
SMARCB1 loss in MRT causes upregulation of trimethylase on histone H3K27 and 
repression of p16Ink4a (Kia et al., 2008). In line with these findings, studies have 
demonstrated the efficacy of selective inhibitors for EZH2 as a mean of MRT treatment 
(Knutson et al., 2013, Alimova et al., 2012).  
In this study, we report a potential therapeutic target for MRT which is BMI1. Inhibition of 
BMI1 using small molecular inhibitor, PTC209 demonstrated the possible mechanism of 
post-translation modification. It has been demonstrated in other studies that BMI1 regulates 
the transcriptional silencing through catalysing mono-ubiquitination of lysine 119 on histone 
H2A (Kreso et al., 2014, Bolomsky et al., 2016, Alzrigat et al., 2017). Similarly, to the 
methylation process, ubiquitination proteins have been shown to play a significant crucial 
role in several drug responses and therefore disease prognosis. Interestingly, impaired BMI1 
protein production resulted in growth suppression of SMARCB1-deleted cells accompanied 
by downregulation of cell cycle promoting genes and upregulation of cell cycle inhibitors 
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including p16. Study of PTC209 in squamous cell carcinoma demonstrated suppression of 
ubiquitination of histone H2A following BMI1 inactivation (Wang et al., 2015). Therefore, 
ChIP analysis of BMI1-deficient MRT cells will determine to what extent BMI1 loss can 
affect global histone modification and interaction with another member of the SWI/SNF 
complex in impeding MRT cell growth.  
7.4.4 BMI1 knockdown mimics the effect of SMARCB1 re-expression in MRT cells: a 
way to counteract MRT tumourigenesis 
Despite minimal gene expression analysis presented in this study, findings demonstrated 
remarkable similarity between BMI1-deficient MRT cells with SMARCB1 re-expression in 
MRT cells, suggesting that BMI1 might represent an ideal target for therapeutic intervention. 
Therefore, more comprehensive genome-wide studies with primary and model MRT data 
should be performed to verify the observations from the current study and also to illustrate 
an effect of BMI1 loss on transcriptomic or methylation profiles. Given this study was able 
to provide proof-of-concept for inhibitor targeting expression of BMI1 in vitro, the efficacy 
of this drug should be further evaluated in Phase I clinical trials.  
PRC proteins have been shown to have antagonistic effects with SWI/SNF chromatin 
remodelling (Wilson et al., 2010a). The PRC2 complex is commonly linked with MRT 
tumourigenesis due to the significant role of EZH2 in catalysing methylation on histones. 
However, there is no single study reporting the potential impact of PRC1 complex on 
regulatory of SWI/SNF complex in MRT. Previous ChIP analysis illustrated the co-
occupancy of both PRC complexes at a promoter region in mediating transcriptional 
silencing of p16Ink4a (Kia et al., 2008), a critical gene that is associated with MRT 
tumourigenesis. Therefore, investigation of deregulation of genes expression following 
BMI1 loss in MRT cells by RNAseq may provide knowledge of anti-tumour activity of 
PTC209 and also canonical PRC1 complex in MRT tumourigenesis. More importantly, this 
will highlight the potential synergistic drug development of PRC proteins for MRT 
treatment.  
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7.5 Final conclusion 
The aims of this study were to identify the cell of origin and “stemness” of Malignant 
Rhabdoid Tumours as new therapeutic approach for these lethal childhood malignancies.  
The first aim of this study is to identify the cell of origin for MRT. Through comparative 
genomic studies of stem cell population with primary and model MRT, I have identified 
important findings that there is no common cell of origin within MRT and that cellular 
origins are possibly subtype specific. Moreover, cross-referencing between these datasets 
was applied to identify gene signatures within primary and model MRT that resemble to 
stem cell populations. Importantly, the analysis demonstrated dysregulation of 
developmental genes that differed between subtypes within MRT. From the bioinformatics 
analysis, three potential cells of origins have been identified; neural crest (NC) cells, 
mesenchymal stem cells (MSC) and neural stem cells (NSC). To further investigate the 
relevance of these cells as cell of origin for MRT, CRISPR/Cas9 system was utilised in 
experimental studies to knock out functional Smarcb1 in NC cells. This investigation has 
made a substantial contribution to knowledge in the cell of origin for MRT research through 
characterisation of cell phenotypes and gene expression profiles (i.e cell cycle) that 
resembles human MRT. Furthermore, this study has demonstrated that whilst the majority 
of cell types do not tolerate having Smarcb1 loss except neural crest cells which grew, and 
display increased the proliferative capacity. Altogether, a system for ranking putative cells 
of origin was established and a practical means for testing Smarcb1 mutation ex vivo was 
carried out using CRISPR/Cas9 technology.  
Besides that, this study was also aimed to characterize how SMARCB1 mutations alter 
“stemness/self-renewal” programmes in order to affect tumourigenesis. To achieve this aim, 
assessment of the expression of self-renewal genes that are deregulated in MRT cells was 
performed through comparative studies of self-renewal genes with RNA-seq data of primary 
and cells, and CRISPR GeCKO screening of MRT cells. From this analysis, I’ve identified 
BMI1 as SMARCB1-dependent gene in MRT. The third and final aim of this study was to 
test and validate at least one targetable "stemness/self-renewal" gene/pathway as a potential 
novel anti-MRT therapy. To this end, expression of BMI1 was further studied in four MRT 
cell lines using shRNA and small molecular inhibitor, PTC209. Of note, BMI1 knockdown 
mimics the effect of SMARCB1 re-expression in MRT. Therefore, this study illustrates 
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BMI1 is one potential therapeutic target for MRT, but its expression needs to be explored 
further.   
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